<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Endocr Connect</journal-id><journal-id journal-id-type="iso-abbrev">Endocr Connect</journal-id><journal-id journal-id-type="pmc-domain-id">2122</journal-id><journal-id journal-id-type="pmc-domain">endoconn</journal-id><journal-id journal-id-type="publisher-id">EC</journal-id><journal-title-group><journal-title>Endocrine Connections</journal-title></journal-title-group><issn pub-type="epub">2049-3614</issn><publisher><publisher-name>Bioscientifica Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12793969</article-id><article-id pub-id-type="pmcid-ver">PMC12793969.1</article-id><article-id pub-id-type="pmcaid">12793969</article-id><article-id pub-id-type="pmcaiid">12793969</article-id><article-id pub-id-type="pmid">41428801</article-id><article-id pub-id-type="doi">10.1530/EC-25-0463</article-id><article-id pub-id-type="publisher-id">EC-25-0463</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group><subj-group subj-group-type="specialities"><compound-subject><compound-subject-part content-type="code">EC-Metabolic-Syndrome-and-Diabetes</compound-subject-part><compound-subject-part content-type="label">Metabolic Syndrome and Diabetes</compound-subject-part></compound-subject></subj-group></article-categories><title-group><article-title>Rapid and selective gut microbiome modulation by polyherbal formulation in type 2 diabetes</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Sauša</surname><given-names initials="S">Sintija</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zodāne</surname><given-names initials="A">Annija</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kumar</surname><given-names initials="S">Somit</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Plūme</surname><given-names initials="J">Jānis</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Baranova</surname><given-names initials="J">Jana</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kozlova</surname><given-names initials="T">Tatjana</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Klētnieks</surname><given-names initials="U">Uģis</given-names></name><xref rid="aff4" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saušs</surname><given-names initials="H">Harijs</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kloviņš</surname><given-names initials="J">Jānis</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pīrāgs</surname><given-names initials="V">Valdis</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mitravinda</surname><given-names initials="KS">Kakarla Sai</given-names></name><xref rid="aff5" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kistkins</surname><given-names initials="S">Svjatoslavs</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3031-2243</contrib-id><name name-style="western"><surname>Brīvība</surname><given-names initials="M">Monta</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="cor1" ref-type="corresp"/></contrib><aff id="aff1"><label><sup>1</sup></label><institution>Pauls Stradiņš Clinical University Hospital</institution>, <city>Riga</city>, <country>Latvia</country></aff><aff id="aff2"><label><sup>2</sup></label><institution>University of Latvia</institution>, <city>Riga</city>, <country>Latvia</country></aff><aff id="aff3"><label><sup>3</sup></label><institution>Latvian Biomedical Research and Study Centre</institution>, <city>Riga</city>, <country>Latvia</country></aff><aff id="aff5"><label><sup>4</sup></label><institution>AVP Research Foundation</institution>, <city>Coimbatore</city>, <country>India</country></aff><aff id="aff4"><label><sup>5</sup></label><institution>Longevity Alliance Baltic</institution>, <city>Riga</city>, <country>Latvia</country></aff><aff id="aff6"><label><sup>6</sup></label><institution>Riga Technical University</institution>, <city>Riga</city>, <country>Latvia</country></aff></contrib-group><author-notes><corresp id="cor1">Correspondence should be addressed to M Brīvība: <email>monta.briviba@biomed.lu.lv</email></corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>1</month><year>2026</year></pub-date><pub-date pub-type="epreprint"><day>22</day><month>12</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2026</year></pub-date><volume>15</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">503964</issue-id><elocation-id>e250463</elocation-id><history><date date-type="received"><day>25</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>26</day><month>11</month><year>2025</year></date><date date-type="accepted"><day>19</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>09</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>13</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-13 00:25:14.880"><day>13</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© the author(s)</copyright-statement><copyright-year>2026</copyright-year><copyright-holder>the author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="88x31.jpg"/>This work is licensed under a <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License.</ext-link></license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="EC-25-0463.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="EC-25-0463.pdf"/><abstract><sec><title>Background</title><p>Metformin, the first-line treatment for type 2 diabetes, often induces gastrointestinal side effects, affecting treatment adherence. Recent research suggests that the gut microbiome mediates both the efficacy and tolerability of metformin. This study evaluates the effect of a polyherbal formulation, used as an add-on to metformin, on the gut microbiota in patients with type 2 diabetes and metformin intolerance.</p></sec><sec><title>Methods</title><p>We report preliminary findings from the first 7-day intervention phase of an ongoing randomized, placebo-controlled, crossover trial (NCT06846138) in 27 adults with type 2 diabetes. Participants received either polyherbal formulations or a placebo alongside metformin for 7 days. Stool samples were collected pre- and post-intervention for shotgun metagenomic sequencing. Microbial diversity, composition, and pathway functions were analyzed using Kraken2, Bracken, and HUMAnN3. Continuous glucose monitoring was used to assess glycemic metrics.</p></sec><sec><title>Results</title><p>No significant alpha-diversity changes were observed; however, beta-diversity differed significantly between arms (PERMANOVA <italic toggle="yes">R</italic><sup>2</sup> = 0.04, <italic toggle="yes">P</italic> = 0.04). In the polyherbal formulation group, 17 species changed post-treatment (FDR &lt; 0.25), with significant increases in six <italic toggle="yes">Bifidobacterium</italic> spp. (e.g., <italic toggle="yes">B. adolescentis</italic>, <italic toggle="yes">B. ruminantium</italic>). In contrast, the placebo group showed no major microbial shifts. Polyherbal formulation also altered ten microbial pathways (FDR &lt; 0.25). Continuous glucose monitoring revealed no short-term changes in glycemic levels.</p></sec><sec><title>Conclusion</title><p>Short-term polyherbal formulation co-administration significantly modulates gut microbiota, promoting beneficial taxa, such as <italic toggle="yes">Bifidobacterium</italic> in metformin-treated type 2 diabetes patients. This supports the potential role of the polyherbal formulation in microbiome-targeted strategies to improve metformin tolerability and effectiveness.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>gut microbiome</kwd><kwd>metformin</kwd><kwd>polyherbal formulation</kwd><kwd>type 2 diabetes</kwd><kwd>randomized-controlled trial</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>ifp:collection</meta-name><meta-value>EC-Metabolic-Syndrome-and-Diabetes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Metformin is globally recommended as the first-line therapy for type 2 diabetes (T2D) due to its efficacy, cardioprotective benefits, and affordability. However, up to 30% of patients experience gastrointestinal (GI) side effects, such as bloating and diarrhea, leading to poor adherence and premature treatment discontinuation (<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>). Growing evidence implicates the gut microbiome in metformin’s pharmacodynamics, as microbial shifts have been associated with both therapeutic response and side effect profiles (<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref>). We have previously reported clear and immediate gut microbiome alterations following metformin treatment in both healthy individuals and T2D patients (<xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>). In the well-characterized OPTIMED cohort of treatment-naïve T2D patients, we observed distinct microbial shifts already within 7 days of therapy. A decrease of <italic toggle="yes">Clostridium bartlettii</italic> and <italic toggle="yes">Barnesiella intestinihominis</italic> was observed, while <italic toggle="yes">Parabacteroides distasonis</italic> and <italic toggle="yes">Oscillibacter</italic> were increased (<xref rid="bib6" ref-type="bibr">6</xref>). Furthermore, microbiome profiles differed by severity of metformin-induced GI side effects, with <italic toggle="yes">Streptococcus parasanguinis</italic> enriched in severe cases and <italic toggle="yes">Ruminococcus lactaris</italic> in those with none or mild symptoms (<xref rid="bib5" ref-type="bibr">5</xref>). Metformin use in the literature has also been linked to increased levels of <italic toggle="yes">Escherichia coli</italic> and <italic toggle="yes">Akkermansia muciniphila</italic>, and decreased levels of <italic toggle="yes">Intestinibacter</italic>, changes that may underlie both therapeutic effects and adverse events (<xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>).</p><p>Co-administration of probiotics, such as <italic toggle="yes">Bifidobacterium bifidum</italic> G9-1, with metformin has been shown to reduce GI side effects. Moreover, fecal microbiota transplantation from metformin-treated donors has been shown to improve glucose tolerance in germ-free mice (<xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib9" ref-type="bibr">9</xref>), and metagenomic studies have suggested that the baseline composition of the gut microbiota may predict both efficacy and tolerability of metformin (<xref rid="bib10" ref-type="bibr">10</xref>).</p><p>Alongside probiotics, prebiotics are also widely explored for managing GI dysbiosis (<xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref>). In this context, polyherbal formulations (PHFs) have emerged as promising prebiotics and have been extensively studied. PHFs contain synergistic combinations of botanicals with established anti-inflammatory, antioxidant, and insulin-sensitizing effects (<xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref>). These studies highlight a range of beneficial effects, including increased levels of gut commensals, reduction of opportunistic pathobionts, modulation of gut dysbiosis, decreased intestinal inflammation, and hypoglycemic, antioxidant, and insulin-sensitizing properties. For instance, among various plant-based options, several individual herbs have been shown in preclinical and clinical studies to increase beneficial taxa, such as <italic toggle="yes">Bifidobacterium</italic>, suppress gut inflammation, and improve metabolic profiles (<xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>). <italic toggle="yes">Phyllanthus emblica</italic> (also known as <italic toggle="yes">Emblica officinalis</italic>) supports the growth of beneficial bacteria, such as <italic toggle="yes">Bifidobacterium</italic> and <italic toggle="yes">Lactobacillus</italic>, while reducing harmful species, such as <italic toggle="yes">Ruminococcus spp</italic>. and <italic toggle="yes">Clostridium spp</italic>. It has shown prebiotic activity, reduces gut inflammation, and helps modulate dysbiosis (<xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref>). Similarly, <italic toggle="yes">Curcuma longa</italic> enhances levels of beneficial microbiota, including genera <italic toggle="yes">Bifidobacterium</italic> and <italic toggle="yes">Lactobacillus</italic>, and reduces populations of opportunistic bacteria belonging to the families <italic toggle="yes">Prevotellaceae</italic> and <italic toggle="yes">Enterobacteriaceae</italic>, and the order <italic toggle="yes">Coriobacterales</italic>, thereby exhibiting strong anti-inflammatory and antioxidant effects (<xref rid="bib20" ref-type="bibr">20</xref>). In rodent models, supplementation with <italic toggle="yes">Zingiber officinale</italic> increased the abundance of beneficial gut bacteria, including the families <italic toggle="yes">Lactobacillaceae</italic>, <italic toggle="yes">Bacteroidaceae</italic>, and species within the genus <italic toggle="yes">Bifidobacterium</italic>, while reducing potentially pathogenic taxa, such as the families <italic toggle="yes">Clostridiaceae</italic>, <italic toggle="yes">Ruminococcaceae</italic>, and <italic toggle="yes">Desulfovibrionaceae</italic> (<xref rid="bib21" ref-type="bibr">21</xref>). Finally, <italic toggle="yes">Piper nigrum</italic> supports the growth of beneficial gut flora, such as genera <italic toggle="yes">Bifidobacterium</italic> and <italic toggle="yes">Lactobacillus</italic>, while reducing the relative abundance of phylum <italic toggle="yes">Firmicutes</italic> and <italic toggle="yes">Bacteroides</italic>, showing both prebiotic and anti-inflammatory properties (<xref rid="bib22" ref-type="bibr">22</xref>). Collectively, these herbs contribute meaningfully to the modulation of gut microbiota and offer therapeutic potential for maintaining gastrointestinal health.</p><p>Despite these advances, robust clinical trials evaluating PHFs in metformin-intolerant T2D patients remain scarce. Such studies should ideally incorporate high-resolution metagenomic profiling, continuous glucose monitoring (CGM), and standardized assessment of GI symptoms. Importantly, gut microbiome-based predictive tools for T2D response and tolerability must be tailored to the patient’s age and geographical context (<xref rid="bib23" ref-type="bibr">23</xref>).</p><p>In this randomized-controlled trial, we assessed the short-term effects of a PHF – comprising the previously described herbs (details in the ‘Methods’ section) – co-administered with metformin in T2D patients with prior metformin-related GI intolerance. We hypothesized that PHF would beneficially modulate gut microbial composition and function, enhancing tolerability without compromising glycemic control. While this is the overarching aim of the ongoing clinical trial, this article presents preliminary data supporting this hypothesis. By integrating shotgun metagenomics, CGM, and clinical assessments, this trial seeks to generate translational insights into the role of PHFs as adjuncts in modern, personalized diabetes care.</p></sec><sec id="sec2"><title>Methods</title><sec id="sec2-1"><title>Study design</title><p>This study is a randomized, placebo-controlled, crossover clinical trial registered at ClinicalTrials.gov (ID: NCT06846138). This article reports the preliminary results from the initial 7-day intervention phase, corresponding to the first treatment period only, during which each participant received either PHF or placebo (but not both). The full 48-week crossover analysis will be reported upon study completion. It was designed to evaluate the effects of an add-on polyherbal formulation on gut microbiota composition, functional pathways, and glycemic outcomes and side effects in patients with T2D undergoing metformin therapy. The study protocol was approved by an institutional ethics committee (Approval No. 061124-1L). All study procedures adhered to the principles outlined in the Declaration of Helsinki and followed good clinical practice (ICH-GCP) guidelines.</p><p>The ongoing clinical trial is conducted in a certified clinical environment, with sample processing, metagenomic sequencing, and multi-omics analyses performed in accredited research facilities using standardized protocols. The full trial consists of six clinical visits over a 48-week period, with the current report focusing on the short-term outcomes from the first 7-day intervention phase.</p></sec><sec id="sec2-2"><title>Patient recruitment</title><p>Between April and June 2025, a total of 30 participants aged 25–80 years were recruited. All patients had a confirmed diagnosis of T2D according to the WHO criteria and a history of documented or self-reported symptoms of gastrointestinal intolerance to metformin. All participants were maintained on their maximum individually tolerable metformin dose, predominantly as extended-release formulations, reflecting standard practice for patients with prior immediate-release-related gastrointestinal intolerance. Additional inclusion criteria consisted of HbA1c between 6.5 and 8.5%, ongoing stable oral antidiabetic therapy (metformin monotherapy or metformin combination with DPP-4 inhibitors or SGLT2 inhibitors) for at least 6 months. Participants had to be willing and able to provide written informed consent.</p><p>Individuals were excluded if they had type 1 diabetes, chronic kidney disease stage IIIb or higher, recent cardiovascular events, such as stroke or myocardial infarction, within the past 6 months, severe diabetic complications, or any active infections requiring antibiotic therapy. Pregnant or lactating women were excluded, as were individuals who had used any polyherbal supplements or probiotics within the 6 months before enrollment. Three participants were excluded from the preliminary analysis: two due to the use of non-metformin antidiabetic therapies and one who exhibited extreme outlier patterns in gut microbiome composition. The latter deviation was likely related to the participant’s extensive use of psychotropic medications – drug classes known to influence gut microbiome composition.</p></sec><sec id="sec2-3"><title>Randomization and intervention</title><p>Randomization was performed using a computer-generated sequence in a 1:1 ratio to allocate participants into one of two treatment sequences: sequence A received PHF first, followed by placebo (<italic toggle="yes">n</italic> = 14), while sequence B received placebo first, followed by PHF (<italic toggle="yes">n</italic> = 13). Each participant completed a 7-day intervention phase, during which blood and stool samples were collected before and after the period. While the full trial is designed to span 48 weeks in a crossover design – with two 24-week treatment periods per participant – this report focuses on the initial 7-day intervention. Both the PHF and placebo capsules were identical in size, color, weight, and appearance to maintain blinding.</p><p>The investigational product was a polyherbal formulation provided in 718 mg capsules and produced by a GMP-certified manufacturer. Each capsule contained a proprietary, standardized blend of authenticated herbal extracts with previously reported gut microbiota – modulating and anti-inflammatory properties (the detailed composition is provided in Supplementary Table S7 (see the section on <xref rid="supp1" ref-type="sec">Supplementary materials</xref> given at the end of the article)). The placebo capsules matched the PHF in appearance and composition of excipients and were produced under identical manufacturing and quality control protocols to ensure inertness and safety.</p><p>Participants received either PHF or placebo in combination with their prescribed extended-release metformin regimen. The short-term microbiome and glycemic monitoring phase of the trial spanned 7 days per arm, with longer-term clinical and metabolic follow-up continuing for 24 weeks per arm (data to be reported separately). Participants were instructed to take three capsules before breakfast and three before dinner throughout the 7-day intervention while maintaining their existing metformin dose. Adherence was assessed at the day 8 follow-up visit using capsule count verification and a structured self-report questionnaire on dosing compliance and gastrointestinal symptoms; no major deviations were reported.</p><p>The short-term intervention phase comprised three key visits. At the baseline visit (day 0), eligibility was confirmed, written informed consent was obtained, and anthropometric and clinical data were collected. CGM devices were distributed, and baseline stool and blood samples were collected. On day 1, participants began the assigned intervention (PHF or placebo) in combination with their existing metformin dose. Instructions for capsule administration and sample collection were provided. At the follow-up visit on day 8, CGM sensors were removed, post-intervention stool and blood samples were collected, and participants completed a tolerability questionnaire documenting any gastrointestinal symptoms experienced during the intervention. This same visit structure will be repeated in the second phase of the crossover, beginning at week 24.</p></sec><sec id="sec2-4"><title>Biological sample collection and processing</title><p>Blood samples for biochemical analyses were collected in a clinical laboratory by certified personnel following standard procedures. Participants collected stool samples at home using standardized sterile kits containing nucleic acid preservative buffers (Copan eNAT system, Italy). Samples were stored at −20°C for short-term and at −80°C for long-term storage until analysis. DNA extraction was performed with the MGIEasy Stool Microbiome DNA Extraction Kit on the MGISP-960 automated platform (MGI Tech Co., Ltd, China). The quality and quantity of extracted nucleic acids were assessed using the Agilent 4200 TapeStation System (Agilent Technologies, USA) and the Qubit 4 Fluorometer (Thermo Fisher Scientific, USA), respectively.</p><p>Library preparation was performed with the MGIEasy Universal DNA Library Prep Set (MGI Tech Co., Ltd, China), followed by sequencing on the DNBSEQ-G400RS platform (MGI Tech Co., Ltd, China), using DNBSEQ-G400RS high-throughput sequencing set (FCL PE150) (MGI Tech Co., Ltd, China) and obtaining paired-end 150 bp reads with a target depth of 20 million reads per sample.</p></sec><sec id="sec2-5"><title>Gut microbiome data analysis</title><p>Sequencing data underwent quality control with FastQC and Trimmomatic; human DNA contamination was removed using Bowtie2. Taxonomic profiling was performed with Kraken2 and Bracken against the NCBI RefSeq database. Functional pathway profiling was conducted using HUMAnN3 with pathway annotations from the MetaCyc database.</p><p>Alpha diversity (Shannon index) was calculated with the vegan package (v2.6.10) in R (v4.3.3), and statistical comparisons were made using the Wilcoxon rank-sum test. Beta diversity was assessed using Bray–Curtis dissimilarities, and the influence of explanatory variables on microbial community composition was analyzed using canonical correspondence analysis (CCA) in R (v4.3.3). Ordinations in this article were constrained by arm and time, the primary variables of interest identified <italic toggle="yes">a priori</italic>. Additional ordinations, adjusting for potential covariates (age, body mass index (BMI), sex, and sequencing batch), were provided in Supplementary Figs S2 and S3. Permutational multivariate analysis of variance (PERMANOVA) based on the Bray–Curtis distances was applied using the adonis2 function from the vegan package in R (v4.3.3) to identify significant factors explaining microbial variance. Differential abundance analyses were conducted using MaAsLin2 (v1.15.1) in R (v4.3.3), adjusting for sex, age, BMI, diabetes duration, metformin dose, and sequencing batch; arm was included for cross-sectional models, and patient ID was incorporated as a random effect for longitudinal analyses. All covariates were included irrespective of their univariate significance because they represent known biological or technical sources of variation in microbiome composition. Taxa were filtered by ≥10% prevalence and ≥0.01 relative abundance, whereas pathways were filtered by prevalence only, since pathway abundances are inherently low and an abundance threshold would remove biologically relevant features. The default false discovery rate (FDR) threshold used in MaAsLin2 and also other microbiome studies is &lt;0.25. This relatively permissive threshold reflects the high dimensionality and inherent variability of microbiome data, where stringent cutoffs may overlook biologically relevant associations. Taxon-level associations with FDR-adjusted <italic toggle="yes">q</italic>-values below 0.25 are therefore commonly interpreted as statistically significant, while still requiring independent validation to confirm their biological relevance, which will be conducted during the upcoming phases of this clinical trial (<xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref>). All visualizations were generated using ggplot2 in R (v4.3.3).</p></sec><sec id="sec2-6"><title>Continuous glucose monitoring</title><p>Participants were equipped with Dexcom ONE + CGM sensors, which were applied at the initiation of the intervention (day 1) and removed on day 8. The devices recorded real-time interstitial glucose concentrations every 5 min over the 7-day period. Glycemic parameters assessed included average glucose levels, the glucose management indicator (GMI), coefficient of variation (CV%), time in range (TIR, defined as 3.9–10.0 mmol/L), time above range (TAR, &gt;10.0 mmol/L), and time below range (TBR, &lt;3.9 mmol/L). All CGM data were reviewed for technical integrity, and any datasets from malfunctioning or incomplete sensors were excluded from analysis.</p></sec><sec id="sec2-7"><title>Statistical analysis of clinical data</title><p>Statistical analysis of clinical, laboratory, and CGM data was performed considering a significance level of <italic toggle="yes">P</italic> ≤ 0.05, which was deemed statistically significant. Descriptive statistics were applied to all study variables. Qualitative variables were represented as numbers and percentages of the total study sample. The normality of study variables was assessed using the one-sample Kolmogorov–Smirnov test, and data distribution was visually represented with histograms. Given the non-normal distribution of most of the continuous variables, we reported the median values and interquartile ranges (Q25; Q75). In particular, the Wilcoxon rank-sum test and Chi-squared test were employed for the comparison of different anthropometric and biochemical data involving two or more groups, respectively.</p></sec></sec><sec id="sec3"><title>Results</title><sec id="sec3-1"><title>Study participants and randomization</title><p>Twenty-seven participants with T2D and a history of metformin intolerance were randomized 1:1 to receive either PHF and metformin or placebo and metformin for a 7-day intervention phase. The demographic and clinical characteristics of the two groups were well balanced at baseline (<xref rid="tbl1" ref-type="table">Table 1</xref>). No statistically significant differences were observed in age, sex distribution, BMI, diabetes duration, or prevalence of comorbidities, supporting successful randomization.</p><table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>Baseline demographic and clinical characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">PHF group (<italic toggle="yes">n</italic> = 13)</th><th align="center" rowspan="1" colspan="1">Placebo group (<italic toggle="yes">n</italic> = 14)</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years), median (IQR)</td><td align="center" rowspan="1" colspan="1">68 (61–69)</td><td align="center" rowspan="1" colspan="1">62.5 (45.5–68.5)</td><td align="center" rowspan="1" colspan="1">2.74E−01</td></tr><tr><td rowspan="1" colspan="1">Female, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1">10 (76.9%)</td><td align="center" rowspan="1" colspan="1">10 (71.4%)</td><td align="center" rowspan="1" colspan="1">1.00E+00</td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>), median (IQR)</td><td align="center" rowspan="1" colspan="1">33.98 (29.94–35.43)</td><td align="center" rowspan="1" colspan="1">34.33 (29.84–38.74)</td><td align="center" rowspan="1" colspan="1">9.35E−01</td></tr><tr><td rowspan="1" colspan="1">Diabetes duration (years), median (IQR)</td><td align="center" rowspan="1" colspan="1">5 (4–14)</td><td align="center" rowspan="1" colspan="1">6 (3–6)</td><td align="center" rowspan="1" colspan="1">7.83E−01</td></tr><tr><td rowspan="1" colspan="1">Cardiovascular disease, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1">2 (15.4%)</td><td align="center" rowspan="1" colspan="1">4 (28.6%)</td><td align="center" rowspan="1" colspan="1">6.48E−01</td></tr><tr><td rowspan="1" colspan="1">GI disease, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1">4 (30.8%)</td><td align="center" rowspan="1" colspan="1">6 (42.9%)</td><td align="center" rowspan="1" colspan="1">6.95E−01</td></tr></tbody></table><table-wrap-foot><fn><p>PHF, polyherbal formulation; IQR, interquartile range; BMI, body mass index; GI, gastrointestinal.</p></fn></table-wrap-foot></table-wrap><p>No significant differences were observed in renal, hepatic, or metabolic parameters at baseline. Of note, calcium levels were lower in the placebo group (<italic toggle="yes">P</italic> = 0.049), but all values remained within reference ranges (<xref rid="tbl2" ref-type="table">Table 2</xref>).</p><table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>Selected biochemical parameters at baseline (median (IQR)).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">PHF group (<italic toggle="yes">n</italic> = 13)</th><th align="center" rowspan="1" colspan="1">Placebo group (<italic toggle="yes">n</italic> = 14)</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">HbA1c (%)</td><td align="center" rowspan="1" colspan="1">6.12 (5.62–6.41)</td><td align="center" rowspan="1" colspan="1">6.05 (5.88–6.20)</td><td align="center" rowspan="1" colspan="1">8.65E−01</td></tr><tr><td rowspan="1" colspan="1">Fasting glucose (mmol/L)</td><td align="center" rowspan="1" colspan="1">6.22 (5.29–6.48)</td><td align="center" rowspan="1" colspan="1">6.21 (5.72–6.81)</td><td align="center" rowspan="1" colspan="1">6.62E−01</td></tr><tr><td rowspan="1" colspan="1">Ferritin (ng/mL)</td><td align="center" rowspan="1" colspan="1">117 (48.1–189)</td><td align="center" rowspan="1" colspan="1">112.2 (66.7–178.25)</td><td align="center" rowspan="1" colspan="1">8.84E−01</td></tr><tr><td rowspan="1" colspan="1">ALAT (U/L)</td><td align="center" rowspan="1" colspan="1">25 (21–32)</td><td align="center" rowspan="1" colspan="1">25.5 (21.3–36.8)</td><td align="center" rowspan="1" colspan="1">9.81E−01</td></tr><tr><td rowspan="1" colspan="1">Creatinine (μmol/L)</td><td align="center" rowspan="1" colspan="1">67.9 (61.1–86.8)</td><td align="center" rowspan="1" colspan="1">71.4 (66.3–78.22)</td><td align="center" rowspan="1" colspan="1">5.93E−01</td></tr><tr><td rowspan="1" colspan="1">eGFR (CKD-EPI, mL/min/1.73 m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">85 (84–96)</td><td align="center" rowspan="1" colspan="1">96 (79.5–99.8)</td><td align="center" rowspan="1" colspan="1">4.52E−01</td></tr><tr><td rowspan="1" colspan="1">Calcium (mmol/L)</td><td align="center" rowspan="1" colspan="1">2.41 (2.36–2.49)</td><td align="center" rowspan="1" colspan="1">2.33 (2.31–2.36)</td><td align="center" rowspan="1" colspan="1">4.90E−02</td></tr><tr><td rowspan="1" colspan="1">Magnesium (mmol/L)</td><td align="center" rowspan="1" colspan="1">0.78 (0.74–0.81)</td><td align="center" rowspan="1" colspan="1">0.78 (0.73–0.8)</td><td align="center" rowspan="1" colspan="1">4.96E−01</td></tr><tr><td rowspan="1" colspan="1">Cholesterol (mmol/L)</td><td align="center" rowspan="1" colspan="1">4.61 (3.44–5.12)</td><td align="center" rowspan="1" colspan="1">4.16 (3.67–5.02)</td><td align="center" rowspan="1" colspan="1">9.61E−01</td></tr></tbody></table><table-wrap-foot><fn><p>PHF, polyherbal formulation; ALAT: alanine aminotransferase; eGFR: estimated glomerular filtration rate.</p></fn></table-wrap-foot></table-wrap><p>In the first recruitment block, seven out of 27 participants – five in the PHF group and two in the placebo group – reported mild gastrointestinal symptoms associated with the intervention. These included bloating or meteorism, reported by five participants, and loose stools (1–3 episodes) reported by three participants. All symptoms appeared within the first 4 days of treatment. None of the side effects interfered with daily activities or led to discontinuation. No serious adverse events occurred during the 7-day intervention. These findings will be further explored in subsequent phases of the trial with a larger sample size and extended follow-up.</p><p>CGM was successfully deployed in 22 of the 27 participants; however, four datasets were excluded due to incomplete data capture, resulting in 18 participants (nine PHF and nine placebo) included in the final CGM analyses. No statistically significant improvements in CGM-related outcomes were observed during the 7-day intervention in the PHF group (<xref rid="tbl3" ref-type="table">Table 3</xref>).</p><table-wrap position="float" id="tbl3" orientation="portrait"><label>Table 3</label><caption><p>CGM metrics after 7-day intervention.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Metric</th><th align="center" rowspan="1" colspan="1">Placebo group (<italic toggle="yes">n</italic> = 9)</th><th align="center" rowspan="1" colspan="1">PHF group (<italic toggle="yes">n</italic> = 9)</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Average glucose (mmol/L)</td><td align="center" rowspan="1" colspan="1">7.3 (6.25–7.8)</td><td align="center" rowspan="1" colspan="1">6.6 (5.85–7.05)</td><td align="center" rowspan="1" colspan="1">1.35E−01</td></tr><tr><td rowspan="1" colspan="1">GMI (%)</td><td align="center" rowspan="1" colspan="1">6.5 (6.0–6.65)</td><td align="center" rowspan="1" colspan="1">6.2 (5.85–6.4)</td><td align="center" rowspan="1" colspan="1">1.86E−01</td></tr><tr><td rowspan="1" colspan="1">Coefficient of variation (%)</td><td align="center" rowspan="1" colspan="1">17.2 (14.9–22.5)</td><td align="center" rowspan="1" colspan="1">16.2 (15.0–17.35)</td><td align="center" rowspan="1" colspan="1">1.55E−01</td></tr><tr><td rowspan="1" colspan="1">TIR (%)</td><td align="center" rowspan="1" colspan="1">97 (87–98.5)</td><td align="center" rowspan="1" colspan="1">99 (92–99.5)</td><td align="center" rowspan="1" colspan="1">1.87E−01</td></tr><tr><td rowspan="1" colspan="1">TAR (%)</td><td align="center" rowspan="1" colspan="1">3 (1–13)</td><td align="center" rowspan="1" colspan="1">1 (0–5)</td><td align="center" rowspan="1" colspan="1">8.90E−02</td></tr><tr><td rowspan="1" colspan="1">TBR (%)</td><td align="center" rowspan="1" colspan="1">0 (0–0.5)</td><td align="center" rowspan="1" colspan="1">0 (0–0.5)</td><td align="center" rowspan="1" colspan="1">4.76E−01</td></tr></tbody></table><table-wrap-foot><fn><p>PHF, polyherbal formulation; GMI, glucose management indicator; TIR, time in range; TAR, time above range; TBR, time below range.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3-2"><title>Microbiome composition and diversity</title><p>A total of 54 stool samples were collected from 27 T2D patients treated with metformin (13 in the PHF group and 14 in the placebo group) before and after a 7-day intervention. Shotgun sequencing yielded a median of 19,304,844 reads per sample (IQR: 17,025,742–20,794,100), with 89% of reads classified across 788 species-level taxa. Four comparisons were performed to assess both between-group differences and within-group changes over the 7-day intervention: i) placebo vs PHF group before the intervention, ii) placebo vs PHF group after the intervention, iii) within the placebo group – post-intervention vs pre-intervention samples, and iv) within the PHF group – post-intervention vs pre-intervention samples.</p><p>Measures of intra-sample variability, expressed as the Shannon index, showed no statistically significant differences in any of the contrasts analyzed (Supplementary Fig. S1, Supplementary Table S1). To assess the influence of environmental variables on gut microbiome composition, CCA combined with permutational multivariate analysis of variance (PERMANOVA) was applied (<xref rid="fig1" ref-type="fig">Fig. 1A</xref>, Supplementary Figs S2 and S3). PERMANOVA identified study arm as a significant factor explaining variation in gut microbiome composition (<italic toggle="yes">R</italic><sup>2</sup> = 0.04; <italic toggle="yes">P</italic> = 4.01E-02), along with patient identity (<italic toggle="yes">R</italic><sup>2</sup> = 0.88; <italic toggle="yes">P</italic> = 1.00E-04) (Supplementary Table S2).</p><fig position="float" fig-type="figure" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p>CCA and taxonomic composition of the gut microbiome. (A) CCA of gut microbiome profiles in PHF-treated patients (salmon) and the placebo group (pale green) before and after the 7-day intervention. Time points are distinguished by shape: circles indicate the baseline (before intervention) and triangles indicate the post-intervention period. The colored ellipses represent grouping by study arm (PHF or placebo) and time (samples collected pre- or post-intervention). The arrows represent the centroids of the constrained factors (arm and time) in the CCA model. Only arm was identified as a significant contributor to microbiome variation by PERMANOVA; time is shown for visualization. (B) Taxonomic composition of the 20 most abundant bacterial species across all samples, shown as relative abundances in stacked bar plots. The samples are grouped by study arm and time (placebo group before intervention, placebo group after intervention, polyherbal formulation group before intervention, and polyherbal formulation group after intervention), with taxa ordered by the mean abundance within each group. CCA: canonical correspondence analysis; PHF: polyherbal formulation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="EC-25-0463fig1.jpg"/></fig><p><italic toggle="yes">Phocaeicola dorei</italic> was the most abundant species in the placebo group at both baseline (9.27%) and after the intervention (8.11%). In the PHF group, however, <italic toggle="yes">P. dorei</italic> was not the dominant species at either time point. At baseline, <italic toggle="yes">Prevotella sp900557255</italic> was already more abundant (7.77%) than <italic toggle="yes">P. dorei</italic> (7.11%). Following the 7-day intervention, this difference became more pronounced, with <italic toggle="yes">Prevotella sp900557255</italic> increasing to 11.40%, while <italic toggle="yes">P. dorei</italic> decreased to 5.54% (<xref rid="fig1" ref-type="fig">Fig. 1B</xref>).</p><p>Among the four comparisons performed – i) placebo vs PHF group before the intervention, ii) placebo vs PHF group after the intervention, iii) within the placebo group (post-intervention vs pre-intervention), and iv) within the PHF group (post-intervention vs pre-intervention) – only the longitudinal comparison within the PHF group revealed statistically significant differences (FDR &lt; 0.25). In total, 17 taxa exhibited significant changes in abundance during the 7-day intervention in the PHF group (<xref rid="fig2" ref-type="fig">Fig. 2A and B</xref>). Among these, all six detected <italic toggle="yes">Bifidobacterium</italic> species increased, with the strongest associations observed for <italic toggle="yes">B. adolescentis</italic> (coef. = 3.99, FDR = 4.52E-02) and <italic toggle="yes">B. ruminantium</italic> (coef. = 3.54, FDR = 5.12E-02) (<xref rid="fig2" ref-type="fig">Fig. 2C and D</xref>). Among the taxa that decreased, <italic toggle="yes">Roseburia intestinalis</italic> (coef. = −2.42, FDR = 7.78E-02) and <italic toggle="yes">Roseburia sp900552665</italic> (coef. = −2.40, FDR = 1.32-01) showed the strongest negative associations (Supplementary Table S3).</p><fig position="float" fig-type="figure" id="fig2" orientation="portrait"><label>Figure 2</label><caption><p>Changes in gut microbiota associated with polyherbal formulation intake during the intervention. (A) Volcano plot showing species associated with polyherbal formulation intake in the longitudinal comparison (post- vs pre-intervention) within the PHF arm (FDR &lt; 0.25). (B) Heatmap of relative abundances (<italic toggle="yes">z</italic>-scored) of the significantly associated species (FDR &lt; 0.25) in PHF arm samples at baseline (time 1) and after the intervention (time 2). (C) Relative abundance of <italic toggle="yes">Bifidobacterium adolescentis</italic> before and after PHF intake. (D) Relative abundance of <italic toggle="yes">Bifidobacterium ruminantium</italic> before and after PHF intake. Boxplots (C and D) show individual data points and box interquartile ranges. PHF: polyherbal formulation; FDR: false discovery rate.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="EC-25-0463fig2.jpg"/></fig></sec><sec id="sec3-3"><title>Functional analysis</title><p>The functional profiling of the gut microbiome, based on gene family-derived MetaCyc pathway abundances, was assessed using the same comparison groups as in the taxonomic analyses. To identify key factors explaining the variance in microbial pathway composition, we applied PERMANOVA, which revealed that each individual patient (<italic toggle="yes">R</italic><sup>2</sup> = 0.85, <italic toggle="yes">P</italic> = 1.00E-04), study arm (PHF vs placebo) (<italic toggle="yes">R</italic><sup>2</sup> = 0.07, <italic toggle="yes">P</italic> = 1.28E-02) and sex (<italic toggle="yes">R</italic><sup>2</sup> = 0.06, <italic toggle="yes">P</italic> = 2.64E-02) significantly contributed to the variation (Supplementary Table S4). Differential abundance analysis identified ten pathways significantly associated with PHF intake (FDR &lt; 0.25), with eight showing decreased abundance – for example, the methylglyoxal degradation pathway (METHGLYUT-PWY, coef. = −0.0043, FDR = 9.92E-02) – and two showing increased abundance, including the <italic toggle="yes">Bifidobacterium</italic> shunt (P124-PWY, coef. = 0.0146, FDR = 2.24E-01) and Chorismate biosynthesis I (ARO-PWY, coef. = 0.0029, FDR = 2.27E-01) (<xref rid="fig3" ref-type="fig">Fig. 3</xref>, Supplementary Table S5). In the placebo group, a small but significant increase was observed in the incomplete reductive tricarboxylic acid (TCA) cycle pathway (P42-PWY, coef. = 0.0061, FDR = 2.27E-01) (Supplementary Table S6).</p><fig position="float" fig-type="figure" id="fig3" orientation="portrait"><label>Figure 3</label><caption><p>Differentially abundant MetaCyc pathways in the polyherbal formulation group when comparing post-intervention samples to pre-intervention samples. The bar plot shows the MaAsLin2-derived effect sizes (coefficients) for MetaCyc pathways that changed significantly (FDR &lt; 0.25) after the intervention in the PHF group. Positive coefficients indicate higher pathway abundance post-intervention, whereas negative coefficients indicate lower abundance post-intervention. PHF: polyherbal formulation; FDR: false discovery rate.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="EC-25-0463fig3.jpg"/></fig></sec></sec><sec id="sec4"><title>Discussion</title><p>This preliminary analysis of the first 7-day intervention phase of a randomized, placebo-controlled crossover trial provides evidence that a polyherbal formulation co-administered with metformin can rapidly and selectively modulate the gut microbiome of individuals with T2D who experience gastrointestinal intolerance to metformin. Although glycemic metrics remained unchanged after a short-term intervention, the significant compositional and functional shifts in the microbiota – particularly the enrichment of <italic toggle="yes">Bifidobacterium</italic> spp. – suggest a promising microbiome-targeted approach for enhancing the tolerability and potentially the long-term efficacy of metformin therapy (<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib8" ref-type="bibr">8</xref>).</p><p>Consistent with prior studies on the gut microbiome modulatory effects of PHF, we did not observe any significant changes in alpha diversity but noted a significant shift in beta diversity in the PHF group after the 7-day intervention (<xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib7" ref-type="bibr">7</xref>). Importantly, our metagenomic analysis revealed the selective enrichment of six <italic toggle="yes">Bifidobacterium</italic> species, including <italic toggle="yes">B. adolescentis</italic> (coef. = 3.99; FDR = 4.52E-02) and <italic toggle="yes">B. ruminantium</italic> (coef. = 3.54; FDR = 5.12E-02), both of which have been associated with anti-inflammatory effects, improved intestinal barrier function, and beneficial carbohydrate metabolism (<xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref>). These microbial shifts occurred in the absence of similar changes in the placebo group, suggesting a direct effect of PHF on gut ecology. The enrichment of <italic toggle="yes">Bifidobacterium</italic> may be mechanistically significant. Several strains within this genus are known to produce acetate and lactate, lowering luminal pH, which can inhibit the growth of pathobionts and promote mucosal integrity (<xref rid="bib28" ref-type="bibr">28</xref>). Moreover, <italic toggle="yes">Bifidobacterium spp</italic>. can degrade complex plant-derived polysaccharides, indicating that PHF may act via a prebiotic-like mechanism, selectively fueling beneficial taxa (<xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib29" ref-type="bibr">29</xref>). This aligns with other reports, where PHF enhanced microbial richness and host tolerance to antidiabetic drugs (<xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref>). Notably, the functional relevance of increased <italic toggle="yes">Bifidobacterium</italic> abundance is further supported by our pathway analysis, which showed a significant increase in the <italic toggle="yes">Bifidobacterium</italic> shunt metabolic pathway in the PHF group during the 7-day intervention. The <italic toggle="yes">Bifidobacterium</italic> shunt, also known as the fructose-6-phosphate phosphoketolase pathway, is a distinctive metabolic route in <italic toggle="yes">Bifidobacterium</italic> species that enables efficient carbohydrate utilization and leads to the production of beneficial short-chain fatty acids (SCFAs), such as acetate and lactate. These SCFAs contribute to gut health by supporting epithelial integrity, modulating immune responses, and inhibiting pathogenic microbes (<xref rid="bib30" ref-type="bibr">30</xref>). This functional evidence strengthens the hypothesis that PHF exerts its effects, at least in part, through promoting beneficial microbial activity within the gut ecosystem.</p><p>Interestingly, we observed a significant decrease in several <italic toggle="yes">Roseburia</italic> species during the PHF intervention, including <italic toggle="yes">Roseburia intestinalis</italic> and <italic toggle="yes">Roseburia sp900552665</italic> (coefficients ranging from −2.42 to −1.64 accordingly; FDR &lt; 0.25). Although <italic toggle="yes">Roseburia</italic> is a butyrate-producing genus generally linked to gut health, recent studies have shown a negative association between <italic toggle="yes">Roseburia</italic> abundance and T2D (<xref rid="bib31" ref-type="bibr">31</xref>). Furthermore, metformin therapy has been previously reported to reduce <italic toggle="yes">Roseburia</italic> levels in T2D patients (<xref rid="bib32" ref-type="bibr">32</xref>, <xref rid="bib33" ref-type="bibr">33</xref>). Our findings suggest that PHF may enhance this metformin-associated decline in <italic toggle="yes">Roseburia</italic>, potentially amplifying metformin’s impact on gut microbiota composition. While the functional significance of <italic toggle="yes">Roseburia</italic> reduction remains uncertain, these results highlight the complexity of host–microbiome–drug interactions and imply that the role of butyrate producers, such as <italic toggle="yes">Roseburia</italic>, may be context-dependent in T2D. Further studies are warranted to determine whether this decline contributes to PHF’s clinical effects or reflects a specific microbial adaptation to the combined treatment.</p><p>In addition, we observed a significant, although mild, increase in the abundance of <italic toggle="yes">Collinsella sp900555955</italic> during the PHF intervention (coef. = 1.57, FDR = 1.24E-01). The genus <italic toggle="yes">Collinsella</italic> has been controversially linked to metabolic disturbances, such as gestational diabetes mellitus, increased circulating insulin levels, and low dietary fiber intake (<xref rid="bib34" ref-type="bibr">34</xref>, <xref rid="bib35" ref-type="bibr">35</xref>). In obese pregnant women, higher fiber intake was associated with reduced <italic toggle="yes">Collinsella</italic> abundance – a change considered beneficial (<xref rid="bib35" ref-type="bibr">35</xref>). These associations seem to conflict with the hypothesis that PHF promotes a healthier gut microbiome composition. However, previous studies relied on 16S rRNA gene sequencing, offering only genus-level resolution (<xref rid="bib35" ref-type="bibr">35</xref>, <xref rid="bib36" ref-type="bibr">36</xref>), whereas our shotgun metagenomic approach provides species-level insights. This higher resolution may uncover species-specific functional traits within the <italic toggle="yes">Collinsella</italic> genus that were not detected in earlier studies. The observed increase in <italic toggle="yes">Collinsella sp900555955</italic> may thus reflect distinct ecological roles or metabolic activities, highlighting the importance of species-level investigations in understanding host–microbiome interactions in metabolic disease contexts.</p><p>In addition to the increased abundance of the <italic toggle="yes">Bifidobacterium</italic> shunt pathway in the PHF group during the 7-day intervention, our analysis revealed differences in several other microbial metabolic pathways due to the administration of PHF. These included a lower abundance of the methylglyoxal degradation and anhydromuropeptide recycling pathways. Given that dysregulated methylglyoxal (MG) metabolism and impaired glyoxalase activity in human tissues are strongly implicated in the development of diabetes and its complications (<xref rid="bib37" ref-type="bibr">37</xref>), emerging evidence that gut microbes also possess MG-detoxifying pathways capable of modulating host carbonyl stress (<xref rid="bib38" ref-type="bibr">38</xref>) highlights the potential relevance of the observed changes in the microbial methylglyoxal degradation pathway in our cohort. In contrast, the anhydromuropeptide recycling pathway reflects how bacteria break down and rebuild their cell wall, a process that releases small muropeptide fragments. These fragments can activate host immune sensors, such as nucleotide-binding oligomerization domain-like (NOD) receptors, and thereby influence intestinal inflammatory responses (<xref rid="bib39" ref-type="bibr">39</xref>). Nevertheless, as these findings are based on gene family abundance predictions rather than direct metabolite measurements, they remain indirect and require validation – an aim to be addressed in the ongoing trial through planned stool metabolomics analyses.</p><p>Despite notable microbiota changes, no significant differences in glycemic metrics were observed between PHF and placebo groups during the 7-day intervention (<xref rid="tbl3" ref-type="table">Table 3</xref>). This aligns with the expected pharmacokinetics of metformin and its mechanisms of glucose lowering, which generally require several weeks to manifest fully (<xref rid="bib40" ref-type="bibr">40</xref>). Nonetheless, there was a non-significant trend toward lower average glucose and TAR in the PHF group. These early patterns, if confirmed in the ongoing longer-term arm of the trial, could suggest a potential synergistic effect between PHF and metformin in improving glucose control. However, short duration and small sample size preclude definitive conclusions at this stage.</p><p>Metformin remains the cornerstone of T2D management worldwide; however, 30–50% of patients experience gastrointestinal side effects, and nearly half discontinue therapy over the long term (<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib16" ref-type="bibr">16</xref>). Identifying strategies to mitigate these adverse effects is essential for improving treatment adherence and outcomes. In this first-in-human study, we observed that a standardized, GMP-certified polyherbal formulation – already registered for clinical use – induced shifts in the gut microbiota that may be associated with improved gastrointestinal health over time. While these microbial changes are promising, their clinical relevance remains uncertain, as no improvement in glycemic control or gastrointestinal side effects was observed within the short intervention period. Importantly, the long-term clinical hypothesis that will be tested in this crossover study is that by favorably shifting the gut microbiome, PHF could reduce metformin-related gastrointestinal intolerance and potentially enhance its glycemic efficacy. Given its multi-herbal composition, PHF may exert broad-spectrum modulatory effects on the gut microbiome, potentially complementing existing approaches, such as probiotics or prebiotics (<xref rid="bib13" ref-type="bibr">13</xref>). In addition, its oral administration and lack of systemic pharmacodynamic targets suggest a low risk of adverse interactions, which may be particularly advantageous in elderly or comorbid T2D patients. However, its role as an adjunct to metformin therapy requires further validation in longer-term studies with clinical endpoints.</p><p>This interim analysis has several limitations that must be acknowledged. First, the short intervention duration of 7 days, while adequate to observe early microbial shifts, is insufficient to assess long-term clinical or metabolic outcomes. Second, the sample size, although powered for microbiome endpoints, limits broader generalizability and may not capture smaller glycemic effects. Third, malfunction or incomplete data from 20% of CGM devices reduced statistical power to detect differences in glycemic variability. Fourth, the study did not employ a validated gastrointestinal symptom questionnaire, relying instead on qualitative participant reports. This will be rectified in subsequent phases with structured symptom scoring and stool metabolomics. Fifth, participants followed habitual diets with only partial dietary monitoring through food diaries, which introduces potential confounding from uncontrolled dietary intake. Finally, we observed slightly lower baseline blood calcium levels in the placebo group compared to the PHF group (2.33 vs 2.41 mmol/L; <italic toggle="yes">P</italic> = 0.049); however, after reviewing comorbidities, this difference was considered clinically insignificant.</p><p>In this initial phase of a larger clinical trial, a 7-day course of PHF added to metformin significantly altered the gut microbiome in patients with T2D, notably increasing the abundance of <italic toggle="yes">Bifidobacterium</italic> species. These shifts occurred without compromising glycemic control but, at this stage, cannot be directly linked to clinical benefit, including improved gastrointestinal tolerability. While these early findings suggest that PHF may have potential as a microbiome-modulating adjunct to metformin, further validation is needed. The ongoing 48-week crossover trial will provide long-term clinical and microbiome data, along with stool metabolomics, to better understand functional implications and potential therapeutic benefits of PHF co-administration in T2D. In particular, it will evaluate whether favorable modulation of the gut microbiome by PHF can mitigate metformin-related gastrointestinal side effects and enhance its glycemic efficacy.</p></sec><sec sec-type="supplementary-material" id="supp1"><title>Supplementary materials</title><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="supplementary_figures.pdf" id="d67e1193" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD2" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="supplementary_tables.xlsx" id="d67e1195" position="anchor" orientation="portrait"/></supplementary-material></sec><sec sec-type="COI-statement"><title>Declaration of interest</title><p>The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the work reported.</p></sec><sec sec-type="funding"><title>Funding</title><p>Funded by the Latvian Council of Science (Fundamental and Applied Research Project No. lzp-2023/1-0422 ‘MetHerb: Enhancing the efficacy and tolerability of metformin in the analysis of gut microbiome by add-on polyherbal formulation’).</p></sec><sec sec-type="data-availability"><title>Data availability</title><p>Metagenomic data have been deposited in the European Nucleotide Archive (ENA).</p></sec><sec sec-type="ethics-approval"><title>Ethics approval</title><p>Approved by the Ethics Committee of Pauls Stradiņš Clinical University Hospital (Approval No. 061124-1L).</p></sec><sec sec-type="trial-registration"><title>Trial registration</title><p>This study is registered at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> (ID: NCT06846138).</p></sec><sec sec-type="investigational-product"><title>Investigational product</title><p>The investigational product Herbomix® was manufactured by Himalaya Nutravedics India Private. The formulation is registered for clinical use by the Latvian Food and Veterinary Agency (Registration No. 16958).</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors thank the Genome Database of the Latvian Population for providing biological samples and data, and the study participants for their time and contribution.</p></ack><ref-list><title>References</title><ref id="bib1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McCreight</surname>
<given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Bailey</surname>
<given-names>CJ</given-names></string-name> &amp; <string-name name-style="western"><surname>Pearson</surname>
<given-names>ER</given-names></string-name></person-group>. <article-title>Metformin and the gastrointestinal tract</article-title>. <source>Diabetologia</source>
<year>2016</year>
<volume>59</volume>
<fpage>426</fpage>–<lpage>435</lpage>. (<pub-id pub-id-type="doi">10.1007/s00125-015-3844-9</pub-id>)<pub-id pub-id-type="pmid">26780750</pub-id>
<pub-id pub-id-type="pmcid">PMC4742508</pub-id></mixed-citation></ref><ref id="bib2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Syafhan</surname>
<given-names>NF</given-names></string-name>, <string-name name-style="western"><surname>Donnelly</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Harper</surname>
<given-names>R</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Adherence to metformin in adults with type 2 diabetes: a combined method approach</article-title>. <source>J Pharm Policy Pract</source>
<year>2022</year>
<volume>15</volume>
<elocation-id>61</elocation-id>. (<pub-id pub-id-type="doi">10.1186/s40545-022-00457-5</pub-id>)<pub-id pub-id-type="pmid">36224634</pub-id>
<pub-id pub-id-type="pmcid">PMC9554867</pub-id></mixed-citation></ref><ref id="bib3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Esteve</surname>
<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Tremaroli</surname>
<given-names>V</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug</article-title>. <source>Nat Med</source>
<year>2017</year>
<volume>23</volume>
<fpage>850</fpage>–<lpage>858</lpage>. (<pub-id pub-id-type="doi">10.1038/nm.4345</pub-id>)<pub-id pub-id-type="pmid">28530702</pub-id>
</mixed-citation></ref><ref id="bib4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pryor</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Norvaisas</surname>
<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Marinos</surname>
<given-names>G</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Host-microbe-drug-nutrient screen identifies bacterial effectors of metformin therapy</article-title>. <source>Cell</source>
<year>2019</year>
<volume>178</volume>
<fpage>1299</fpage>–<lpage>1312.e29</lpage>. (<pub-id pub-id-type="doi">10.1016/j.cell.2019.08.003</pub-id>)<pub-id pub-id-type="pmid">31474368</pub-id>
<pub-id pub-id-type="pmcid">PMC6736778</pub-id></mixed-citation></ref><ref id="bib5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Elbere</surname>
<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Kalnina</surname>
<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Silamikelis</surname>
<given-names>I</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Association of metformin administration with gut microbiome dysbiosis in healthy volunteers</article-title>. <source>PLoS One</source>
<year>2018</year>
<volume>13</volume>
<fpage>e0204317</fpage>. (<pub-id pub-id-type="doi">10.1371/journal.pone.0204317</pub-id>)<pub-id pub-id-type="pmid">30261008</pub-id>
<pub-id pub-id-type="pmcid">PMC6160085</pub-id></mixed-citation></ref><ref id="bib6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Elbere</surname>
<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Silamikelis</surname>
<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Dindune</surname>
<given-names>II</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Baseline gut microbiome composition predicts metformin therapy short-term efficacy in newly diagnosed type 2 diabetes patients</article-title>. <source>PLoS One</source>
<year>2020</year>
<volume>15</volume>
<fpage>e0241338</fpage>. (<pub-id pub-id-type="doi">10.1371/journal.pone.0241338</pub-id>)<pub-id pub-id-type="pmid">33125401</pub-id>
<pub-id pub-id-type="pmcid">PMC7598494</pub-id></mixed-citation></ref><ref id="bib7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Forslund</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hildebrand</surname>
<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Nielsen</surname>
<given-names>T</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota</article-title>. <source>Nature</source>
<year>2015</year>
<volume>528</volume>
<fpage>262</fpage>–<lpage>266</lpage>. (<pub-id pub-id-type="doi">10.1038/nature15766</pub-id>)<pub-id pub-id-type="pmid">26633628</pub-id>
<pub-id pub-id-type="pmcid">PMC4681099</pub-id></mixed-citation></ref><ref id="bib8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lee</surname>
<given-names>H</given-names></string-name> &amp; <string-name name-style="western"><surname>Ko</surname>
<given-names>G</given-names></string-name></person-group>. <article-title>Effect of metformin on metabolic improvement and gut microbiota</article-title>. <source>Appl Environ Microbiol</source>
<year>2014</year>
<volume>80</volume>
<fpage>5935</fpage>–<lpage>5943</lpage>. (<pub-id pub-id-type="doi">10.1128/aem.01357-14</pub-id>)<pub-id pub-id-type="pmid">25038099</pub-id>
<pub-id pub-id-type="pmcid">PMC4178684</pub-id></mixed-citation></ref><ref id="bib9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sun</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname>
<given-names>G</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Gut microbiota and intestinal FXR mediate the clinical benefits of metformin</article-title>. <source>Nat Med</source>
<year>2018</year>
<volume>24</volume>
<fpage>1919</fpage>–<lpage>1929</lpage>. (<pub-id pub-id-type="doi">10.1038/s41591-018-0222-4</pub-id>)<pub-id pub-id-type="pmid">30397356</pub-id>
<pub-id pub-id-type="pmcid">PMC6479226</pub-id></mixed-citation></ref><ref id="bib10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bar</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Korem</surname>
<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Weissbrod</surname>
<given-names>O</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>A reference map of potential determinants for the human serum metabolome</article-title>. <source>Nature</source>
<year>2020</year>
<volume>588</volume>
<fpage>135</fpage>–<lpage>140</lpage>. (<pub-id pub-id-type="doi">10.1038/s41586-020-2896-2</pub-id>)<pub-id pub-id-type="pmid">33177712</pub-id>
</mixed-citation></ref><ref id="bib11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yoo</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jung</surname>
<given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Kwak</surname>
<given-names>K</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>The role of prebiotics in modulating gut microbiota: implications for human health</article-title>. <source>Int J Mol Sci</source>
<year>2024</year>
<volume>25</volume>
<fpage>4834</fpage>. (<pub-id pub-id-type="doi">10.3390/ijms25094834</pub-id>)<pub-id pub-id-type="pmid">38732060</pub-id>
<pub-id pub-id-type="pmcid">PMC11084426</pub-id></mixed-citation></ref><ref id="bib12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Smolinska</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Popescu</surname>
<given-names>FD</given-names></string-name> &amp; <string-name name-style="western"><surname>Zemelka-Wiacek</surname>
<given-names>MA</given-names></string-name></person-group>. <article-title>Review of the influence of prebiotics, probiotics, synbiotics, and postbiotics on the human gut microbiome and intestinal integrity</article-title>. <source>J Clin Med</source>
<year>2025</year>
<volume>14</volume>
<fpage>3673</fpage>. (<pub-id pub-id-type="doi">10.3390/jcm14113673</pub-id>)<pub-id pub-id-type="pmid">40507435</pub-id>
<pub-id pub-id-type="pmcid">PMC12156228</pub-id></mixed-citation></ref><ref id="bib13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lyu</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname>
<given-names>YF</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname>
<given-names>GW</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Balancing herbal medicine and functional food for prevention and treatment of cardiometabolic diseases through modulating gut microbiota</article-title>. <source>Front Microbiol</source>
<year>2017</year>
<volume>8</volume>
<elocation-id>2146</elocation-id>. (<pub-id pub-id-type="doi">10.3389/fmicb.2017.02146</pub-id>)<pub-id pub-id-type="pmid">29167659</pub-id>
<pub-id pub-id-type="pmcid">PMC5682319</pub-id></mixed-citation></ref><ref id="bib14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huda</surname>
<given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname>
<given-names>M</given-names></string-name> &amp; <string-name name-style="western"><surname>Bennett</surname>
<given-names>BJ</given-names></string-name></person-group>. <article-title>Modulating the microbiota as a therapeutic intervention for type 2 diabetes</article-title>. <source>Front Endocrinol</source>
<year>2021</year>
<volume>12</volume>
<elocation-id>632335</elocation-id>. (<pub-id pub-id-type="doi">10.3389/fendo.2021.632335</pub-id>)<pub-id pub-id-type="pmcid">PMC8060771</pub-id><pub-id pub-id-type="pmid">33897618</pub-id></mixed-citation></ref><ref id="bib15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zheng</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Gou</surname>
<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname>
<given-names>L</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Interactions between gut microbiota, host, and herbal medicines: a review of new insights into the pathogenesis and treatment of type 2 diabetes</article-title>. <source>Front Cell Infect Microbiol</source>
<year>2020</year>
<volume>10</volume>
<elocation-id>360</elocation-id>. (<pub-id pub-id-type="doi">10.3389/fcimb.2020.00360</pub-id>)<pub-id pub-id-type="pmid">32766169</pub-id>
<pub-id pub-id-type="pmcid">PMC7379170</pub-id></mixed-citation></ref><ref id="bib16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname>
<given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname>
<given-names>JX</given-names></string-name>, <string-name name-style="western"><surname>Lian</surname>
<given-names>FM</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Therapeutic mechanisms of traditional Chinese medicine to improve metabolic diseases via the gut microbiota</article-title>. <source>Biomed Pharmacother</source>
<year>2021</year>
<volume>133</volume>
<elocation-id>110857</elocation-id>. (<pub-id pub-id-type="doi">10.1016/j.biopha.2020.110857</pub-id>)<pub-id pub-id-type="pmid">33197760</pub-id>
</mixed-citation></ref><ref id="bib17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Qin</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname>
<given-names>Z</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>A metagenome-wide association study of gut microbiota in type 2 diabetes</article-title>. <source>Nature</source>
<year>2012</year>
<volume>490</volume>
<fpage>55</fpage>–<lpage>60</lpage>. (<pub-id pub-id-type="doi">10.1038/nature11450</pub-id>)<pub-id pub-id-type="pmid">23023125</pub-id>
</mixed-citation></ref><ref id="bib18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brochot</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Azalbert</surname>
<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Landrier</surname>
<given-names>JF</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>A two-week treatment with plant extracts changes gut microbiota, caecum metabolome, and markers of lipid metabolism in ob/ob mice</article-title>. <source>Mol Nutr Food Res</source>
<year>2019</year>
<volume>63</volume>
<elocation-id>1900403</elocation-id>. (<pub-id pub-id-type="doi">10.1002/mnfr.201900403</pub-id>)<pub-id pub-id-type="pmid">31206248</pub-id>
<pub-id pub-id-type="pmcid">PMC6771983</pub-id></mixed-citation></ref><ref id="bib19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname>
<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname>
<given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Aqueous extract of <italic toggle="yes">Phyllanthus emblica</italic> L. alleviates functional dyspepsia through regulating gastrointestinal hormones and gut microbiome in vivo</article-title>. <source>Foods</source>
<year>2022</year>
<volume>11</volume>
<fpage>1491</fpage>. (<pub-id pub-id-type="doi">10.3390/foods11101491</pub-id>)<pub-id pub-id-type="pmid">35627061</pub-id>
<pub-id pub-id-type="pmcid">PMC9141879</pub-id></mixed-citation></ref><ref id="bib20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Scazzocchio</surname>
<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Minghetti</surname>
<given-names>L</given-names></string-name> &amp; <string-name name-style="western"><surname>D’archivio</surname>
<given-names>M</given-names></string-name></person-group>. <article-title>Interaction between gut microbiota and curcumin: a new key of understanding for the health effects of curcumin</article-title>. <source>Nutrients</source>
<year>2020</year>
<volume>12</volume>
<fpage>1</fpage>–<lpage>18</lpage>. (<pub-id pub-id-type="doi">10.3390/nu12092499</pub-id>)<pub-id pub-id-type="pmcid">PMC7551052</pub-id><pub-id pub-id-type="pmid">32824993</pub-id></mixed-citation></ref><ref id="bib21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Crichton</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Marshall</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Marx</surname>
<given-names>W</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Effect of ginger root powder on gastrointestinal bacteria composition, gastrointestinal symptoms, mental health, fatigue, and quality of life: a double-blind placebo-controlled trial</article-title>. <source>J Nutr</source>
<year>2023</year>
<volume>153</volume>
<fpage>3193</fpage>–<lpage>3206</lpage>. (<pub-id pub-id-type="doi">10.1016/j.tjnut.2023.09.002</pub-id>)<pub-id pub-id-type="pmid">37690779</pub-id>
</mixed-citation></ref><ref id="bib22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kondapalli</surname>
<given-names>NB</given-names></string-name>, <string-name name-style="western"><surname>Hemalatha</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Uppala</surname>
<given-names>S</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title><italic toggle="yes">Ocimum sanctum</italic>, <italic toggle="yes">Zingiber officinale</italic>, and <italic toggle="yes">Piper nigrum</italic> extracts and their effects on gut microbiota modulations (prebiotic potential), basal inflammatory markers and lipid levels: oral supplementation study in healthy rats</article-title>. <source>Pharm Biol</source>
<year>2022</year>
<volume>60</volume>
<fpage>437</fpage>–<lpage>450</lpage>. (<pub-id pub-id-type="doi">10.1080/13880209.2022.2033797</pub-id>)<pub-id pub-id-type="pmid">35188051</pub-id>
<pub-id pub-id-type="pmcid">PMC8865113</pub-id></mixed-citation></ref><ref id="bib23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>O’Callaghan</surname>
<given-names>A</given-names></string-name> &amp; <string-name name-style="western"><surname>van Sinderen</surname>
<given-names>D</given-names></string-name></person-group>. <article-title>Bifidobacteria and their role as members of the human gut microbiota</article-title>. <source>Front Microbiol</source>
<year>2016</year>
<volume>7</volume>
<fpage>925</fpage>. (<pub-id pub-id-type="doi">10.3389/fmicb.2016.00925</pub-id>)<pub-id pub-id-type="pmid">27379055</pub-id>
<pub-id pub-id-type="pmcid">PMC4908950</pub-id></mixed-citation></ref><ref id="bib24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stewart</surname>
<given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Ajami</surname>
<given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>O’Brien</surname>
<given-names>JL</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Temporal development of the gut microbiome in early childhood from the TEDDY study</article-title>. <source>Nature</source>
<year>2018</year>
<volume>562</volume>
<fpage>583</fpage>–<lpage>588</lpage>. (<pub-id pub-id-type="doi">10.1038/s41586-018-0617-x</pub-id>)<pub-id pub-id-type="pmid">30356187</pub-id>
<pub-id pub-id-type="pmcid">PMC6415775</pub-id></mixed-citation></ref><ref id="bib25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stražar</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Temba</surname>
<given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Vlamakis</surname>
<given-names>H</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Gut microbiome-mediated metabolism effects on immunity in rural and urban African populations</article-title>. <source>Nat Commun</source>
<year>2021</year>
<volume>12</volume>
<elocation-id>4845</elocation-id>. (<pub-id pub-id-type="doi">10.1038/s41467-021-25213-2</pub-id>)<pub-id pub-id-type="pmid">34381036</pub-id>
<pub-id pub-id-type="pmcid">PMC8357928</pub-id></mixed-citation></ref><ref id="bib26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname>
<given-names>DD</given-names></string-name>, <string-name name-style="western"><surname>Nguyen</surname>
<given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Li</surname>
<given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>The gut microbiome modulates the protective association between a mediterranean diet and cardiometabolic disease risk</article-title>. <source>Nat Med</source>
<year>2021</year>
<volume>27</volume>
<fpage>333</fpage>–<lpage>343</lpage>. (<pub-id pub-id-type="doi">10.1038/s41591-020-01223-3</pub-id>)<pub-id pub-id-type="pmid">33574608</pub-id>
<pub-id pub-id-type="pmcid">PMC8186452</pub-id></mixed-citation></ref><ref id="bib27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Arboleya</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Watkins</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Stanton</surname>
<given-names>C</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Gut bifidobacteria populations in human health and aging</article-title>. <source>Front Microbiol</source>
<year>2016</year>
<volume>7</volume>
<fpage>1204</fpage>. (<pub-id pub-id-type="doi">10.3389/fmicb.2016.01204</pub-id>)<pub-id pub-id-type="pmid">27594848</pub-id>
<pub-id pub-id-type="pmcid">PMC4990546</pub-id></mixed-citation></ref><ref id="bib28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fukuda</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Toh</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hase</surname>
<given-names>K</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Bifidobacteria can protect from enteropathogenic infection through production of acetate</article-title>. <source>Nature</source>
<year>2011</year>
<volume>469</volume>
<fpage>543</fpage>–<lpage>547</lpage>. (<pub-id pub-id-type="doi">10.1038/nature09646</pub-id>)<pub-id pub-id-type="pmid">21270894</pub-id>
</mixed-citation></ref><ref id="bib29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname>
<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats</article-title>. <source>Sci Rep</source>
<year>2015</year>
<volume>5</volume>
<elocation-id>14405</elocation-id>. (<pub-id pub-id-type="doi">10.1038/srep14405</pub-id>)<pub-id pub-id-type="pmid">26396057</pub-id>
<pub-id pub-id-type="pmcid">PMC4585776</pub-id></mixed-citation></ref><ref id="bib30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pokusaeva</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Fitzgerald</surname>
<given-names>GF</given-names></string-name> &amp; <string-name name-style="western"><surname>Van Sinderen</surname>
<given-names>D</given-names></string-name></person-group>. <article-title>Carbohydrate metabolism in bifidobacteria</article-title>. <source>Gene Nutr</source>
<year>2011</year>
<volume>6</volume>
<fpage>285</fpage>–<lpage>306</lpage>. (<pub-id pub-id-type="doi">10.1007/s12263-010-0206-6</pub-id>)<pub-id pub-id-type="pmcid">PMC3145055</pub-id><pub-id pub-id-type="pmid">21484167</pub-id></mixed-citation></ref><ref id="bib31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gurung</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname>
<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>You</surname>
<given-names>H</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Role of gut microbiota in type 2 diabetes pathophysiology</article-title>. <source>EBioMedicine</source>
<year>2020</year>
<volume>51</volume>
<elocation-id>102590</elocation-id>. (<pub-id pub-id-type="doi">10.1016/j.ebiom.2019.11.051</pub-id>)<pub-id pub-id-type="pmid">31901868</pub-id>
<pub-id pub-id-type="pmcid">PMC6948163</pub-id></mixed-citation></ref><ref id="bib32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hiel</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gianfrancesco</surname>
<given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Rodriguez</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Link between gut microbiota and health outcomes in inulin -treated obese patients: lessons from the Food4Gut multicenter randomized placebo-controlled trial</article-title>. <source>Clin Nutr</source>
<year>2020</year>
<volume>39</volume>
<fpage>3618</fpage>–<lpage>3628</lpage>. (<pub-id pub-id-type="doi">10.1016/j.clnu.2020.04.005</pub-id>)<pub-id pub-id-type="pmid">32340903</pub-id>
</mixed-citation></ref><ref id="bib33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mueller</surname>
<given-names>NT</given-names></string-name>, <string-name name-style="western"><surname>Differding</surname>
<given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Metformin affects gut microbiome composition and function and circulating short-chain fatty acids: a randomized trial</article-title>. <source>Diabetes Care</source>
<year>2021</year>
<volume>44</volume>
<fpage>1462</fpage>–<lpage>1471</lpage>. (<pub-id pub-id-type="doi">10.2337/dc20-2257</pub-id>)<pub-id pub-id-type="pmid">34006565</pub-id>
<pub-id pub-id-type="pmcid">PMC8323185</pub-id></mixed-citation></ref><ref id="bib34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bokoliya</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>McClellan</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname>
<given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Exploring the influence of microbiota on gestational diabetes and its potential as a biomarker</article-title>. <source>Front Bacteriol</source>
<year>2024</year>
<volume>3</volume>
<elocation-id>1352227</elocation-id>. (<pub-id pub-id-type="doi">10.3389/fbrio.2024.1352227</pub-id>)</mixed-citation></ref><ref id="bib35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gomez-Arango</surname>
<given-names>LF</given-names></string-name>, <string-name name-style="western"><surname>Barrett</surname>
<given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Wilkinson</surname>
<given-names>SA</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Low dietary fiber intake increases collinsella abundance in the gut microbiota of overweight and obese pregnant women</article-title>. <source>Gut Microbes</source>
<year>2018</year>
<volume>9</volume>
<fpage>189</fpage>–<lpage>201</lpage>. (<pub-id pub-id-type="doi">10.1080/19490976.2017.1406584</pub-id>)<pub-id pub-id-type="pmid">29144833</pub-id>
<pub-id pub-id-type="pmcid">PMC6219589</pub-id></mixed-citation></ref><ref id="bib36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Crusell</surname>
<given-names>MKW</given-names></string-name>, <string-name name-style="western"><surname>Hansen</surname>
<given-names>TH</given-names></string-name>, <string-name name-style="western"><surname>Nielsen</surname>
<given-names>T</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum</article-title>. <source>Microbiome</source>
<year>2018</year>
<volume>6</volume>
<fpage>89</fpage>. (<pub-id pub-id-type="doi">10.1186/s40168-018-0472-x</pub-id>)<pub-id pub-id-type="pmid">29764499</pub-id>
<pub-id pub-id-type="pmcid">PMC5952429</pub-id></mixed-citation></ref><ref id="bib37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maessen</surname>
<given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Stehouwer</surname>
<given-names>CD</given-names></string-name> &amp; <string-name name-style="western"><surname>Schalkwijk</surname>
<given-names>CG</given-names></string-name></person-group>. <article-title>The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases</article-title>. <source>Clin Sci</source>
<year>2015</year>
<volume>128</volume>
<fpage>839</fpage>–<lpage>861</lpage>. (<pub-id pub-id-type="doi">10.1042/cs20140683</pub-id>)<pub-id pub-id-type="pmid">25818485</pub-id></mixed-citation></ref><ref id="bib38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Akinrimisi</surname>
<given-names>OI</given-names></string-name>, <string-name name-style="western"><surname>Maasen</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Scheijen</surname>
<given-names>JLJM</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Does gut microbial methylglyoxal metabolism impact human physiology?</article-title>
<source>Antioxidants</source>
<year>2025</year>
<volume>14</volume>
<fpage>763</fpage>. (<pub-id pub-id-type="doi">10.3390/antiox14070763</pub-id>)<pub-id pub-id-type="pmid">40722867</pub-id>
<pub-id pub-id-type="pmcid">PMC12291648</pub-id></mixed-citation></ref><ref id="bib39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Orsini Delgado</surname>
<given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Gamelas Magalhaes</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Morra</surname>
<given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Muropeptides and muropeptide transporters impact on host immune response.</article-title>
<source>Gut Microbes</source>
<year>2024</year>
<volume>16</volume>
<elocation-id>2418412</elocation-id>. (<pub-id pub-id-type="doi">10.1080/19490976.2024.2418412</pub-id>)<pub-id pub-id-type="pmid">39439228</pub-id>
<pub-id pub-id-type="pmcid">PMC11509177</pub-id></mixed-citation></ref><ref id="bib40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rena</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Hardie</surname>
<given-names>DG</given-names></string-name> &amp; <string-name name-style="western"><surname>Pearson</surname>
<given-names>ER</given-names></string-name></person-group>. <article-title>The mechanisms of action of metformin</article-title>. <source>Diabetologia</source>
<year>2017</year>
<volume>60</volume>
<fpage>1577</fpage>–<lpage>1585</lpage>. (<pub-id pub-id-type="doi">10.1007/s00125-017-4342-z</pub-id>)<pub-id pub-id-type="pmid">28776086</pub-id>
<pub-id pub-id-type="pmcid">PMC5552828</pub-id></mixed-citation></ref></ref-list></back></article><article id="dta70000" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Test Anal</journal-id><journal-id journal-id-type="iso-abbrev">Drug Test Anal</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">DTA</journal-id><journal-title-group><journal-title>Drug Testing and Analysis</journal-title></journal-title-group><issn pub-type="ppub">1942-7603</issn><issn pub-type="epub">1942-7611</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12796554</article-id><article-id pub-id-type="pmcid-ver">PMC12796554.1</article-id><article-id pub-id-type="pmcaid">12796554</article-id><article-id pub-id-type="pmcaiid">12796554</article-id><article-id pub-id-type="pmid">41261763</article-id><article-id pub-id-type="doi">10.1002/dta.70000</article-id><article-id pub-id-type="publisher-id">DTA70000</article-id><article-id pub-id-type="other">7768947</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Metformin in the Horse: Pharmacokinetics and Detection Times Using Monte Carlo Simulations</article-title></title-group><contrib-group><contrib id="dta70000-cr-0001" contrib-type="author"><name name-style="western"><surname>Jacobs</surname><given-names initials="M">Megan E.</given-names></name><xref rid="dta70000-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="dta70000-cr-0002" contrib-type="author"><name name-style="western"><surname>Blea</surname><given-names initials="J">Jeff</given-names></name><xref rid="dta70000-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="dta70000-cr-0003" contrib-type="author"><name name-style="western"><surname>Hardy</surname><given-names initials="M">Michael</given-names></name><xref rid="dta70000-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="dta70000-cr-0004" contrib-type="author"><name name-style="western"><surname>McKemie</surname><given-names initials="D">Daniel S.</given-names></name><xref rid="dta70000-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="dta70000-cr-0005" contrib-type="author"><name name-style="western"><surname>Traynham</surname><given-names initials="M">Megan</given-names></name><xref rid="dta70000-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="dta70000-cr-0006" contrib-type="author" corresp="yes"><name name-style="western"><surname>Knych</surname><given-names initials="H">Heather K.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8676-4970</contrib-id><xref rid="dta70000-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="dta70000-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><address><email>hkknych@ucdavis.edu</email></address></contrib></contrib-group><aff id="dta70000-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">K.L. Maddy Equine Analytical Chemistry Laboratory (Pharmacology Section), School of Veterinary Medicine</named-content>
<institution>University of California</institution>
<city>Davis</city>
<country country="US">USA</country>
</aff><aff id="dta70000-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">School of Veterinary Medicine</named-content>
<institution>University of California</institution>
<city>Davis</city>
<country country="US">USA</country>
</aff><aff content-type="private-address" id="dta70000-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Racing Medication and Testing Consortium</institution>
<city>Lexington</city>
<named-content content-type="country-part">Kentucky</named-content>
<country country="US">USA</country>
</aff><aff id="dta70000-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Molecular Biosciences, School of Veterinary Medicine</named-content>
<institution>University of California</institution>
<city>Davis</city>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Heather K. Knych (<email>hkknych@ucdavis.edu</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>11</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2026</year></pub-date><volume>18</volume><issue seq="150">1</issue><issue-id pub-id-type="pmc-issue-id">504992</issue-id><issue-id pub-id-type="doi">10.1002/dta.v18.1</issue-id><fpage>139</fpage><lpage>148</lpage><history><date date-type="rev-recd"><day>27</day><month>10</month><year>2025</year></date><date date-type="received"><day>12</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>31</day><month>10</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>13</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>14</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-14 00:25:13.580"><day>14</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">© 2025 The Author(s). <italic toggle="yes">Drug Testing and Analysis</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="DTA-18-139.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:DTA-18-139.pdf"/><abstract><title>ABSTRACT</title><p>The racehorse industry has strict regulations regarding the detection of prohibited substances in horses. Metformin, a diabetes medication, is a prohibited substance that has been reported in post‐race blood and urine samples collected from racehorses. For further characterization of the disposition of metformin, 12 Thoroughbred horses were administered metformin orally and intravenously in a randomized, balanced, two‐way crossover design. Serum and urine samples were collected, and drug concentrations determined via liquid chromatography–tandem mass spectrometry. The serum data were analyzed using both noncompartmental analysis and a population pharmacokinetic model. Metformin concentrations were below the LOQ (0.25 ng/mL) in six of 12 horses by Day 11 postadministration, and below the LOQ for all horses on Day 25. The maximum serum concentration of metformin (mean ± SD) was 941.0 ± 467.8 ng/mL, and the mean terminal t<sub>1/2</sub> was 85.8 ± 15.1 h. Based on Monte Carlo simulations the time that serum metformin concentrations fell below the proposed HISA Anti‐Doping and Medication Control (ADMC) minimum reporting level (MRL; 0.5 ng/mL) in a simulated population of 1000 Thoroughbred horses was 475 hrs (~20 days). Metformin concentrations in urine fluctuated significantly between and within individual horses, and there was not a consistent relationship between blood and urine samples across time points. Results of the present study demonstrate a prolonged detection time; thus, a prolonged withdrawal time is needed to prevent a positive finding following exposure to metformin. Additionally, these results suggest that blood is the preferred matrix for regulatory purposes due to the inconsistent elimination in urine.</p></abstract><abstract abstract-type="graphical"><p>In recent years, the detection of metformin in blood and urine samples collected from racehorses has raised concern among regulators. This study describes blood and urine concentrations and the pharmacokinetics of metformin following IV and oral administration to horses. Data presented here can be used to establish screening limits and withdrawal times to appropriately regulate this drug in performance horses.
<boxed-text position="anchor" content-type="graphic" id="dta70000-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="DTA-18-139-g002.jpg"/></boxed-text>
</p></abstract><funding-group><award-group id="funding-0001"><funding-source>
<institution-wrap><institution>Racing Medication and Testing Consortium</institution></institution-wrap>
</funding-source></award-group><award-group id="funding-0002"><funding-source>
<institution-wrap><institution>Horseracing Integrity and Safety Authority</institution></institution-wrap>
</funding-source></award-group><award-group id="funding-0003"><funding-source>
<institution-wrap><institution>Horseracing Integrity &amp; Welfare Unit</institution></institution-wrap>
</funding-source></award-group><award-group id="funding-0004"><funding-source>
<institution-wrap><institution>California Horse Racing Board</institution><institution-id institution-id-type="doi">10.13039/100017060</institution-id></institution-wrap>
</funding-source></award-group></funding-group><counts><fig-count count="5"/><table-count count="5"/><page-count count="10"/><word-count count="6200"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2026</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.8 mode:remove_FC converted:13.01.2026</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="dta70000-cit-1001">
<string-name name-style="western">
<given-names>M.</given-names>
<surname>Jacobs</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>Blea</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Hardy</surname>
</string-name>, <string-name name-style="western">
<given-names>D.</given-names>
<surname>McKemie</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Traynham</surname>
</string-name>, and <string-name name-style="western">
<given-names>H.</given-names>
<surname>Knych</surname>
</string-name>, “<article-title>Metformin in the Horse: Pharmacokinetics and Detection Times Using Monte Carlo Simulations</article-title>,” <source>Drug Testing and Analysis</source>
<volume>18</volume>, no. <issue>1</issue> (<year>2026</year>): <fpage>139</fpage>–<lpage>148</lpage>, <pub-id pub-id-type="doi">10.1002/dta.70000</pub-id>.<pub-id pub-id-type="pmcid">PMC12796554</pub-id><pub-id pub-id-type="pmid">41261763</pub-id></mixed-citation>
</p><fn-group id="dta70000-ntgp-0001"><fn fn-type="funding" id="dta70000-note-0001"><p>
<bold>Funding:</bold> The authors would like to acknowledge the Racing Medication and Testing Consortium, the Horseracing Integrity and Safety Authority in partnership with the Horseracing Integrity &amp; Welfare Unit, and the California Horse Racing Board for providing financial support for this study.</p></fn></fn-group></notes></front><body id="dta70000-body-0001"><sec id="dta70000-sec-0001"><label>1</label><title>Introduction</title><p>Metformin (1,1‐dimethylbiguanide) is a medication used commonly for the treatment of type 2 diabetes mellitus and is one of the most prescribed drugs for humans [<xref rid="dta70000-bib-0001" ref-type="bibr">1</xref>]. It lowers hepatic glucose production and increases peripheral tissue sensitivity to insulin, lowering blood glucose concentrations [<xref rid="dta70000-bib-0002" ref-type="bibr">2</xref>]. In humans, metformin has a wide safety margin, moderate oral bioavailability, and minimal side effects, making it a good choice as a first‐line treatment for type 2 diabetes. Reported adverse effects associated with metformin are usually related to gastrointestinal intolerance, which is thought to be due to variations in organic cation transporter 1 (OCT1) function in the gastrointestinal tract [<xref rid="dta70000-bib-0003" ref-type="bibr">3</xref>].</p><p>The use of metformin is much less common in veterinary medicine. Its use in cats and dogs is limited, due to minimal efficacy. Similarly in horses, its effectiveness is questionable. In one study, investigators noted that it did not improve insulin sensitivity in insulin‐resistant ponies following oral administration [<xref rid="dta70000-bib-0004" ref-type="bibr">4</xref>]. There is limited information regarding the pharmacokinetics of metformin in horses, but, unlike humans, the oral bioavailability of metformin in horses is reportedly poor (~6%) [<xref rid="dta70000-bib-0005" ref-type="bibr">5</xref>]. Metformin is characterized by a short plasma half‐life and is eliminated primarily as the parent compound in horses [<xref rid="dta70000-bib-0005" ref-type="bibr">5</xref>].</p><p>In recent years, the detection of metformin in blood and urine samples collected from racehorses has raised concern among regulators. Metformin is considered a prohibited substance by the Horse Racing Integrity and Safety Authority (HISA) due to its lack of recognized therapeutic benefit in young, fit Thoroughbred racehorses, and its potential to impact performance. Although the potential impact of metformin on athletic performance in horses is unknown, there is some evidence that the drug improves heart rate and respiratory exchange ratio during exercise in humans [<xref rid="dta70000-bib-0006" ref-type="bibr">6</xref>].</p><p>The increase in detection of this prohibited substance in regulatory samples, coupled with its widespread use in human medicine and potential for exposure through contamination, necessitates a better understanding of the behavior of this drug in horses. To that end, the first objective of the current study was to describe blood and urine concentrations and the pharmacokinetics of metformin in horses, using a highly sensitive analytical assay. A second objective was to use Monte Carlo simulations to provide estimated withdrawal times based on measured concentrations from experimental horses.</p></sec><sec sec-type="methods" id="dta70000-sec-0002"><label>2</label><title>Methods</title><sec id="dta70000-sec-0003"><label>2.1</label><title>Animals</title><p>Twelve healthy, university‐owned, exercised Thoroughbred horses (five mares and seven geldings, aged 2–7 years, weighing 471–660 kg) were studied. Horses were exercised via Equineciser (Centaur Horse Walkers Inc., Mira Loma, CA, USA) and a high‐speed treadmill (Mustang 2200, Graber AG, Switzerland) prior to and for the duration of the study, with the exception of the day of drug administration, following standard protocols established by our laboratory [<xref rid="dta70000-bib-0007" ref-type="bibr">7</xref>]. Before beginning the study, horses were subject to a physical examination, complete blood count, and a serum biochemistry panel to determine health status. Blood sample analyses were performed by the Clinical Pathology Laboratory of the William R. Pritchard Veterinary Medical Teaching Hospital of the University of California, Davis. An appropriate washout period was observed for any drugs administered to horses prior to enrollment to ensure the animals had no other medications in their system prior to beginning the study. All animals were housed in 12 × 12‐ft stalls for the duration of the study. This study was approved by the Institutional Animal Care and Use Committee of the University of California, Davis.</p></sec><sec id="dta70000-sec-0004"><label>2.2</label><title>Instrumentation and Drug Administration</title><p>This study was conducted in two phases, using a balanced, randomized, two‐way crossover design. In Phase I, six horses received metformin orally (15 g; 22.7–31.8 mg/kg) and six received the drug intravenously (IV; 5 mg/kg). In Phase II, the horses received the opposite treatment. Phase II commenced when metformin concentrations were no longer detected in serum and urine from the Phase I administration (based on the analysis of samples collected prior to the administration of drug in Phase II). The order in which each horse received each administration type was determined with a computerized random number generator. The oral dose was selected based on evaluation of medication reports filed by owners and trainers for horses competing in other performance horse disciplines. The IV dose was selected based on a previous report [<xref rid="dta70000-bib-0005" ref-type="bibr">5</xref>]. Food was withheld for oral administration for 12 h prior and 2‐h postadministration; horses had free access to food for IV administration. All horses had access to water ad libitum for the duration of the study. For oral administration, commercially available metformin tablets (Aurobindo Pharma, Hyderabad, Telangana, India) were crushed and suspended in water and administered within 1 h of dosing. The suspension was administered directly into the oral cavity via a dosing syringe. As there is no commercially available injectable metformin formulation, commercially available metformin powder (&gt; 95% purity) was suspended in 0.9% NaCl using sterile technique. The formulation was filter sterilized and administered within 1 h of preparation. The formulation was tested via liquid chromatography–tandem mass spectrometry (LC–MS/MS), as described below, to ensure the concentration was within 10% of the nominal concentration. Immediately prior to dosing, a 14‐gauge IV catheter was placed aseptically in one jugular vein for blood sample collection and a second in the contralateral vein for IV drug administration. Dosing catheters were removed 1 h after dosing; sampling catheters were removed 18 h after dosing. All subsequent blood samples were collected via direct venipuncture.</p></sec><sec id="dta70000-sec-0005"><label>2.3</label><title>Sample Collection</title><p>Blood samples were collected into tubes devoid of anticoagulant (Kendall/Tyco Healthcare, Mansfield, MA) for drug concentration determination at time 0 (prior to drug administration) and at 5, 10, 15, 30, and 45 min and 1‐, 1.5‐, 2‐, 3‐, 4‐, 5‐, 6‐, 8‐, 12‐, 18‐, 24‐, 30‐, 36‐, 48‐, 72‐, 96‐, 120‐, 144‐, and 168‐h postadministration for both treatment groups. At 168 h (7 days), samples were analyzed using LC–MS/MS for determination of metformin concentrations. As the drug was still detected, additional samples were collected at 24‐h intervals until 14‐day postadministration, then 3 times per week until 28‐day postadministration. Samples were kept at room temperature for approximately 20 min until centrifugation at 3000 × g for 10 min. Serum was separated, transferred to storage vials and stored at −20°C until drug concentration analysis.</p><p>Horses utilized in this study are trained to urinate upon whistle command; therefore, urine samples were collected via free‐catch. Samples were collected at 4‐, 24‐, 48‐, 72‐, 96‐, 120‐, 144‐, and 168‐h post dosing. Urine samples collected at 168 h were analyzed for metformin using LC–MS/MS (in Phase I). As metformin was still detected in the 168‐h sample, additional samples were collected at 24‐h intervals until 14‐day postadministration, then 3 times per week until 25 days post administration. The Day 25 urine samples were analyzed for the determination of metformin concentrations prior to the commencement of Phase II. Since drug was detected in the last urine samples collected during Phase I (Day 25), the collection duration was extended in Phase II. In Phase II, additional samples were collected 3–4 times per week until the drug concentration was below the limit of quantitation (LOQ) for all horses (80‐day postadministration). Following collection, urine samples were kept on ice, then stored at −20°C until drug concentration determination.</p></sec><sec id="dta70000-sec-0006"><label>2.4</label><title>Determination of Metformin Concentrations</title><p>Serum sample analysis: Metformin working standard solutions were prepared by dilution of the metformin stock solutions (Cerilliant, Round Rock, TX) with methanol to concentrations of 0.01, 0.1, 1, 10, and 100 ng/μL. Serum calibrators were prepared by dilution of the working standard solutions with drug‐free equine serum to concentrations ranging from 0.25 to 25,000 ng/mL. Calibration curves and negative control samples were prepared fresh for each quantitative assay. In addition, quality control samples (drug‐free equine serum fortified with analyte at three concentrations within the standard curve) were included as an additional check of accuracy.</p><p>Prior to analysis, 0.5 mL of the serum samples was diluted with 0.5 mL of acetonitrile (ACN):1‐M acetic acid (9:1, v:v) containing 20 ng/mL of d6‐metformin (Cayman Chemical Company, Ann Arbor, MI), to precipitate proteins. The samples were vortexed for 1.5 min to mix, refrigerated for 20 min, vortexed for an additional 1 min, centrifuged (4300 rpm/3102 g) for 10 min at 4°C, and 500 μL of the organic layer was transferred to a tube and dried under nitrogen at 55°C. Samples were dissolved in 140 μL of ACN:1‐M acetic acid (9:1, v:v). All samples were then transferred to 2‐mL Eppendorf tubes, centrifuged at 14,000 rpm (12,753 g) for 5 min, and 20 μL was injected into the LC–MS/MS system.</p><p>The concentration of metformin was measured in serum by LC–MS/MS using positive heated electrospray ionization (HESI(+)). Quantitative analysis was performed on a TSQ Altis triple quadrupole mass spectrometer coupled with a Vanquish liquid chromatography system (Thermo Scientific, San Jose, CA). The spray voltage was 3500 V, the vaporizer temperature was 350°C, and the sheath and auxiliary gas were 50 and 10, respectively (arbitrary units). Product masses and collision energies of analyte and stable isotopically labeled internal standard were optimized by infusing the standards into the TSQ Altis. Chromatography employed an EZ:faast 4u AAA:MS 250 × 2‐mm column (Phenomenex, Torrance, CA) and a linear gradient of ACN in water with a constant 0.2% formic acid at a flow rate of 0.3 mL/min. The initial ACN concentration was held at 1% for 0.6 min, ramped to 25% over 2.4 min, ramped to 95% over 0.5 min, held at that concentration for 0.1 min, before re‐equilibrating for 3.3 min at initial conditions.</p><p>Detection and quantification were conducted using selective reaction monitoring (SRM) of the initial precursor ion for metformin (mass to charge ratio [m/z] 130.1) and the internal standard d6‐metformin (m/z 136.1). The response for the product ion for metformin (m/z 60.0) and the internal standard (m/z 59.9) was plotted, and peaks at the proper retention time were integrated, using Quanbrowser software (Thermo Scientific). Quanbrowser software was used to generate calibration curves and quantitate analytes in all samples by linear regression analysis. A weighting factor of 1/X was used for all calibration curves.</p><p>Urine sample analysis: Urine calibrators were prepared by dilution of the working standard solutions with drug‐free equine urine to concentrations ranging from 0.5 to 25,000 ng/mL. Prior to analysis, 0.5‐mL urine was diluted with 2.0‐mL 0.1‐M pH 7 phosphate buffer and 0.1‐mL water containing the internal standard (d6‐metformin; 0.05 ng/mL). All samples were vortexed gently to mix and subjected to solid phase extraction using Strata‐X‐CW columns 200 mg/3 mL (Phenomenex). In brief, the columns were conditioned with 2 mL of methanol and 2.5 mL of water. The samples were loaded onto the column, and a minimum of 2 min was allowed for samples to pass through the column. The columns were rinsed consecutively with 2.8 mL of water and 1‐mL methanol prior to eluting with 2.5‐mL methanol:ACN (1:1, v:v) containing 2% formic acid. Samples were dried under nitrogen and dissolved in 150 μL of 10% ACN in water, both with 0.2% formic acid. The injection volume was 10 μL into the LC–MS/MS system. Detection and quantification were the same as serum.</p><p>The instrument response was linear and gave correlation coefficients of 0.99 or better. For both serum and urine, the precision and accuracy of the assay were determined by assaying quality control samples in replicates (<italic toggle="yes">n</italic> = 6). Quality control samples met accuracy and precision acceptance criteria as described in the FDA's Guidance for Bioanalytical Method Development and Validation [<xref rid="dta70000-bib-0008" ref-type="bibr">8</xref>] (Table <xref rid="dta70000-tbl-0001" ref-type="table">1</xref>). The LOQ was the lowest calibrator that could be measured with acceptable precision (back‐calculated concentration not exceeding 20% of the coefficient of variation [CV]) and accuracy (within 20% of the nominal concentration), and the limit of detection (LOD) was established based on the lowest calibrator with a 3:1 signal‐to‐noise ratio. The technique was optimized to provide an LOQ of 0.25 ng/mL in serum and 0.5 ng/mL in urine. The LOD was approximately 0.1 and 0.25 ng/mL for metformin in serum and urine, respectively.</p><table-wrap position="float" id="dta70000-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Accuracy and precision values (average of six replicates) for LC–MS/MS analysis of metformin in equine serum and urine.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Matrix</th><th align="center" valign="bottom" rowspan="1" colspan="1">Concentration (ng/mL)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Intraday accuracy (% nominal concentration)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Intraday precision (% relative SD)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Interday accuracy (% nominal concentration)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Interday precision (% relative SD)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Serum</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.75</td><td align="center" valign="top" rowspan="1" colspan="1">88.0</td><td align="center" valign="top" rowspan="1" colspan="1">5.0</td><td align="center" valign="top" rowspan="1" colspan="1">87.0</td><td align="center" valign="top" rowspan="1" colspan="1">6.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">40.0</td><td align="center" valign="top" rowspan="1" colspan="1">96.0</td><td align="center" valign="top" rowspan="1" colspan="1">3.0</td><td align="center" valign="top" rowspan="1" colspan="1">98.0</td><td align="center" valign="top" rowspan="1" colspan="1">5.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">5000</td><td align="center" valign="top" rowspan="1" colspan="1">92.0</td><td align="center" valign="top" rowspan="1" colspan="1">2.0</td><td align="center" valign="top" rowspan="1" colspan="1">94.0</td><td align="center" valign="top" rowspan="1" colspan="1">3.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Urine</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.75</td><td align="center" valign="top" rowspan="1" colspan="1">85.0</td><td align="center" valign="top" rowspan="1" colspan="1">4.0</td><td align="center" valign="top" rowspan="1" colspan="1">85.0</td><td align="center" valign="top" rowspan="1" colspan="1">7.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">100</td><td align="center" valign="top" rowspan="1" colspan="1">87.0</td><td align="center" valign="top" rowspan="1" colspan="1">6.0</td><td align="center" valign="top" rowspan="1" colspan="1">92.0</td><td align="center" valign="top" rowspan="1" colspan="1">4.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">5000</td><td align="center" valign="top" rowspan="1" colspan="1">94.0</td><td align="center" valign="top" rowspan="1" colspan="1">2.0</td><td align="center" valign="top" rowspan="1" colspan="1">99.0</td><td align="center" valign="top" rowspan="1" colspan="1">4.0</td></tr></tbody></table></table-wrap></sec><sec id="dta70000-sec-0007"><label>2.5</label><title>Metformin Concentration and Pharmacokinetic Analysis</title><p>To evaluate the relationship between blood and urine concentrations, the urine to blood ratio was calculated for each horse at each timepoint, using the formula:
<disp-formula id="dta70000-disp-0001">
<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="jats-math-1" display="block" overflow="scroll"><mml:mtext>Urine concentration</mml:mtext><mml:mo>/</mml:mo><mml:mtext>blood concentration</mml:mtext></mml:math>
</disp-formula>
</p><p>The maximal concentration (C<sub>max</sub>) and time of maximal concentration (T<sub>max</sub>) were determined directly from the concentration data. As an aid in determining initial estimates for model fitting, noncompartmental analysis (NCA) was performed on metformin serum concentrations using commercially available software (Phoenix WinNonlin v8.3; Certara, Princeton, NJ).</p><p>Following NCA, concentration data for all horses from both routes of administration (IV and oral) were modeled simultaneously with a population model using a nonlinear mixed‐effect (NLME) modeling approach with the Phoenix software. Different compartmental models and different residual error models (additive, multiplicative, Poisson, and mixed additive/multiplicative residual) were assessed. Goodness of fit and the appropriate error term were selected through visual analysis of observed compared with predicted concentration graphs and residual plots, as well as Akaike Information Criterion, and % CV of parameter estimates.</p></sec><sec id="dta70000-sec-0008"><label>2.6</label><title>Monte Carlo Simulations</title><p>Monte Carlo simulations were performed in WinNonlin using the final population PK model. Serum concentrations for a virtual population of 1000 horses were simulated using the estimated fixed effects and interindividual variability from the 12 experimental horses. Each simulated subject received a standard dose matching the experimental protocol. Using this meta‐population, the withdrawal time corresponding to the proposed MRL of 0.5 ng/mL and screening limits of 1, 2, and 4 ng/mL were estimated. The concentration data generated for the simulated population were then analyzed with the WinNonlin statistical tool in order to compute the quantiles of interest (50 and 99th).</p></sec></sec><sec sec-type="results" id="dta70000-sec-0009"><label>3</label><title>Results</title><p>Following oral metformin administration, five horses showed mild signs of abdominal discomfort, such as pawing and rolling 4 h after the drug was administered; these signs resolved on their own within 2 h.</p><p>Individual and mean metformin serum concentrations with respect to time following intravenous and oral administration are depicted in Figure <xref rid="dta70000-fig-0001" ref-type="fig">1</xref>. Metformin concentrations were below the LOQ (0.25 ng/mL) in all 12 horses following both oral and intravenous administration at 504 h (Day 21). The mean ± SD and median and range of select pharmacokinetic parameters following NCA for both routes of administration are listed in Table <xref rid="dta70000-tbl-0002" ref-type="table">2</xref>. The C<sub>max</sub> (mean ± SD) was 941.0 ± 467.8 ng/mL at 0.86 ± 0.66 h following oral administration. The terminal half‐life was 85.5 ± 11.6 and 85.8 ± 15.1 h following IV and oral administration, respectively. Using a compartmental modeling approach, based on evaluation of goodness of fit criteria, a 3‐compartment multiplicative error model, parameterized with respect to clearance, gave the best fit to the data. Pharmacokinetic parameters generated from compartmental analysis are listed in Table <xref rid="dta70000-tbl-0003" ref-type="table">3</xref>. The absorption rate constant was 0.362 1/h, and the bioavailability was 11.6% following oral administration.</p><fig position="float" fig-type="FIGURE" id="dta70000-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Serum metformin concentrations following a single (A) IV administration of 5 mg/kg or (B) oral administration of 15 g to 12 horses. Mean concentrations are shown with solid points (±SD), and individual points are shown with open circles. The inset for B represents the first 2‐h postdrug administration.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="DTA-18-139-g001.jpg"/></fig><table-wrap position="float" id="dta70000-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Pharmacokinetic parameters for metformin following a single IV (5 mg/kg) or oral (15 g) administration to 12 horses. Parameters generated using noncompartmental analysis.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">Parameter</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Intravenous</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Oral</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Mean ± SD</th><th align="center" valign="bottom" rowspan="1" colspan="1">Median (range)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Mean ± SD</th><th align="center" valign="bottom" rowspan="1" colspan="1">Median (range)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">C(0) (ng/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">25,553 ± 3850.7</td><td align="center" valign="top" rowspan="1" colspan="1">28,243.7 (20,340.9–34,370.8)</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">C<sub>max</sub> (ng/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">941.0 ± 467.8</td><td align="center" valign="top" rowspan="1" colspan="1">832.6 (542.8–2346.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">T<sub>max</sub> (h)</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">0.86 ± 0.66</td><td align="center" valign="top" rowspan="1" colspan="1">0.88 (0.08–1.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AUC<sub>inf</sub> (h * ng/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">10,489.8 ± 2364.7</td><td align="center" valign="top" rowspan="1" colspan="1">9987.0 (6972.6–14,107.3)</td><td align="center" valign="top" rowspan="1" colspan="1">4324.7 ± 1072.3</td><td align="center" valign="top" rowspan="1" colspan="1">4586.4 (2785.5–6263.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AUC % extrap</td><td align="center" valign="top" rowspan="1" colspan="1">0.55 ± 0.16</td><td align="center" valign="top" rowspan="1" colspan="1">0.50 (0.37–0.83)</td><td align="center" valign="top" rowspan="1" colspan="1">1.09 ± 0.45</td><td align="center" valign="top" rowspan="1" colspan="1">0.96 (0.60–2.34)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bioavailability (%)</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">7.86 ± 1.65</td><td align="center" valign="top" rowspan="1" colspan="1">8.02 (5.25–10.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Clearance (mL/h/kg)</td><td align="center" valign="top" rowspan="1" colspan="1">499.8 ± 114.1</td><td align="center" valign="top" rowspan="1" colspan="1">500.8 (354.4–717.1)</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vd<sub>ss</sub> (L/kg)</td><td align="center" valign="top" rowspan="1" colspan="1">4.37 ± 1.62</td><td align="center" valign="top" rowspan="1" colspan="1">4.15 (2.48–8.19)</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Terminal t<sub>1/2</sub> (h)</td><td align="center" valign="top" rowspan="1" colspan="1">85.5 ± 11.6</td><td align="center" valign="top" rowspan="1" colspan="1">86.7 (64.1–105.6)</td><td align="center" valign="top" rowspan="1" colspan="1">85.8 ± 15.1</td><td align="center" valign="top" rowspan="1" colspan="1">87.8 (56.5–111.0)</td></tr></tbody></table><table-wrap-foot id="dta70000-ntgp-0002"><fn id="dta70000-note-0002"><p>
<italic toggle="yes">Note:</italic> C(0), calculated initial plasma concentration following IV administration; C<sub>max</sub>, maximum serum drug concentration; T<sub>max</sub>, time of maximum serum drug concentration; AUC <sub>inf</sub>, area under the curve extrapolated to infinity; AUC % extrap, percent of area under the curve extrapolated; Vd<sub>ss</sub>, volume of distribution at steady state; HL lambda z, terminal half‐life.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="dta70000-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Model typical values (tv) for metformin following a single IV (5 mg/kg) and oral (15 g) administration to 12 horses as determined using a 3‐compartment multiplicative error population model and modeling IV and oral administration simultaneously.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom"/><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Parameters</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Random effects: between subject variability</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Estimate</th><th align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">CV(%)</th><th align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Estimate</th><th align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">CV(%)</th></tr></thead><tbody valign="top"><tr><td colspan="2" align="left" valign="top" rowspan="1">Fitted model parameters</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">tvKa (1/h)</td><td align="center" valign="top" rowspan="1" colspan="1">0.362</td><td align="center" valign="top" rowspan="1" colspan="1">25.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.799</td><td align="center" valign="top" rowspan="1" colspan="1">110.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">tvV (L/kg)</td><td align="center" valign="top" rowspan="1" colspan="1">0.313</td><td align="center" valign="top" rowspan="1" colspan="1">5.99</td><td align="center" valign="top" rowspan="1" colspan="1">0.013</td><td align="center" valign="top" rowspan="1" colspan="1">11.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">tvV2 (L/kg)</td><td align="center" valign="top" rowspan="1" colspan="1">5.11</td><td align="center" valign="top" rowspan="1" colspan="1">17.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.249</td><td align="center" valign="top" rowspan="1" colspan="1">53.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">tvV3 (L/kg)</td><td align="center" valign="top" rowspan="1" colspan="1">1.57</td><td align="center" valign="top" rowspan="1" colspan="1">11.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.088</td><td align="center" valign="top" rowspan="1" colspan="1">30.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">tvCl (mL/min/kg)</td><td align="center" valign="top" rowspan="1" colspan="1">9.22</td><td align="center" valign="top" rowspan="1" colspan="1">5.11</td><td align="center" valign="top" rowspan="1" colspan="1">0.023</td><td align="center" valign="top" rowspan="1" colspan="1">15.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">tvCl2 (mL/min/kg)</td><td align="center" valign="top" rowspan="1" colspan="1">0.537</td><td align="center" valign="top" rowspan="1" colspan="1">8.24</td><td align="center" valign="top" rowspan="1" colspan="1">0.048</td><td align="center" valign="top" rowspan="1" colspan="1">22.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">tvCl3 (mL/min/kg)</td><td align="center" valign="top" rowspan="1" colspan="1">3.16</td><td align="center" valign="top" rowspan="1" colspan="1">7.52</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1">3.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">tvFbio (%)</td><td align="center" valign="top" rowspan="1" colspan="1">11.6</td><td align="center" valign="top" rowspan="1" colspan="1">5.47</td><td align="center" valign="top" rowspan="1" colspan="1">0.023</td><td align="center" valign="top" rowspan="1" colspan="1">15.1</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">Derived parameters</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">K10 HL (h)</td><td align="center" valign="top" rowspan="1" colspan="1">0.393</td><td align="center" valign="top" rowspan="1" colspan="1">6.40</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Effective HL (h)</td><td align="center" valign="top" rowspan="1" colspan="1">8.77</td><td align="center" valign="top" rowspan="1" colspan="1">13.4</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Vd<sub>ss</sub> (L/kg)</td><td align="center" valign="top" rowspan="1" colspan="1">7.00</td><td align="center" valign="top" rowspan="1" colspan="1">13.3</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">stdev0</td><td align="center" valign="top" rowspan="1" colspan="1">0.410</td><td align="center" valign="top" rowspan="1" colspan="1">3.37</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="dta70000-ntgp-0003"><fn id="dta70000-note-0003"><p>
<italic toggle="yes">Note:</italic> tvKa, rate of absorption; tvV, the volume of the central compartment; tvV2, denotes the volume of the peripheral compartment; tvV3, denotes the volume of the deep peripheral compartment; tvCl, the clearance of drug from plasma; tvCL2, the clearance of drug from the peripheral compartment; tvCL3, the clearance of drug from the deep peripheral compartment; tvFbio, oral bioavailability; K10 HL, K10 half‐life; effective HL, half‐life that accounts for drug accumulation and redistribution; Vd<sub>ss</sub>, volume of distribution at steady state; stdev0, the estimated residual standard deviation for plasma data; CV(%), coefficient of variation.</p></fn></table-wrap-foot></table-wrap><p>Individual and mean metformin urine concentrations with respect to time for both routes of administration are depicted in Figure <xref rid="dta70000-fig-0002" ref-type="fig">2</xref>. Metformin was not detected in urine samples prior to drug administration in Phase II. For both IV and oral administration, urine concentrations fluctuated unpredictably with some horses showing decreases followed by increases at later time points. Metformin concentrations were below the LOQ (LOQ = 0.5 ng/mL) in four of 12 horses at 25‐day postadministration (the last time point collected in Phase I). At 80‐day postadministration (the last time point collected in Phase II), metformin concentrations in urine were below the LOQ in three of 12 horses (two IV and one oral).</p><fig position="float" fig-type="FIGURE" id="dta70000-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Urine metformin concentrations following a single (A) IV administration of 5 mg/kg or (B) oral administration of 15 g to 12 horses. Mean concentrations are shown with solid points (±SD), and individual points are shown with open circles. Samples after Day 25 were only collected from six horses.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="DTA-18-139-g004.jpg"/></fig><p>Corresponding metformin urine and blood concentrations as well as the urine to blood ratio from 24 h to 14 days are listed in Tables <xref rid="dta70000-tbl-0004" ref-type="table">4</xref> and <xref rid="dta70000-tbl-0005" ref-type="table">5</xref> for IV and oral administration, respectively. The urine‐to‐blood concentration ratios varied widely between horses at each time point for both routes of administration.</p><table-wrap position="float" id="dta70000-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Metformin blood (serum) and urine concentrations as well as the urine to blood ratio following a single IV administration of 5 mg/kg to 12 horses.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">Time</th><th align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">[Blood] (ng/mL)</th><th align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">[Urine] (ng/mL)</th><th align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Urine: blood<xref rid="dta70000-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Range</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">24 h</td><td align="center" valign="top" rowspan="1" colspan="1">8.14–42.7</td><td align="center" valign="top" rowspan="1" colspan="1">835.3–19,600.9</td><td align="center" valign="top" rowspan="1" colspan="1">64.7–387.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">48 h</td><td align="center" valign="top" rowspan="1" colspan="1">2.97–12.8</td><td align="center" valign="top" rowspan="1" colspan="1">182.1–2484.4</td><td align="center" valign="top" rowspan="1" colspan="1">65.0–375.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">72 h</td><td align="center" valign="top" rowspan="1" colspan="1">1.58–3.84</td><td align="center" valign="top" rowspan="1" colspan="1">55.3–534.7</td><td align="center" valign="top" rowspan="1" colspan="1">29.8–183.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">96 h</td><td align="center" valign="top" rowspan="1" colspan="1">0.85–2.93</td><td align="center" valign="top" rowspan="1" colspan="1">20.2–350.7</td><td align="center" valign="top" rowspan="1" colspan="1">13.2–141.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">120 h</td><td align="center" valign="top" rowspan="1" colspan="1">0.87–2.71</td><td align="center" valign="top" rowspan="1" colspan="1">11.6–163.0</td><td align="center" valign="top" rowspan="1" colspan="1">10.6–80.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">144 h</td><td align="center" valign="top" rowspan="1" colspan="1">0.61–7.27</td><td align="center" valign="top" rowspan="1" colspan="1">14.7–52.1</td><td align="center" valign="top" rowspan="1" colspan="1">3.70–54.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">168 h</td><td align="center" valign="top" rowspan="1" colspan="1">0.54–3.94</td><td align="center" valign="top" rowspan="1" colspan="1">7.33–54.6</td><td align="center" valign="top" rowspan="1" colspan="1">4.03–53.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">192 h</td><td align="center" valign="top" rowspan="1" colspan="1">0.55–1.60</td><td align="center" valign="top" rowspan="1" colspan="1">2.17–80.3</td><td align="center" valign="top" rowspan="1" colspan="1">1.91–50.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">216 h</td><td align="center" valign="top" rowspan="1" colspan="1">0.47–1.49</td><td align="center" valign="top" rowspan="1" colspan="1">3.16–28.92</td><td align="center" valign="top" rowspan="1" colspan="1">5.02–59.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Day 10</td><td align="center" valign="top" rowspan="1" colspan="1">0.34–0.83</td><td align="center" valign="top" rowspan="1" colspan="1">2.49–39.1</td><td align="center" valign="top" rowspan="1" colspan="1">6.01–69.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Day 11</td><td align="center" valign="top" rowspan="1" colspan="1">ND—0.67</td><td align="center" valign="top" rowspan="1" colspan="1">1.05–23.2</td><td align="center" valign="top" rowspan="1" colspan="1">ND—45.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Day 12</td><td align="center" valign="top" rowspan="1" colspan="1">ND—0.47</td><td align="center" valign="top" rowspan="1" colspan="1">1.40–27.2</td><td align="center" valign="top" rowspan="1" colspan="1">ND—18.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Day 13</td><td align="center" valign="top" rowspan="1" colspan="1">ND—0.42</td><td align="center" valign="top" rowspan="1" colspan="1">0.94–93.0</td><td align="center" valign="top" rowspan="1" colspan="1">ND—10.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Day 14</td><td align="center" valign="top" rowspan="1" colspan="1">ND</td><td align="center" valign="top" rowspan="1" colspan="1">1.34–17.5</td><td align="center" valign="top" rowspan="1" colspan="1">—</td></tr></tbody></table><table-wrap-foot id="dta70000-ntgp-0004"><fn id="dta70000-note-0004"><p>Abbreviation: ND, not detected.</p></fn><fn id="dta70000-note-0005"><label>
<sup>a</sup>
</label><p>Urine to blood ratio = urine concentration/blood concentration.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="dta70000-tbl-0005" content-type="TABLE" orientation="portrait"><label>TABLE 5</label><caption><p>Metformin blood (serum) and urine concentrations as well as the urine to blood ratio following a single oral administration of 15 g to 12 horses.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">Time</th><th align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">[Blood] (ng/mL)</th><th align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">[Urine] (ng/mL)</th><th align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">Urine: blood<xref rid="dta70000-note-0007" ref-type="table-fn">
<sup>a</sup>
</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Range</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">24 h</td><td align="center" valign="top" rowspan="1" colspan="1">19.2–50.3</td><td align="center" valign="top" rowspan="1" colspan="1">4368.5–33,486.3</td><td align="center" valign="top" rowspan="1" colspan="1">185–722</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">48 h</td><td align="center" valign="top" rowspan="1" colspan="1">1.77–12.8</td><td align="center" valign="top" rowspan="1" colspan="1">570.6–5346.7</td><td align="center" valign="top" rowspan="1" colspan="1">55–571</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">72 h</td><td align="center" valign="top" rowspan="1" colspan="1">0.57–3.46</td><td align="center" valign="top" rowspan="1" colspan="1">52.0–712.3</td><td align="center" valign="top" rowspan="1" colspan="1">50–209</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">96 h</td><td align="center" valign="top" rowspan="1" colspan="1">0.5–2.61</td><td align="center" valign="top" rowspan="1" colspan="1">28.9–404.9</td><td align="center" valign="top" rowspan="1" colspan="1">28–172</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">120 h</td><td align="center" valign="top" rowspan="1" colspan="1">0.44–2.27</td><td align="center" valign="top" rowspan="1" colspan="1">18.5–472.4</td><td align="center" valign="top" rowspan="1" colspan="1">19–208</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">144 h</td><td align="center" valign="top" rowspan="1" colspan="1">0.40–1.69</td><td align="center" valign="top" rowspan="1" colspan="1">12.7–141.9</td><td align="center" valign="top" rowspan="1" colspan="1">12–193</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">168 h</td><td align="center" valign="top" rowspan="1" colspan="1">0.54–1.06</td><td align="center" valign="top" rowspan="1" colspan="1">11.0–146.8</td><td align="center" valign="top" rowspan="1" colspan="1">18–139</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">192 h</td><td align="center" valign="top" rowspan="1" colspan="1">0.34–1.00</td><td align="center" valign="top" rowspan="1" colspan="1">5.52–100.0</td><td align="center" valign="top" rowspan="1" colspan="1">10–167</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">216 h</td><td align="center" valign="top" rowspan="1" colspan="1">0.33–0.90</td><td align="center" valign="top" rowspan="1" colspan="1">3.16–201.0</td><td align="center" valign="top" rowspan="1" colspan="1">7–231</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Day 10</td><td align="center" valign="top" rowspan="1" colspan="1">&lt; LOQ—0.58</td><td align="center" valign="top" rowspan="1" colspan="1">2.83–71.0</td><td align="center" valign="top" rowspan="1" colspan="1">8–152</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Day 11</td><td align="center" valign="top" rowspan="1" colspan="1">ND—0.57</td><td align="center" valign="top" rowspan="1" colspan="1">2.30–152.0</td><td align="center" valign="top" rowspan="1" colspan="1">17–276</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Day 12</td><td align="center" valign="top" rowspan="1" colspan="1">ND—0.47</td><td align="center" valign="top" rowspan="1" colspan="1">1.90–240.4</td><td align="center" valign="top" rowspan="1" colspan="1">38–179</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Day 13</td><td align="center" valign="top" rowspan="1" colspan="1">ND—0.30</td><td align="center" valign="top" rowspan="1" colspan="1">2.19–50.6</td><td align="center" valign="top" rowspan="1" colspan="1">31–172</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Day 14</td><td align="center" valign="top" rowspan="1" colspan="1">ND</td><td align="center" valign="top" rowspan="1" colspan="1">7.70–51.8</td><td align="center" valign="top" rowspan="1" colspan="1">—</td></tr></tbody></table><table-wrap-foot id="dta70000-ntgp-0005"><fn id="dta70000-note-0006"><p>Abbreviations: LOQ, limit of quantitation; ND, not detected.</p></fn><fn id="dta70000-note-0007"><label>
<sup>a</sup>
</label><p>Urine to blood ratio = urine concentration/blood concentration.</p></fn></table-wrap-foot></table-wrap><p>Based on the Monte Carlo simulations, the time at which 50% and 99% of the simulated population would fall below the proposed MRL of 0.5 ng/mL was approximately 245 and 475 h, respectively (Figure <xref rid="dta70000-fig-0003" ref-type="fig">3</xref>). Monte Carlo simulations showing the time at which metformin concentrations would fall below screening limits 1, 2, and 4 ng/mL are shown in Figure <xref rid="dta70000-fig-0004" ref-type="fig">4</xref>.</p><fig position="float" fig-type="FIGURE" id="dta70000-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Plot of the 50% and 99% quantiles for a hypothetical horse population (1000 Thoroughbred horses) obtained via Monte Carlo simulation for the proposed Horseracing and Integrity Safey Authority (HISA) minimum reporting limit (MRL) of 0.5 ng/mL for metformin. The times of intersection of the predicted concentration curves with the screening limit line represent the detection time for 50% and 99% of the hypothetical population.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="DTA-18-139-g005.jpg"/></fig><fig position="float" fig-type="FIGURE" id="dta70000-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Plot of the 50% and 99% quantiles for a hypothetical horse population (1000 Thoroughbred horses) obtained via Monte Carlo simulation for theoretical screening limits of (A) 1.0 ng/mL, (B) 2.0 ng/mL, and (C) 4.0 ng/mL for metformin. The times of intersection of the predicted concentration curves with the screening limit line represent the detection time for 50% and 99% of the hypothetical population.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="DTA-18-139-g003.jpg"/></fig></sec><sec sec-type="discussion" id="dta70000-sec-0010"><label>4</label><title>Discussion</title><p>Recent reports of the detection of metformin in urine and blood samples collected from racehorses post‐race are a concern for regulators. The current study describes blood and urine concentrations and the pharmacokinetics of metformin following IV and oral administration to horses, utilizing a NLME population modeling approach.</p><p>The maximum concentration (C<sub>max</sub>) in the presently reported study (941.0 ± 467.8 ng/mL) was approximately 2.5 times higher than a previous report describing the pharmacokinetics of metformin in horses (400 ± 100 ng/mL) [<xref rid="dta70000-bib-0005" ref-type="bibr">5</xref>], consistent with the higher dose administered here (15 g vs. 6‐g PO). The time of maximum concentration was comparable between the two studies (0.86 ± 0.66 vs. 0.9 ± 0.1 h) [<xref rid="dta70000-bib-0005" ref-type="bibr">5</xref>].</p><p>Serum concentration versus time data were fit to an NLME population PK (Pop PK) model. This modeling approach is used commonly in human medicine and is slowly being utilized more in veterinary medicine [<xref rid="dta70000-bib-0009" ref-type="bibr">9</xref>]. Pop PK models may also be useful in the regulation of drugs in horseracing and other equestrian disciplines [<xref rid="dta70000-bib-0010" ref-type="bibr">10</xref>]. The reader is referred to a recent review for more details regarding the utility of this modeling approach in this area [<xref rid="dta70000-bib-0010" ref-type="bibr">10</xref>]. Serum concentration data in the current study were best fit by a 3‐compartment model. The use of both 2‐ and 3‐compartment models has been reported in metformin pharmacokinetic studies in humans [<xref rid="dta70000-bib-0011" ref-type="bibr">11</xref>, <xref rid="dta70000-bib-0012" ref-type="bibr">12</xref>]. Metformin absorption was more rapid in the current study (Ka = 0.399 1/h) compared to reports in humans (Ka = 1.19 1/h) [<xref rid="dta70000-bib-0011" ref-type="bibr">11</xref>]. In humans, metformin is absorbed in the small intestine primarily by active transporters [<xref rid="dta70000-bib-0003" ref-type="bibr">3</xref>] and is saturable [<xref rid="dta70000-bib-0013" ref-type="bibr">13</xref>]. In the current study, a linear absorption model provided the best fit indicating saturation was not apparent. Since the current study only evaluated a single oral dose, additional study is needed to ascertain whether absorption is saturable in horses at higher doses.</p><p>The oral bioavailability of metformin was low (7.86% ± 1.65% [NCA], 11.6% [Pop PK]). This is comparable to previous reports in horses (7.1% ± 1.5%) [<xref rid="dta70000-bib-0005" ref-type="bibr">5</xref>], but much lower than that reported for humans (50%–60%) [<xref rid="dta70000-bib-0012" ref-type="bibr">12</xref>, <xref rid="dta70000-bib-0013" ref-type="bibr">13</xref>]. In the presently reported study, the terminal half‐life (mean ± SD) of metformin in horses was 85.5 ± 11.6 h (IV) and 85.8 ± 15.1 h (oral), which is significantly longer than previously reported in horses (24.9 ± 0.4 h) [<xref rid="dta70000-bib-0005" ref-type="bibr">5</xref>]. This is likely due to differences in sampling protocols, with sample collection being more prolonged in the current study. Additionally, the LC–MS/MS assay used in the current study was more sensitive, compared to the previous study in horses (0.25 vs. 0.50 ng/mL). Both the longer sampling time and the lower LOQ in the present study allowed for more complete characterization of the terminal portion of the concentration time curve, explaining the longer terminal half‐life. This is especially important from a regulatory perspective, when extremely low concentrations of metformin can result in regulatory action against the trainer. The reason for the prolonged residence time in horses, and hence the long terminal half‐life, is not clear. In humans, there is evidence that metformin partitions into erythrocytes and may be sequestered for extended periods of time [<xref rid="dta70000-bib-0014" ref-type="bibr">14</xref>]. Although further study is necessary, it is possible that this is the case in horses as well, and it may explain the long terminal half‐life of metformin in this species.</p><p>Urine is a common biological matrix for drug testing of equine athletes. In the current study, urinary metformin concentrations varied greatly between horses resulting in a large range of concentrations at each time point. To understand the relationship between urine and blood, the metformin urine to blood ratio was calculated for each horse at each timepoint where urine was collected and blood concentrations remained above the LOQ. At all timepoints, for both routes of administration, there was a large degree of variability between and within horses with respect to the urine to blood ratio, resulting in a wide range. Additionally, when comparing the ratios between timepoints, the urine to blood ratio was inconsistent. It is also important to note that for some horses, unpredictable increases in metformin urine concentrations were noted at later timepoints. With any drug exposure, there are multiple factors that can influence urine concentrations. This includes things such as hydration status and urinary pH [<xref rid="dta70000-bib-0015" ref-type="bibr">15</xref>], both of which may be different after high‐intensity exercise compared to a horse at rest. Another potential explanation for the “spikes” in urine concentrations is sequestration in tissues and/or cells and subsequent release. As discussed above, in humans, metformin sequesters in various sites within the body (i.e., erythrocytes). If this proves to be the case in horses, this may explain the fluctuating urine concentrations. Drug may be slowly and/or inconsistently released into the serum and subsequently eliminated in the urine. These fluctuations in urine metformin concentrations, along with the inconsistent relationship between blood and urine, call into question the reliability of urine as a matrix for regulating metformin. Aside from the unpredictable behavior of metformin in urine, the prolonged detection time would necessitate excessive restriction of this drug.</p><p>Monte Carlo simulations provide a powerful and statistically rigorous approach to estimate withdrawal times for medications by generating a large theoretical population of horses and determining the time at which concentrations would be expected to fall below an established screening limit for this population. The theoretical population is generated from data gathered from an experimental group with varying individual pharmacokinetic parameters; thus, it reflects the natural biological variability within the investigated horse population [<xref rid="dta70000-bib-0016" ref-type="bibr">16</xref>, <xref rid="dta70000-bib-0017" ref-type="bibr">17</xref>]. Monte Carlo simulations were used in the current study to determine the metformin withdrawal time in serum, for a virtual population of 1000 horses using the current proposed HISA MRL for serum (0.5 ng/mL). Based on these simulations, a very prolonged withdrawal time (~20 days) is necessary for 99% of the virtual 1000 horse population to avoid an adverse analytical finding with the current HISA MRL. Although notably, concentrations of metformin in blood following unintentional exposure resulting from environmental contamination are unknown, based on the widespread use of metformin in human medicine and the reported prevalence of this compound in the environment, Monte Carlo simulations were used to make predictions. For the purposes of this exercise, withdrawal times for hypothetical MRLs of 1, 2, and 4 ng/mL were chosen in the current study. Based on these simulations, for 99% of the virtual horse population withdrawal times of 306 h (~13 days), 168 h (7 days), and 120 h (5 days) would be appropriate for 1, 2, and 4 ng/mL, respectively.</p><p>The results of the current study show that metformin is detectable in the serum and urine of horses for an extended period of time after administration by both IV and oral routes. Urine concentrations can be unpredictable, making blood a more effective matrix for confirming the presence of metformin in regulatory samples in relation to the application of reporting limits. In the case of oral administration, the current proposed HISA MRL would correspond to a minimum detection time of 20 days. It is also important to note that with how common metformin is as a prescription medication in humans and reports of environmental contamination [<xref rid="dta70000-bib-0018" ref-type="bibr">18</xref>], accidental exposure may pose a risk of horses testing positive for the drug with the proposed HISA MRL. Results of the present study support revisiting the way in which metformin is regulated in racehorses. Furthermore, based on the widespread use of this drug and concern over administration and exposure in horseracing, further investigation into the behavior of this drug in horses is warranted.</p></sec><sec sec-type="COI-statement" id="dta70000-sec-0012"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec></body><back><ack id="dta70000-sec-0011"><title>Acknowledgments</title><p>The authors would like to acknowledge the Racing Medication and Testing Consortium, the Horseracing Integrity and Safety Authority in partnership with the Horseracing Integrity &amp; Welfare Unit and the California Horse Racing Board for providing financial support for this study. The authors would like to thank Dr Camilo Morales, Sandy Yim, Stacy Steinmetz, Juliana Sullivan, and Anabella Lynch for technical assistance.</p></ack><sec sec-type="data-availability" id="dta70000-sec-0014"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list content-type="cited-references" id="dta70000-bibl-0001"><title>References</title><ref id="dta70000-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dta70000-cit-0001">
<string-name name-style="western">
<given-names>C. J.</given-names>
<surname>Bailey</surname>
</string-name> and <string-name name-style="western">
<given-names>R. C.</given-names>
<surname>Turner</surname>
</string-name>, “<article-title>Metformin</article-title>,” <source>New England Journal of Medicine</source>
<volume>334</volume>, no. <issue>9</issue> (<year>1996</year>): <fpage>574</fpage>–<lpage>579</lpage>, <pub-id pub-id-type="doi">10.1056/NEJM199602293340906</pub-id>.<pub-id pub-id-type="pmid">8569826</pub-id>
</mixed-citation></ref><ref id="dta70000-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dta70000-cit-0002">
<string-name name-style="western">
<given-names>G.</given-names>
<surname>Rena</surname>
</string-name>, <string-name name-style="western">
<given-names>D. G.</given-names>
<surname>Hardie</surname>
</string-name>, and <string-name name-style="western">
<given-names>E. R.</given-names>
<surname>Pearson</surname>
</string-name>, “<article-title>The Mechanisms of Action of Metformin</article-title>,” <source>Diabetologia</source>
<volume>60</volume>, no. <issue>9</issue> (<year>2017</year>): <fpage>1577</fpage>–<lpage>1585</lpage>, <pub-id pub-id-type="doi">10.1007/s00125-017-4342-z</pub-id>.<pub-id pub-id-type="pmid">28776086</pub-id>
<pub-id pub-id-type="pmcid">PMC5552828</pub-id></mixed-citation></ref><ref id="dta70000-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dta70000-cit-0003">
<string-name name-style="western">
<given-names>L. J.</given-names>
<surname>McCreight</surname>
</string-name>, <string-name name-style="western">
<given-names>C. J.</given-names>
<surname>Bailey</surname>
</string-name>, and <string-name name-style="western">
<given-names>E. R.</given-names>
<surname>Pearson</surname>
</string-name>, “<article-title>Metformin and the Gastrointestinal Tract</article-title>,” <source>Diabetologia</source>
<volume>59</volume>, no. <issue>3</issue> (<year>2016</year>): <fpage>426</fpage>–<lpage>435</lpage>, <pub-id pub-id-type="doi">10.1007/s00125-015-3844-9</pub-id>.<pub-id pub-id-type="pmid">26780750</pub-id>
<pub-id pub-id-type="pmcid">PMC4742508</pub-id></mixed-citation></ref><ref id="dta70000-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dta70000-cit-0004">
<string-name name-style="western">
<given-names>K. D.</given-names>
<surname>Tinworth</surname>
</string-name>, <string-name name-style="western">
<given-names>R. C.</given-names>
<surname>Boston</surname>
</string-name>, <string-name name-style="western">
<given-names>P. A.</given-names>
<surname>Harris</surname>
</string-name>, <string-name name-style="western">
<given-names>M. N.</given-names>
<surname>Sillence</surname>
</string-name>, <string-name name-style="western">
<given-names>S. L.</given-names>
<surname>Raidal</surname>
</string-name>, and <string-name name-style="western">
<given-names>G. K.</given-names>
<surname>Noble</surname>
</string-name>, “<article-title>The Effect of Oral Metformin on Insulin Sensitivity in Insulin‐Resistant Ponies</article-title>,” <source>Veterinary Journal</source>
<volume>191</volume>, no. <issue>1</issue> (<year>2012</year>): <fpage>79</fpage>–<lpage>84</lpage>, <pub-id pub-id-type="doi">10.1016/j.tvjl.2011.01.015</pub-id>.<pub-id pub-id-type="pmid">21349749</pub-id>
</mixed-citation></ref><ref id="dta70000-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dta70000-cit-0005">
<string-name name-style="western">
<given-names>J. L.</given-names>
<surname>Hustace</surname>
</string-name>, <string-name name-style="western">
<given-names>A. M.</given-names>
<surname>Firshman</surname>
</string-name>, and <string-name name-style="western">
<given-names>J. E.</given-names>
<surname>Mata</surname>
</string-name>, “<article-title>Pharmacokinetics and Bioavailability of Metformin in Horses</article-title>,” <source>American Journal of Veterinary Research</source>
<volume>70</volume>, no. <issue>5</issue> (<year>2009</year>): <fpage>665</fpage>–<lpage>668</lpage>, <pub-id pub-id-type="doi">10.2460/ajvr.70.5.665</pub-id>.<pub-id pub-id-type="pmid">19405907</pub-id>
</mixed-citation></ref><ref id="dta70000-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dta70000-cit-0006">
<string-name name-style="western">
<given-names>S.</given-names>
<surname>Das</surname>
</string-name>, <string-name name-style="western">
<given-names>S. K.</given-names>
<surname>Behera</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Srinivasan</surname>
</string-name>, et al., “<article-title>Effect of Metformin on Exercise Capacity: A Meta‐Analysis</article-title>,” <source>Diabetes Research and Clinical Practice</source>
<volume>144</volume> (<year>2018</year>): <fpage>270</fpage>–<lpage>278</lpage>, <pub-id pub-id-type="doi">10.1016/j.diabres.2018.08.022</pub-id>.<pub-id pub-id-type="pmid">30217594</pub-id>
</mixed-citation></ref><ref id="dta70000-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dta70000-cit-0007">
<string-name name-style="western">
<given-names>H. K.</given-names>
<surname>Knych</surname>
</string-name>, <string-name name-style="western">
<given-names>R. M.</given-names>
<surname>Arthur</surname>
</string-name>, <string-name name-style="western">
<given-names>M. M.</given-names>
<surname>Mitchell</surname>
</string-name>, et al., “<article-title>Pharmacokinetics and Selected Pharmacodynamics of Cobalt Following a Single Intravenous Administration to Horses</article-title>,” <source>Drug Testing and Analysis</source>
<volume>7</volume>, no. <issue>7</issue> (<year>2015</year>): <fpage>619</fpage>–<lpage>625</lpage>, <pub-id pub-id-type="doi">10.1002/dta.1737</pub-id>.<pub-id pub-id-type="pmid">25327415</pub-id>
</mixed-citation></ref><ref id="dta70000-bib-0008"><label>8</label><mixed-citation publication-type="miscellaneous" id="dta70000-cit-0008">
<collab collab-type="authors">Fda, Cder</collab>
“<article-title>Bioanalytical Method Validation Guidance for Industry Biopharmaceutics Bioanalytical Method Validation Guidance for Industry Biopharmaceutics Contains Nonbinding Recommendations</article-title>” (<year>2018</year>) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf" ext-link-type="uri">https://www.fda.gov/files/drugs/published/Bioanalytical‐Method‐Validation‐Guidance‐for‐Industry.pdf</ext-link>.</mixed-citation></ref><ref id="dta70000-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dta70000-cit-0009">
<string-name name-style="western">
<given-names>C.</given-names>
<surname>Bon</surname>
</string-name>, <string-name name-style="western">
<given-names>P. L.</given-names>
<surname>Toutain</surname>
</string-name>, <string-name name-style="western">
<given-names>D.</given-names>
<surname>Concordet</surname>
</string-name>, et al., “<article-title>Mathematical Modeling and Simulation in Animal Health. Part III: Using Nonlinear Mixed‐Effects to Characterize and Quantify Variability in Drug Pharmacokinetics</article-title>,” <source>Journal of Veterinary Pharmacology and Therapeutics</source>
<volume>41</volume>, no. <issue>2</issue> (<year>2018</year>): <fpage>171</fpage>–<lpage>183</lpage>, <pub-id pub-id-type="doi">10.1111/jvp.12473</pub-id>.<pub-id pub-id-type="pmid">29226975</pub-id>
</mixed-citation></ref><ref id="dta70000-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dta70000-cit-0010">
<string-name name-style="western">
<given-names>P. L.</given-names>
<surname>Toutain</surname>
</string-name>, “<article-title>Why the Racing Industry and Equestrian Disciplines Need to Implement Population Pharmacokinetics: To Learn, Explain, Summarize, Harmonize, and Individualize</article-title>,” <source>Drug Testing and Analysis</source>
<volume>17</volume>, no. <issue>2</issue> (<year>2025</year>): <fpage>250</fpage>–<lpage>258</lpage>, <pub-id pub-id-type="doi">10.1002/dta.3706</pub-id>.<pub-id pub-id-type="pmid">38685692</pub-id>
<pub-id pub-id-type="pmcid">PMC11842173</pub-id></mixed-citation></ref><ref id="dta70000-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dta70000-cit-0011">
<string-name name-style="western">
<given-names>S.</given-names>
<surname>Choi</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Jeon</surname>
</string-name>, and <string-name name-style="western">
<given-names>S.</given-names>
<surname>Han</surname>
</string-name>, “<article-title>Population Pharmacokinetic Analysis of Metformin Administered as Fixed‐Dose Combination in Korean Healthy Adults</article-title>,” <source>Translational and Clinical Pharmacology</source>
<volume>26</volume>, no. <issue>1</issue> (<year>2018</year>): <fpage>25</fpage>–<lpage>31</lpage>, <pub-id pub-id-type="doi">10.12793/tcp.2018.26.1.25</pub-id>.<pub-id pub-id-type="pmid">32055544</pub-id>
<pub-id pub-id-type="pmcid">PMC6989222</pub-id></mixed-citation></ref><ref id="dta70000-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dta70000-cit-0012">
<string-name name-style="western">
<given-names>P. J.</given-names>
<surname>Pentikäinen</surname>
</string-name>, <string-name name-style="western">
<given-names>P. J.</given-names>
<surname>Neuvonen</surname>
</string-name>, and <string-name name-style="western">
<given-names>A.</given-names>
<surname>Penttilä</surname>
</string-name>, “<article-title>Pharmacokinetics of Metformin After Intravenous and Oral Administration to Man</article-title>,” <source>European Journal of Clinical Pharmacology</source>
<volume>16</volume>, no. <issue>3</issue> (<year>1979</year>): <fpage>195</fpage>–<lpage>202</lpage>, <pub-id pub-id-type="doi">10.1007/BF00562061</pub-id>.<pub-id pub-id-type="pmid">499320</pub-id>
</mixed-citation></ref><ref id="dta70000-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dta70000-cit-0013">
<string-name name-style="western">
<given-names>G. T.</given-names>
<surname>Tucker</surname>
</string-name>, <string-name name-style="western">
<given-names>C.</given-names>
<surname>Casey</surname>
</string-name>, <string-name name-style="western">
<given-names>P. J.</given-names>
<surname>Phillips</surname>
</string-name>, <string-name name-style="western">
<given-names>H.</given-names>
<surname>Connor</surname>
</string-name>, <string-name name-style="western">
<given-names>J. D.</given-names>
<surname>Ward</surname>
</string-name>, and <string-name name-style="western">
<given-names>H. F.</given-names>
<surname>Woods</surname>
</string-name>, “<article-title>Metformin Kinetics in Healthy Subjects and in Patients With Diabetes Mellitus</article-title>,” <source>British Journal of Clinical Pharmacology</source>
<volume>12</volume>, no. <issue>2</issue> (<year>1981</year>): <fpage>235</fpage>–<lpage>246</lpage>, <pub-id pub-id-type="doi">10.1111/j.1365-2125.1981.tb01206.x</pub-id>.<pub-id pub-id-type="pmid">7306436</pub-id>
<pub-id pub-id-type="pmcid">PMC1401849</pub-id></mixed-citation></ref><ref id="dta70000-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dta70000-cit-0014">
<string-name name-style="western">
<given-names>F.</given-names>
<surname>Robert</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Fendri</surname>
</string-name>, <string-name name-style="western">
<given-names>L.</given-names>
<surname>Hary</surname>
</string-name>, <string-name name-style="western">
<given-names>C.</given-names>
<surname>Lacroix</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Andréjak</surname>
</string-name>, and <string-name name-style="western">
<given-names>J. D.</given-names>
<surname>Lalau</surname>
</string-name>, “<article-title>Kinetics of Plasma and Erythrocyte Metformin After Acute Administration in Healthy Subjects</article-title>,” <source>Diabetes &amp; Metabolism</source>
<volume>29</volume>, no. <issue>3</issue> (<year>2003</year>): <fpage>279</fpage>–<lpage>283</lpage>, <pub-id pub-id-type="doi">10.1016/s1262-3636(07)70037-x</pub-id>.<pub-id pub-id-type="pmid">12909816</pub-id>
</mixed-citation></ref><ref id="dta70000-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dta70000-cit-0015">
<string-name name-style="western">
<given-names>R.</given-names>
<surname>Masereeuw</surname>
</string-name> and <string-name name-style="western">
<given-names>F. G.</given-names>
<surname>Russel</surname>
</string-name>, “<article-title>Mechanisms and Clinical Implications of Renal Drug Excretion</article-title>,” <source>Drug Metabolism Reviews</source>
<volume>33</volume>, no. <issue>3–4</issue> (<year>2001</year>): <fpage>299</fpage>–<lpage>351</lpage>, <pub-id pub-id-type="doi">10.1081/dmr-120000654</pub-id>.<pub-id pub-id-type="pmid">11768771</pub-id>
</mixed-citation></ref><ref id="dta70000-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="dta70000-cit-0016">
<string-name name-style="western">
<given-names>P. L.</given-names>
<surname>Toutain</surname>
</string-name>, “<article-title>How to Extrapolate a Withdrawal Time From an EHSLC Published Detection Time: A Monte Carlo Simulation Appraisal</article-title>,” <source>Equine Veterinary Journal</source>
<volume>42</volume>, no. <issue>3</issue> (<year>2010</year>): <fpage>248</fpage>–<lpage>254</lpage>, <pub-id pub-id-type="doi">10.1111/j.2042-3306.2010.00028.x</pub-id>.<pub-id pub-id-type="pmid">20486982</pub-id>
</mixed-citation></ref><ref id="dta70000-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="dta70000-cit-0017">
<string-name name-style="western">
<given-names>T.</given-names>
<surname>Kuroda</surname>
</string-name>, <string-name name-style="western">
<given-names>Y.</given-names>
<surname>Minamijima</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Nomura</surname>
</string-name>, et al., “<article-title>Medication Control of Flunixin in Racing Horses: Possible Detection Times Using Monte Carlo Simulations</article-title>,” <source>Equine Veterinary Journal</source>
<volume>54</volume>, no. <issue>5</issue> (<year>2022</year>): <fpage>979</fpage>–<lpage>988</lpage>, <pub-id pub-id-type="doi">10.1111/evj.13532</pub-id>.<pub-id pub-id-type="pmid">34719043</pub-id>
<pub-id pub-id-type="pmcid">PMC9546317</pub-id></mixed-citation></ref><ref id="dta70000-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="dta70000-cit-0018">
<string-name name-style="western">
<given-names>M.</given-names>
<surname>Scheurer</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Michel</surname>
</string-name>, <string-name name-style="western">
<given-names>H. J.</given-names>
<surname>Brauch</surname>
</string-name>, <string-name name-style="western">
<given-names>W.</given-names>
<surname>Ruck</surname>
</string-name>, and <string-name name-style="western">
<given-names>F.</given-names>
<surname>Sacher</surname>
</string-name>, “<article-title>Occurrence and Fate of the Antidiabetic Drug Metformin and Its Metabolite Guanylurea in the Environment and During Drinking Water Treatment</article-title>,” <source>Water Research</source>
<volume>46</volume>, no. <issue>15</issue> (<year>2012</year>): <fpage>4790</fpage>–<lpage>4802</lpage>, <pub-id pub-id-type="doi">10.1016/j.watres.2012.06.019</pub-id>.<pub-id pub-id-type="pmid">22770965</pub-id>
</mixed-citation></ref></ref-list></back></article><article article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Drug Metab Pharmacokinet</journal-id><journal-id journal-id-type="iso-abbrev">Eur J Drug Metab Pharmacokinet</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>European Journal of Drug Metabolism and Pharmacokinetics</journal-title></journal-title-group><issn pub-type="ppub">0378-7966</issn><issn pub-type="epub">2107-0180</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12394267</article-id><article-id pub-id-type="pmcid-ver">PMC12394267.1</article-id><article-id pub-id-type="pmcaid">12394267</article-id><article-id pub-id-type="pmcaiid">12394267</article-id><article-id pub-id-type="pmid">40839056</article-id><article-id pub-id-type="doi">10.1007/s13318-025-00961-4</article-id><article-id pub-id-type="publisher-id">961</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title>Bioequivalence and Pharmacokinetic Evaluation of Two Metformin Hydrochloride Tablets Under Fasting and Fed Conditions in Healthy Chinese Volunteers</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Huang</surname><given-names initials="Y">Yuxing</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Cai</surname><given-names initials="Q">Qiuhan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="M">Meifang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guo</surname><given-names initials="S">Shengxuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dong</surname><given-names initials="G">Gaiying</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hu</surname><given-names initials="S">Siyuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6200-0749</contrib-id><name name-style="western"><surname>Zhong</surname><given-names initials="C">Chengliang</given-names></name><address><email>clitripro@sina.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02fsmcz03</institution-id><institution-id institution-id-type="GRID">grid.412635.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1799 2712</institution-id><institution>Clinical Trials Center, </institution><institution>First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, </institution></institution-wrap>No. 88 ChangLin Road, XiQing District, Tianjin, 300193 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05dfcz246</institution-id><institution-id institution-id-type="GRID">grid.410648.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 1816 6218</institution-id><institution>National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, </institution></institution-wrap>Tianjin, 300193 China </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>50</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">495778</issue-id><fpage>431</fpage><lpage>440</lpage><history><date date-type="accepted"><day>22</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>21</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>30</day><month>08</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-08-30 01:25:20.207"><day>30</day><month>08</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>© The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13318_2025_Article_961.pdf"/><abstract id="Abs1"><sec><title>Background and Objectives</title><p id="Par1">With diabetes prevalence rising and original formulations unable to meet demand, establishing generic equivalence is crucial for treatment accessibility. This study evaluated the bioequivalence of generic metformin hydrochloride (0.25 g) versus the reference drug in Chinese volunteers under fasting and fed conditions.</p></sec><sec><title>Methods</title><p id="Par2">In this randomized, open-label, two-period crossover trial, 26 healthy volunteers per group received single doses under fasting and fed conditions. Plasma concentrations were measured using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, pharmacokinetic metrics were calculated using the WinNonlin 6.3 software, and bioequivalence was evaluated using SAS 9.4.</p></sec><sec><title>Results</title><p id="Par3">Under fasting conditions, the geometric mean ratios (GMRs) between the test and reference groups were 103.12% (C<sub>max</sub>), 103.65% (AUC<sub>0-t</sub>), and 103.31% (AUC<sub>0-∞</sub>), with 90% CIs of 92.64–114.78%, 96.04–111.85%, and 96.00–111.17%, respectively. Fed conditions yielded GMRs of 93.98% (C<sub>max</sub>), 97.34% (AUC<sub>0-t</sub>), and 96.97% (AUC<sub>0-∞</sub>), with 90% CIs of 89.42–98.78%, 92.72–102.18%, and 92.40–101.78%, respectively. All these parameters met bioequivalence criteria (80–125%). Median T<sub>max</sub> was delayed under fed conditions (2.125 h vs. 4.000 h), with consistent food effects (reduced C<sub>max</sub> and AUC) and safety profiles between formulations.</p></sec><sec><title>Conclusion</title><p id="Par4">These results demonstrate that the generic metformin formulation is bioequivalent to the innovative product and well tolerated in Chinese healthy volunteers under both fasting and fed conditions.</p></sec></abstract><funding-group><award-group><funding-source><institution>Tianjin Kangrui Pharmaceutical Co., Ltd.</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© Springer Nature Switzerland AG 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="FPar1"><title>Key Points</title><p id="Par500">
<table-wrap id="Taba" position="float" orientation="portrait"><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="2" rowspan="1"><p>Bioequivalence was demonstrated between generic and branded metformin tablets in healthy Chinese volunteers, with 90% CIs for Cmax, AUC0-t and AUC0-∞ geometric mean ratios all falling within the 80–125% acceptance range.</p><p>Food intake confirmed comparable pharmacokinetic impacts (delayed T<sub>max</sub>, reduced C<sub>max</sub>, and AUC) for both formulations.</p><p>No serious adverse events were reported, supporting the clinical suitability of the generic formulation.</p></td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec1"><title>Introduction</title><p id="Par5">Background and Objectives: diabetes mellitus (DM) is one of the most serious diseases in the world. It is a metabolic disease characterized by hyperglycemia and accompanied by some complications such as macrovascular and microvascular diseases [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. According to the International Diabetes Federation, the number of patients with diabetes worldwide reached 366 million in 2011 and will be 552 million by 2030 [<xref ref-type="bibr" rid="CR3">3</xref>]; about 93.7% of total diabetes cases are type 2 (T2DM) [<xref ref-type="bibr" rid="CR4">4</xref>]. Especially in developing countries like China, the incidence of T2DM is very high [<xref ref-type="bibr" rid="CR5">5</xref>]. Therefore, in order to meet the market demand, it is urgent to develop drugs for the treatment of T2DM.</p><p id="Par6">Metformin hydrochloride (MH) tablets are now included in the Chinese Pharmacopoeia and the National Basic Medical Insurance Directory, and are widely used in clinical practice for the first-line treatment of T2DM. They are currently listed as a Class A national essential drug. Metformin was first approved in France as a hypoglycemic drug, and has been used clinically for over 60 years [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. As a kind of guanidine antidiabetic drug [<xref ref-type="bibr" rid="CR8">8</xref>], metformin can reduce the basic and fed blood glucose of T2DM patients and improve blood glucose tolerance by reducing liver glucose production and absorption and improving insulin-mediated glucose uptake and utilization [<xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par7">Due to its huge market demand and excellent sugar control effect, many metformin generic drugs have entered the market, making bioequivalence testing for evaluating generic drugs and innovative drugs a very important research tool. According to the requirements of the China Food and Drug Administration (CFDA), before being marketed, any generic drug must be evaluated for its quality and efficacy equivalent to the original drug. There are reports showing that pharmacokinetic properties of MH can affected by food [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Therefore, the aim of this study was to investigate the bioequivalence and safety of generic MH tablets under fasting and fed conditions in Chinese health volunteers.</p></sec><sec id="Sec2"><title>Materials and Methods</title><p id="Par8">This clinical trial was registered in the Chinese Clinical Trial Registry (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml">http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml</ext-link>; registration no.: CTR20180793), and its study protocol was approved by the Medical Ethics Committee at the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. The experiment was conducted at the Clinical Trial Center of the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, and the entire trial process fully complied with the ICH-GCP management standards and the principles of the Helsinki Declaration [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>], and all subjects signed informed consent forms.</p><sec id="Sec3"><title>Study Pharmaceuticals</title><p id="Par9">Generic formulations [test formulation (T)]: MH tablets, specification: 0.25 g/tablet, Lot 171201, 171202, 171203, produced and provided by Tianjin Kangrui Pharmaceutical. The main component was 1,1-dimethylbiguanide hydrochloride (C<sub>4</sub>H<sub>11</sub>N<sub>5</sub>·HCl), with a content of 102.4%, which complied with the assay standard of 95–105% of the labeled amount (Chinese Pharmacopoeia 2015 Edition). The excipients primarily included pregelatinized starch (diluent), mannitol (diluent), sorbitol (diluent), povidone K30 (binder), magnesium stearate (lubricant), and film-coating agent (coating agent).</p><p id="Par10">Innovative products [reference formulation (R)]: MH tablets (Glycoran), specification: 0.25 g/tablet, Lot 357801, produced by Nippon Shinyaku, provided by Tianjin Kangrui Pharmaceutical. Its main active ingredient was the same as that of the test preparation, with a content of 102.6%. The excipients mainly included mannitol (diluent), starch (filler), hydroxypropyl methyl cellulose (binder), magnesium stearate (lubricant), and coating agent.</p><p id="Par11">MH tablets manufactured by Tianjin Kangrui Pharmaceutical demonstrated significantly different dissolution profiles (at pH 1.2, 4.0, 6.8, and in water) from the reference product, prompting comprehensive formulation and process optimization. Based on the reference tablet specifications (280 mg weight with 88% active content), the development focused on resolving dissolution and compressibility challenges inherent to this high-drug load formulation. Given the lamellar crystal structure of the active pharmaceutical ingredient, a milling process followed by wet granulation was employed. Through systematic excipient selection including pregelatinized starch (enhancing compressibility and disintegration), mannitol/sorbitol (improving both compressibility and dissolution), and povidone (as a water-soluble binder), an optimized formulation was successfully developed that achieves over 90% drug release within 15 min.</p><p id="Par12">Based on dissolution testing results, the test and reference preparations can be concluded to exhibit similar dissolution profiles with consistent in vitro dissolution curves when meeting all the following criteria: (1) the relative standard deviation (RSD) of dissolution amounts at the first sampling time point was ≤ 20% for each batch across all four dissolution media (at pH 1.2, 4.0, 6.8, and in water); (2) the RSD of dissolution amounts at all subsequent sampling time points was ≤10%; and (3) both preparations achieved ≥ 85% dissolution within 15 min.</p></sec><sec id="Sec4"><title>Study Population</title><p id="Par13">Inclusion criteria: Chinese volunteers aged 18-45 years, with a BMI of 19-26 kg/m<sup>2</sup> and weighing ≥ 50 kg (male) or ≥ 45 kg (female), were recruited; no clinically significant abnormalities in medical history, physical examination, laboratory tests, or other assessments, as determined by the investigator; ability to communicate effectively with the investigator and comply with all study requirements; full understanding of the trial’s purpose, procedures, potential benefits, risks, and inconveniences; voluntary participation; and provision of written informed consent.</p><p id="Par14">Exclusion criteria: as determined by the investigator, subjects were excluded if they had: drug/component allergies; lactic acidosis or significant organ/psychiatric disorders; clinically relevant test abnormalities; bleeding risk; recent drug abuse/positive screen; alcohol abuse/excessive use; high caffeine intake (&gt; 8 cups/day); other trial participation (3 months); smoking &gt; 5 cigarettes/day or non-abstinence; recent medication use (2 weeks); or HBV/HCV/syphilis/HIV seropositivity.</p></sec><sec id="Sec5"><title>Trial Design</title><p id="Par15">This trial employed a single-dose, randomized, open-label, two-period crossover design to evaluate oral administration under both fasting and fed conditions (Fig<xref rid="Fig1" ref-type="fig">. 1</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Schematic of the study design. Test formulations (T): metformin hydrochloride tablets, Tianjin Kangrui Pharmaceutical. Reference formulations (R): metformin hydrochloride tablets (Glycoran), Nippon Shinyaku</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="13318_2025_961_Fig1_HTML.jpg"/></fig></p><p id="Par16">Fasting trial: 26 subjects were randomly divided into groups A and B based on screening numbers from small to large. In the first period, group A received the test formulation, and group B received the reference formulation. After a 7-day washout period, in the second period, group A received the reference formulation, and group B received the test formulation, with a dose of 0.25 g/person. During the trial, 4 mL of venous blood was collected from the elbow before administration (− 30 min) and at 0.25 h, 0.5 h, 1 h, 1.5 h, 1.75 h, 2 h, 2.25 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 16 h, and 24 h after administration into lithium heparin tubes. After blood collection, the tubes were placed in a pre-cooled low-temperature centrifuge and centrifuged at 4–8 ℃, 3000 rpm for 10 min. The plasma was transferred to corresponding sample storage tubes and stored at – 70 ℃ until analysis.</p><p id="Par17">Fed trial: In this trial, there were also 26 subjects. Except for taking the medication half an hour after a meal and collecting 4 mL of venous blood from the elbow before administration (− 30 min) and at 0.25 h, 0.5 h, 1 h, 1.5 h, 1.75 h, 2 h, 2.25 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, and 24 h after administration into lithium heparin tubes, the other parts of the trial were the same as the fasting trial.</p></sec><sec id="Sec6"><title>Pharmacokinetic Methods</title><p id="Par18">Plasma concentrations of metformin were determined by Tianjin Pharmaceutical Research Institute New Drug Evaluation, and analyzed using a validated liquid chromatography–tandem mass spectrometry (LC-MS/MS) method. The LC-MS/MS system consisted of an LC-30AD binary gradient pump (Shimadzu, Japan), a Sciex TRIPLE QUADTM 5500 triple quadrupole tandem mass spectrometer (Applied Biosystems, USA), and Analyst Instrument Control and Processing Software 1.5.2 (Applied Biosystems).</p><p id="Par19">Liquid chromatography was performed using a Venusil ASB C18 (4.6 × 150 mm, 5 μm) column, with a temperature of 40 ℃. The mobile phases were 100% acetonitrile (phase A) and an aqueous solution of 0.1% formic acid, 5% acetonitrile, and 10 mM ammonium acetate (phase B). The injection volume was 5 μL, the injector temperature was 6 ℃, and the run time was 10 min. The gradient of the mobile phase was 0 min 70% phase A, 3 min 40% phase A, 5.5 min 40% phase A, 5.6 min 5% phase A, 8 min 5% phase A, 8.1 min 70% phase A, and 10 min phase A.</p><p id="Par20">Mass spectrometry was using with the following parameters: ion source: ESI<sup>+</sup>; detection mode: MRM; ion source spray voltage: 4000 V; curtain gas: 35 psi; collision gas: 7 psi; source temperature: 350 ℃; source gas 1 (Gas1): 50 psi; source gas 2 (Gas2): 50 psi; metformin hydrochloride ion pair <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 130.1/59.9, declustering potential (DP): 30 V, collision energy (CE): 15 eV; metformin hydrochloride-d6 (internal standard, IS) ion pair 136.0/60.0, DP: 30 V, CE: 18 eV.</p><p id="Par21">In accordance with the <italic toggle="yes">Technical Guidelines for Clinical Pharmacokinetic Studies of Chemical Drugs</italic> [<xref ref-type="bibr" rid="CR16">16</xref>] and <italic toggle="yes">Guidelines for Bioanalytical Method Validation</italic> [<xref ref-type="bibr" rid="CR17">17</xref>], we developed and fully validated an LC-MS/MS method for metformin quantification in human plasma, demonstrating reliability, accuracy, and sensitivity. The detailed results are as follows: quality control (QC) samples at low (LQC, 12.5 ng/mL), medium (MQC, 80 ng/mL), and high (HQC, 800 ng/mL) concentrations were analyzed to assess precision and accuracy. The lower limit of quantification (LLOQ) was established at 5.00 ng/mL, with a mean accuracy of 99.2%, intra-batch precision of 1.13–2.78%, and inter-batch precision of 3.05%. Carryover was evaluated by injecting blank plasma following the HQC sample, confirming analyte response &lt; 20% of the LLOQ and IS response &lt; 5% of the LLOQ IS. The assay exhibited linearity over the range of 5.00–1000 ng/mL (<italic toggle="yes">r</italic> ≥ 0.9989).</p><p id="Par23">For the metformin QC samples, mean accuracy ranged from 95.4% to 108%, with intra-batch precision of 0.883–2.29% and inter-batch precision of 1.57–3.66%. Recovery rates at the three QC levels were 90.7%, 88.5%, and 107%, respectively, with an overall recovery coefficient of variation (CV) of 1.99%. No significant matrix effect was observed. Stability was demonstrated for metformin stock solutions, working solutions, and drug-containing plasma under ambient, frozen, and freeze–thaw conditions (for both LQC and HQC samples, accuracy: 92.3–105%), all meeting acceptance criteria (accuracy: 85–115%).</p></sec><sec id="Sec7"><title>Safety Assessment</title><p id="Par24">Safety was monitored through subject-reported adverse events (AEs), changes in clinical laboratory results (including routine blood and urine tests, blood biochemistry), electrocardiogram results, clinical symptoms, and vital sign measurements. All safety data, including prespecified evaluations, were assessed by investigators to determine their clinical significance. Any abnormalities or AEs were documented, graded for severity, and evaluated for potential relationship to the study intervention. The AE-related terms and their severity levels were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.</p></sec><sec id="Sec8"><title>Statistical Analysis</title><p id="Par25">WinNonlin 6.3 software was used for calculation. The pharmacokinetic parameters of metformin were calculated using a non-compartmental model. C<sub>max</sub> and T<sub>max</sub> were derived directly from the observed blood concentration-time data. All pharmacokinetic analyses were performed using actual sampling times. AUC<sub>0-t</sub> represents the area under the concentration–time curve from administration (time 0) to the last quantifiable concentration time point. AUC<sub>0-∞</sub> denotes the area under the curve extrapolated to infinity, calculated as AUC<sub>0-t</sub> + Ct/λz; Ct is the last measurable concentration; λz is the elimination rate constant, determined as the slope of the terminal phase of the log-transformed concentration-time curve using linear regression, and T<sub>1</sub><sub>/2</sub> is calculated as 0.693/λz.</p><p id="Par26">In the comparative analysis of pharmacokinetic parameters between groups during fasting and fed studies, normally distributed parameters were analyzed using Student's <italic toggle="yes">t</italic> test, while non-normally distributed parameters were evaluated with the Wilcoxon rank-sum test.</p><p id="Par27">The main pharmacokinetic parameters (C<sub>max</sub>, AUC<sub>0-t</sub>, AUC<sub>0-∞</sub>) were logarithmically transformed and analyzed by variance analysis (ANOVA). The ANOVA model considered factors including administration sequence, drug, and period within the sequence. The geometric mean ratio (GMR) of these primary pharmacokinetic metrics (T/R) and their 90% confidence intervals (CIs) were calculated. The two preparations were considered bioequivalent if the 90% CIs of the ratios of GMR of the primary pharmacokinetic metrics were within the predefined acceptance range of 80–125%.</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Demographics</title><p id="Par28">The total number of participants in this trial was 52 subjects (fasting group <italic toggle="yes">n</italic> = 26, fed group <italic toggle="yes">n</italic> = 26). All 26 subjects (14 male, 12 female) in the fasting group completed the study. The demographic details (mean ± SD) were as follows: age 28.46 ± 4.55 years, height 162.27 ± 7.75 cm, weight 60.26 ± 7.66 kg, and BMI 22.82 ± 1.74 kg/m<sup>2</sup>. A total of 26 subjects (10 male, 16 female) were enrolled in the fed group. The demographic details (mean ± SD) were as follows: age 25.46 ± 1.90 years, height 163.77 ± 9.75 cm, weight 60.28 ± 9.79 kg, and BMI 22.37 ± 2.08 kg/m<sup>2</sup>.</p></sec><sec id="Sec11"><title>Pharmacokinetics</title><sec id="Sec12"><title>Fasting Group</title><p id="Par29">The average plasma concentration–time curves of metformin in 26 healthy subjects after oral administration of the test or reference formulation under fasting conditions are shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref>.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Average plasma concentration–time curve of metformin in 26 subjects after a single dose of the test and reference formulations under fasting conditions. <bold>A</bold> linear plot, <bold>B</bold> semilogarithmic plot, <italic toggle="yes">R</italic> reference formulation, <italic toggle="yes">T</italic> test formulation</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="13318_2025_961_Fig2_HTML.jpg"/></fig></p><p id="Par30">The pharmacokinetic parameters of metformin in 26 healthy subjects after oral administration of the test or reference formulation under fasting conditions are shown in Table <xref rid="Tab1" ref-type="table">1</xref>. The values of main pharmacokinetic parameters of the T and R formulations of metformin in plasma were as follows: C<sub>max</sub> were 649.962 ± 187.753 and 639.346 ± 238.045 ng/ml, AUC<sub>0-t</sub> were 4046.110 ± 671.011 and 3980.744 ± 1050.723 h × (ng/ml), AUC<sub>0-∞</sub> were 4096.179 ± 668.817 and 4039.428 ± 1048.122 h × (ng/ml), and T<sub>max</sub> were both 2.125 (0.500, 5.000) h.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Pharmacokinetic parameters of metformin after oral administration of the test and reference formulations under fasting (<italic toggle="yes">n = </italic>26) and fed (<italic toggle="yes">n = </italic>26) conditions</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Metrics</th><th align="left" colspan="1" rowspan="1">Fasting group (<italic toggle="yes">n = </italic>26)</th><th align="left" colspan="1" rowspan="1">Fed group (<italic toggle="yes">n = </italic>26)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1"><italic toggle="yes">Test formulation</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">C<sub>max</sub>, ng/mL</td><td align="left" colspan="1" rowspan="1">649.962 ± 187.753 (28.89)</td><td align="left" colspan="1" rowspan="1">328.154 ± 69.591 (21.21)</td><td align="left" colspan="1" rowspan="1">&lt;0.0001<sup>a</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">AUC<sub>0–t</sub>, h × ng/mL</td><td align="left" colspan="1" rowspan="1">4046.110 ± 671.011 (16.58)</td><td align="left" colspan="1" rowspan="1">2791.888 ± 632.374 (22.65)</td><td align="left" colspan="1" rowspan="1">&lt;0.0001<sup>a</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">AUC<sub>0–∞</sub>, h × ng/mL</td><td align="left" colspan="1" rowspan="1">4096.179 ± 668.817 (16.33)</td><td align="left" colspan="1" rowspan="1">2799.979 ± 587.624 (20.99)</td><td align="left" colspan="1" rowspan="1">&lt;0.0001<sup>a</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">T<sub>max</sub>, h</td><td align="left" colspan="1" rowspan="1">2.125 (0.500, 5.000)</td><td align="left" colspan="1" rowspan="1">4.000 (1.000, 8.000)</td><td align="left" colspan="1" rowspan="1">0.0002<sup>b</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">t<sub>½</sub>, h</td><td align="left" colspan="1" rowspan="1">3.801 ± 0.431 (11.35)</td><td align="left" colspan="1" rowspan="1">3.604 ± 0.403 (11.19)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">λ<sub>z</sub>, 1/h</td><td align="left" colspan="1" rowspan="1">0.185 ± 0.021 (11.33)</td><td align="left" colspan="1" rowspan="1">0.195 ± 0.023 (11.97)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><italic toggle="yes">Reference formulation</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">C<sub>max</sub>, ng/mL</td><td align="left" colspan="1" rowspan="1">639.346 ± 238.045 (37.23)</td><td align="left" colspan="1" rowspan="1">347.769 ± 66.178 (19.03)</td><td align="left" colspan="1" rowspan="1">&lt;0.0001<sup>a</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">AUC<sub>0–t</sub>, h × ng/mL</td><td align="left" colspan="1" rowspan="1">3980.744 ± 1050.723 (26.40)</td><td align="left" colspan="1" rowspan="1">2846.963 ± 556.941 (19.56)</td><td align="left" colspan="1" rowspan="1">&lt;0.0001<sup>a</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">AUC<sub>0–∞</sub>, h × ng/mL</td><td align="left" colspan="1" rowspan="1">4039.428 ± 1048.122 (25.95)</td><td align="left" colspan="1" rowspan="1">2903.056 ± 555.024 (19.12)</td><td align="left" colspan="1" rowspan="1">&lt;0.0001<sup>a</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">T<sub>max</sub>, h, median (min, max)</td><td align="left" colspan="1" rowspan="1">2.125 (0.500, 5.000)</td><td align="left" colspan="1" rowspan="1">4.000 (0.500, 6.000)</td><td align="left" colspan="1" rowspan="1">0.0049<sup>b</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">t<sub>½</sub>, h</td><td align="left" colspan="1" rowspan="1">3.388 ± 0.586 (17.29)</td><td align="left" colspan="1" rowspan="1">3.563 ± 0.333 (9.35)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">λ<sub>z</sub>, 1/h</td><td align="left" colspan="1" rowspan="1">0.212 ± 0.044 (20.63)</td><td align="left" colspan="1" rowspan="1">0.196 ± 0.022 (11.33)</td><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>Data are presented as arithmetic mean ± standard deviation (% coefficient of variation), except T<sub>max</sub> presented as median (min, max)</p><p><sup>a</sup>The comparative analysis of C<sub>max</sub>, AUC<sub>0–t</sub> and AUC<sub>0–∞</sub> between groups during fasting and fed studies, were analyzed using Student’s <italic toggle="yes">t</italic> test</p><p><sup>b</sup>The comparative analysis of T<sub>max</sub> between groups during fasting and fed studies was evaluated with the Wilcoxon rank-sum test</p></table-wrap-foot></table-wrap></p><p id="Par31">The values of GMRs of C<sub>max</sub>, AUC<sub>0-t</sub> and AUC<sub>0-∞</sub> of metformin in plasma between the test and reference groups were 103.12%, 103.65%, and 103.31%. The 90% CIs (91.30–113.75% for C<sub>max</sub>, 95.07–111.17% for AUC<sub>0-t</sub>, 5.13–110.67% for AUC<sub>0-∞</sub>) of the GMR for these pharmacokinetic parameters (T/R) were within the predefined equivalence limit of 80.00–125.00% (Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Bioequivalence analysis of the metformin in the fasting group (<italic toggle="yes">n=</italic>26)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Metrics</th><th align="left" colspan="3" rowspan="1">Geometric mean and radio</th><th align="left" rowspan="2" colspan="1">90%CI</th><th align="left" rowspan="2" colspan="1">CV (%)</th><th align="left" rowspan="2" colspan="1">Power</th></tr><tr><th align="left" colspan="1" rowspan="1">Test</th><th align="left" colspan="1" rowspan="1">Reference</th><th align="left" colspan="1" rowspan="1">T/R%</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Ln (C<sub>max</sub>)</td><td char="." align="char" colspan="1" rowspan="1">624.419</td><td char="." align="char" colspan="1" rowspan="1">605.552</td><td char="." align="char" colspan="1" rowspan="1">103.12</td><td align="left" colspan="1" rowspan="1">92.64~114.78</td><td char="." align="char" colspan="1" rowspan="1">22.87</td><td char="." align="char" colspan="1" rowspan="1">0.9619</td></tr><tr><td align="left" colspan="1" rowspan="1">Ln (AUC<sub>0–t</sub>)</td><td char="." align="char" colspan="1" rowspan="1">3990.079</td><td char="." align="char" colspan="1" rowspan="1">3849.701</td><td char="." align="char" colspan="1" rowspan="1">103.65</td><td align="left" colspan="1" rowspan="1">96.04~111.85</td><td char="." align="char" colspan="1" rowspan="1">16.16</td><td char="." align="char" colspan="1" rowspan="1">0.9985</td></tr><tr><td align="left" colspan="1" rowspan="1">Ln (AUC<sub>0–∞</sub>)</td><td char="." align="char" colspan="1" rowspan="1">4041.067</td><td char="." align="char" colspan="1" rowspan="1">3911.626</td><td char="." align="char" colspan="1" rowspan="1">103.31</td><td align="left" colspan="1" rowspan="1">96.00~111.17</td><td char="." align="char" colspan="1" rowspan="1">15.55</td><td char="." align="char" colspan="1" rowspan="1">0.9991</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">CI</italic> confidence interval, <italic toggle="yes">CV</italic> coefficient of variation</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Fed Group</title><p id="Par32">The average plasma concentration-time curves of metformin in 26 healthy subjects after oral administration of the test or reference formulation under fed conditions are shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>.<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Average plasma concentration-time curve of metformin in 26 subjects after a single dose of the test and reference formulations under fed conditions. <bold>A</bold> linear plot, <bold>B</bold> semilogarithmic plot, <italic toggle="yes">R</italic> reference formulation, <italic toggle="yes">T</italic> test formulation</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="13318_2025_961_Fig3_HTML.jpg"/></fig></p><p id="Par33">The pharmacokinetic parameters of metformin in 26 healthy subjects after oral administration of the test or reference formulation under fasting conditions are shown in Tables <xref rid="Tab1" ref-type="table">1</xref>. The values of main pharmacokinetic parameters of the T and R formulations of metformin in plasma were as follows: C<sub>max</sub> were 328.154 ± 69.591 and 347.769 ± 66.178 ng/ml, AUC<sub>0-t</sub> were 2791.888 ± 632.374 and 2846.963 ± 556.941 h × (ng/ml), AUC<sub>0-∞</sub> were 2799.979 ± 587.624 and 2903.056 ± 555.024 h × (ng/ml), and T<sub>max</sub> were 4.000 (1.000, 8.000) and 4.000 (0.500, 6.000) h.</p><p id="Par34">The values of GMRs of C<sub>max</sub>, AUC<sub>0-t</sub> and AUC<sub>0-∞</sub> of metformin in plasma between the test and reference groups were 93.98%, 97.34%, and 96.97%. The 90% CIs (89.42–98.78% for C<sub>max</sub>, 92.72–102.18% for AUC<sub>0-t</sub>, 92.40–101.78% for AUC<sub>0-∞</sub>) of the GMR for these pharmacokinetic parameters (T/R) were within the predefined equivalence limit of 80.00–125.00% (Table <xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Bioequivalence analysis of the metformin in the fed group (<italic toggle="yes">n = </italic>26)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Metrics</th><th align="left" colspan="3" rowspan="1">Geometric mean and radio</th><th align="left" rowspan="2" colspan="1">90%CI</th><th align="left" rowspan="2" colspan="1">CV (%)</th><th align="left" rowspan="2" colspan="1">Power</th></tr><tr><th align="left" colspan="1" rowspan="1">Test</th><th align="left" colspan="1" rowspan="1">Reference</th><th align="left" colspan="1" rowspan="1">T/R%</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Ln (C<sub>max</sub>)</td><td char="." align="char" colspan="1" rowspan="1">321.263</td><td char="." align="char" colspan="1" rowspan="1">341.843</td><td char="." align="char" colspan="1" rowspan="1">93.98</td><td align="left" colspan="1" rowspan="1">89.42~98.78</td><td char="." align="char" colspan="1" rowspan="1">10.52</td><td char="." align="char" colspan="1" rowspan="1">1.0000</td></tr><tr><td align="left" colspan="1" rowspan="1">Ln (AUC<sub>0–t</sub>)</td><td char="." align="char" colspan="1" rowspan="1">2721.320</td><td char="." align="char" colspan="1" rowspan="1">2795.770</td><td char="." align="char" colspan="1" rowspan="1">97.34</td><td align="left" colspan="1" rowspan="1">92.72~102.18</td><td char="." align="char" colspan="1" rowspan="1">10.26</td><td char="." align="char" colspan="1" rowspan="1">1.0000</td></tr><tr><td align="left" colspan="1" rowspan="1">Ln (AUC<sub>0–∞</sub>)</td><td char="." align="char" colspan="1" rowspan="1">2767.690</td><td char="." align="char" colspan="1" rowspan="1">2854.137</td><td char="." align="char" colspan="1" rowspan="1">96.97</td><td align="left" colspan="1" rowspan="1">92.40~101.78</td><td char="." align="char" colspan="1" rowspan="1">10.00</td><td char="." align="char" colspan="1" rowspan="1">1.0000</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">CI</italic> confidence interval, <italic toggle="yes">CV</italic> coefficient of variation</p></table-wrap-foot></table-wrap></p><p id="Par35">Additionally, in both the fasting and fed states, three-way ANOVA of the primary pharmacokinetic parameters (C<sub>max</sub>, AUC<sub>0-t</sub> and AUC<sub>0-∞</sub>) revealed no statistically significant differences (all <italic toggle="yes">p</italic> &gt; 0.05) between the T and R formulations, with no significant sequence, period, or formulation observed (Table <xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Results (<italic toggle="yes">p</italic> values) of ANOVA test of bioequivalence between the two formulations in the fasting and fed groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Influence factor</th><th align="left" colspan="3" rowspan="1">Fasting group</th><th align="left" colspan="3" rowspan="1">Fed group</th></tr><tr><th align="left" colspan="1" rowspan="1">Ln (C<sub>max</sub>)</th><th align="left" colspan="1" rowspan="1">Ln (AUC<sub>0–t</sub>)</th><th align="left" colspan="1" rowspan="1">Ln (AUC<sub>0–∞</sub>)</th><th align="left" colspan="1" rowspan="1">Ln (C<sub>max</sub>)</th><th align="left" colspan="1" rowspan="1">Ln (AUC<sub>0–t</sub>)</th><th align="left" colspan="1" rowspan="1">Ln (AUC<sub>0–∞</sub>)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Sequence</td><td char="." align="char" colspan="1" rowspan="1">0.4785</td><td char="." align="char" colspan="1" rowspan="1">0.6561</td><td char="." align="char" colspan="1" rowspan="1">0.6507</td><td char="." align="char" colspan="1" rowspan="1">0.0978</td><td char="." align="char" colspan="1" rowspan="1">0.7076</td><td char="." align="char" colspan="1" rowspan="1">0.6452</td></tr><tr><td align="left" colspan="1" rowspan="1">Periods</td><td char="." align="char" colspan="1" rowspan="1">0.8274</td><td char="." align="char" colspan="1" rowspan="1">0.9543</td><td char="." align="char" colspan="1" rowspan="1">0.9104</td><td char="." align="char" colspan="1" rowspan="1">0.8313</td><td char="." align="char" colspan="1" rowspan="1">0.0073</td><td char="." align="char" colspan="1" rowspan="1">0.0058</td></tr><tr><td align="left" colspan="1" rowspan="1">Formulation</td><td char="." align="char" colspan="1" rowspan="1">0.6286</td><td char="." align="char" colspan="1" rowspan="1">0.4291</td><td char="." align="char" colspan="1" rowspan="1">0.4551</td><td char="." align="char" colspan="1" rowspan="1">0.0433</td><td char="." align="char" colspan="1" rowspan="1">0.3516</td><td char="." align="char" colspan="1" rowspan="1">0.2868</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec14"><title>Safety Analysis</title><p id="Par36">Both the test and reference formulations demonstrated good tolerability throughout the study period under both fasting and fed conditions. No protocol violations or serious adverse events (SAEs) were reported in any treatment group. A total of 9 subjects experienced adverse events (AEs), with 2 cases occurring during the fasting test and 7 cases during the fed test (Table <xref rid="Tab5" ref-type="table">5</xref>). All reported AEs were mild to moderate in severity and resolved without sequelae. The incidence of AEs was consistent with the known safety profile of the investigational product, and no new safety concerns were identified during the trial.<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Adverse events in the fasting and fed groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Administration conditions</th><th align="left" colspan="1" rowspan="1">Random number</th><th align="left" colspan="1" rowspan="1">AEs</th><th align="left" colspan="1" rowspan="1">Treatment</th><th align="left" colspan="1" rowspan="1">Grade<sup>a</sup></th><th align="left" colspan="1" rowspan="1">Relationship to study drug</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Fasting</td><td align="left" colspan="1" rowspan="1">208</td><td align="left" colspan="1" rowspan="1">Occasional atrial premature beats</td><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Probably related</td></tr><tr><td align="left" colspan="1" rowspan="1">224</td><td align="left" colspan="1" rowspan="1">Electrocardiogram T-wave abnormal</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Probably related</td></tr><tr><td align="left" rowspan="7" colspan="1">Fed</td><td align="left" colspan="1" rowspan="1">306</td><td align="left" colspan="1" rowspan="1">Abnormal coagulation indicators</td><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Probably related</td></tr><tr><td align="left" colspan="1" rowspan="1">307</td><td align="left" colspan="1" rowspan="1">Abnormal coagulation indicators</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Probably related</td></tr><tr><td align="left" colspan="1" rowspan="1">308</td><td align="left" colspan="1" rowspan="1">Elevated urine red blood cell count</td><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Probably related</td></tr><tr><td align="left" colspan="1" rowspan="1">309</td><td align="left" colspan="1" rowspan="1">Abnormal coagulation indicators</td><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Probably related</td></tr><tr><td align="left" colspan="1" rowspan="1">311</td><td align="left" colspan="1" rowspan="1">Blood bilirubin increased</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Probably related</td></tr><tr><td align="left" colspan="1" rowspan="1">317</td><td align="left" colspan="1" rowspan="1">Diarrhea</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Probably related</td></tr><tr><td align="left" colspan="1" rowspan="1">322</td><td align="left" colspan="1" rowspan="1">Abnormal coagulation indicators</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Probably related</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>The severity of AEs was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, including Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Life-threatening), Grade 5 (Death)</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec15"><title>Effect of Food on Pharmacokinetics</title><p id="Par37">The effect of food on the primary pharmacokinetics of test and reference formulations was further explored. Comparative analyses between fasting and fed studies demonstrated statistically significant differences (<italic toggle="yes">p</italic>&lt; 0.05) in C<sub>max</sub>, AUC<sub>0-t</sub>, AUC<sub>0-∞</sub> and T<sub>max</sub>. Compared to the fasting conditions, the fed state consistently delayed T<sub>max</sub> by 2 h for both test and reference formulations. Notably, mean C<sub>max</sub> showed substantial reductions of 50% (test) and 45% (reference), with corresponding decreases of 31% and 28% in mean AUC values.</p></sec></sec><sec id="Sec16"><title>Discussion</title><p id="Par38">The clinical trial protocol was developed in compliance with the <italic toggle="yes">Drug Registration Management Measures</italic> [<xref ref-type="bibr" rid="CR18">18</xref>] and the <italic toggle="yes">Technical Guidelines for Human Bioequivalence Studies of Chemical Generic Drugs Using Pharmacokinetic Parameters as Endpoint Evaluation Indicators</italic> [<xref ref-type="bibr" rid="CR19">19</xref>]. Given that the FDA bioequivalence guidelines for metformin hydrochloride recommend trials in healthy subjects under both fasting and fed conditions [<xref ref-type="bibr" rid="CR20">20</xref>], this study adopted a dual-design (fasting/fed) to support rational clinical use. Furthermore, as specified in Item 37 of the CFDA’s fifth batch of generic drug reference preparations, metformin hydrochloride tablets (Glycoran, 0.25 g) by Nippon Shinyaku (Japan) are designated as the reference standard for bioequivalence trials. Consequently, this product was selected as the reference formulation in our study. Meanwhile, according to the relevant CFDA guidelines for bioequivalence studies [<xref ref-type="bibr" rid="CR21">21</xref>], the sample size for non-highly variable drugs (CV &lt; 30%) in bioequivalence studies is typically 18–24 subjects. Metformin hydrochloride is a low-variability drug (variability range: 0.17–0.29). Taking into account factors such as an estimated 10% dropout rate, this study ultimately set the number of subjects for both fasting and postprandial tests at 26 each.</p><p id="Par39">The study demonstrated favorable safety profiles for both formulations, with no SAEs reported throughout the trial period. All observed adverse events (AEs) were mild in severity and self-limiting, requiring no medical intervention or leading to study discontinuation. The adverse drug reaction profile was consistent with previously published literature, confirming comparable safety and tolerability of the test and reference formulations in the healthy Chinese subject population [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par40">The two formulations exhibited comparable primary PK parameters in both fasting and fed states. ANOVA revealed no notable differences in lnC<sub>max</sub>, lnAUC<sub>0-t</sub>, or lnAUC<sub>0-∞</sub> between the drugs (<italic toggle="yes">p</italic> &gt; 0.05). The 90% CIs for the GMRs (T/R) of these pharmacokinetic metrics fell within the acceptable range of 80.00–125.00%. These results support the conclusion that the two formulations are bioequivalent under both conditions.</p><p id="Par41">The results of the comparative analysis of primary pharmacokinetic parameters between the fasting and fed studies imply that high-fat dietary intake not only delays but also diminishes metformin absorption. Huang et al. observed T<sub>max</sub> delays of 1.0 h (test formulation) and 0.5 h (reference formulation) for 0.25-g MH tablets, accompanied by 41% C<sub>max</sub> reduction and 28–31% AUC decreases [<xref ref-type="bibr" rid="CR12">12</xref>]. These findings were corroborated by Sun et al., who reported 0.84 h T<sub>max</sub> delay with 42.24% C<sub>max</sub> reduction and 30.34–30.78% AUC decreases under postprandial conditions [<xref ref-type="bibr" rid="CR23">23</xref>]. These literature reports fully corroborate the significant impact of food on the drug's pharmacokinetics, which is highly consistent with our research findings.</p><p id="Par42">Metformin is typically administered orally as a hydrochloride salt in tablet form, with primary absorption occurring in the small intestine. At physiological pH, it predominantly exists as a hydrophilic cation with low lipid solubility, precluding rapid passive diffusion across cell membranes [<xref ref-type="bibr" rid="CR24">24</xref>]. Its absorption occurs principally via active transport, consistent with a transporter-dependent mechanism involving several transporters including organic cation transporters (OCT1–3), plasma membrane monoamine transporter, and serotonin transporter [<xref ref-type="bibr" rid="CR25">25</xref>–<xref ref-type="bibr" rid="CR28">28</xref>]. Both genetic polymorphisms of these transporters and concomitant use of transporter-inhibiting drugs may influence metformin uptake and tolerance [<xref ref-type="bibr" rid="CR29">29</xref>]. Furthermore, the study by Marathe et al. demonstrated that the absorption phase of metformin plasma concentrations was consistently synchronized with gastric emptying processes [<xref ref-type="bibr" rid="CR30">30</xref>]. Consequently, dietary components may reduce metformin absorption through dual mechanisms: inhibition of these transporter proteins and delayed gastric emptying. However, more precise mechanistic interpretations require validation through additional experimental studies.</p></sec><sec id="Sec17"><title>Conclusion</title><p id="Par43">This study evaluated the bioequivalence of test and reference formulations (0.25-g metformin hydrochloride tablets) in healthy Chinese subjects under fasting and fed conditions. The results demonstrated bioequivalence between the two formulations. Pharmacokinetic analysis revealed that food intake significantly influenced both the absorption rate and extent of metformin. Both formulations exhibited favorable tolerability profiles in the study population.</p></sec></body><back><fn-group><fn><p>Yuxing Huang and Qiuhan Cai are co-first
authors.</p></fn></fn-group><notes><title>Declarations</title><notes notes-type="author-contribution"><title>Author Contributions</title><p>All authors made substantial contributions to the study conception, data acquisition, analysis, or interpretation. The initial manuscript draft was prepared by Yuxing Huang, with all coauthors contributing to critical revision of the content. All authors approved the final version for submission and assume full responsibility for the academic integrity of this work.</p></notes><notes notes-type="funding"><title>Funding</title><p>This trial was sponsored by Tianjin Kangrui Pharmaceutical Co., Ltd.</p></notes><notes><title>Data Availability</title><p>Data archiving is not mandated but data will be made available on reasonable request.</p></notes><notes><title>Code Availability</title><p>Not applicable.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par44">Yuxing Huang, Qiuhan Cai, Mei fang Li, Shengxuan Guo, Gaiying Dong, Siyuan Hu and Chengliang Zhong are all employees of the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine. All of the authors declare no conflicts of interest.</p></notes><notes id="FPar3"><title>Ethical Approval</title><p id="Par45">This study protocol was approved by the Medical Ethics Committee at the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine on 23 January 2018 (registration number: TYLL2018Y002).</p></notes><notes id="FPar4"><title>Consent to Participate</title><p id="Par46">All study participants provided written informed consent.</p></notes><notes id="FPar5"><title>Consent for Publication</title><p id="Par47">Not applicable.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>YY</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>YZ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>A decision support software to improve the standard care in Chinese type 2 diabetes</article-title><source>J Diabetes Res</source><year>2019</year><pub-id pub-id-type="doi">10.1155/2019/5491743</pub-id><pub-id pub-id-type="pmid">31828162</pub-id><pub-id pub-id-type="pmcid">PMC6881560</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Luo YY, Zhu YZ, Chen J, et al. A decision support software to improve the standard care in Chinese type 2 diabetes. J Diabetes Res. 2019. 10.1155/2019/5491743.<pub-id pub-id-type="pmid">31828162</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2019/5491743</pub-id><pub-id pub-id-type="pmcid">PMC6881560</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saeedi</surname><given-names>P</given-names></name><name name-style="western"><surname>Petersohn</surname><given-names>I</given-names></name><name name-style="western"><surname>Salpea</surname><given-names>P</given-names></name><etal/></person-group><article-title>Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition</article-title><source>Diabetes Res Clin Pract</source><year>2019</year><volume>157</volume><fpage>107843</fpage><pub-id pub-id-type="doi">10.1016/j.diabres.2019.107843</pub-id><pub-id pub-id-type="pmid">31518657</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157: 107843. 10.1016/j.diabres.2019.107843.<pub-id pub-id-type="pmid">31518657</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2019.107843</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whiting</surname><given-names>DR</given-names></name><name name-style="western"><surname>Guariguata</surname><given-names>L</given-names></name><name name-style="western"><surname>Weil</surname><given-names>C</given-names></name><etal/></person-group><article-title>IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030</article-title><source>Diabetes Res Clin Pract</source><year>2011</year><volume>94</volume><issue>3</issue><fpage>311</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2011.10.029</pub-id><pub-id pub-id-type="pmid">22079683</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311–21. 10.1016/j.diabres.2011.10.029.<pub-id pub-id-type="pmid">22079683</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2011.10.029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>QH</given-names></name><name name-style="western"><surname>Wang</surname><given-names>ZD</given-names></name></person-group><article-title>Investigation of diabetes status in China</article-title><source>Guide China Med.</source><year>2011</year><volume>9</volume><issue>13</issue><fpage>206</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.15912/j.cnki.gocm.2011.13.136</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Dai QH, Wang ZD. Investigation of diabetes status in China. Guide China Med. 2011;9(13):206–8. 10.15912/j.cnki.gocm.2011.13.136.</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>LM</given-names></name><name name-style="western"><surname>Wen</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>ZP</given-names></name><etal/></person-group><article-title>Prevalence and treatment of diabetes in China, 2013–2018</article-title><source>JAMA</source><year>2021</year><volume>326</volume><issue>24</issue><fpage>2498</fpage><lpage>2506</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.22208</pub-id><pub-id pub-id-type="pmid">34962526</pub-id><pub-id pub-id-type="pmcid">PMC8715349</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Wang LM, Wen P, Zhao ZP, et al. Prevalence and treatment of diabetes in China, 2013–2018. JAMA. 2021;326(24):2498–506. 10.1001/jama.2021.22208.<pub-id pub-id-type="pmid">34962526</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2021.22208</pub-id><pub-id pub-id-type="pmcid">PMC8715349</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flory</surname><given-names>J</given-names></name><name name-style="western"><surname>Lipska</surname><given-names>K</given-names></name></person-group><article-title>Metformin in 2019</article-title><source>JAMA</source><year>2019</year><volume>321</volume><issue>19</issue><fpage>1926</fpage><lpage>1927</lpage><pub-id pub-id-type="doi">10.1001/jama.2019.3805</pub-id><pub-id pub-id-type="pmid">31009043</pub-id><pub-id pub-id-type="pmcid">PMC7552083</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Flory J, Lipska K. Metformin in 2019. JAMA. 2019;321(19):1926–7. 10.1001/jama.2019.3805.<pub-id pub-id-type="pmid">31009043</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2019.3805</pub-id><pub-id pub-id-type="pmcid">PMC7552083</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abrahami</surname><given-names>D</given-names></name><name name-style="western"><surname>D’Andrea</surname><given-names>E</given-names></name><name name-style="western"><surname>Yin</surname><given-names>H</given-names></name><etal/></person-group><article-title>Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom</article-title><source>Diabetes Obes Metab</source><year>2023</year><volume>25</volume><issue>10</issue><fpage>2980</fpage><lpage>2988</lpage><pub-id pub-id-type="doi">10.1111/dom.15196</pub-id><pub-id pub-id-type="pmid">37395339</pub-id><pub-id pub-id-type="pmcid">PMC10527897</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Abrahami D, D’Andrea E, Yin H, et al. Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom. Diabetes Obes Metab. 2023;25(10):2980–8. 10.1111/dom.15196.<pub-id pub-id-type="pmid">37395339</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.15196</pub-id><pub-id pub-id-type="pmcid">PMC10527897</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2020. Diabetes Care 2020; 43(Suppl. 1): S98-S110. Diabetes Care. 2020; 43(8): 1979. 10.2337/dc20-ad08a.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc20-S009</pub-id><pub-id pub-id-type="pmid">31862752</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bailey</surname><given-names>CJ</given-names></name></person-group><article-title>Metformin: historical overview</article-title><source>Diabetologia</source><year>2017</year><volume>60</volume><issue>9</issue><fpage>1566</fpage><lpage>1576</lpage><pub-id pub-id-type="doi">10.1007/s00125-017-4318-z</pub-id><pub-id pub-id-type="pmid">28776081</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566–76. 10.1007/s00125-017-4318-z.<pub-id pub-id-type="pmid">28776081</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-017-4318-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeFronzo</surname><given-names>RA</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>AM</given-names></name></person-group><article-title>Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus</article-title><source>N Engl J Med</source><year>1995</year><volume>333</volume><issue>9</issue><fpage>541</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1056/nejm199508313330902</pub-id><pub-id pub-id-type="pmid">7623902</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333(9):541–9. 10.1056/nejm199508313330902.<pub-id pub-id-type="pmid">7623902</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM199508313330902</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindenberg</surname><given-names>M</given-names></name><name name-style="western"><surname>Kopp</surname><given-names>S</given-names></name><name name-style="western"><surname>Dressman</surname><given-names>JB</given-names></name></person-group><article-title>Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system</article-title><source>Eur J Pharm Biopharm</source><year>2004</year><volume>58</volume><issue>2</issue><fpage>265</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2004.03.001</pub-id><pub-id pub-id-type="pmid">15296954</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58(2):265–78. 10.1016/j.ejpb.2004.03.001.<pub-id pub-id-type="pmid">15296954</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejpb.2004.03.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>XM</given-names></name><name name-style="western"><surname>Wang</surname><given-names>GZ</given-names></name><name name-style="western"><surname>He</surname><given-names>BB</given-names></name><etal/></person-group><article-title>Bioequivalence and pharmacokinetic evaluation of two metformin hydrochloride tablets under fasting and fed conditions in healthy Chinese volunteers</article-title><source>Clin Pharmacol Drug Dev</source><year>2020</year><volume>9</volume><issue>8</issue><fpage>910</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1002/cpdd.849</pub-id><pub-id pub-id-type="pmid">32936533</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Huang XM, Wang GZ, He BB, et al. Bioequivalence and pharmacokinetic evaluation of two metformin hydrochloride tablets under fasting and fed conditions in healthy Chinese volunteers. Clin Pharmacol Drug Dev. 2020;9(8):910–7. 10.1002/cpdd.849.<pub-id pub-id-type="pmid">32936533</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpdd.849</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>ML</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F</given-names></name><name name-style="western"><surname>Yan</surname><given-names>P</given-names></name><etal/></person-group><article-title>Effects of food on pharmacokinetics and safety of metformin hydrochloride tablets: a meta-analysis of pharmacokinetic, bioavailability, or bioequivalence studies</article-title><source>Heliyon</source><year>2023</year><volume>9</volume><issue>7</issue><fpage>e17906</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2023.e17906</pub-id><pub-id pub-id-type="pmid">37455965</pub-id><pub-id pub-id-type="pmcid">PMC10344758</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Sun ML, Liu F, Yan P, et al. Effects of food on pharmacokinetics and safety of metformin hydrochloride tablets: a meta-analysis of pharmacokinetic, bioavailability, or bioequivalence studies. Heliyon. 2023;9(7): e17906. 10.1016/j.heliyon.2023.e17906.<pub-id pub-id-type="pmid">37455965</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2023.e17906</pub-id><pub-id pub-id-type="pmcid">PMC10344758</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><collab>World Medical Association</collab><collab>A.</collab></person-group><article-title>World Medical Association declaration of Helsinki ethical principles for medical research involving human subjects</article-title><source>JAMA</source><year>2013</year><volume>310</volume><issue>20</issue><fpage>2191</fpage><lpage>2194</lpage><pub-id pub-id-type="doi">10.1001/jama.2013.281053</pub-id><pub-id pub-id-type="pmid">24141714</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">World Medical Association, A. World Medical Association declaration of Helsinki ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4. 10.1001/jama.2013.281053.<pub-id pub-id-type="pmid">24141714</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2013.281053</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Switula</surname><given-names>D</given-names></name></person-group><article-title>Principles of good clinical practice (GCP) in clinical research</article-title><source>Sci Eng Ethics</source><year>2000</year><volume>6</volume><issue>1</issue><fpage>71</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1007/s11948-000-0025-z</pub-id><pub-id pub-id-type="pmid">11273440</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Switula D. Principles of good clinical practice (GCP) in clinical research. Sci Eng Ethics. 2000;6(1):71–7. 10.1007/s11948-000-0025-z.<pub-id pub-id-type="pmid">11273440</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11948-000-0025-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">CFDA. Technical Guidelines for Clinical Pharmacokinetic Studies of Chemical Drugs, 2016. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20050318010101201.html">www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20050318010101201.html</ext-link>. Accessed 18 Mar 2005.</mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Chinese Pharmacopoeia Commission. Guidelines for bioanalytical method validation. In: Pharmacopoeia of the People’s Republic of China. 2015ed. Beijing, China Medical Science Press; 2015. p363–368, Accessed 5 jun 2015</mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">CFDA. Drug Registration Management Measures, 2020. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/bmgzh/20200330180501220.html">www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/bmgzh/20200330180501220.html</ext-link>. Accessed 22 Jan 2020.</mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">CFDA. Technical Guidelines for Human Bioequivalence Studies of Chemical Generic Drugs Using Pharmacokinetic Parameters as Endpoint Evaluation Indicators, 2016. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nmpa.gov.cn/zhuanti/ypqxgg/ggzhcfg/20160318210001633.html">www.nmpa.gov.cn/zhuanti/ypqxgg/ggzhcfg/20160318210001633.html</ext-link>.</mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">U.S. Food and Drug Administration. (2010). Bioequivalence recommendations for specific products. U.S. Department of Health and Human Services. 2016, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/">www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/</ext-link>. Accessed Jun 2010.</mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">CFDA. Technical Guidelines for Bioequivalence Studies in Generic Drug Quality Consistency Evaluation, 2015. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nmpa.gov.cn/xxgk/zhqyj/zhqyjyp/20151030120001643.html">www.nmpa.gov.cn/xxgk/zhqyj/zhqyjyp/20151030120001643.html</ext-link>. Accessed 30 Oct 2015.</mixed-citation></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>WY</given-names></name><name name-style="western"><surname>Guan</surname><given-names>YF</given-names></name><name name-style="western"><surname>Shentu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes</article-title><source>J Diabetes</source><year>2012</year><volume>4</volume><issue>3</issue><fpage>227</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1111/j.1753-0407.2012.00213.x</pub-id><pub-id pub-id-type="pmid">22672586</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Yang WY, Guan YF, Shentu Y, et al. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. J Diabetes. 2012;4(3):227–37. 10.1111/j.1753-0407.2012.00213.x.<pub-id pub-id-type="pmid">22672586</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1753-0407.2012.00213.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suna</surname><given-names>M-L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F</given-names></name><name name-style="western"><surname>Yan</surname><given-names>P</given-names></name><etal/></person-group><article-title>Effects of food on pharmacokinetics and safety of metformin hydrochloride tablets: a meta-analysis of pharmacokinetic, bioavailability, or bioequivalence studies</article-title><source>Heliyon.</source><year>2023</year><volume>9</volume><issue>7</issue><fpage>e17906</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2023.e17906</pub-id><pub-id pub-id-type="pmid">37455965</pub-id><pub-id pub-id-type="pmcid">PMC10344758</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Suna M-L, Liu F, Yan P, et al. Effects of food on pharmacokinetics and safety of metformin hydrochloride tablets: a meta-analysis of pharmacokinetic, bioavailability, or bioequivalence studies. Heliyon. 2023;9(7):e17906. 10.1016/j.heliyon.2023.e17906.<pub-id pub-id-type="pmid">37455965</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2023.e17906</pub-id><pub-id pub-id-type="pmcid">PMC10344758</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>GG</given-names></name><name name-style="western"><surname>Punt</surname><given-names>J</given-names></name><name name-style="western"><surname>Arora</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clinical pharmacokinetics of metformin</article-title><source>Clin Pharmacokinet</source><year>2011</year><volume>50</volume><issue>2</issue><fpage>81</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">21241070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/11534750-000000000-00000</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81–98.<pub-id pub-id-type="pmid">21241070</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/11534750-000000000-00000</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koepsell</surname><given-names>H</given-names></name><name name-style="western"><surname>Endou</surname><given-names>H</given-names></name></person-group><article-title>The SLC22 drug transporter family</article-title><source>Pflugers Arch</source><year>2004</year><volume>447</volume><issue>5</issue><fpage>666</fpage><lpage>676</lpage><pub-id pub-id-type="pmid">12883891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00424-003-1089-9</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Koepsell H, Endou H. The SLC22 drug transporter family. Pflugers Arch. 2004;447(5):666–76.<pub-id pub-id-type="pmid">12883891</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00424-003-1089-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>N</given-names></name><name name-style="western"><surname>Duan</surname><given-names>H</given-names></name><name name-style="western"><surname>Hebert</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Taste of a pill: organic cation transporter-3 (OCT3) mediates metformin accumulation and secretion in salivary glands</article-title><source>J Biol Chem.</source><year>2014</year><volume>289</volume><issue>39</issue><fpage>27055</fpage><lpage>27064</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.570564</pub-id><pub-id pub-id-type="pmid">25107910</pub-id><pub-id pub-id-type="pmcid">PMC4175343</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Lee N, Duan H, Hebert MF, et al. Taste of a pill: organic cation transporter-3 (OCT3) mediates metformin accumulation and secretion in salivary glands. J Biol Chem. 2014;289(39):27055–64. 10.1074/jbc.M114.570564.<pub-id pub-id-type="pmid">25107910</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M114.570564</pub-id><pub-id pub-id-type="pmcid">PMC4175343</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engel</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Identification and characterization of a novel monoamine transporter in the human brain</article-title><source>J Biol Chem.</source><year>2004</year><volume>279</volume><issue>48</issue><fpage>50042</fpage><lpage>50049</lpage><pub-id pub-id-type="doi">10.1074/jbc.M407913200</pub-id><pub-id pub-id-type="pmid">15448143</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Engel K, Zhou M, Wang J. Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem. 2004;279(48):50042–9. 10.1074/jbc.M407913200.<pub-id pub-id-type="pmid">15448143</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M407913200</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>M</given-names></name><name name-style="western"><surname>Xia</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma mem brane monoamine transporter) expressed in human intestine</article-title><source>Drug Metab Dispos.</source><year>2007</year><volume>35</volume><issue>10</issue><fpage>1956</fpage><lpage>1962</lpage><pub-id pub-id-type="doi">10.1124/dmd.107.015495</pub-id><pub-id pub-id-type="pmid">17600084</pub-id><pub-id pub-id-type="pmcid">PMC2672958</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma mem brane monoamine transporter) expressed in human intestine. Drug Metab Dispos. 2007;35(10):1956–62. 10.1124/dmd.107.015495.<pub-id pub-id-type="pmid">17600084</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.107.015495</pub-id><pub-id pub-id-type="pmcid">PMC2672958</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCreight</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>ER</given-names></name></person-group><article-title>Metformin and the gastrointestinal tract</article-title><source>Diabetologia.</source><year>2016</year><volume>59</volume><issue>3</issue><fpage>426</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1007/s00125-015-3844-9</pub-id><pub-id pub-id-type="pmid">26780750</pub-id><pub-id pub-id-type="pmcid">PMC4742508</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426–35. 10.1007/s00125-015-3844-9.<pub-id pub-id-type="pmid">26780750</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-015-3844-9</pub-id><pub-id pub-id-type="pmcid">PMC4742508</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marathe</surname><given-names>PH</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Norton</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effect of altered gastric emptying and gastrointestinal motility on metformin absorption</article-title><source>Br J Clin Pharmacol.</source><year>2015</year><volume>50</volume><issue>4</issue><fpage>325</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2125.2000.00264.x</pub-id><pub-id pub-id-type="pmcid">PMC2015004</pub-id><pub-id pub-id-type="pmid">11012555</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Marathe PH, Wen Y, Norton J, et al. Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. Br J Clin Pharmacol. 2015;50(4):325–32. 10.1046/j.1365-2125.2000.00264.x.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.2000.00264.x</pub-id><pub-id pub-id-type="pmcid">PMC2015004</pub-id><pub-id pub-id-type="pmid">11012555</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12886820</article-id><article-id pub-id-type="pmcid-ver">PMC12886820.1</article-id><article-id pub-id-type="pmcaid">12886820</article-id><article-id pub-id-type="pmcaiid">12886820</article-id><article-id pub-id-type="pmid">41651891</article-id><article-id pub-id-type="doi">10.1038/s41598-025-34082-4</article-id><article-id pub-id-type="publisher-id">34082</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Bioequivalence assessment between two formulations of a film-coated fixed-dose combination of metformin and vildagliptin (850/50mg) in healthy Tunisian subjects under fed conditions</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Ferchichi</surname><given-names initials="K">Khouloud</given-names></name><address><email>kholod.ferchichi@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gaies</surname><given-names initials="E">Emna</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ben Hammamia</surname><given-names initials="S">Syrine</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>El Jebari</surname><given-names initials="H">Hanene</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Daldoul</surname><given-names initials="M">Mouna</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ghorbel</surname><given-names initials="S">Salma</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Srairi</surname><given-names initials="S">Semia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guermazi</surname><given-names initials="S">Sami</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gorgi</surname><given-names initials="Y">Yousr</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Boutiba</surname><given-names initials="I">Ilhem</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bouzid</surname><given-names initials="K">Kahena</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abbessi</surname><given-names initials="A">Aimen</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Daghfous</surname><given-names initials="R">Riadh</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ben Sassi</surname><given-names initials="M">Mouna</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Trabelsi</surname><given-names initials="S">Sameh</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label>Department of Clinical Pharmacology, National Center Chalbi Belkahia of Pharmacovigilance, Rue Zouhaier Essafi, 1006 Tunis, Tunisia </aff><aff id="Aff2"><label>2</label>Research Laboratory of Clinical and Experimental Pharmacology (LR16SP02), Tunis, Tunisia </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/029cgt552</institution-id><institution-id institution-id-type="GRID">grid.12574.35</institution-id><institution-id institution-id-type="ISNI">0000000122959819</institution-id><institution>Faculty of Medicine of Tunis, </institution><institution>University of Tunis El Manar, </institution></institution-wrap>1007 Tunis, Tunisia </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02f6ghw27</institution-id><institution-id institution-id-type="GRID">grid.413827.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0594 6356</institution-id><institution>Hematology Medical Laboratory at Charles Nicolle Hospital, </institution></institution-wrap>Tunis, Tunisia </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02f6ghw27</institution-id><institution-id institution-id-type="GRID">grid.413827.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0594 6356</institution-id><institution>Immunology Medical Laboratory at Charles Nicolle Hospital, </institution></institution-wrap>Tunis, Tunisia </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02f6ghw27</institution-id><institution-id institution-id-type="GRID">grid.413827.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0594 6356</institution-id><institution>Microbiology Medical Laboratory at Charles Nicolle Hospital, </institution></institution-wrap>Tunis, Tunisia </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02f6ghw27</institution-id><institution-id institution-id-type="GRID">grid.413827.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0594 6356</institution-id><institution>Biochemistry Medical Laboratory at Charles Nicolle Hospital, </institution></institution-wrap>Tunis, Tunisia </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02f6ghw27</institution-id><institution-id institution-id-type="GRID">grid.413827.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0594 6356</institution-id><institution>Pharmacy at Charles Nicolle Hospital, </institution></institution-wrap>Tunis, Tunisia </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>2</month><year>2026</year></pub-date><pub-date pub-type="collection"><year>2026</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">503847</issue-id><elocation-id>5407</elocation-id><history><date date-type="received"><day>21</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>24</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>02</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>11</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-11 00:25:14.143"><day>11</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2025_Article_34082.pdf"/><abstract id="Abs1"><p id="Par1">In Tunisia, bioequivalence studies have been required for generic drug approval since 2008. This study aimed to assess the bioequivalence of vildagliptin and metformin fixed-dose combination (FDC) 850/50 mg for a tested (Bi-Galvine) versus the approved reference products (Galvumet). A randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study with a washout period of 7 days to compare metformin/vildagliptin film-coated tablets in 18 healthy Tunisian subjects aged between 18 and 50 years under fed conditions was conducted at the National Center Chalbi Belkahia of Pharmacovigilance. During each period, 20 blood samples were collected from each subject at pre-dosing (0.00) and between 0.25 and 24.00 h after dosing. The bioequivalence between the test (T) and reference (R) products required 90% confidence intervals (CIs) for the geometric least square (LS) mean T/R ratio to be within 80–125% for the pharmacokinetic parameters, maximum plasma concentration (C<sub>max</sub>), and Area Under the Curve from zero to 24 h (AUC<sub>0–24 h</sub>). The 90% CIs of the geometric means of the T/R ratios for C<sub>max</sub> and AUC<sub>0–24 h</sub> for metformin were 92.01–102.66% and 93.55–101.80%, respectively; the corresponding results for vildagliptin were 96.03–107.09% and 94.46–101.92%, respectively. Other parameters, such as AUC<sub>0-∞</sub>, time to maximum concentration (T<sub>max</sub>), and terminal half-life (t<sub>1/2</sub>), were comparable between the test and reference products. Adverse events (AEs), mainly hypoglycemia and loose stools events, were reported without relevant differences between the test and reference products. AEs were generally mild and transient. No severe or serious AEs occurred. The new generic drug product of metformin/vildagliptin FDC 850/50 mg demonstrated bioequivalence to the approved product and is therefore expected to provide similar therapeutic effects.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Metformin</kwd><kwd>Vildagliptin</kwd><kwd>Bioequivalence</kwd><kwd>Tunisia</kwd><kwd>Bioavailability</kwd><kwd>Diabetes</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Diseases</kwd><kwd>Drug discovery</kwd><kwd>Health care</kwd><kwd>Medical research</kwd></kwd-group><funding-group><award-group><funding-source><institution>This study was sponsored by SAIPH Pharma (Société Arabe des Industries Pharmaceutiques)</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© Springer Nature Limited 2026</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par19">Diabetes mellitus is a chronic disease that poses a major public health issue with a steadily rising prevalence, making it one of the top healthcare system concerns<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Clinical trials have shown that adjuvant vildagliptin treatment in patients with inadequate glycemic control despite metformin monotherapy induced statistically significant mean reductions in glycosylated hemoglobin (HbA1c) compared with placebo<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. The development of a fixed-dose combination (FDC) of metformin and vildagliptin is a strategic approach to address the complex challenges of diabetes management, providing effective glycemic control while potentially improving patient adherence and reducing healthcare costs. Ensuring the availability of a safe and effective locally manufactured FDC is particularly important for the Tunisian population.</p><p id="Par20">This clinical trial was therefore designed to evaluate the bioequivalence between the test product, Bi-Galvine 850/50 mg Film-Coated Tablets (SAIPH Pharma, Tunisia), and the reference product, Galvumet 850/50 mg Film-Coated Tablets (Novartis Pharma Schweiz AG, Risch, Switzerland). Demonstrating bioequivalence ensures therapeutic interchangeability and constitutes a regulatory requirement for marketing authorization of the test product according to Tunisian health authority guidelines. The primary objective of the study was to compare the rate and extent of absorption of metformin and vildagliptin between the test and reference formulations after a single oral dose under fed conditions.</p></sec><sec id="Sec2"><title>Materials &amp; methods</title><p id="Par21">The study was conducted at the Bioequivalence Unit of the Clinical Pharmacology Department affiliated with The National Center of Pharmacovigilance in Tunisia, according to the Declaration of Helsinki and Good Clinical Practice guidelines<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref></sup>. The study protocol was approved by the Committee of Persons Protection - Tunisia North (approval no. CPPN_15_2022_AMD_BiGalvineFed). The study was registered on ClinicalTrials.gov under the number: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06103747">NCT06103747</ext-link> on 17th December 2022 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT06103747?cond=metformin&amp;lat=36.8045507&amp;lng=10.1654236&amp;locStr=Bab%20Souika,%20Tunis,%20Tunisia&amp;distance=50&amp;rank=3#more-information">https://clinicaltrials.gov/study/NCT06103747?cond=metformin&amp;lat=36.8045507&amp;lng=10.1654236&amp;locStr=Bab%20Souika,%20Tunis,%20Tunisia&amp;distance=50&amp;rank=3#more-information</ext-link>).</p><sec id="Sec3"><title>Study drugs</title><p id="Par22">The test product Bi-Galvine 850/50 mg Film-Coated Tablets, was manufactured by SAIPH Pharma, Tunisia, batch number 1M235 and expiry date is March 2024.</p><p id="Par23">The reference product was Galvumet 850/50 mg Film-Coated Tablet of the Marketing Authorization Holder: Novartis Pharma Schweiz AG, Risch, batch number KEV82 and expiry date is November 2023.</p></sec></sec><sec id="Sec4"><title>Study design</title><p id="Par25">This study was an open-label, randomized, single-dose, two-treatment, two-period, two-sequence, crossover bioequivalence study under fed conditions with a washout interval of one week between periods. For fixed-dose combinations containing metformin—such as metformin/vildagliptin—both the <bold>FDA</bold> and <bold>EMA</bold> guidelines<sup><xref ref-type="bibr" rid="CR5">5</xref></sup> specify that bioequivalence should be demonstrated under the conditions stated in the product labeling of the reference product. Galvumet is labeled to be taken with food to reduce gastrointestinal side effects of metformin<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. Therefore, a fed study is required to match real clinical use and to ensure fair comparison of test and reference products.</p><p id="Par26">In each study period, the drugs were administered according to the randomization plan with 240 ± 2 mL of warm 20% glucose solution. The subjects’ ingestion of the dose was checked and verified. The subjects stayed in bed in an upright position for the first 4 h after dosing.</p><p id="Par27">During each study period, the subjects fasted for at least 10 h and then ate breakfast prior to drug intake, and food was not allowed for 6 h after drug administration. Standardized high-fat breakfast (800–1000 calories) was served 30 min before dosing. During their housing, the subjects were not allowed to have meals or fluids other than those served by the study team. All meals were identical in both periods and served at the same time.</p></sec><sec id="Sec5"><title>Study population</title><p id="Par28">The study sample size was determined following recommendations from the bioequivalence guidelines of the FDA and the EMA<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup>.</p><p id="Par29">The sample size for this study was calculated considering the following data: within-subject variability driven from the literature data was 8.95% for metformin and 15.85% for vildagliptin<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>; the significance level was α = 5%; the desired statistical power (1−β) was 90% and the 90% confidence interval (90% CI) around the ratio of geometric means fall within the bounds of bioequivalence, typically [80.00–125.00%] for primary endpoint<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>.</p><p id="Par30">The calculated sample size was 13<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>, accounting for potential dropouts or withdrawals we estimated a dropout rate of 25%. Thus, the final sample size was 18.</p><p id="Par31">The study population consisted of healthy volunteers aged between 18 and 50 years.</p><p id="Par32">Each subject was well informed about the study objectives, procedures, possible risks, and interests before providing written informed consent. Healthy subjects aged 18–50 years with body mass indices ranging from 18.5 to 30.0 kg/m<sup>2</sup> were eligible to participate in the study. The health status of the subjects was assessed on the basis of vital signs (temperature, blood pressure, and pulse), medical history, routine physical examination, 12-lead electrocardiogram (ECG), clinical laboratory tests (hematology, blood biochemistry, coagulation function, urinalysis, drug screening), and serology (hepatitis B surface antigen, hepatitis C virus antibody, and HIV antigen/antibody). Subjects with any allergy, hypersensitivity history, known lactose intolerance, drug or alcohol abuse, or taking medications or food supplements within 2 weeks before the first dosing were excluded.</p></sec><sec id="Sec6"><title>Sample collection and analysis</title><p id="Par33">During each period, 20 blood samples were collected from each subject at pre dosing (0.00) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 14 and 24 h after dosing under fed conditions. The samples were subsequently centrifuged at 4000 rpm for 5 min at 4 °C within 30 min after collection. The plasma tubes were then stored in an Ultra freezer (− 80 °C) until analysis. The plasma concentrations of both metformin and vildagliptin were measured via in-house previously validated liquid chromatography tandem mass spectrometry (LC‒MS/MS) according to ICH M10<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. Protein precipitation with acetonitrile containing diazepam as an internal standard was used for plasma extraction of both metformin and vildagliptin.</p><p id="Par34">Sample analysis was performed via LC‒MS/MS via an ODS HypersylTM 125*4.6 mm column and a Waters Acquity H CLASSP ULC® liquid chromatography pump with the following mobile phases: A, 300 mL ammonium formate + 300 µL formic acid; and B, 700 mL methanol + 700 µL formic acid at a flow rate of 0.8 mL/min.</p><p id="Par35">Detection was performed via a Waters Triple Quad (TQ-S micro Xévo) detector. Mass spectrometry was performed with multiple reaction monitoring (M/z 130.128/60.04 for metformin, M/z 304.294/154.189 for vildagliptin and M/z 285.157/154.114 for diazepam). The linearity range of the method was 20–3000 ng/mL for metformin and 5–320 ng/mL for vildagliptin.</p><p id="Par36">The LC–MS/MS methods used for measuring metformin and vildagliptin plasma concentrations were fully validated according to ICH M10 guidelines<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>, ensuring accuracy, precision, selectivity, linearity, and stability.</p></sec><sec id="Sec7"><title>Safety assessment</title><p id="Par37">Safety and tolerability assessments included vital signs (temperature, blood pressure, and heart rate), physical examination, ECG, blood glucose, and laboratory tests at regular intervals throughout the study. Vital signs were measured before dosing at -12.00 and − 1.00 h and at 2, 4, 6, 8, 12, and 24 h after dosing. Blood glucose was measured at 1.5 h and 3.5 h after dosing. Physical examination, ECG, and laboratory tests (hematology, blood chemistry, and urinalysis) were performed at screening and at the end of the study.</p><p id="Par38">Subjects were closely monitored for any adverse events (AEs) that may have occurred during the study from the initiation of any study procedures to the end of the study.</p><sec id="Sec8"><title>Pharmacokinetic and statistical analyses</title><p id="Par39">The primary study endpoints were maximum plasma concentration (C<sub>max</sub>), Area Under the Curve from zero to 24 h (AUC<sub>0–24 h</sub>) and from zero to infinity (AUC<sub>0 – ∞</sub>).</p><p id="Par40">Non-compartmental analysis approach implemented in R (version 4.3.1) with the PKNCA<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> package (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cran.r-project.org/package=PKNCA">https://cran.r-project.org/package=PKNCA</ext-link>) was performed to calculate these pharmacokinetic (PK) parameters as follows:<list list-type="bullet"><list-item><p id="Par42">The values of C<sub>max</sub> and time to maximum concentration (T<sub>max</sub>) were obtained directly from the concentration versus time curve of each subject.</p></list-item><list-item><p id="Par43">The terminal elimination rate constant (K<sub>e</sub>) was estimated for each subject and for each drug substance via linear regression of the last points (at least three points were used) at the terminal phase of the log-concentration versus time curve of each subject.</p></list-item><list-item><p id="Par44">The terminal half-life (T<sub>1/2</sub>) was calculated from 0.693/K<sub>e</sub>.</p></list-item><list-item><p id="Par45">AUC<sub>0 − 24 h</sub> was calculated via the the linear-up trapezoidal method.</p></list-item><list-item><p id="Par46">The extrapolated area, (AUC<sub>24h−∞</sub>) is the area under the plasma concentration‒time curve from 24 h to infinity and was calculated as the last concentration (C<sub>last</sub>) divided by the elimination rate constant C<sub>last</sub>/K<sub>e</sub>. It is also called the residual area expressed as a percentage of the AUC<sub>0−∞</sub>.</p></list-item><list-item><p id="Par47">AUC<sub>0−∞</sub> was calculated from the sum of AUC<sub>0 − t</sub> and AUC<sub>t−∞</sub>.</p></list-item></list></p><p id="Par48">The assessment of bioequivalence was based upon 90% confidence intervals for the ratio of the population geometric means (test/reference) for the parameters under consideration. This confidence interval was then back-transformed to obtain the desired confidence interval for the ratio on the original scale.</p><p id="Par49">For both metformin and vildagliptin, the 90% confidence intervals for C<sub>max</sub> and AUC<sub>₀–24 h</sub> lie within the acceptance range of 80.00–125.00%.</p><p id="Par50">Analysis of variance (ANOVA) was performed to assess the effects of the following factors: period, sequence, subjects nested within sequence and treatment (formulation or product).</p><p id="Par51">ANOVA was applied for the Ln-transformed values of C<sub>max</sub>, AUC<sub>0–24 h</sub> and AUC<sub>0−∞</sub> for metformin and vildagliptin. For each mentioned factor, the differences were not statistically significant at the 5% significance level (<italic toggle="yes">p</italic> ≥ 0.05).</p><p id="Par52">The Residual Mean Square (MSE), which is the residual within-subject variance from the ANOVA on ln-transformed data, was used to estimate the intra-subject coefficient of variation (CV%) according to the regulatory guidelines<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. The CV% was calculated separately for each pharmacokinetic parameter and reported as percentage.</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Demographic characteristics</title><p id="Par53">Eighteen healthy subjects, 13 males and five females, were enrolled in this study as planned. The mean age was 28.61 ± 10.33 years. The mean BMI was 24.14 ± 3.22 kg/m. All the subjects were nonsmokers and had no concurrent alcohol consumption. All 18 subjects were randomized under fed conditions and completed both periods. All 18 subjects ware included in the pharmacokinetics analysis.</p></sec><sec id="Sec11"><title>Pharmacokinetic analysis</title><p id="Par54">The mean plasma concentration–time curves of metformin and vildagliptin obtained after a single oral administration of the test and reference products under fed conditions are shown in Figs. <xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig2" ref-type="fig">2</xref>, which show superposable curves for both products.</p><p id="Par55">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Logarithmic arithmetic mean plasma metformin concentration (ng/ml) versus time (hour) curve following a single oral dose of metformin and vildagliptin 850/50 mg Film-Coated Tablets.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e535" position="float" orientation="portrait" xlink:href="41598_2025_34082_Fig1_HTML.jpg"/></fig>
</p><p id="Par56">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Logarithmic arithmetic mean of the plasma vildagliptin concentration (ng/ml) versus time (hour) curve following a single oral dose of metformin or vildagliptin 850/50 mg in film-coated tablets.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e545" position="float" orientation="portrait" xlink:href="41598_2025_34082_Fig2_HTML.jpg"/></fig>
</p><p id="Par59">Metformin HCl plasma concentrations were undetectable at predosing (00:00) for both the test and reference products.</p><p id="Par60">The arithmetic mean C<sub>max</sub> of metformin was 1693.76 ± 222.44 ng/mL for the test group and 1737.51 ± 211.99 ng/mL for the reference group.</p><p id="Par61">The arithmetic means of metformin AUC<sub>0→24 h</sub> and AUC<sub>0→∞</sub> were 12798.6 ± 2268.79 ng·hr/mL and 13026.80 ± 2329.01 ng hr/mL, respectively, for the test product and 13002.57 ± 1722.89 ng hr/mL and 13263.02 ± 1782.65 ng·hr/mL, respectively, for the reference product.</p><p id="Par62">Vildagliptin plasma concentrations were undetectable at predosing (00:00) and 24 h postdosing for both the test and reference products.</p><p id="Par63">The arithmetic mean C<sub>max</sub> of vildagliptin was 243.72 ± 70.11 ng/mL for the test group and 237.03 ± 55.20 ng/mL for the reference group.</p><p id="Par64">The AUC<sub>0→24 h</sub> and AUC<sub>₀→∞</sub> arithmetic means for vildagliptin were identical and were 962.71 ± 199.45 ng hr/mL for the test product and 982 ± 2214.51 ng hr/mL for the reference product.</p><p id="Par65">The major PK parameters of metformin and vildagliptin are summarized in Table <xref rid="Tab1" ref-type="table">1</xref>.</p><p id="Par66">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Main Pharmacokinetic parameters of Metformin and vildagliptin in both test and reference products.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" colspan="1">Parameters</th><th align="left" colspan="2" rowspan="1">Metformin</th><th align="left" colspan="2" rowspan="1">Vildagliptin</th></tr><tr><th align="left" colspan="1" rowspan="1">Test<break/>(<italic toggle="yes">N</italic> = 18)</th><th align="left" colspan="1" rowspan="1">Reference<break/>(<italic toggle="yes">N</italic> = 18)</th><th align="left" colspan="1" rowspan="1">Test<break/>(<italic toggle="yes">N</italic> = 18)</th><th align="left" colspan="1" rowspan="1">Reference<break/>(<italic toggle="yes">N</italic> = 18)</th></tr><tr><th align="left" colspan="1" rowspan="1">Arithmetic mean ± SD</th><th align="left" colspan="1" rowspan="1">Arithmetic mean ± SD</th><th align="left" colspan="1" rowspan="1">Arithmetic mean ± SD</th><th align="left" colspan="1" rowspan="1">Arithmetic mean ± SD</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">C<sub>max</sub>(ng/ml)</td><td align="left" colspan="1" rowspan="1">1693.76 ± 222.44</td><td align="left" colspan="1" rowspan="1">1737.51 ± 211.99</td><td align="left" colspan="1" rowspan="1">243.72 ± 70.11</td><td align="left" colspan="1" rowspan="1">237.03 ± 55.20</td></tr><tr><td align="left" colspan="1" rowspan="1">AUC<sub>0→24 h</sub> (ng.hr/mL)</td><td align="left" colspan="1" rowspan="1">12798.60 ± 2268.79</td><td align="left" colspan="1" rowspan="1">13002.57 ± 1722.89</td><td align="left" colspan="1" rowspan="1">962.71 ± 199.45</td><td align="left" colspan="1" rowspan="1">982.00 ± 214.51</td></tr><tr><td align="left" colspan="1" rowspan="1">AUC<sub>0→∞</sub> (ng.hr/mL)</td><td align="left" colspan="1" rowspan="1">13026.80 ± 2329.01</td><td align="left" colspan="1" rowspan="1">13263.02 ± 1782.65</td><td align="left" colspan="1" rowspan="1">962.71 ± 199.45</td><td align="left" colspan="1" rowspan="1">982.00 ± 214.51</td></tr><tr><td align="left" colspan="1" rowspan="1">T<sub>max</sub> (hr)</td><td align="left" colspan="1" rowspan="1">3.75 ± 0.97</td><td align="left" colspan="1" rowspan="1">3.81 ± 0.97</td><td align="left" colspan="1" rowspan="1">1.99 ± 0.84</td><td align="left" colspan="1" rowspan="1">2.09 ± 0.99</td></tr><tr><td align="left" colspan="1" rowspan="1">T<sub>1/2</sub> (hr)</td><td align="left" colspan="1" rowspan="1">4.06 ± 0.65</td><td align="left" colspan="1" rowspan="1">4.21 ± 0.57</td><td align="left" colspan="1" rowspan="1">1.94 ± 0.31</td><td align="left" colspan="1" rowspan="1">2.02 ± 0.39</td></tr><tr><td align="left" colspan="1" rowspan="1">Residual area (%)</td><td align="left" colspan="1" rowspan="1">1.71 ± 0.84</td><td align="left" colspan="1" rowspan="1">1.93 ± 0.87</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">λz (hr<sup>−1</sup>)</td><td align="left" colspan="1" rowspan="1">0.18 ± 0.04</td><td align="left" colspan="1" rowspan="1">0.17 ± 0.02</td><td align="left" colspan="1" rowspan="1">0.37 ± 0.06</td><td align="left" colspan="1" rowspan="1">0.35 ± 0.07</td></tr></tbody></table><table-wrap-foot><p>SD: standard deviation, λz: elimination rate constant, T<sub>1/2</sub>: terminal elimination half-life, T<sub>max</sub>: maximum concentration time, AUC<sub>0→24 h</sub>: area under the curve from zero to 24 h, AUC<sub>0→∞</sub>: area under the curve from zero to infinity, C<sub>max</sub>: maximum concentration, hr: <italic toggle="yes">hour</italic>, PK: pharmacokinetic.</p></table-wrap-foot></table-wrap>
</p><p id="Par67">The geometric mean T/R ratios (GMRs) of metformin for AUC<sub>0→∞</sub>, AUC<sub>0→24 h</sub> and C<sub>max</sub> were 97.45%, 98.68% and 97.33%, respectively. The geometric mean T/R ratios of vildagliptin for AUC<sub>0→∞</sub>, AUC<sub>0→24 h</sub> and C<sub>max</sub> were 98.19%, 98.19% and 101.56%, respectively. For bioequivalence evaluation, the PK parameters for both metformin and vildagliptin between the test and reference products, GMR, and 90% CIs were all within the range of 80–125%. See Table <xref rid="Tab2" ref-type="table">2</xref>.</p><p id="Par68">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Bioequivalence analysis of Metformin and vildagliptin after single oral administration of test and reference products.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Parameters</th><th align="left" colspan="2" rowspan="1">Geometric means</th><th align="left" rowspan="2" colspan="1">GMR%</th><th align="left" rowspan="2" colspan="1">90% CI</th><th align="left" rowspan="2" colspan="1">CV%</th></tr><tr><th align="left" colspan="1" rowspan="1">Test (N = 18)</th><th align="left" colspan="1" rowspan="1">Reference (N = 18)</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">Metformin</td></tr><tr><td align="left" colspan="1" rowspan="1"> C<sub>max</sub>(ng/ml)</td><td align="left" colspan="1" rowspan="1">1679.60</td><td align="left" colspan="1" rowspan="1">1725.66</td><td align="left" colspan="1" rowspan="1">97.33</td><td align="left" colspan="1" rowspan="1">92.01–102.66</td><td align="left" colspan="1" rowspan="1">14.11</td></tr><tr><td align="left" colspan="1" rowspan="1"> AUC<sub>0→24h</sub> (ng.hr/mL)</td><td align="left" colspan="1" rowspan="1">12596.34</td><td align="left" colspan="1" rowspan="1">12895.93</td><td align="left" colspan="1" rowspan="1">97.68</td><td align="left" colspan="1" rowspan="1">93.55–101.80</td><td align="left" colspan="1" rowspan="1">10.89</td></tr><tr><td align="left" colspan="1" rowspan="1"> AUC<sub>0→∞</sub> (ng.hr/mL)</td><td align="left" colspan="1" rowspan="1">12815.62</td><td align="left" colspan="1" rowspan="1">13150.77</td><td align="left" colspan="1" rowspan="1">97.45</td><td align="left" colspan="1" rowspan="1">93.32–101.58</td><td align="left" colspan="1" rowspan="1">10.93</td></tr><tr><td align="left" colspan="6" rowspan="1">Vildagliptin</td></tr><tr><td align="left" colspan="1" rowspan="1"> C<sub>max</sub>(ng/ml)</td><td align="left" colspan="1" rowspan="1">234.58</td><td align="left" colspan="1" rowspan="1">230.98</td><td align="left" colspan="1" rowspan="1">101.56</td><td align="left" colspan="1" rowspan="1">96.03–107.09</td><td align="left" colspan="1" rowspan="1">14.05</td></tr><tr><td align="left" colspan="1" rowspan="1"> AUC<sub>0→24h</sub> (ng.hr/mL)</td><td align="left" colspan="1" rowspan="1">945.25</td><td align="left" colspan="1" rowspan="1">962.70</td><td align="left" colspan="1" rowspan="1">98.19</td><td align="left" colspan="1" rowspan="1">94.46–101.92</td><td align="left" colspan="1" rowspan="1">9.80</td></tr><tr><td align="left" colspan="1" rowspan="1"> AUC<sub>0→∞</sub> (ng.hr/mL)</td><td align="left" colspan="1" rowspan="1">945.25</td><td align="left" colspan="1" rowspan="1">962.70</td><td align="left" colspan="1" rowspan="1">98.19</td><td align="left" colspan="1" rowspan="1">94.46–101.92</td><td align="left" colspan="1" rowspan="1">9.80</td></tr></tbody></table><table-wrap-foot><p>CI: confidence interval, AUC<sub>0→24 h</sub>: area under the curve zero to 24 h, AUC<sub>0→∞</sub>: area under the curve zero to infinity, C<sub>max</sub>: maximum concentration, GMR: geometric mean T/R ratio, CV%: intra-subject coefficient of variation.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec12"><title>Safety assessment</title><p id="Par69">Four subjects (two in each period) presented glucose levels below 70 mg/dL. Overall, 6 out of 108 (5.5%) blood glucose measurements were below 70 mg/dL. The assessment of other vital signs, including blood pressure, heart rate, and temperature, did not reveal any clinically significant changes in either period. No serious adverse events or unexpected adverse events occurred during this study for the test or reference products.</p><p id="Par70">Subject 1 was given 60 mL of 20% glucose solution orally twice and kept under monitoring until his blood glucose was normal, as described in the study protocol.</p><p id="Par71">All observed AEs recovered within a few hours and did not require any further investigations.</p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par72">To the best of our knowledge, this is the first bioequivalence study to assess the bioequivalence of two formulations of metformin/vildagliptin in healthy Tunisian volunteers under fed conditions. Our study demonstrated that the new generic film-coated tablet combination of metformin hydrochloride/vildagliptin (850 mg/50 mg) was bioequivalent to the same film-coated tablet strength of the marketed reference. These results support the marketing of this new generic in Tunisia.</p><p id="Par73">Intrasubject variability of C<sub>max</sub> is crucial in bioequivalence trials, as it is a pivotal parameter for sample size determination and thereby influences overall trial validity<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. Unfortunately, these valuable data are often limited in the literature, and in their absence, intersubject variability is frequently utilized, potentially leading to an overestimation of the required sample size<sup><xref ref-type="bibr" rid="CR13">13</xref>–<xref ref-type="bibr" rid="CR15">15</xref></sup>. In our investigation, we determined the intrasubject variability for the C<sub>max</sub> of metformin and vildagliptin to be 14.11% and 14.05%, respectively. Notably, these findings align with literature, where the reported intrasubject variability for vildagliptin C<sub>max</sub> was 15.85%, demonstrating consistency<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. However, our observed intrasubject variability for metformin C<sub>max</sub>, at 14.11%, diverges from the literature-reported value of 8.95% <sup>8</sup>. These results emphasize the importance of considering intrasubject variability in bioequivalence trials and underscore the need for accurate and context-specific data to inform sample size calculations. The nuanced variability between our study and the literature values for metformin further underscores the importance of discerning drug-specific characteristics when designing and interpreting bioequivalence studies.</p><p id="Par74">Our sample size of 18 subjects provided a statistical power of 90% to demonstrate bioequivalence, consistent with regulatory expectations. Previous bioequivalence studies on metformin/vildagliptin have reported variable sample sizes, ranging from 12 to 60 participants. For example, Schnaars et al. conducted a study with a cohort of 60 subjects, with 90% power but different intrasubject variability<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Another bioequivalence study involving only 12 subjects reported the equivalence of the two drug formulations<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. While many regulatory agencies require a minimum of 12 subjects<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>, relying on such a small cohort may compromise study validity due to the inherent risk of withdrawals or protocol deviations. Furthermore, conducting a bioavailability study with more than 40 subjects is generally deemed impractical<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. This underscores the delicate balance that researchers must strike in determining an appropriate and feasible sample size for bioequivalence trials. Ethical considerations also play a role in determining subject numbers to avoid unnecessary exposure of healthy volunteers. In such cases, accepting lower statistical power may become unavoidable. However, a larger subject cohort beyond the defined statistical power (80%) may narrow confidence intervals. In studies involving healthy volunteers in particular, financial and ethical constraints can pose challenges<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>.</p><p id="Par75">The selection of fed conditions for this trial was driven by the pharmacokinetic characteristics of the two drugs. Data from the literature have shown that both vildagliptin and metformin pharmacokinetics are not significantly influenced by age, sex, or BMI<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>; therefore, the inclusion criteria for the present study were set as aforementioned without broad restrictions.</p><p id="Par76">Vildagliptin exposure is minimally affected by food, although food intake may delay T<sub>max</sub>. In contrast, metformin absorption is known to be significantly influenced by food, with reduced Cmax but generally unchanged total exposure. Therefore, a fixed-dose combination of vildagliptin and metformin bioavailability was assessed in this study under fed conditions through a two-way crossover design<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>.</p><p id="Par77">In their open-label study under both fed and fasting conditions, He et al. demonstrated that while food did not impact the pharmacokinetics of vildagliptin, it slowed the absorption rate of metformin without altering its overall extent of absorption. As a result, the fixed-dose combination tablet of vildagliptin and metformin can be administered according to the same guidelines as metformin regarding food intake<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>.</p><p id="Par78">Overall, the pharmacokinetic findings of our study are consistent with previously published data and confirm that the test FDC formulation provides comparable systemic exposure to the reference product. The demonstration of bioequivalence under fed conditions supports the clinical substitutability of the test product and contributes to the availability of a locally manufactured alternative for the management of type 2 diabetes in Tunisia. Demonstrating bioequivalence is a critical regulatory requirement not only for initial marketing authorization but also for ensuring interchangeability with existing therapies. Furthermore, establishing BE supports broader public-health objectives by enabling access to cost-effective therapies and improving adherence.</p></sec><sec id="Sec14"><title>Conclusion</title><p id="Par79">In this single-dose crossover clinical trial conducted under fed conditions, the test product Bi-Galvine 850/50 mg Film-Coated Tablets of SAIPH Pharma, Tunisia, showed bioequivalence to the reference product Galvumet 850/50 mg Film-Coated Tablets of Novartis Pharma Schweiz AG, Risch, Suisse, in terms of the rate and extent of absorption.</p></sec></body><back><fn-group><fn><p><bold>Publisher’s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors thank the participants and all the staff of the clinical pharmacology department. The authors also express their special thanks to Prof. Mohamed Lakhal and Prof. Mohamed Hédi Loueslati (former directors of the Tunisian National Center of Pharmacovigilance), Mrs. Souad Sadraoui (CEO of Charles Nicolle Hospital), Mr. Ramzi Sandi (CEO at Société Arabe des Industries Pharmaceutiques SAIPH), Dr. Ramzi Sarraj (Development and regulatory affairs director Middle East &amp; Africa at Société Arabe des Industries Pharmaceutiques SAIPH), Prof. Alia Jebri (Head of the Anesthesia Department at Charles Nicolle Hospital), Prof. Riadh Ben Slama (Head of the Urology Department at Charles Nicolle Hospital) Prof. Abderrazak Bouzouita (Urology Department at Charles Nicolle Hospital), Mrs. Hanene Zemzmi (Nutritionist at Charles Nicolle Hospital), and Mr. Walid Siala (Engineer at Waters Corporation).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>K Ferchichi: Data curation, writing original draft, E Gaies: Conceptualization, methodology, data analysis, writing—review &amp; editing, S B Hammamia: Investigation, data curation, H E Jebari: Investigation, data curation, M Daldoul: Investigation, data curation, S Ghorbel: Investigation, data curation, S Srairi: Pharmacovigilance data analysis, S Guermazi: Data curation, Y Gorgi: Data curation, I Boutiba: Data curation, K Bouzid: Data curation, A Abbessi: Study drugs handling &amp; dispensing, R Daghfous: Supervision, funding acquisition, M B Sassi: Investigation, data curation, supervision, S Trabelsi:Principal Investigator, conceptualization, supervision .</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was sponsored by SAIPH Pharma (Société Arabe des Industries Pharmaceutiques).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Prof. Sameh Trabelsi M.D, head of the Clinical Pharmacology Department could be contacted if data from this study are requested.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par80">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mbarki</surname><given-names>S</given-names></name><etal/></person-group><article-title>EPIDEMIOLOGIE DU DIABETE SUCRE EN TUNISIE.Etude Hammam Sousse Sahloul heart study (HSHS 2)</article-title><source>Tunis Med.</source><year>2022</year><volume>100</volume><issue>3</issue><fpage>229</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">36005915</pub-id><pub-id pub-id-type="pmcid">PMC9387647</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Mbarki, S. <italic toggle="yes">et al.</italic> EPIDEMIOLOGIE DU DIABETE SUCRE EN TUNISIE.Etude Hammam Sousse Sahloul heart study (HSHS 2). <italic toggle="yes">Tunis Med.</italic><bold>100</bold>(3), 229–240 (2022).<pub-id pub-id-type="pmid">36005915</pub-id>
<pub-id pub-id-type="pmcid">PMC9387647</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Anonymous. Vildagliptin / Metformin Hydrochloride Accord | European Medicines Agency. n.d. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/medicines/human/EPAR/vildagliptin-metformin-hydrochloride-accord">https://www.ema.europa.eu/en/medicines/human/EPAR/vildagliptin-metformin-hydrochloride-accord</ext-link> [Last accessed: 12/17/2023].</mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Anonymous. WMA - The World Medical Association-WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Participants. n.d. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.wma.net/policies-post/wma-declaration-of-helsinki/">https://www.wma.net/policies-post/wma-declaration-of-helsinki/</ext-link> [Last accessed: 11/28/2025].<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2024.21972</pub-id><pub-id pub-id-type="pmid">39425955</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Anonymous &amp; ICH E6 Good Clinical Practice - Scientific Guideline | European Medicines Agency (EMA). (2002). Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/ich-e6-good-clinical-practice-scientific-guideline">https://www.ema.europa.eu/en/ich-e6-good-clinical-practice-scientific-guideline</ext-link> [Last accessed: 11/28/2025].</mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Anonymous. Investigation of Bioequivalence - Scientific Guideline | European Medicines Agency. n.d. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/investigation-bioequivalence-scientific-guideline">https://www.ema.europa.eu/en/investigation-bioequivalence-scientific-guideline</ext-link> [Last accessed: 12/17/2023].</mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Anonymous Compendium.Ch. n.d. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://compendium.ch/product/1138799-galvumet-cpr-pell-50-850-mg/mpro">https://compendium.ch/product/1138799-galvumet-cpr-pell-50-850-mg/mpro</ext-link> [Last accessed: 7/22/2024].</mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Research, C. DE and. Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations. FDA; (2020). Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioavailability-and-bioequivalence-studies-submitted-ndas-or-inds-general-considerations">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioavailability-and-bioequivalence-studies-submitted-ndas-or-inds-general-considerations</ext-link> [Last accessed: 12/17/2023].</mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sen</surname><given-names>P</given-names></name><etal/></person-group><article-title>Bioequivalence study of vildagliptin and Metformin fixed dose combinations in healthy volunteers</article-title><source>Indian Practitioner</source><year>2020</year><volume>73</volume><issue>1</issue><fpage>28</fpage><lpage>33</lpage></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Sen, P. et al. Bioequivalence study of vildagliptin and Metformin fixed dose combinations in healthy volunteers. <italic toggle="yes">Indian Practitioner</italic>. <bold>73</bold> (1), 28–33 (2020).</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chow</surname><given-names>S-C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>On sample size calculation in bioequivalence trials</article-title><source>J. Pharmacokinet. Pharmacodyn.</source><year>2001</year><volume>28</volume><issue>2</issue><fpage>155</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1023/A:1011503032353</pub-id><pub-id pub-id-type="pmid">11381568</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Chow, S-C. &amp; Wang, H. On sample size calculation in bioequivalence trials. <italic toggle="yes">J. Pharmacokinet. Pharmacodyn.</italic><bold>28</bold>(2), 155–169. 10.1023/A:1011503032353 (2001).<pub-id pub-id-type="pmid">11381568</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1011503032353</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Anonymous &amp; ICH M10 on Bioanalytical Method Validation - Scientific Guideline | European Medicines Agency. n.d. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/ich-m10-bioanalytical-method-validation-scientific-guideline">https://www.ema.europa.eu/en/ich-m10-bioanalytical-method-validation-scientific-guideline</ext-link> [Last accessed: 12/17/2023].</mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Denney, W., Duvvuri, S. &amp; Buckeridge, C. Simple, automatic noncompartmental analysis: The PKNCA R Package. <italic toggle="yes">J. Pharmacokinet. Pharmacodyn.</italic><bold>42</bold>(1), 11–107, S65. ISSN 1573–8744. 10.1007/s10928-015-9432-2, R package version 0.12.1, (2015). <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/humanpred/pknca">https://github.com/humanpred/pknca</ext-link></mixed-citation></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhupathi</surname><given-names>C</given-names></name><name name-style="western"><surname>Vajjha</surname><given-names>VH</given-names></name></person-group><article-title>Sample size recommendation for a bioequivalent study</article-title><source>Statistica</source><year>2017</year><volume>77</volume><issue>1</issue><fpage>65</fpage><lpage>71</lpage></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Bhupathi, C. &amp; Vajjha, V. H. Sample size recommendation for a bioequivalent study. <italic toggle="yes">Statistica</italic><bold>77</bold> (1), 65–71 (2017).</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramírez</surname><given-names>E</given-names></name><etal/></person-group><article-title>A preliminary model to avoid the overestimation of sample size in bioequivalence studies</article-title><source>Drug Res.</source><year>2013</year><volume>63</volume><issue>02</issue><fpage>98</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1055/s-0032-1333296</pub-id><pub-id pub-id-type="pmid">23427051</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Ramírez, E. et al. A preliminary model to avoid the overestimation of sample size in bioequivalence studies. <italic toggle="yes">Drug Res.</italic><bold>63</bold> (02), 98–103. 10.1055/s-0032-1333296 (2013).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0032-1333296</pub-id><pub-id pub-id-type="pmid">23427051</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>L</given-names></name><etal/></person-group><article-title>Pharmacokinetics and bioequivalence of a generic Fixed-Dose combination tablet of Metformin Hydrochloride/Vildagliptin versus a branded product in healthy Chinese subjects under fed and fasting conditions</article-title><source>Clin. Pharmacol. Drug Dev.</source><year>2022</year><volume>11</volume><issue>1</issue><fpage>63</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1002/cpdd.992</pub-id><pub-id pub-id-type="pmid">34273258</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Ye, L. et al. Pharmacokinetics and bioequivalence of a generic Fixed-Dose combination tablet of Metformin Hydrochloride/Vildagliptin versus a branded product in healthy Chinese subjects under fed and fasting conditions. <italic toggle="yes">Clin. Pharmacol. Drug Dev.</italic><bold>11</bold> (1), 63–70. 10.1002/cpdd.992 (2022).<pub-id pub-id-type="pmid">34273258</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpdd.992</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>P</given-names></name><etal/></person-group><article-title>Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers</article-title><source>J. Clin. Pharmacol.</source><year>2009</year><volume>49</volume><issue>1</issue><fpage>39</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1177/0091270008325152</pub-id><pub-id pub-id-type="pmid">18832295</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Hu, P. et al. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. <italic toggle="yes">J. Clin. Pharmacol.</italic><bold>49</bold> (1), 39–49. 10.1177/0091270008325152 (2009).<pub-id pub-id-type="pmid">18832295</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0091270008325152</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schnaars</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Bioequivalence studies of new generic formulations of vildagliptin and fixed-drug combination of vildagliptin and Metformin versus respective originator products in healthy volunteers</article-title><source>Diabetes Ther.</source><year>2022</year><volume>13</volume><issue>6</issue><fpage>1215</fpage><lpage>1229</lpage><pub-id pub-id-type="doi">10.1007/s13300-022-01269-1</pub-id><pub-id pub-id-type="pmid">35543870</pub-id><pub-id pub-id-type="pmcid">PMC9174400</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Schnaars, Y. et al. Bioequivalence studies of new generic formulations of vildagliptin and fixed-drug combination of vildagliptin and Metformin versus respective originator products in healthy volunteers. <italic toggle="yes">Diabetes Ther.</italic><bold>13</bold> (6), 1215–1229. 10.1007/s13300-022-01269-1 (2022).<pub-id pub-id-type="pmid">35543870</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13300-022-01269-1</pub-id><pub-id pub-id-type="pmcid">PMC9174400</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y-L</given-names></name><etal/></person-group><article-title>Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers</article-title><source>Curr. Med. Res. Opin.</source><year>2008</year><volume>24</volume><issue>6</issue><fpage>1703</fpage><lpage>1709</lpage><pub-id pub-id-type="doi">10.1185/03007990802114070</pub-id><pub-id pub-id-type="pmid">18471347</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">He, Y-L. et al. Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers. <italic toggle="yes">Curr. Med. Res. Opin.</italic><bold>24</bold> (6), 1703–1709. 10.1185/03007990802114070 (2008).<pub-id pub-id-type="pmid">18471347</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1185/03007990802114070</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xml:lang="en" article-type="case-report" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Des Devel Ther</journal-id><journal-id journal-id-type="iso-abbrev">Drug Des Devel Ther</journal-id><journal-id journal-id-type="pmc-domain-id">958</journal-id><journal-id journal-id-type="pmc-domain">dddt</journal-id><journal-id journal-id-type="publisher-id">dddt</journal-id><journal-title-group><journal-title>Drug Design, Development and Therapy</journal-title></journal-title-group><issn pub-type="epub">1177-8881</issn><publisher><publisher-name>Dove Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12423445</article-id><article-id pub-id-type="pmcid-ver">PMC12423445.1</article-id><article-id pub-id-type="pmcaid">12423445</article-id><article-id pub-id-type="pmcaiid">12423445</article-id><article-id pub-id-type="pmid">40951699</article-id><article-id pub-id-type="doi">10.2147/DDDT.S526915</article-id><article-id pub-id-type="publisher-id">526915</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Clinical Trial Report</subject></subj-group></article-categories><title-group><article-title>Pharmacokinetic and Pharmacodynamic Interaction of Metformin and Ojeok-san in Healthy Volunteers</article-title><alt-title alt-title-type="running-authors">Lee et al</alt-title><alt-title alt-title-type="running-title">Lee et al</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4800-4348</contrib-id><name name-style="western"><surname>Lee</surname><given-names initials="S">Sooyoung</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chae</surname><given-names initials="S">Sumin</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0001-3558-8516</contrib-id><name name-style="western"><surname>Kwon</surname><given-names initials="M">Minji</given-names></name><xref rid="aff0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0903-1386</contrib-id><name name-style="western"><surname>Shim</surname><given-names initials="WS">Wang-Seob</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3141-3727</contrib-id><name name-style="western"><surname>Lee</surname><given-names initials="KT">Kyung-Tae</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff0005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="aff0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4393-800X</contrib-id><name name-style="western"><surname>Yim</surname><given-names initials="SV">Sung-Vin</given-names></name><xref rid="aff0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3233-2918</contrib-id><name name-style="western"><surname>Kim</surname><given-names initials="BH">Bo-Hyung</given-names></name><xref rid="aff0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff0007" ref-type="aff">
<sup>7</sup>
</xref><xref rid="aff0008" ref-type="aff">
<sup>8</sup>
</xref><xref rid="aff0009" ref-type="aff">
<sup>9</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><aff id="aff0001"><label>1</label><institution>Department of Life and Nanopharmaceutical Sciences, Graduate School, Kyung Hee University</institution>, <addr-line>Seoul</addr-line>, <country>Republic of Korea</country></aff><aff id="aff0002"><label>2</label><institution>Department of Surgery, Kyung Hee University College of Medicine, Kyung Hee University Hospital</institution>, <addr-line>Seoul</addr-line>, <country>Republic of Korea</country></aff><aff id="aff0003"><label>3</label><institution>Department of Clinical Pharmacology and Therapeutics, Kyung Hee University Hospital</institution>, <addr-line>Seoul</addr-line>, <country>Republic of Korea</country></aff><aff id="aff0004"><label>4</label><institution>Kyung Hee Drug Analysis Center, College of Pharmacy, Kyung Hee University</institution>, <addr-line>Seoul</addr-line>, <country>Republic of Korea</country></aff><aff id="aff0005"><label>5</label><institution>Department of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University</institution>, <addr-line>Seoul</addr-line>, <country>Republic of Korea</country></aff><aff id="aff0006"><label>6</label><institution>Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University</institution>, <addr-line>Seoul</addr-line>, <country>Republic of Korea</country></aff><aff id="aff0007"><label>7</label><institution>Department of Clinical Pharmacology and Therapeutics, College of Medicine, Kyung Hee University</institution>, <addr-line>Seoul</addr-line>, <country>Republic of Korea</country></aff><aff id="aff0008"><label>8</label><institution>Department of Biomedical Science and Technology, Graduate School, Kyung Hee University</institution>, <addr-line>Seoul</addr-line>, <country>Republic of Korea</country></aff><aff id="aff0009"><label>9</label><institution>East-West Medical Research Institute, Kyung Hee University</institution>, <addr-line>Seoul</addr-line>, <country>Republic of Korea</country></aff></contrib-group><author-notes><corresp id="an0001">Correspondence: Bo-Hyung Kim, <institution>Department of Clinical Pharmacology and Therapeutics, Kyung Hee University Hospital</institution>, <addr-line>Seoul</addr-line>, <country>Republic of Korea</country>, Email bhkim98@khu.ac.kr</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>19</volume><issue-id pub-id-type="pmc-issue-id">478870</issue-id><fpage>7825</fpage><lpage>7836</lpage><history><date date-type="received"><day>24</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>19</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>12</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-15 15:25:19.733"><day>15</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>© 2025 Lee et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Lee et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v4.0) License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="dddt-19-7825.pdf"/><abstract><sec><title>Purpose</title><p>This study aimed to evaluate the pharmacokinetics and pharmacodynamics of metformin and Ojeok-san (OJS) co-administration to healthy volunteers compared to those with metformin alone.</p></sec><sec><title>Methods</title><p>This was an open-label, one-sequence, crossover study, with two 2-day hospitalization schedules lasting up to 14 days. Metformin was administered once daily on days 1 and 2. OJS was administered alone three times a day on days 3–7 and co-administered with metformin once a day on days 8 and 9. Plasma concentrations of metformin were measured using a validated LC-MS/MS method. To evaluate pharmacodynamics, oral glucose tolerance tests (OGTTs) were performed on days 1, 2, 8 and 9.</p></sec><sec><title>Results</title><p>Fifteen participants were enrolled. The coadministration decreased C<sub>max</sub> (1757.7 to 1668.9 ng/mL) and AUC<sub>last</sub> (10407.4 to 9901.1 ng·h/mL), compared to those with metformin alone. Geometric mean ratios (90% Confidence Interval) of C<sub>max</sub> and AUC<sub>last</sub> between the co-administration with OJS and metformin alone were 92.15% (82.79–102.57) and 94.57% (85.6–104.48), respectively. Co-administration with OJS did not significantly change the mean glucose level compared to that with metformin alone.</p></sec><sec><title>Conclusion</title><p>Co-administration with OJS decreased the plasma concentrations of metformin compared to that with metformin alone. However, the degree of decrease was not significant based on the geometric mean of the C<sub>max</sub> and AUC<sub>last</sub>. Considering the OGTT results, these changes in metformin concentration did not affect glucose concentration. In addition, there were no significant findings regarding safety profiles.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>metformin</kwd><kwd>ojeok-san</kwd><kwd>drug-herb interaction</kwd><kwd>pharmacokinetics</kwd><kwd>pharmacodynamics</kwd></kwd-group><funding-group><award-group><funding-source>
<institution-wrap><institution>Korea Health Technology R&amp;D Project through the Korea Health Industry Development Institute</institution></institution-wrap>
</funding-source></award-group><award-group><funding-source>
<institution-wrap><institution>Ministry of Health &amp; Welfare, Republic of Korea</institution></institution-wrap>
</funding-source></award-group><funding-statement>This research was supported by grants from the Korea Health Technology R&amp;D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health &amp; Welfare, Republic of Korea (grant numbers RS-2020-KH087722 and HI22C2060).</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="2"/><ref-count count="31"/><page-count count="12"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s0001"><title>Introduction</title><p>Type 2 diabetes mellitus (DM) is a chronic disease in which blood sugar levels are elevated due to an abnormal response of beta cells to insulin activity.<xref rid="cit0001" ref-type="bibr">1</xref>,<xref rid="cit0002" ref-type="bibr">2</xref> It leads to microvascular and macrovascular complications, which are major problems associated with morbidity and mortality in patients with type 2 DM.<xref rid="cit0003" ref-type="bibr">3</xref> Microvascular complications include retinopathy, neuropathy, and nephropathy, whereas macrovascular complications include coronary artery disease, cerebrovascular disease, peripheral artery disease, and heart failure. These complications cause significant psychological and physical suffering in patients and place a substantial burden on public health systems.<xref rid="cit0001" ref-type="bibr">1</xref>,<xref rid="cit0004" ref-type="bibr">4</xref> The prevalence of diabetes was reported to be 13.9% in 2020 in Korea and 11.6% in 2021 in the United States.<xref rid="cit0005" ref-type="bibr">5</xref>,<xref rid="cit0006" ref-type="bibr">6</xref> Considering the numerous patients, diabetes is a major disease requiring long-term public health management.</p><p>To control blood glucose levels, patients with diabetes should take hypoglycemic agents regularly and consistently. Among these drugs, metformin is the first-line medication prescribed to patients with type 2 DM because it can effectively manage glucose levels and has a favorable safety profiles.<xref rid="cit0007" ref-type="bibr">7</xref> Furthermore, clinical evidence indicates that metformin reduces the incidence of cardiovascular events in patients with diabetes.<xref rid="cit0008" ref-type="bibr">8</xref></p><p>Individuals with type 2 DM may take other hypoglycemic drugs or medications along with metformin for various medical reasons. Therefore, there have been continuous reports on drug interactions following the concomitant administration of metformin and other drugs.<xref rid="cit0009" ref-type="bibr">9</xref> Interactions between metformin and other drugs must be evaluated in terms of their pharmacokinetics and pharmacodynamics. Metformin is excreted in an unchanged form in urine without metabolism and widely distributed in the body by organic cation transporters (OCTs).<xref rid="cit0010" ref-type="bibr">10</xref> Therefore, the pharmacokinetics of these drug transporters must be evaluated. Metformin lowers blood glucose levels by suppressing hepatic glucose production and facilitating glucose uptake in peripheral tissues, and these pharmacological effects can be affected by other drugs.<xref rid="cit0009" ref-type="bibr">9</xref>,<xref rid="cit0011" ref-type="bibr">11</xref> Additionally, alterations in the pharmacokinetics and pharmacodynamics of metformin are possible because of its interaction with herbal drugs rather than chemical drugs.<xref rid="cit0012" ref-type="bibr">12</xref></p><p>Ojeok-san (OJS) is one of most widely used herbal medicines in Korea, reported to account for the highest percentage (18.6%) of the total insurance claims for mixed herbal medicine prescriptions.<xref rid="cit0013" ref-type="bibr">13</xref> OJS is consists of 17 medicinal herbs.<xref rid="cit0014" ref-type="bibr">14</xref> It is used to control gastrointestinal and gynecological symptoms and various types of pain, such as arthritis, back pain, and headaches. Taking OJS for these various reasons means that patients with type 2 DM are more likely to take metformin along with OJS. Plasma concentrations of metformin could be increased or decreased when metformin and OJS are co-administered. This is because any of the 17 medicinal herbs in OJS can act as substrates, inhibitors, or inducers of OCTs.</p><p>Metformin is not metabolized and is excreted directly in urine.<xref rid="cit0010" ref-type="bibr">10</xref> Therefore, an evaluation of the absorption and excretion of metformin is required. Plasma membrane monoamine transporter (PMAT) and OCT1 play important roles in intestinal absorption.<xref rid="cit0015" ref-type="bibr">15</xref> The hepatic uptake of metformin is mainly mediated by OCT1 and may also be mediated by OCT3.<xref rid="cit0016" ref-type="bibr">16</xref>,<xref rid="cit0017" ref-type="bibr">17</xref> Metformin transfer from circulation into renal epithelial cells is facilitated by OCT2, and renal excretion of metformin into the lumen is mediated by human multidrug and toxin extrusion 1 (MATE1) and MATE2-K.<xref rid="cit0009" ref-type="bibr">9</xref>,<xref rid="cit0010" ref-type="bibr">10</xref> Metformin and OJS interactions were evaluated through the inhibition of metformin transporters (OCTs and MATEs). Relevant in vitro or in vivo studies on transporters in OJS to design this clinical trial were not found.</p><p>If blood glucose is not adequately controlled by the co-administration of metformin and OJS, OJS should be replaced with other herbal medicines or drugs. These herb-drug interactions require quantitative evaluation of changes in the pharmacokinetics and pharmacodynamics of metformin through prospective clinical trials administering metformin alone or metformin plus OJS to healthy volunteers. Therefore, this study aimed to evaluate the pharmacokinetics and pharmacodynamics of metformin, alone and in combination with OJS, in healthy volunteers.</p></sec><sec id="s0002"><title>Materials and Methods</title><sec id="s0002-s2001"><title>Participants</title><p>Healthy male participants, 19 to 45 years old, with a body mass index of 18.0 to 29.0 kg/m<sup>2</sup> were enrolled in this study. Participants provided written informed consent after receiving a detailed explanation of the study and were screened for eligibility. The screening assessment included medical history, physical examination, 12-lead electrocardiography, and clinical laboratory tests. The study protocol and informed consent forms were approved by the Korean Ministry of Food and Drug Safety, Institutional Review Board (IRB; IRB number: KHUH 2021-05-007) of Kyung Hee University Hospital (KHUH, Seoul, Republic of Korea), and IRB (IRB number: KOMCIRB 2021-06-004) of Kyung Hee University Korean Medical Hospital (KHUKMH, Seoul, Republic of Korea).</p></sec><sec id="s0002-s2002"><title>Design</title><p>This open-label, single-sequence, crossover clinical study was conducted in accordance with the Declaration of Helsinki and Korean Good Clinical Practice (Clinical Research Information Service, CRIS [<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cris.nih.go.kr" ext-link-type="uri">https://cris.nih.go.kr</ext-link></underline>]; registry number: KCT0006799).</p><p>The study included two 2-day hospitalization schedules that lasted up to 14 days, excluding the screening schedule (<xref rid="f0001" ref-type="fig">Figure 1</xref> and <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/526915/526915%20Supplementary%20files.docx" ext-link-type="uri">Supplementary Table 1</ext-link></underline>). In the first period (days 1–2), all participants enrolled in the screening evaluation were hospitalized on the morning of day 1 and discharged on the evening of day 2. In the second period, patients were hospitalized and discharged over the same amount of time on days 8–9. Metformin was administered once daily on days 1 and 2. In the second period (days 3–10), OJS was administered alone on days 3–7 and co-administered with metformin once daily on days 8–9. The 1000 mg metformin tablet was orally administered once daily at approximately 1 PM on days 1 and 8 and approximately 8 AM on days 2 and 9. The 4.35 g/pack OJS was orally administered thrice daily at approximately 7–10AM, 12–3 PM, and 6–9 PM on days 4–9. (The 4.35 g/pack OJS was orally administered thrice daily, approximately 6 h apart, from morning to night on days 4–9). When metformin and OJS were co-administered on the morning of days 8 and 9 of hospitalization, OJS was administered 1 h earlier than metformin. All the participants received standard meals during hospitalization.
<fig position="float" id="f0001" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><p>Schedule of the clinical study.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="DDDT-19-7825-g0001.jpg"/></fig></p><p>For the pharmacokinetic analysis of metformin, blood samples were collected before every drug administration on days 1, 2, 8, and 9. On days 2 and 9, steady-state blood samples were sequentially collected before metformin administration (0 h) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 h after administration.</p><p>For pharmacodynamic analysis, all the oral glucose tolerance tests (OGTTs) were conducted for 3 h. The OGTTs on days 1 and 8 were conducted from 10 AM to 1 PM, just before the administration of metformin, and those on days 2 and 9 were conducted from 2 to 5 h after the administration of metformin. The start time for all OGTTs was approximately 10 AM. For the OGTT, glucose (75 g) was orally administered, and blood samples were collected before (0 h) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, and 3 h after glucose intake. All participants were required to fast for 8 h before the OGTT.</p><p>All participants were discharged on the morning of day 10. The clinical study was completed after evaluating the safety profile through an outpatient visit (post-study visit) on one day from days 11 to 14.</p></sec><sec id="s0002-s2003"><title>Determination of Metformin Concentration</title><p>Plasma metformin concentrations were estimated using LC-MS/MS with an API 2000 triple quadrupole mass spectrometer (ABSciex, Framingham, MA, USA) coupled with an Agilent 1100 series HPLC system (Agilent Technologies, Waldronn, Germany). Metformin and metformin-d6 (IS) were separated using a Gemini<sup>®</sup> C18 column (50 × 2.0 mm, 3 µm; Phenomenex, USA) at 40 °C. The mobile phase consisted of 10 mM ammonium formate (pH 3.2) and 100% acetonitrile (80:20, v/v) with a flow rate of 150 µL/min. The compounds were detected in positive mode using an electrospray ionization source. The mass spectrometer was operated in multiple reaction monitoring mode with a mass-to-charge ratio (m/z) of 129.93 → 71.10 for metformin and 136.90 → 77.10 for IS. Samples were extracted using protein precipitation using acetonitrile. The injection volume was 7 µL. Metformin showed a linear response in the range of 50–5000 ng/mL (r<sup>2</sup> ≥ 0.9940) and the lower limit of quantification was determined as 50 ng/mL with S/N ratio ≥ 14.1. The intra- and inter-day precisions for metformin were less than 4.64% and 6.83%, respectively. The intra- and inter-day accuracies for metformin were less than 8.94% and 6.33%, respectively.</p></sec><sec id="s0002-s2004"><title>Pharmacokinetic and Pharmacodynamic Analysis</title><p>Pharmacokinetic parameters were calculated using the noncompartmental method in Phoenix™ WinNonlin<sup>®</sup> 8.3 (Certara USA Inc., Princeton, NJ, USA). The maximum plasma concentration (C<sub>max</sub>) and time to reach C<sub>max</sub> (T<sub>max</sub>) were directly determined using individually observed concentration-time profiles. The terminal elimination rate constant (kz) was obtained from the regression line of the log-linear decrease in the plasma concentration-time profile, and the terminal elimination half-life (t<sub>1/2</sub>) was calculated from the natural logarithm of 2 divided by kz. The area under the plasma concentration-time curve (AUC) from the time of second dose of metformin to the last measurable time point (AUC<sub>last</sub>) was calculated using the linear/log trapezoidal rule. The AUC from the time second dosing to infinity (AUC<sub>inf</sub>) was calculated as the sum of the AUC<sub>last</sub> and the extrapolated area, which was the last measurable concentration divided by kz. The apparent clearance (CL/F) was calculated as the metformin dose divided by the AUC<sub>inf</sub>.</p><p>Pharmacodynamic parameters were also calculated using the noncompartmental method in Phoenix™ WinNonlin<sup>®</sup> 8.3. The maximum serum glucose concentration (G<sub>max</sub>) and 2-h post-OGTT glucose levels (PP2) were obtained from individual glucose concentration-time profiles. The area under the glucose concentration-time curve for 3 h after glucose administration (AUG<sub>0-3h</sub>) was calculated using the linear trapezoidal rule. To assess the glucose-lowering effect of metformin for each period, the change and percent change (%change) were derived from the OGTT performed before metformin administration (days 1 and 8) to that performed after administration (days 2 and 9) as follows changes of G<sub>max</sub>, AUG<sub>0-3h</sub>, and PP2 were calculated as changes between Day 2 and Day 1 (=“Day2 - Day1”) and between Day 9 and Day 8 (=“Day9 - Day8”). The %changes were calculated as changes divided by those on Day 1 or 8, ie “100×(Day2 - Day1)/Day1” or “100×(Day9 - Day8)/Day8”.</p></sec><sec id="s0002-s2005"><title>Safety and Tolerability Assessment</title><p>Safety and tolerability were assessed during the study period. The occurrence of adverse events (AEs) was monitored and investigators assessed their causal relationship with metformin or OJS. Vital signs, 12-lead electrocardiogram, physical examinations, and clinical laboratory tests were performed and reviewed. Changes from baseline with respect to these results were considered in the tolerability assessment.</p></sec><sec id="s0002-s2006"><title>Statistical Analysis</title><p>All statistical analyses were performed using SAS 9.4 (SAS Institute Inc. Cary, NC, USA). Descriptive statistics (eg, arithmetic means, standard deviations, and ranges) for continuous variables were calculated. The pharmacokinetic parameters, C<sub>max</sub>, AUC<sub>last</sub>, and AUC<sub>inf</sub>, were converted into logarithmic forms and compared between period 1 (metformin alone) and period 2 (metformin with OJS) using the paired <italic toggle="yes">t</italic>-test. These comparisons were calculated as geometric mean (GMR) ratios (%) with 90% confidence intervals (CI), assessed using a conventional bioequivalence range of 80–125%. The pharmacodynamic parameters, G<sub>max</sub>, AUG<sub>0-3h</sub>, and PP2, were expressed as absolute and percentage changes, and compared using a paired <italic toggle="yes">t</italic>-test. The results were summarized as the mean difference with 95% CI. Scatter plots of both pharmacokinetic and pharmacodynamic parameters were reviewed to visually represent the data, and the coefficient of determination (R²) from a linear regression model was calculated to evaluate their association. All figures were visualized using the ggplot2 package in the R program (version 4.4.2).<xref rid="cit0018" ref-type="bibr">18</xref>,<xref rid="cit0019" ref-type="bibr">19</xref></p></sec></sec><sec id="s0003"><title>Results</title><sec id="s0003-s2001"><title>Demographic Characteristics</title><p>Fifteen participants were enrolled in the study. All participants completed the study without withdrawing, and were included in the pharmacokinetic and pharmacodynamic analyses. The mean (standard deviation, ranges) of age, weight, height, and body mass index for the 15 participants was 26.47 (2.97, 22–32) years, 71.45 (9.65, 58.3–88.8) kg, 177.18 (6.15, 165.8–191.2) cm, and 22.71 (2.28, 18.32–26.68) kg/m<sup>2</sup>, respectively.</p></sec><sec id="s0003-s2002"><title>Pharmacokinetic Characteristics</title><p>The mean concentrations of metformin decreased with co-administration, compared to that with metformin alone (<xref rid="f0002" ref-type="fig">Figure 2</xref>). Metformin and OJS co-administration delayed median T<sub>max</sub> by 0.5 h, compared to that with metformin alone (<xref rid="t0001" ref-type="table">Table 1</xref>). The co-administration decreased C<sub>max</sub> (1757.7 to 1668.9 ng/mL) and AUC<sub>last</sub> (10407.4 to 9901.1 ng·h/mL), compared to those with metformin alone. Geometric mean ratios (90% CI) of C<sub>max</sub> and AUC<sub>last</sub> between metformin with OJS and metformin alone were 92.15% (82.79–102.57) and 94.57% (85.6–104.48), respectively (<xref rid="t0001" ref-type="table">Table 1</xref>). In addition, in two-thirds of all participants, the co-administration of metformin and OJS reduced the C<sub>max</sub> and AUC<sub>last</sub> compared to those with metformin alone (<xref rid="f0003" ref-type="fig">Figure 3</xref>).<table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1</label><caption><p>Comparisons of Pharmacokinetic Parameters of Metformin When Administration of Metformin and Ojeok-San Compared to Those with Administration of Metformin Alone</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Parameter</th><th rowspan="1" colspan="1">Metformin (n=15)</th><th rowspan="1" colspan="1">Metformin + Ojeok-San (n=15)</th><th rowspan="1" colspan="1">Geometric Mean Ratio (%, 90% CI)<sup>a</sup></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">T<sub>max</sub> (h)</td><td rowspan="1" colspan="1">2.5 (1.0–4.0)</td><td rowspan="1" colspan="1">3.0 (1.0–5.0)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">C<sub>max</sub> (ng/mL)</td><td rowspan="1" colspan="1">1757.66 ± 424.46</td><td rowspan="1" colspan="1">1668.87 ± 606.54</td><td rowspan="1" colspan="1">92.15 (82.79–102.57)</td></tr><tr><td rowspan="1" colspan="1">AUC<sub>last</sub> (ng∙h/mL)</td><td rowspan="1" colspan="1">10407.39 ± 3021.23</td><td rowspan="1" colspan="1">9901.14 ± 3009.21</td><td rowspan="1" colspan="1">94.57 (85.60–104.48)</td></tr><tr><td rowspan="1" colspan="1">AUC<sub>inf</sub> (ng∙h/mL)</td><td rowspan="1" colspan="1">10927.43 ± 3067.01</td><td rowspan="1" colspan="1">10,503.13 ± 3067.01</td><td rowspan="1" colspan="1">95.69 (86.78–105.52)</td></tr><tr><td rowspan="1" colspan="1">AUC<sub>extra</sub> (%)</td><td rowspan="1" colspan="1">4.95 ± 2.05</td><td rowspan="1" colspan="1">6.05 ± 2.63</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">t<sub>1/2</sub> (h)</td><td rowspan="1" colspan="1">3.68 ± 1.42</td><td rowspan="1" colspan="1">3.50 ± 1.27</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">CL/F (L/h)</td><td rowspan="1" colspan="1">99.79 ± 35.10</td><td rowspan="1" colspan="1">104.53 ± 35.40</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p><bold>Notes</bold>: <sup>a</sup>The geometric mean ratio and the 90% confidence interval were calculated using a paired <italic toggle="yes">t</italic>-test.</p></fn><fn id="tfn0002"><p><bold>Abbreviations</bold>: T<sub>max</sub>, time to reach maximum concentration; C<sub>max</sub>, maximum concentration; AUC<sub>last</sub>, area under the curve from time zero to the last measurable concentration; AUC<sub>inf</sub>, area under the curve from time zero to infinity; AUC<sub>extra</sub>, area under the curve from the last measurable concentration to infinity; t<sub>1/2</sub>, half-life; CL/F, clearance after oral administration; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap>
<fig position="float" id="f0002" fig-type="figure" orientation="portrait"><label>Figure 2</label><caption><p>Mean concentration-time curves of metformin after the administration of metformin alone or coadministration of metformin with Ojeok-san in (<bold>A</bold>) linear and (<bold>B</bold>) logarithmic scale. The error bar indicates the standard deviation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="DDDT-19-7825-g0002.jpg"/></fig>
<fig position="float" id="f0003" fig-type="figure" orientation="portrait"><label>Figure 3</label><caption><p>Individual values of (<bold>A</bold>) C<sub>max</sub> and (<bold>B</bold>) AUC<sub>last</sub> of metformin after the administration of metformin alone and coadministration of metformin and Ojeok-san.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="DDDT-19-7825-g0003.jpg"/><attrib><bold>Note</bold>: Each symbol connected by a line represents an individual participant and the changes observed across treatment conditions. Colors indicate the treatment condition: Metformin versus Metformin + Ojeok-san.</attrib><attrib><bold>Abbreviations</bold>: C<sub>max</sub>, maximum concentration; AUC<sub>last</sub>, area under the curve from time zero to last measurable concentration.</attrib></fig></p></sec><sec id="s0003-s2003"><title>Pharmacodynamic Characteristics</title><p>The mean glucose concentrations were compared before and after metformin administration on days 1–2 and 8–9 (<xref rid="f0004" ref-type="fig">Figure 4</xref>). There were no significant differences in individual glucose levels at each time point (before and after treatment) between metformin alone and co-administration with OJS (<xref rid="f0004" ref-type="fig">Figure 4</xref>). There were also no marked changes or %changes in glucose levels between metformin alone and co-administration with OJS (<xref rid="f0005" ref-type="fig">Figure 5</xref>). Changes or %changes in G<sub>max</sub>, AUG<sub>0-3h</sub>, and PP2 were not significantly different between metformin alone and co-administration with OJS (<xref rid="t0002" ref-type="table">Table 2</xref>).<table-wrap position="float" id="t0002" orientation="portrait"><label>Table 2</label><caption><p>Comparisons of Oral Glucose Tolerance Test (OGTT) Results Before and After Administration of Metformin or Metformin and Ojeok-San</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Parameter</th><th colspan="2" rowspan="1">Metformin (n=15)</th><th colspan="2" rowspan="1">Metformin + Ojeok-San (n=15)</th><th rowspan="1" colspan="1">Difference<sup>a</sup></th></tr><tr><th rowspan="1" colspan="1">Before</th><th rowspan="1" colspan="1">After</th><th rowspan="1" colspan="1">Before</th><th rowspan="1" colspan="1">After</th><th rowspan="1" colspan="1">Mean (95% CI)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">G<sub>max</sub> (mg/dL)</td><td rowspan="1" colspan="1">161.60 ± 27.79</td><td rowspan="1" colspan="1">139.13 ± 14.16</td><td rowspan="1" colspan="1">176.13 ± 31.06</td><td rowspan="1" colspan="1">146.93 ± 19.46</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Change (mg/dL)</td><td colspan="2" rowspan="1">−22.47 ± 22.89</td><td colspan="2" rowspan="1">−29.20 ± 25.54</td><td rowspan="1" colspan="1">−6.73 (−22.32, 8.85)</td></tr><tr><td rowspan="1" colspan="1">%change (%)</td><td colspan="2" rowspan="1">−12.38 ± 12.47</td><td colspan="2" rowspan="1">−15.12 ± 13.66</td><td rowspan="1" colspan="1">−2.74 (−11.70, 6.23)</td></tr><tr><td rowspan="1" colspan="1">AUG<sub>0-3h</sub> (mg∙h/dL)</td><td rowspan="1" colspan="1">377.13 ± 54.75</td><td rowspan="1" colspan="1">349.17 ± 26.60</td><td rowspan="1" colspan="1">397.66 ± 50.26</td><td rowspan="1" colspan="1">364.33 ± 40.38</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Change (mg∙h/dL)</td><td colspan="2" rowspan="1">−27.97 ± 38.12</td><td colspan="2" rowspan="1">−33.33 ± 34.71</td><td rowspan="1" colspan="1">−5.37 (−31.88, 21.15)</td></tr><tr><td rowspan="1" colspan="1">%change (%)</td><td colspan="2" rowspan="1">−6.40 ± 8.74</td><td colspan="2" rowspan="1">−7.91 ± 8.33</td><td rowspan="1" colspan="1">−1.51 (−8.14, 5.12)</td></tr><tr><td rowspan="1" colspan="1">PP2 (mg/dL)</td><td rowspan="1" colspan="1">119.73 ± 27.78</td><td rowspan="1" colspan="1">116.60 ± 12.03</td><td rowspan="1" colspan="1">132.73 ± 21.42</td><td rowspan="1" colspan="1">120.53 ± 17.61</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Change (mg/dL)</td><td colspan="2" rowspan="1">−3.13 ± 20.45</td><td colspan="2" rowspan="1">−12.20 ± 21.08</td><td rowspan="1" colspan="1">−9.07 (−21.27, 3.14)</td></tr><tr><td rowspan="1" colspan="1">%change (%)</td><td colspan="2" rowspan="1">1.11 ± 19.45</td><td colspan="2" rowspan="1">−7.84 ± 15.33</td><td rowspan="1" colspan="1">−8.95 (−19.52, 1.62)</td></tr></tbody></table><table-wrap-foot><fn id="tfn0003"><p><bold>Notes</bold>: <sup>a</sup>The mean difference and the 95% confidence interval were calculated using a paired <italic toggle="yes">t</italic>-test.</p></fn><fn id="tfn0004"><p><bold>Abbreviations</bold>: G<sub>max</sub>, maximum glucose concentration; AUG<sub>0-3h</sub>, area under the glucose concentration-time curve from 0 to 3 h; PP2, 2-hpost-OGTT glucose level; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap>
<fig position="float" id="f0004" fig-type="figure" orientation="portrait"><label>Figure 4</label><caption><p>Mean concentration-time curves of glucose after oral glucose tolerance tests (OGTTs) (<bold>A</bold>) before and after metformin administration on days 1 and 2, (<bold>B</bold>) after Ojeok-san administration, before metformin administration, and after coadministration of metformin and Ojeok-san on days 8 and 9. (<bold>C</bold>) Changes in glucose concentration before and after metformin administration during OGTT, calculated as “day 2 - day 1” and “day 9 - day 8”. The error bar indicates the standard deviation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="DDDT-19-7825-g0004.jpg"/></fig>
<fig position="float" id="f0005" fig-type="figure" orientation="portrait"><label>Figure 5</label><caption><p>Individual changes and %changes of glucose (<bold>A</bold> and <bold>D</bold>) G<sub>max</sub>, (<bold>B</bold> and <bold>E</bold>) AUG<sub>0-3h</sub>, (<bold>C</bold> and <bold>F</bold>) PP2.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="DDDT-19-7825-g0005.jpg"/><attrib><bold>Note</bold>: Box plots represent the median and interquartile range. Each symbol connected by a line represents an individual participant and the changes observed across treatment conditions. Colors indicate the treatment condition: Metformin versus Metformin + Ojeok-san.</attrib><attrib><bold>Abbreviations</bold>: G<sub>max</sub>, maximum glucose concentration; AUG<sub>0-3h</sub>, area under the glucose concentration-time curve from 0 to 3 h; PP2, 2-h post-OGTT glucose level.</attrib></fig></p></sec><sec id="s0003-s2004"><title>Pharmacokinetic and Pharmacodynamic Relationships</title><p>Individual changes or %changes in G<sub>max</sub>, AUG<sub>0-3h</sub>, and PP2 are displayed according to the C<sub>max</sub> or AUC<sub>0-8h</sub> of metformin between metformin alone and co-administration with OJS (<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/526915/526915%20Supplementary%20files.docx" ext-link-type="uri">Supplementary Figures 1</ext-link></underline> and <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/526915/526915%20Supplementary%20files.docx" ext-link-type="uri">2</ext-link></underline>). Although co-administration with OJS resulted in modest mean changes in the pharmacokinetic and pharmacodynamic parameters compared to metformin alone, no clinically meaningful correlations were observed between pharmacokinetic and pharmacodynamic findings (<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/526915/526915%20Supplementary%20files.docx" ext-link-type="uri">Supplementary Figures 3</ext-link></underline> and <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/526915/526915%20Supplementary%20files.docx" ext-link-type="uri">4</ext-link></underline>). Specifically, the differences in the changes of G<sub>max</sub>, AUG<sub>0-3h</sub>, and PP2 were not consistently associated with the individual ratios of metformin C<sub>max</sub> or AUC<sub>0-8h</sub>, as indicated by the low R² values in all comparisons. No clinically relevant pharmacokinetic-pharmacodynamic relationship was observed in either metformin alone or co-administration with OJS.</p></sec><sec id="s0003-s2005"><title>Safety Profiles and Tolerability</title><p>Among the 15 participants, seven (46.7%) in period 1 and nine (60.0%) in period 2 reported AEs. All AEs were evaluated as being related to the administration of metformin or OJS, except for one AE reported in period 2. The AEs were diarrhea (seven cases in period 1 and eight in period 2) and abdominal discomfort (one in period 2). The AEs in period 1 were considered to be associated with metformin and those in period 2 were considered to be associated with metformin or OJS. None of the participants withdrew from the study because of AEs. Safety profiles and tolerability assessments, including vital signs, physical examination, and clinical laboratory tests, showed no significant results or changes from baseline assessments. In particular, no significant increase was observed in liver function-related parameters, such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/526915/526915%20Supplementary%20files.docx" ext-link-type="uri">Supplementary Figure 5</ext-link></underline>).</p></sec></sec><sec id="s0004"><title>Discussion</title><p>Metformin is excreted unchanged in urine, requiring an evaluation of its absorption and excretion when co-administered with OJS.<xref rid="cit0010" ref-type="bibr">10</xref> Its transport involves PMAT, OCTs, and MATEs.<xref rid="cit0015" ref-type="bibr">15–17</xref> The interaction with OJS was assessed based on potential transporter inhibition, but no relevant in vitro or in vivo studies were found. Although OJS has not been directly studied, a similar pharmacokinetic pattern was observed in a clinical study that investigated the interaction between metformin and another herbal medicine, goldenseal.<xref rid="cit0020" ref-type="bibr">20</xref> In that study, there was a noted decrease in metformin’s AUC without a significant change in its half-life. This effect was attributed to mechanisms involving the inhibition or induction of OCTs, which may also apply to the current study. Nevertheless, considering the quantitative pharmacokinetic results of the current study, it was concluded that the effect of OJS on the transporter is minimal.</p><p>Metformin was administered once daily for two consecutive days in each period. It was concluded that it would be possible to evaluate drug interactions with OJS even after taking metformin for 1 to 2 days, because the half-life of metformin is reported to be 1.52 to 5.1 h.<xref rid="cit0021" ref-type="bibr">21</xref>,<xref rid="cit0022" ref-type="bibr">22</xref> In the current study, the mean terminal half-life was 3.50 and 3.68 h. In addition, because the metformin concentrations at 0 h before the metformin administration on the days 2 or 9 were less than 5% of C<sub>max</sub> in all the participants, except for two participants in period 2, there may be little drug accumulation regarding pharmacokinetics when taking 1000 mg of metformin once daily.</p><p>In a previous study on OGTTs using 75 g of glucose in healthy Korean participants (N=34), the mean AUG<sub>0-3h</sub>/PP2 value (SD) before dosing was 384 (65.9) mg⋅h/dL/120.2 (33.9) mg/dL.<xref rid="cit0023" ref-type="bibr">23</xref> In another study evaluating OGTTs using 75 g glucose in healthy participants, two median AUG<sub>0-3h</sub>/PP2 values (interquartile ranges, IQR) at pre-dose were 391.2 (19.8) mg⋅h/dL/132.5 (19.0) mg/dL (N=10) and 397.8 (67.8) mg⋅h/dL/139.0 (38.0) mg/dL (N=10).<xref rid="cit0022" ref-type="bibr">22</xref> In this previous study, OGTT was performed at 2 h after the dose of metformin 1000 mg, and the median AUG<sub>0-3h</sub>/PP2 value (IQR) at post-dose was 370.3 (39.6) mg⋅h/dL/125.5 (31.0) mg/dL. The median value of individual AUG<sub>0-3h</sub>/PP2 differences (reduction) between post-dose and pre-dose values was 41.9 (60.1) mg⋅h/dL/16.5 (22.0) mg/dL. These differences were comparable with the results of the current study; median value (IQR) of individual AUG<sub>0-3h</sub>/PP2 reductions was 23.63 (43.75) mg⋅h/dL/0 (21) mg/dL at period 1 (metformin alone) and 39.13 (37.38)/10 (24.5) at period 2 (OJS coadministration). Comparing the AUC<sub>0-3h</sub> or PP2 reductions in the previous study and those in the current study, the differences in AUC<sub>0-3h</sub>/PP2 changes between the two periods were not clinically significant.</p><p>In the clinical study for the repeated OGTTs using 75 g of glucose (N=8), changes of glucose AUG<sub>0-120min</sub> for each repeated glucose measurement during 3 days were reported as −3.7 to 47.4 mmol/L⋅120/min (−1.11 to 14.23 mg⋅h/dL).<xref rid="cit0024" ref-type="bibr">24</xref> Therefore, mean AUG<sub>0-3h</sub>(SD) difference before dosing between periods 1 and 2, ie “377.13(54.75) mg⋅h/dL” versus “397.66(50.26) mg⋅h/dL” can be regarded as inter-day variability of glucose, although OJS administered 3 h before glucose dosing at period 2 could increase glucose levels. Meanwhile, the difference in PP2 changes between both periods was marked, especially regarding glucose changes from 1.5 to 2 h (<xref rid="f0004" ref-type="fig">Figure 4</xref>). These findings could be interpreted as the result of glucose levels at 1.5 and 2 h before dosing (on day 8) in period 2 being higher than those (on day 1) in period 1.</p><p>The AEs in the current study were diarrhea (seven cases in period 1 and eight cases in period 2) and abdominal discomfort (one case in period 2), which have been reported following the administration of metformin in previous studies.<xref rid="cit0025" ref-type="bibr">25</xref> These AEs were not reported during OJS administration alone on days 3–7. Therefore, we concluded that the AEs in period 2 were related to metformin rather than to OJS. OJS has the potential to increase ALT or AST levels when administered repeatedly. No increasing trends in ALT or AST levels were found in any of the participants, although one participant’s ALT level was above the reference range during the screening period (<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dovepress.com/article/supplementary_file/526915/526915%20Supplementary%20files.docx" ext-link-type="uri">Supplementary Figure 5</ext-link></underline>).</p><p>In this study, the co-administration of metformin and OJS led to an approximately 5% decrease in the AUC of metformin. This reduction is not considered clinically significant according to the FDA’s criteria for assessing drug-drug interactions and does not necessitate a dose adjustment.<xref rid="cit0026" ref-type="bibr">26</xref> Additionally, although a decrease in AUC and C<sub>max</sub> was observed, the OGTT results indicated a trend toward lower average blood glucose levels in the coadministration of metformin with OJS, even though this trend did not reach statistical significance. These small and statistically non-significant changes in pharmacokinetics likely had minimal impact on pharmacodynamic outcomes, as no meaningful correlation was observed between pharmacokinetic and pharmacodynamic parameters. This indicates a lack of a consistent pharmacokinetic–pharmacodynamic relationship in either treatment condition. Based on the integrated pharmacokinetic–pharmacodynamic findings, dose adjustment of metformin does not appear to be warranted when used in combination with OJS.</p><p>Typically, drug interaction studies are conducted with 10 to 40 participants, depending on the objective of the study and the intra-individual variability of pharmacokinetic parameters. Previous pharmacokinetic interaction studies involving metformin have included relatively small sample sizes, ranging from about 6 to 20 subjects.<xref rid="cit0009" ref-type="bibr">9</xref> The reported coefficient of variation (CV) for metformin’s AUC is approximately 13% with a range of 4 to 23%.<xref rid="cit0021" ref-type="bibr">21</xref> In our study, the within-subject CV for AUC<sub>last</sub> was around 15%, and a post hoc power analysis indicated a statistical power of 87.75%. Based on these findings, a sample size of 15 participants in the present study is considered adequate to evaluate pharmacokinetic changes with acceptable precision and reliability.</p><p>This study represents the first prospective investigation to evaluate the impact of OJS on pharmacokinetics and glucose-lowering effects when co-administered with metformin. However, several limitations should be acknowledged. First, the study enrolled only healthy volunteers rather than diabetic patients. Differences in physiological and metabolic conditions between healthy individuals and diabetic patients could influence the pharmacokinetic and pharmacodynamic responses. Although one retrospective study reported a glucose-lowering effect of OJS in diabetic patients without renal impairment when combined with hypoglycemic agents, including metformin,<xref rid="cit0027" ref-type="bibr">27</xref> the evidence remains limited and observational. Second, the current study focused exclusively on male volunteers, which may pose limitations on the generalizability of our findings to female populations. However, previous studies have demonstrated no significant differences in metformin’s pharmacokinetics between sexes, suggesting that our conclusions may also be applicable to females.<xref rid="cit0028" ref-type="bibr">28</xref>,<xref rid="cit0029" ref-type="bibr">29</xref> Additionally, this prior study comparing healthy individuals with DM patients without renal impairment found no significant differences in metformin AUC, supporting the relevance of our data to DM patients without renal impairment.<xref rid="cit0029" ref-type="bibr">29</xref> Nevertheless, the literature and clinical guidelines recommend dose reduction or cautious use of metformin in diabetic patients with impaired renal function.<xref rid="cit0030" ref-type="bibr">30</xref>,<xref rid="cit0031" ref-type="bibr">31</xref> Consequently, the pharmacokinetic and glycemic effects of OJS when co-administered with metformin may differ in patients with renal impairment compared to those who are healthy or have preserved renal function. These considerations underscore the need for further long-term, prospective clinical studies involving larger and more diverse patient populations, along with comprehensive safety evaluations.</p></sec><sec id="s0005"><title>Conclusion</title><p>This study evaluated the pharmacokinetic and pharmacodynamic effects of OJS on metformin in healthy male volunteers through an open-label, single-sequence, crossover clinical design. The co-administration of OJS and metformin decreased the plasma concentrations of metformin. However, considering the GMR of C<sub>max</sub> and AUC<sub>last</sub>, the degree of decrease was not clinically significant. Additionally, considering the OGTT results, it was determined that these changes in metformin concentration did not affect glucose concentration. Although this study was conducted in healthy participants, further research is warranted to assess potential changes in glucose levels in diabetic patients. Nonetheless, based on the present findings, the impact of co-administration on glycemic control in diabetic patients is expected to be minimal.</p></sec></body><back><ack><title>Acknowledgments</title><p>We sincerely thank the Clinical Research Coordinators of the Department of Clinical Pharmacology and Therapeutics at Kyung Hee University Hospital for their invaluable support and assistance throughout this study. Their expertise was essential for the successful completion of the study.</p></ack><sec sec-type="data-availability" id="s0006"><title>Data Sharing Statement</title><p>The data can be made available upon request from the corresponding author.</p></sec><sec id="s0007"><title>Ethics Statement</title><p>This open-label, single-sequence, crossover clinical study was conducted in accordance with the Declaration of Helsinki and Korean Good Clinical Practice (Clinical Research Information Service, CRIS [<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cris.nih.go.kr" ext-link-type="uri">https://cris.nih.go.kr</ext-link></underline>]; registry number: KCT0006799). The protocol and informed consent forms were approved by the Korean Ministry of Food and Drug Safety, the institutional review board (IRB, IRB number: KHUH 2021-05-007) of Kyung Hee University Hospital (KHUH, Seoul, Republic of Korea), and IRB (IRB number: KOMCIRB 2021-06-004) of Kyung Hee University Korean Medical Hospital (KHUKMH, Seoul, Republic of Korea).</p></sec><sec id="s0008"><title>Author Contributions</title><p>All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.</p></sec><sec sec-type="COI-statement" id="s0009"><title>Disclosure</title><p>The authors report no conflicts of interest in this work.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chatterjee</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Khunti</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Davies</surname>
<given-names>MJ</given-names></string-name>. <article-title>Type 2 diabetes</article-title>. <source><italic toggle="yes">Lancet</italic></source>. <year>2017</year>;<volume>389</volume>(<issue>10085</issue>):<fpage>2239</fpage>–<lpage>2251</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(17)30058-2</pub-id><pub-id pub-id-type="pmid">28190580</pub-id>
</mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="webpage"><collab>WHO</collab>. <article-title>Classification of diabetes mellitus</article-title>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://apps.who.int/iris/handle/10665/325182" ext-link-type="uri">https://apps.who.int/iris/handle/10665/325182</ext-link>. <date-in-citation>Accessed <month>March</month>
<day>10</day>, 2025</date-in-citation>.</mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kosiborod</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gomes</surname>
<given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Nicolucci</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)</article-title>. <source><italic toggle="yes">Cardiovasc Diabetol</italic></source>. <year>2018</year>;<volume>17</volume>(<issue>1</issue>):<fpage>150</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12933-018-0787-8</pub-id><pub-id pub-id-type="pmid">30486889</pub-id>
<pub-id pub-id-type="pmcid">PMC6260731</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Collaborators</surname>
<given-names>GBDD</given-names></string-name>. <article-title>Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021</article-title>. <source><italic toggle="yes">Lancet</italic></source>. <year>2023</year>;<volume>402</volume>(<issue>10397</issue>):<fpage>203</fpage>–<lpage>234</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(23)01301-6</pub-id><pub-id pub-id-type="pmid">37356446</pub-id>
<pub-id pub-id-type="pmcid">PMC10364581</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bae</surname>
<given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Han</surname>
<given-names>KD</given-names></string-name>, <string-name name-style="western"><surname>Ko</surname>
<given-names>SH</given-names></string-name>, et al. <article-title>Diabetes fact sheet in Korea 2021</article-title>. <source><italic toggle="yes">Diabetes Metab J</italic></source>. <year>2022</year>;<volume>46</volume>(<issue>3</issue>):<fpage>417</fpage>–<lpage>426</lpage>. doi:<pub-id pub-id-type="doi">10.4093/dmj.2022.0106</pub-id><pub-id pub-id-type="pmid">35656565</pub-id>
<pub-id pub-id-type="pmcid">PMC9171160</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="webpage"><collab>Centers for Disease Control and Prevention</collab>. <article-title>National diabetes statistics report website</article-title>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/diabetes/php/data-research/index.html" ext-link-type="uri">https://www.cdc.gov/diabetes/php/data-research/index.html</ext-link>. <date-in-citation>Accessed <month>March</month>
<day>10</day>, 2025</date-in-citation>.</mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Solini</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tricò</surname>
<given-names>D</given-names></string-name>. <article-title>Clinical efficacy and cost-effectiveness of metformin in different patient populations: a narrative review of real-world evidence</article-title>. <source><italic toggle="yes">Diabetes Obes Metab</italic></source>. <year>2024</year>;<volume>26</volume>(<issue>3</issue>):<fpage>20</fpage>–<lpage>30</lpage>. doi:<pub-id pub-id-type="doi">10.1111/dom.15729</pub-id><pub-id pub-id-type="pmid">38939954</pub-id>
</mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bu</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname>
<given-names>X</given-names></string-name>, et al. <article-title>Protective effects of metformin in various cardiovascular diseases: clinical evidence and AMPK-dependent mechanisms</article-title>. <source><italic toggle="yes">J Cell Mol Med</italic></source>. <year>2022</year>;<volume>26</volume>(<issue>19</issue>):<fpage>4886</fpage>–<lpage>4903</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jcmm.17519</pub-id><pub-id pub-id-type="pmid">36052760</pub-id>
<pub-id pub-id-type="pmcid">PMC9549498</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Stage</surname>
<given-names>TB</given-names></string-name>, <string-name name-style="western"><surname>Brosen</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Christensen</surname>
<given-names>MM</given-names></string-name>. <article-title>A comprehensive review of drug-drug interactions with metformin</article-title>. <source><italic toggle="yes">Clin Pharmacokinet</italic></source>. <year>2015</year>;<volume>54</volume>(<issue>8</issue>):<fpage>811</fpage>–<lpage>824</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40262-015-0270-6</pub-id><pub-id pub-id-type="pmid">25943187</pub-id>
</mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Szymczak-Pajor</surname>
<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Wenclewska</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Śliwińska</surname>
<given-names>A</given-names></string-name>. <article-title>Metabolic action of metformin</article-title>. <source><italic toggle="yes">Pharmaceuticals</italic></source>. <year>2022</year>;<volume>15</volume>(<issue>7</issue>):<fpage>810</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ph15070810</pub-id><pub-id pub-id-type="pmid">35890109</pub-id>
<pub-id pub-id-type="pmcid">PMC9317619</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Polianskyte-Prause</surname>
<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Tolvanen</surname>
<given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Lindfors</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Metformin increases glucose uptake and acts renoprotectively by reducing SHIP2 activity</article-title>. <source><italic toggle="yes">FASEB J</italic></source>. <year>2019</year>;<volume>33</volume>(<issue>2</issue>):<fpage>2858</fpage>–<lpage>2869</lpage>. doi:<pub-id pub-id-type="doi">10.1096/fj.201800529RR</pub-id><pub-id pub-id-type="pmid">30321069</pub-id>
<pub-id pub-id-type="pmcid">PMC6338644</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gupta</surname>
<given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Nammi</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bensoussan</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bilinski</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Roufogalis</surname>
<given-names>BD</given-names></string-name>. <article-title>Interactions between antidiabetic drugs and herbs: an overview of mechanisms of action and clinical implications</article-title>. <source><italic toggle="yes">Diabetol Metab Syndr</italic></source>. <year>2017</year>;<volume>9</volume>(<issue>1</issue>):<fpage>59</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13098-017-0254-9</pub-id><pub-id pub-id-type="pmid">28770011</pub-id>
<pub-id pub-id-type="pmcid">PMC5527439</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="webpage"><collab>Korean National Health Insurance Service (KNHIS)</collab>. <article-title>Report on insurance claims for reimbursement from the National Health Insurance Service (NHIS)</article-title>. <year>2023</year>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020045010000%26brdScnBltNo=4%26brdBltNo=2405%26pageIndex=1%26pageIndex2=1" ext-link-type="uri">https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020045010000&amp;brdScnBltNo=4&amp;brdBltNo=2405&amp;pageIndex=1&amp;pageIndex2=1</ext-link>. <date-in-citation>Accessed <month>March</month>
<day>10</day>, 2025</date-in-citation>.</mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kim</surname>
<given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Seo</surname>
<given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname>
<given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Shin</surname>
<given-names>HK</given-names></string-name>. <article-title>Quality assessment of ojeok-san, a traditional herbal formula, using high-performance liquid chromatography combined with chemometric analysis</article-title>. <source><italic toggle="yes">J Anal Methods Chem</italic></source>. <year>2015</year>;<volume>2015</volume>:<fpage>607252</fpage>. doi:<pub-id pub-id-type="doi">10.1155/2015/607252</pub-id><pub-id pub-id-type="pmid">26539304</pub-id>
<pub-id pub-id-type="pmcid">PMC4619932</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Han</surname>
<given-names>TK</given-names></string-name>, <string-name name-style="western"><surname>Proctor</surname>
<given-names>WR</given-names></string-name>, <string-name name-style="western"><surname>Costales</surname>
<given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Everett</surname>
<given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Thakker</surname>
<given-names>DR</given-names></string-name>. <article-title>Four cation-selective transporters contribute to apical uptake and accumulation of metformin in Caco-2 cell monolayers</article-title>. <source><italic toggle="yes">J Pharmacol Exp Ther</italic></source>. <year>2015</year>;<volume>352</volume>(<issue>3</issue>):<fpage>519</fpage>–<lpage>528</lpage>. doi:<pub-id pub-id-type="doi">10.1124/jpet.114.220350</pub-id><pub-id pub-id-type="pmid">25563903</pub-id>
<pub-id pub-id-type="pmcid">PMC4352590</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Peng</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gong</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>Association between organic cation transporter genetic polymorphisms and metformin response and intolerance in T2DM individuals: a systematic review and meta-analysis</article-title>. <source><italic toggle="yes">Front Public Health</italic></source>. <year>2023</year>;<volume>11</volume>:<fpage>1183879</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fpubh.2023.1183879</pub-id><pub-id pub-id-type="pmid">37546319</pub-id>
<pub-id pub-id-type="pmcid">PMC10400771</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wang</surname>
<given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Leask</surname>
<given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname>
<given-names>K</given-names></string-name>, et al. <article-title>The population-specific Thr44Met OCT3 coding variant affects metformin pharmacokinetics with subsequent effects on insulin sensitivity in C57Bl/6J mice</article-title>. <source><italic toggle="yes">Diabetologia</italic></source>. <year>2025</year>;<volume>68</volume>(<issue>3</issue>):<fpage>537</fpage>–<lpage>548</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00125-024-06287-1</pub-id><pub-id pub-id-type="pmid">39422716</pub-id>
<pub-id pub-id-type="pmcid">PMC11832584</pub-id></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="book"><string-name name-style="western"><surname>Team</surname>
<given-names>RC</given-names></string-name>. <source><italic toggle="yes">A Language and Environment for Statistical Computing</italic></source>. <publisher-name>R Foundation for Statistical Computing</publisher-name>; <year>2024</year>.</mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="book"><string-name name-style="western"><surname>Wickham</surname>
<given-names>H</given-names></string-name>. <source><italic toggle="yes">ggplot2: Elegant Graphics for Data Analysis</italic></source>. <edition>2nd ed</edition>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer-Verlag</publisher-name>; <year>2016</year>.</mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Nguyen</surname>
<given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname>
<given-names>DD</given-names></string-name>, <string-name name-style="western"><surname>Tanna</surname>
<given-names>RS</given-names></string-name>, et al. <article-title>Assessing transporter-mediated natural product-drug interactions via in vitro-in vivo extrapolation: clinical evaluation with a probe cocktail</article-title>. <source><italic toggle="yes">Clin Pharmacol Ther</italic></source>. <year>2021</year>;<volume>109</volume>(<issue>5</issue>):<fpage>1342</fpage>–<lpage>1352</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cpt.2107</pub-id><pub-id pub-id-type="pmid">33174626</pub-id>
<pub-id pub-id-type="pmcid">PMC8058163</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Graham</surname>
<given-names>GG</given-names></string-name>, <string-name name-style="western"><surname>Punt</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Arora</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Clinical pharmacokinetics of metformin</article-title>. <source><italic toggle="yes">Clin Pharmacokinet</italic></source>. <year>2011</year>;<volume>50</volume>(<issue>2</issue>):<fpage>81</fpage>–<lpage>98</lpage>. doi:<pub-id pub-id-type="doi">10.2165/11534750-000000000-00000</pub-id><pub-id pub-id-type="pmid">21241070</pub-id>
</mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chung</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Oh</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yoon</surname>
<given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname>
<given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname>
<given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Chung</surname>
<given-names>JY</given-names></string-name>. <article-title>A non-linear pharmacokinetic-pharmacodynamic relationship of metformin in healthy volunteers: an open-label, parallel group, randomized clinical study</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2018</year>;<volume>13</volume>(<issue>1</issue>):<fpage>e0191258</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0191258</pub-id><pub-id pub-id-type="pmid">29342199</pub-id>
<pub-id pub-id-type="pmcid">PMC5771593</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yoo</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jang</surname>
<given-names>IJ</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname>
<given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname>
<given-names>S</given-names></string-name>. <article-title>Pharmacokinetic/pharmacodynamic interactions between evogliptin and glimepiride in healthy male subjects</article-title>. <source><italic toggle="yes">Drug Des Devel Ther</italic></source>. <year>2020</year>;<volume>14</volume>:<fpage>5179</fpage>–<lpage>5187</lpage>. doi:<pub-id pub-id-type="doi">10.2147/DDDT.S275343</pub-id><pub-id pub-id-type="pmcid">PMC7699451</pub-id><pub-id pub-id-type="pmid">33262578</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gordon</surname>
<given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Fraser</surname>
<given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Bird</surname>
<given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Benson</surname>
<given-names>AC</given-names></string-name>. <article-title>Reproducibility of multiple repeated oral glucose tolerance tests</article-title>. <source><italic toggle="yes">Diabet Res Clin Pract</italic></source>. <year>2011</year>;<volume>94</volume>(<issue>3</issue>):<fpage>e78</fpage>–<lpage>82</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.diabres.2011.08.025</pub-id><pub-id pub-id-type="pmid">21945562</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>de Jong</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Harmark</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>van Puijenbroek</surname>
<given-names>E</given-names></string-name>. <article-title>Time course, outcome and management of adverse drug reactions associated with metformin from patient’s perspective: a prospective, observational cohort study in the Netherlands</article-title>. <source><italic toggle="yes">Eur J Clin Pharmacol</italic></source>. <year>2016</year>;<volume>72</volume>(<issue>5</issue>):<fpage>615</fpage>–<lpage>622</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00228-016-2019-z</pub-id><pub-id pub-id-type="pmid">26864966</pub-id>
</mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="webpage"><collab>US Food and Drug Administration</collab>. <article-title>M12 Drug Interaction Studies: Guidance for Industry</article-title>. <year>2024</year>. <comment>Available from</comment>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/media/161199/download" ext-link-type="uri">https://www.fda.gov/media/161199/download</ext-link>. <date-in-citation>Accessed <month>August</month>
<day>29</day>, 2025</date-in-citation>.</mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lee</surname>
<given-names>M-S</given-names></string-name>, <string-name name-style="western"><surname>Jeong</surname>
<given-names>S-M</given-names></string-name>, <string-name name-style="western"><surname>Oh</surname>
<given-names>S-H</given-names></string-name>, et al. <article-title>A retrospective study on the effect of the co-administration of ojeok-san and hypoglycemic agents on blood glucose levels in type 2 diabetes mellitus</article-title>. <source><italic toggle="yes">J Int Korean Med</italic></source>. <year>2021</year>;<volume>42</volume>(<issue>1</issue>):<fpage>40</fpage>–<lpage>52</lpage>. doi:<pub-id pub-id-type="doi">10.22246/jikm.2021.42.1.40</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="book"><collab>Company B-MS</collab>. <article-title>Labelling-package insert for GLUCOPHAGE (metformin hydrochloride) tablets</article-title>. <publisher-name>Bristol-Myers Squibb Company</publisher-name>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020357s034,021202s018lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020357s034,021202s018lbl.pdf</ext-link>. <date-in-citation>Accessed <month>May</month>
<day>29</day>, 2025</date-in-citation>.</mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sambol</surname>
<given-names>NC</given-names></string-name>, <string-name name-style="western"><surname>Chiang</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>O’Conner</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus</article-title>. <source><italic toggle="yes">J Clin Pharmacol</italic></source>. <year>1996</year>;<volume>36</volume>(<issue>11</issue>):<fpage>1012</fpage>–<lpage>1021</lpage>. doi:<pub-id pub-id-type="doi">10.1177/009127009603601105</pub-id><pub-id pub-id-type="pmid">8973990</pub-id>
</mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kuan</surname>
<given-names>IHS</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname>
<given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Leishman</surname>
<given-names>JC</given-names></string-name>, et al. <article-title>Metformin doses to ensure efficacy and safety in patients with reduced kidney function</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2021</year>;<volume>16</volume>(<issue>2</issue>):<fpage>e0246247</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0246247</pub-id><pub-id pub-id-type="pmid">33600406</pub-id>
<pub-id pub-id-type="pmcid">PMC7891741</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><collab>KDIGO</collab>. <article-title>Clinical practice guideline for diabetes management in chronic kidney disease</article-title>. <source><italic toggle="yes">Kidney Int</italic></source>. <year>2022</year>;<volume>102</volume>(<issue>5s</issue>):<fpage>S1</fpage>–<lpage>s127</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.kint.2022.06.008</pub-id><pub-id pub-id-type="pmid">36272764</pub-id>
</mixed-citation></ref></ref-list></back></article><article xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Care</journal-id><journal-id journal-id-type="pmc-domain-id">583</journal-id><journal-id journal-id-type="pmc-domain">diacare</journal-id><journal-id journal-id-type="publisher-id">diabetes care</journal-id><journal-title-group><journal-title>Diabetes Care</journal-title></journal-title-group><issn pub-type="ppub">0149-5992</issn><issn pub-type="epub">1935-5548</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12034906</article-id><article-id pub-id-type="pmcid-ver">PMC12034906.1</article-id><article-id pub-id-type="pmcaid">12034906</article-id><article-id pub-id-type="pmcaiid">12034906</article-id><article-id pub-id-type="pmid">39899467</article-id><article-id pub-id-type="doi">10.2337/dc24-2039</article-id><article-id pub-id-type="publisher-id">dc242039</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Short-term Metformin Protects Against Glucocorticoid-Induced Toxicity in Healthy Individuals: A Randomized, Double-Blind, Placebo-Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Thierry</surname><given-names initials="S">Susanne</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Peterson</surname><given-names initials="CJ">Caspar Joyce</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pfammatter</surname><given-names initials="S">Stéphanie</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tardio</surname><given-names initials="PA">Patricia Arroyo</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Meier</surname><given-names initials="C">Christian</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Delko</surname><given-names initials="T">Tarik</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Iten</surname><given-names initials="V">Vasco</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zuern</surname><given-names initials="CS">Christine S.</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kühne</surname><given-names initials="M">Michael</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Epstein</surname><given-names initials="M">Michael</given-names></name><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Othman</surname><given-names initials="A">Alaa</given-names></name><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zamboni</surname><given-names initials="N">Nicola</given-names></name><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Reinisch</surname><given-names initials="I">Isabel</given-names></name><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ghosh</surname><given-names initials="A">Adhideb</given-names></name><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wolfrum</surname><given-names initials="C">Christian</given-names></name><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7092-1986</contrib-id><name name-style="western"><surname>Seelig</surname><given-names initials="E">Eleonora</given-names></name><email>eleonora.seelig@usb.ch</email><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref><xref rid="cor1" ref-type="corresp"/></contrib></contrib-group><aff id="aff1"><label>1</label>Division of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland</aff><aff id="aff2"><label>2</label>Clarunis, Department of Visceral Surgery, University Center for Gastrointestinal and Liver Diseases, St. Claraspital and University Hospital Basel, Basel, Switzerland</aff><aff id="aff3"><label>3</label>Department of Surgery, Hirslanden Hospital, Lucerne, Switzerland</aff><aff id="aff4"><label>4</label>Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland</aff><aff id="aff5"><label>5</label>Cardiology Division, University Hospital Basel, Basel, Switzerland</aff><aff id="aff6"><label>6</label>Statistical Consulting, Letchworth, U.K.</aff><aff id="aff7"><label>7</label>Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland</aff><aff id="aff8"><label>8</label>PHRT Swiss Multi-Omics Center, Zurich, Switzerland</aff><aff id="aff9"><label>9</label>Laboratory of Translational Nutrition Biology, Institute of Food, Nutrition and Health, ETH Zurich, Schwerzenbach, Switzerland</aff><aff id="aff10"><label>10</label>University Center of Internal Medicine, Division of Endocrinology and Diabetes, Cantonal Hospital Baselland, Liestal, Switzerland</aff><author-notes><corresp id="cor1">Corresponding author: Eleonora Seelig, <email>eleonora.seelig@usb.ch</email></corresp></author-notes><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>03</day><month>2</month><year>2025</year></pub-date><volume>48</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">487441</issue-id><fpage>719</fpage><lpage>727</lpage><history><date date-type="received" iso-8601-date="2024-09-19"><day>19</day><month>9</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2025-01-13"><day>13</day><month>1</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>29</day><month>04</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-29 00:25:23.213"><day>29</day><month>04</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>© 2025 by the American Diabetes Association</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2025-02-03">https://www.diabetesjournals.org/journals/pages/license</ali:license_ref><license-p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.diabetesjournals.org/journals/pages/license">https://www.diabetesjournals.org/journals/pages/license</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="dc242039.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="dc242039.pdf"/><abstract><sec><title>OBJECTIVE</title><p>Glucocorticoids (GCs) are potent anti-inflammatory drugs, but strategies to prevent side effects are lacking. We investigated whether metformin could prevent GC-related toxicity and explored the underlying mechanisms.</p></sec><sec><title>RESEARCH DESIGN AND METHODS</title><p>This single-center, randomized, placebo-controlled, double-blind, crossover trial compared metformin with placebo during high-dose GC treatment in 18 lean, healthy, male study participants. The trial was conducted at the University Hospital Basel, Basel, Switzerland. Participants received prednisone 30 mg/day in combination with metformin or placebo for two 7-day periods (1:1 randomization). The primary outcome, change in insulin sensitivity, was assessed using a two-sided paired <italic toggle="yes">t</italic> test. Before and after each study period, we conducted a mixed-meal tolerance test, blood metabolomics, and RNA sequencing of subcutaneous adipose tissue biopsy specimens.</p></sec><sec><title>RESULTS</title><p>Metformin improved insulin sensitivity as assessed by the Matsuda index (<italic toggle="yes">n</italic> = 17; mean change −2.73 ± 3.55 SD for placebo, 2.21 ± 3.95 for metformin; mean difference of change −4.94 [95% CI, −7.24, −2.65]; <italic toggle="yes">P</italic> &lt; 0.001). Metabolomic and transcriptomic analyses revealed that metformin altered fatty acid flux in the blood and downregulated genes involved in fatty acid synthesis in adipose tissue. Metformin reduced markers of protein breakdown and bone resorption. Furthermore, metformin downregulated genes responsible for AMPK inhibition and affected glucagon-like peptide 1 and bile acid metabolism.</p></sec><sec><title>CONCLUSIONS</title><p>Metformin prevents GC-induced insulin resistance and reduces markers of dyslipidemia, myopathy, and, possibly, bone resorption through AMPK-dependent and -independent pathways.</p></sec></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><p>
<fig position="float" id="FGA" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dc242039fGA.jpg"/></fig></p></abstract><funding-group><award-group><funding-source>
<institution-wrap><institution>Novartis Foundation</institution><institution-id institution-id-type="DOI">10.13039/100008273</institution-id></institution-wrap>
</funding-source></award-group><award-group><funding-source>
<institution-wrap><institution>Swiss Federal Institutes</institution></institution-wrap>
</funding-source></award-group><award-group><funding-source>
<institution-wrap><institution>SwissLife Jubilee Foundation</institution></institution-wrap>
</funding-source></award-group><award-group><funding-source>
<institution-wrap><institution>ETH</institution></institution-wrap>
</funding-source></award-group><award-group><funding-source>
<institution-wrap><institution>Swiss Diabetes Foundation</institution></institution-wrap>
</funding-source></award-group><award-group><funding-source>
<institution-wrap><institution>Swiss National Science Foundation</institution></institution-wrap>
</funding-source><award-id>193516</award-id></award-group><funding-statement>E.S. was supported by the Swiss National Science Foundation (grant 193516), SwissLife Jubilee Foundation, Swiss Diabetes Foundation, and Novartis Foundation for Medical-Biological Research. N.Z. received support from the Strategic Focus Area “Personalized Health and Related Technologies” (grant 603) of the ETH Domain (Swiss Federal Institutes of Technology).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Glucocorticoids (GCs) are widely prescribed immunosuppressants used for a broad range of medical conditions. Approximately 3% of the general population receives GCs, and the number of long-term prescriptions is increasing (<xref rid="B1" ref-type="bibr">1</xref>). Despite their strong therapeutic effects, GCs have numerous harmful metabolic side effects, such as type 2 diabetes, dyslipidemia, osteoporosis, and myopathy (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>). These metabolic effects limit GC use and increase morbidity and mortality (<xref rid="B1" ref-type="bibr">1</xref>). Despite recognizing the risks of GC-induced side effects, we lack treatment strategies to overcome GC-induced metabolic side effects (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>).</p><p>A promising candidate for managing GC-induced side effects is metformin (<xref rid="B3" ref-type="bibr">3</xref>). Metformin is a widely prescribed and safe medication to lower glucose levels in patients with type 2 diabetes (<xref rid="B4" ref-type="bibr">4</xref>). However, its exact mechanism of action remains unknown. Although the liver is considered the primary site of metformin action, recent findings suggest its effects extend to various other tissues. Consequently, metformin has attracted interest beyond diabetes treatment and is currently being investigated as an anticancer and antiaging drug (<xref rid="B4" ref-type="bibr">4</xref>). Therefore, understanding the full scope of metformin action is of significant interest across many medical indications.</p><p>We previously demonstrated in a proof-of-concept study that metformin can prevent glycemic deterioration during GC therapy in patients without diabetes with various diseases (<xref rid="B5" ref-type="bibr">5</xref>). However, the heterogeneity of the underlying conditions posed challenges in thoroughly assessing the potential of metformin during GC excess. Therefore, we conducted a randomized, placebo-controlled study of healthy individuals receiving high-dose GCs to address this limitation.</p><p>By integrating clinical data with metabolomic and genetic insights, we had three objectives: validate our previous findings on glucose control, explore the impact of metformin on tissues beyond the liver, and gain deeper insight into the underlying mechanisms of metformin action.</p></sec><sec id="s2"><title>Research Design and Methods</title><sec id="s2A"><title>Study Design</title><p>This randomized, placebo-controlled, double-blind, crossover study was conducted at the University Hospital Basel, Basel, Switzerland. The Ethics Commission of Northwestern and Central Switzerland approved the study, which is registered at ClinicalTrials.gov (identifier <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04659915">NCT04659915</ext-link>). The study was conducted following the ethical guidelines of the Declaration of Helsinki. Written consent was obtained from participants after fully explaining to them the purpose and nature of all study procedures.</p></sec><sec id="s2B"><title>Participants</title><p>Male adults aged 18–40 years with a normal weight (BMI range, 18.5–25 kg/m<sup>2</sup>) were eligible for the trial. Essential exclusion criteria were any significant ongoing diseases; medications, including GCs or metformin until 4 weeks before inclusion; regular alcohol intake; and intensive physical activity (&gt;4 h/week). Participants were recruited from the general population.</p></sec><sec id="s2C"><title>Randomization</title><p>According to a predefined randomization list created by an independent investigator not involved in the study, participants were assigned to receive either metformin or placebo first. The treatment sequence was 1:1. Only the independent investigator, the Hospital Pharmacy of the University Hospital, and the principal investigator had access to the code, which was kept in sealed envelopes. The randomization sequence was unknown to the participants and all study personnel involved in the study.</p></sec><sec id="s2D"><title>Procedures</title><p>After a screening visit, all participants received prednisone 30 mg/day for two 7-day periods separated by a 28-day washout period. In addition, all participants received metformin during one study period and a placebo during the other. Metformin was initiated at a dose of 500 mg/day orally. Metformin was increased by 500 mg every other day until the maximum amount of 2,000 mg was reached on the seventh day of the study period. Identical placebo tablets were administered during the other study period. The compliance was calculated based on the number of returned tablets. All investigators and study participants were blinded to the treatment sequence until the completion of the study.</p><p>All participants had a screening visit followed by four study visits. The visits took place before and after every treatment period. At each visit, the participants were equipped with a portable Holter electrocardiogram monitor the evening before to measure heart rate variability. After an overnight fast, participants attended the research facility at 8 <sc>a.m.</sc> Weight and blood pressure were measured. Basal metabolic rate was measured with indirect calorimetry (Quark RMR; Cosmed) for 20 min. After fasting blood samples were taken, a standardized mixed-meal tolerance test (MMTT; 300 mL of Ensure Plus; Abbott) was conducted, and blood was frequently sampled over 120 min.</p><p>Plasma glucose level was measured with an enzymatic assay (Cobas modular analyzer, Roche Diagnostics). Serum insulin was analyzed by ELISA (Insulin ELISA; Mercodia). C-peptide concentration was measured with a C-peptide ELISA (Mercodia). The HOMA for insulin resistance (HOMA-IR) index was calculated according to Matthews et al. (<xref rid="B6" ref-type="bibr">6</xref>). The Matsuda index was used to calculate whole-body insulin sensitivity (<xref rid="B7" ref-type="bibr">7</xref>). The insulinogenic index, a marker of β-cell function, was calculated as follows: [insulin<sub>30 min</sub> − insulin<sub>fasting</sub>]/[glucose<sub>30 min</sub> − glucose<sub>fasting</sub>] (<xref rid="B8" ref-type="bibr">8</xref>). Incremental area under the curve (AUC) levels over 120 min during the MMTT for insulin, C-peptide, and glucose were calculated based on the trapezoidal rule.</p><p>Lipids were measured with an enzymatic assay (Cobas; Roche Diagnostics). Immunoassays were used to measure thyroid-stimulating hormone (Elecsys TSH, Cobas; Roche Diagnostics), GDF-15 (R-Plex; Mesoscale), and total glucagon-like peptide 1 (GLP-1) (GLP1 total ELISA; Mercodia). C-terminal telopeptide (CTX), intact amino terminal propeptide of type I procollagen, and osteocalcin were analyzed on the IDS-iSYS Multi-Discipline automated analyzer (IDS iSYS; Immunodiagnostics Systems, Boldon, U.K.). The assays are based on chemiluminescence technology. Adiponectin and leptin levels were assessed as exploratory end points using electrochemiluminesence immunoassays (U-Plex Human Adiponectin Assay and V-plex Human Leptin Assay; Meso Scale Discovery). Parathyroid hormone (PTH) and 25-hydroxy vitamin D<sub>3</sub> levels were assessed as exploratory end points using electrochemiluminescence (Elecsys PTH and Elecsys Vitamin D total III; Cobas).</p><p>Heart rate variability (HRV) was measured to determine the autonomic nervous system tone. HRV was analyzed using the cloud-based Cardiomatics software (Cracow, Poland), which provides artificial intelligence–based automatic analysis of Holter monitor electrocardiogram recordings (<xref rid="B9" ref-type="bibr">9</xref>). HRV data were collected overnight from 0000 h to 0500 h while all participants were asleep, followed by an additional 30-min period directly after awakening. Wake-up reactions for changes in average heart rate, high-frequency power, low-frequency power, and root mean square of successive differences (rMSSD) were calculated based on the observed differences between the awake and asleep periods.</p></sec><sec id="s2E"><title>Plasma Metabolome Analysis</title><p>For metabolomic analysis, blood was sampled in the fasting state and 15 min after the intake of the liquid mixed meal at the end of each treatment period. Nontargeted metabolomics identification was performed by flow injection analysis at ETH Zürich, as detailed by Fuhrer et al. (<xref rid="B10" ref-type="bibr">10</xref>). In brief, metabolites were extracted using the Hamilton STAR M methanol protein precipitation protocol, separated into technical duplicates, and analyzed by flow injection analysis on the Agilent Q-TOF 6550 instrument. Raw data acquired from the instrumentation were processed using in-house MATLAB software. This software is optimized to detect metabolites present in quantities close to the background through the use of wavelet transformations to accurately identify metabolite centroids while denoising the ion signal by removal of background wavelet components. Ions with a count of &lt;500 across all scans were filtered out to avoid including rare features that were too infrequently observed to be statistically meaningful. The metabolite centroids identified in the complete set of samples are then aggregated into a single matrix. Centroid masses were binned within the tolerance limit of the instrument (∼0.002 amu at a charge to mass ratio [m/z] of 300), and the weighted average m/z was calculated for each bin. This facilitates metabolite identification by using information across all samples to derive an accurate m/z for each detected ion. Metabolite annotation of these ions was performed based on the m/z ratio, with mass accuracy of 0.001 Da, with reference to an in-house curated set of metabolites initially derived from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database.</p><p>Differential analyses were performed on normalized values of the curated set of metabolites, and differential fold changes in ion intensities were calculated. Significantly differentially expressed metabolites were identified using a Student <italic toggle="yes">t</italic> test, and the resulting <italic toggle="yes">P</italic> values were corrected for multiple testing across the curated metabolite set, using the Benjamini–Hochberg procedure. Pathway enrichment analysis was then performed on the differentially expressed metabolites using fiaMiner, which uses internally curated human metabolome database–based metabolomics pathways.</p></sec><sec id="s2F"><title>Adipose Tissue Biopsies and RNA-Sequencing Analysis</title><p>In a subgroup of 10 participants, subcutaneous adipose tissue biopsy samples were taken at the end of each treatment period. Biopsies were performed after the MMTT. A local anesthesia was administered, a trained surgeon removed ∼100–250 mg of subcutaneous adipose tissue from the periumbilical region. The samples were immediately frozen on dry ice and stored at −80°C.</p><p>Total RNA was extracted from adipose tissue using Trizol reagent (Geneaid, catalog no. GZR200) according to the manufacturer’s instructions, and extracted RNA was purified with columns (QIAGEN, catalog no. 74104). RNA quality was measured by Tapestation. The mRNA was purified from total RNA using poly-T oligo-attached magnetic beads. After fragmentation, the first-strand cDNA was synthesized using random hexamer primers, followed by second-strand cDNA synthesis. Libraries were finalized by end repair, A-tailing, adapter ligation, and size selection. The purified libraries were sequenced on Illumina platforms. Raw sequencing reads of all samples were processed and analyzed using the SUSHI framework developed by Functional Genomics Center Zurich (<xref rid="B11" ref-type="bibr">11</xref>). Adapter sequences and low-quality bases were trimmed off from the raw reads, using fastp, version 0.20, for quality control (<xref rid="B12" ref-type="bibr">12</xref>). Pseudo-alignment of the filtered reads was performed against the human reference genome assembly GRCh38.p13, and gene expression counts were quantified using Kallisto, version 0.46.1 (<xref rid="B13" ref-type="bibr">13</xref>). Differential gene expression was then performed on the gene count matrix, using the DESeq2 R package (version 1.40.2). The patient identification and BMI were incorporated as additional covariates alongside treatment into DESeq2's negative binomial generalized linear model. The genes were then read-count thresholded based on whether, in either of the treatment groups, at least 50% of samples had &gt;10 identifiable reads for the gene.</p><p>To control for multiple testing, the <italic toggle="yes">P</italic> values for the remaining genes were adjusted using the Benjamin–Hochberg method. Differentially expressed genes, determined by the log2 fold change in gene expression between treatment groups, were identified based on the significance threshold of (adjusted) <italic toggle="yes">P</italic> &lt; 0.05. For gene enrichment analysis, differentially expressed genes were imported into ConsensusPathDB (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.consensuspathdb.org" ext-link-type="uri">www.consensuspathdb.org</ext-link>). Pathways defined by the KEGG, REACTOME, HumanCyc, Wikipathways, and PharmGKB databases were selected in the online tool to discover overrepresented pathways from the differential gene expression list, and the <italic toggle="yes">P-</italic>value threshold was set at 0.05.</p></sec><sec id="s2G"><title>Outcomes</title><p>The primary end point was the change in insulin sensitivity between each study period. Secondary end points included changes in plasma glucose, insulin, C-peptide, GLP-1, growth/differentiation factor 15, and lipid levels; blood pressure; weight; body composition; energy expenditure; substrate utilization; and HRV. Additional analyses included changes in insulin secretion, bone turnover markers, metabolites in blood, and RNA expression in subcutaneous adipose tissue. Further exploratory analysis included changes in adiponectin and leptin levels. In addition, 25-hydroxy vitamin D<sub>3</sub> and PTH levels were measured.</p></sec><sec id="s2H"><title>Statistical Analysis</title><p>The statistical analysis was performed according to a prespecified statistical analysis plan, finalized before any comparative analysis. The sample size was estimated based on the observed effect of metformin on insulin sensitivity (HOMA-IR index) in GC-treated patients (<xref rid="B5" ref-type="bibr">5</xref>). From this observed effect, it was calculated that 18 study participants would be required to detect an expected mean difference in the HOMA-IR index of 1.2 at 80% power (probability). This assumes a two-sided test at a significance level of 0.05 and an assumed SD of the HOMA-IR index of 1.4.</p><p>Participants who dropped out of the study and who did not receive the study drug were replaced. The full analysis set included all participants who received the study drug. The complete analysis set (CAS) comprised all participants who completed the study per protocol. The primary end point analysis was conducted in the full analysis set and repeated in the CAS. Secondary end point analyses were performed in the CAS.</p><p>We used a two-sided paired <italic toggle="yes">t</italic> test to analyze the primary outcome: change in insulin sensitivity (HOMA-IR index). To assess any impact of the crossover design, the primary end point was further analyzed with a linear model with treatment sequence, randomization, and their interaction term as fixed effects (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.2337/figshare.28216082" ext-link-type="uri">Supplementary Table 1</ext-link>).</p><p>Missing values for the primary end point were imputed using the mean value for the specific treatment group (i.e., metformin or placebo). Missing values for the secondary end points were not imputed. Secondary end points were similarly analyzed using paired <italic toggle="yes">t</italic> tests. Categorical data were analyzed using the exact binomial test. The Benjamini–Hochberg method was applied to correct for multiple testing. Analysis was carried out using the R statistical software (version 4.3.1). Figures were created in GraphPad Prism, version 10.2.3 (GraphPad Inc., La Jolla, CA).</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><p>From 1 February to 31 August 2021, healthy, lean men were enrolled in the study at the University Hospital Basel, Switzerland. A total of 19 participants [mean age ± SD, 27.0 (±5.2) years, lean, and metabolically healthy (<xref rid="T1" ref-type="table">Table 1</xref>)] were randomly assigned to a study arm (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.2337/figshare.28216082" ext-link-type="uri">Supplementary Fig. 1</ext-link>). One participant withdrew his consent before receiving any study medication. Of the 18 participants who received the study medication, one dropped out due to a bike accident during the washout period. Seventeen participants completed both study arms.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Baseline characteristics of study participants (<italic toggle="yes">N</italic> = 18)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Mean ± SD</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">27.00 ± 5.19</td></tr><tr><td rowspan="1" colspan="1">Height (cm)</td><td align="center" rowspan="1" colspan="1">179.53 ± 8.94</td></tr><tr><td rowspan="1" colspan="1">Weight (kg)</td><td align="center" rowspan="1" colspan="1">73.87 ± 9.93</td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">22.85 ± 1.84</td></tr><tr><td rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">129.44 ± 13.65</td></tr><tr><td rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">75.78 ± 10.65</td></tr><tr><td rowspan="1" colspan="1">Heart rate (bpm)</td><td align="center" rowspan="1" colspan="1">53.18 ± 5.98</td></tr><tr><td rowspan="1" colspan="1">Fasting glucose (mmol/L)</td><td align="center" rowspan="1" colspan="1">4.56 ± 0.26</td></tr><tr><td rowspan="1" colspan="1">Fasting insulin (pmol/L)</td><td align="center" rowspan="1" colspan="1">32.09 ± 12.16</td></tr><tr><td rowspan="1" colspan="1">Fasting C-peptide (pmol/L)</td><td align="center" rowspan="1" colspan="1">431.71 ± 109.36</td></tr><tr><td rowspan="1" colspan="1">Total cholesterol (mmol/L)</td><td align="center" rowspan="1" colspan="1">4.00 ± 1.00</td></tr><tr><td rowspan="1" colspan="1">LDL cholesterol (mmol/L)</td><td align="center" rowspan="1" colspan="1">2.28 ± 0.95</td></tr><tr><td rowspan="1" colspan="1">HDL cholesterol (mmol/L)</td><td align="center" rowspan="1" colspan="1">1.28 ± 0.32</td></tr><tr><td rowspan="1" colspan="1">Triglycerides (mmol/L)</td><td align="center" rowspan="1" colspan="1">0.96 ± 0.37</td></tr><tr><td rowspan="1" colspan="1">PTH (ng/L)</td><td align="center" rowspan="1" colspan="1">23.14 ± 5.49</td></tr><tr><td rowspan="1" colspan="1">25-Hydroxy vitamin D<sub>3</sub> (nmol/L)</td><td align="center" rowspan="1" colspan="1">61.18 ± 27.89</td></tr></tbody></table></table-wrap><p>The results of our analyses are summarized in <xref rid="T2" ref-type="table">Table 2</xref>. During GC treatment, the glucose AUC increased significantly with placebo but remained stable with metformin treatment (<xref rid="F1" ref-type="fig">Fig. 1<italic toggle="yes">A</italic></xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.2337/figshare.28216082" ext-link-type="uri">Supplementary Fig. 2<italic toggle="yes">A</italic> and <italic toggle="yes">B</italic></ext-link>). Similarly, insulin (<xref rid="F1" ref-type="fig">Fig. 1<italic toggle="yes">B</italic></xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.2337/figshare.28216082" ext-link-type="uri">Supplementary Fig. 2<italic toggle="yes">C</italic> and <italic toggle="yes">D</italic></ext-link>) and C-peptide AUCs increased with placebo but remained stable with metformin. Consequently, whole-body insulin sensitivity (Matsuda index) improved with metformin compared with placebo (<xref rid="F1" ref-type="fig">Fig. 1<italic toggle="yes">C</italic></xref>). These findings remained significant after adjusting the <italic toggle="yes">P</italic> values. However, we did not identify a difference between the two treatment groups in the HOMA-IR index and insulinogenic index (<xref rid="F1" ref-type="fig">Fig. 1<italic toggle="yes">D</italic></xref>). There was no evidence for a carryover or a sequence effect for HOMA-IR (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.2337/figshare.28216082" ext-link-type="uri">Supplementary Table 1</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.2337/figshare.28216082" ext-link-type="uri">Supplementary Fig. 3</ext-link>). The regression analysis of the Matsuda index indicated the presence of a sequence effect (placebo → metformin) but no significant interaction effect between the treatment types (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.2337/figshare.28216082" ext-link-type="uri">Supplementary Fig. 4</ext-link>). Fasting lipids remained relatively unchanged across both interventions, with no significant differences in total cholesterol, LDL cholesterol, HDL, and triglyceride levels.</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Treatment responses upon placebo or metformin exposure</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Placebo, mean change ± SD</th><th align="center" rowspan="1" colspan="1">Metformin, mean change ± SD</th><th align="center" rowspan="1" colspan="1">Mean difference of change (95% CI)</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th align="center" rowspan="1" colspan="1">Adjusted <italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Glucose AUC (mmol/L/min)</td><td align="center" rowspan="1" colspan="1">1.18 ± 1.12</td><td align="center" rowspan="1" colspan="1">0.02 ± 1.25</td><td align="center" rowspan="1" colspan="1">1.15 (0.38, 1.93)</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td rowspan="1" colspan="1">Insulin AUC (pmol/L/min)</td><td align="center" rowspan="1" colspan="1">93.78 ± 183.05</td><td align="center" rowspan="1" colspan="1">−182.20 ± 168.29</td><td align="center" rowspan="1" colspan="1">275.98 (188.45, 363.51)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">C-peptide AUC (pmol/L/min)</td><td align="center" rowspan="1" colspan="1">690.67 ± 764.46</td><td align="center" rowspan="1" colspan="1">−701.02 ± 713.94</td><td align="center" rowspan="1" colspan="1">1,391.69 (987.44, 1,795.93)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">HOMA-IR index</td><td align="center" rowspan="1" colspan="1">0.25 ± 0.50</td><td align="center" rowspan="1" colspan="1">0.13 ± 0.36</td><td align="center" rowspan="1" colspan="1">0.12 (−0.25, 0.49)</td><td align="center" rowspan="1" colspan="1">0.51</td><td align="center" rowspan="1" colspan="1">0.55</td></tr><tr><td rowspan="1" colspan="1">Matsuda index</td><td align="center" rowspan="1" colspan="1">−2.73 ± 3.55</td><td align="center" rowspan="1" colspan="1">2.21 ± 3.95</td><td align="center" rowspan="1" colspan="1">−4.94 (−7.24, −2.65)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">Insulinogenic index</td><td align="center" rowspan="1" colspan="1">−89.84 ± 202.79</td><td align="center" rowspan="1" colspan="1">11.15 ± 206.37</td><td align="center" rowspan="1" colspan="1">−101.58 (−308.35, 105.18)</td><td align="center" rowspan="1" colspan="1">0.31</td><td align="center" rowspan="1" colspan="1">0.51</td></tr><tr><td rowspan="1" colspan="1">Total cholesterol (mmol/L)</td><td align="center" rowspan="1" colspan="1">0.15 ± 0.42</td><td align="center" rowspan="1" colspan="1">−0.13 ± 0.41</td><td align="center" rowspan="1" colspan="1">0.28 (−0.06, 0.61)</td><td align="center" rowspan="1" colspan="1">0.10</td><td align="center" rowspan="1" colspan="1">0.35</td></tr><tr><td rowspan="1" colspan="1">LDL cholesterol (mmol/L)</td><td align="center" rowspan="1" colspan="1">−0.18 ± 0.30</td><td align="center" rowspan="1" colspan="1">−0.36 ± 0.35</td><td align="center" rowspan="1" colspan="1">0.18 (−0.06, 0.41)</td><td align="center" rowspan="1" colspan="1">0.13</td><td align="center" rowspan="1" colspan="1">0.37</td></tr><tr><td rowspan="1" colspan="1">HDL cholesterol (mmol/L)</td><td align="center" rowspan="1" colspan="1">0.22 ± 0.14</td><td align="center" rowspan="1" colspan="1">0.18 ± 0.13</td><td align="center" rowspan="1" colspan="1">0.05 (−0.03, 0.12)</td><td align="center" rowspan="1" colspan="1">0.24</td><td align="center" rowspan="1" colspan="1">0.47</td></tr><tr><td rowspan="1" colspan="1">Triglycerides (mmol/L)</td><td align="center" rowspan="1" colspan="1">0.23 ± 0.57</td><td align="center" rowspan="1" colspan="1">0.11 ± 0.41</td><td align="center" rowspan="1" colspan="1">0.12 (−0.19, 0.42)</td><td align="center" rowspan="1" colspan="1">0.42</td><td align="center" rowspan="1" colspan="1">0.54</td></tr><tr><td rowspan="1" colspan="1">GLP-1 AUC (pmol/L/min)</td><td align="center" rowspan="1" colspan="1">3.40 ± 2.85</td><td align="center" rowspan="1" colspan="1">18.89 ± 11.93</td><td align="center" rowspan="1" colspan="1">−15.49 (−21.78, −9.20)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td rowspan="1" colspan="1">GDF-15 (pmol/L)</td><td align="center" rowspan="1" colspan="1">236.24 ± 279.43</td><td align="center" rowspan="1" colspan="1">100.06 ± 189.55</td><td align="center" rowspan="1" colspan="1">136.18 (−44.69, 317.04)</td><td align="center" rowspan="1" colspan="1">0.13</td><td align="center" rowspan="1" colspan="1">0.37</td></tr><tr><td rowspan="1" colspan="1">Thyroid-stimulating hormone (mIU/L)</td><td align="center" rowspan="1" colspan="1">−0.02 ± 0.93</td><td align="center" rowspan="1" colspan="1">0.24 ± 0.70</td><td align="center" rowspan="1" colspan="1">−0.26 (−0.65, 0.14)</td><td align="center" rowspan="1" colspan="1">0.19</td><td align="center" rowspan="1" colspan="1">0.44</td></tr><tr><td rowspan="1" colspan="1">CTX (ng/mL)</td><td align="center" rowspan="1" colspan="1">0.19 ± 0.22</td><td align="center" rowspan="1" colspan="1">0.07 ± 0.21</td><td align="center" rowspan="1" colspan="1">0.12 (0.01, 0.24)</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">0.13</td></tr><tr><td rowspan="1" colspan="1">Propeptide of type I procollagen (ng/mL)</td><td align="center" rowspan="1" colspan="1">−19.60 ± 12.05</td><td align="center" rowspan="1" colspan="1">−21.43 ± 16.48</td><td align="center" rowspan="1" colspan="1">1.83 (−6.27, 9.92)</td><td align="center" rowspan="1" colspan="1">0.64</td><td align="center" rowspan="1" colspan="1">0.66</td></tr><tr><td rowspan="1" colspan="1">Osteocalcin (μg/L)</td><td align="center" rowspan="1" colspan="1">−10.83 ± 6.90</td><td align="center" rowspan="1" colspan="1">−12.09 ± 9.36</td><td align="center" rowspan="1" colspan="1">1.26 (−1.17, 3.69)</td><td align="center" rowspan="1" colspan="1">0.29</td><td align="center" rowspan="1" colspan="1">0.51</td></tr><tr><td rowspan="1" colspan="1">Body weight (kg)</td><td align="center" rowspan="1" colspan="1">0.08 ± 1.12</td><td align="center" rowspan="1" colspan="1">−0.13 ± 0.72</td><td align="center" rowspan="1" colspan="1">0.21 (−0.38, 0.79)</td><td align="center" rowspan="1" colspan="1">0.47</td><td align="center" rowspan="1" colspan="1">0.54</td></tr><tr><td rowspan="1" colspan="1">Basal metabolic rate (kcal/24 h)</td><td align="center" rowspan="1" colspan="1">84.18 ± 191.84</td><td align="center" rowspan="1" colspan="1">131.94 ± 194.65</td><td align="center" rowspan="1" colspan="1">−47.76 (−182.06, 86.53)</td><td align="center" rowspan="1" colspan="1">0.46</td><td align="center" rowspan="1" colspan="1">0.54</td></tr><tr><td rowspan="1" colspan="1">Respiratory quotient</td><td align="center" rowspan="1" colspan="1">0.02 ± 0.18</td><td align="center" rowspan="1" colspan="1">−0.03 ± 0.12</td><td align="center" rowspan="1" colspan="1">0.05 (−0.06, 0.17)</td><td align="center" rowspan="1" colspan="1">0.35</td><td align="center" rowspan="1" colspan="1">0.51</td></tr><tr><td rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">0.76 ± 10.53</td><td align="center" rowspan="1" colspan="1">2.06 ± 7.37</td><td align="center" rowspan="1" colspan="1">−1.29 (−9.35, 6.77)</td><td align="center" rowspan="1" colspan="1">0.74</td><td align="center" rowspan="1" colspan="1">0.74</td></tr><tr><td rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">4.18 ± 8.31</td><td align="center" rowspan="1" colspan="1">1.71 ± 7.58</td><td align="center" rowspan="1" colspan="1">2.47 (−3.07, 8.01)</td><td align="center" rowspan="1" colspan="1">0.36</td><td align="center" rowspan="1" colspan="1">0.51</td></tr><tr><td rowspan="1" colspan="1">Change in average heart rate upon awakening (bpm)</td><td align="center" rowspan="1" colspan="1">−0.38 ± 12.99</td><td align="center" rowspan="1" colspan="1">−5.17 ± 11.38</td><td align="center" rowspan="1" colspan="1">3.92 (−8.02, 15.85)</td><td align="center" rowspan="1" colspan="1">0.49</td><td align="center" rowspan="1" colspan="1">0.54</td></tr><tr><td rowspan="1" colspan="1">Change in high-frequency power upon awakening (Hz)</td><td align="center" rowspan="1" colspan="1">−631.20 ± 4,979.06</td><td align="center" rowspan="1" colspan="1">798.08 ± 2,175.25</td><td align="center" rowspan="1" colspan="1">−2,082.63 (−6,242.04, 2,076.79)</td><td align="center" rowspan="1" colspan="1">0.29</td><td align="center" rowspan="1" colspan="1">0.51</td></tr><tr><td rowspan="1" colspan="1">Change in low-frequency power upon awakening (Hz)</td><td align="center" rowspan="1" colspan="1">−205.26 ± 1,245.23</td><td align="center" rowspan="1" colspan="1">483.26 ± 1,920.77</td><td align="center" rowspan="1" colspan="1">−711.41 (−2,362.64, 939.81)</td><td align="center" rowspan="1" colspan="1">0.36</td><td align="center" rowspan="1" colspan="1">0.51</td></tr><tr><td rowspan="1" colspan="1">Change in rMSSD upon awakening (ms)</td><td align="center" rowspan="1" colspan="1">−14.83 ± 68.88</td><td align="center" rowspan="1" colspan="1">22.50 ± 54.55</td><td align="center" rowspan="1" colspan="1">−46.38 (−117.96, 25.20)</td><td align="center" rowspan="1" colspan="1">0.18</td><td align="center" rowspan="1" colspan="1">0.44</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>Treatment groups were compared using paired <italic toggle="yes">t</italic> tests.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><p>Main study end points comparing the placebo and metformin study groups after a 7-day GC challenge. Changes between baseline and after GC treatment are shown for mixed-meal stimulated glucose calculated as the AUC (<italic toggle="yes">A</italic>), stimulated insulin (<italic toggle="yes">B</italic>), Matsuda index (<italic toggle="yes">C</italic>), HOMA-IR index (<italic toggle="yes">D</italic>), stimulated GLP-1 (<italic toggle="yes">E</italic>), and fasting GDF-15 (<italic toggle="yes">F</italic>). Data are presented as mean changes (bars indicate minimum and maximum values). *Adjusted <italic toggle="yes">P</italic> ≤ 0.05, **adjusted <italic toggle="yes">P</italic> ≤ 0.01, ***adjusted <italic toggle="yes">P</italic> &lt; 0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dc242039f1.jpg"/></fig><p>During the MMTT, total GLP-1 AUC increased significantly with metformin compared with placebo (<xref rid="F1" ref-type="fig">Fig. 1<italic toggle="yes">E</italic></xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.2337/figshare.28216082" ext-link-type="uri">Supplementary Fig. 2<italic toggle="yes">E</italic> and <italic toggle="yes">F</italic></ext-link>). There was no difference in fasting GDF-15 (<xref rid="F1" ref-type="fig">Fig. 1<italic toggle="yes">F</italic></xref>) or thyroid-stimulating hormone levels. The fasting CTX concentration increased with placebo but remained stable with metformin. However, this finding no longer reached significance after adjusting the <italic toggle="yes">P</italic> value. Intact amino terminal propeptide of type I procollagen and osteocalcin decreased with both treatments. PTH and 25-hydroxy vitamin D<sub>3</sub> concentrations were within the normal range at baseline (<xref rid="T1" ref-type="table">Table 1</xref>). No changes in adiponectin and leptin levels were observed (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.2337/figshare.28216082" ext-link-type="uri">Supplementary Fig. 5</ext-link>). Body weight did not differ between the interventions; there was no difference in basal metabolic rate and the respiratory quotient.</p><p>Systolic and diastolic blood pressures remained similar between both study arms. Additionally, upon awakening, no differences were observed in the changes of average heart rate, high-frequency power, low-frequency power, or rMSSD, indicating no relevant change in autonomic nervous system tone.</p><p>Untargeted metabolomic analysis was performed of blood samples of each study participant in the fasting state and 15 min after ingesting a liquid mixed meal, before and after metformin and placebo exposure.</p><p>During fasting, a comparative analysis between metformin and placebo revealed differential expression of 12 metabolites (<xref rid="F2" ref-type="fig">Fig. 2<italic toggle="yes">A</italic></xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.2337/figshare.28216082" ext-link-type="uri">Supplementary Fig. 6</ext-link>). Notably, citrulline and ornithine, components of the urea cycle pathway, exhibited significant downregulation with metformin treatment. Other differentially expressed metabolites were associated with pathways involving fatty acids and bile acids.</p><fig position="float" id="F2" orientation="portrait"><label>Figure 2</label><caption><p>Comparison of plasma metabolome and adipose tissue transcriptome between metformin and placebo groups after a 7-day GC challenge. <italic toggle="yes">A</italic>: Plasma metabolomic changes in 17 participants after treatment with metformin and placebo in the fasting state. <italic toggle="yes">B</italic>: Plasma metabolomic changes in the same participants in the postprandial state. In both panels, yellow points represent metabolites significantly reduced with metformin; purple points represent metabolites significantly increased with metformin. <italic toggle="yes">C</italic>: Differential gene expression in white adipose tissue from 10 participants under metformin and placebo treatment. Orange points represent genes downregulated with metformin, and green points represent upregulated genes. The dotted line represents the adjusted <italic toggle="yes">P</italic>-value cutoff of 0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dc242039f2.jpg"/></fig><p>In the postprandial state, 38 metabolites displayed differential expression with metformin (<xref rid="F2" ref-type="fig">Fig. 2<italic toggle="yes">B</italic></xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.2337/figshare.28216082" ext-link-type="uri">Supplementary Fig. 6</ext-link>). Eleven of these metabolites overlapped with those identified in the fasting state. Once again, citrulline and ornithine had the most significant impact.</p><p>Pathway enrichment analysis revealed that metformin upregulated the citric acid cycle during fasting. In the postprandial state, metformin downregulated bile acid biosynthesis and concurrently upregulated the flux of free fatty acids (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.2337/figshare.28216082" ext-link-type="uri">Supplementary Fig. 7</ext-link>).</p><p>RNA sequencing was performed on subcutaneous white adipose tissue samples obtained from 10 participants at the end of each treatment period. Differential gene expression analysis conducted irrespective of fold change between metformin and placebo unveiled 80 genes exhibiting variations in adipose tissue. Nineteen of these 80 genes were differentially expressed above an absolute log2 fold change of 0.5 (<xref rid="F2" ref-type="fig">Fig. 2<italic toggle="yes">C</italic></xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.2337/figshare.28216082" ext-link-type="uri">Supplementary Table 2</ext-link>). These 19 genes were mainly involved in lipid metabolism (<italic toggle="yes">AACS, FADS1, FADS2, ELOVL6, SREBF1</italic>) and were downregulated with metformin. Other differentially expressed genes were involved in transcription regulation and signaling (<italic toggle="yes">JUNB, PRRT4, NR1D1, FOXN4, THRSP</italic>), cell cycle regulation, and proliferation (<italic toggle="yes">CCNG2, EPHB2</italic>).</p><p>Pathway analysis of differential gene expression further confirmed that metformin primarily affected cholesterol, steroid, and fatty acid pathways (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.2337/figshare.28216082" ext-link-type="uri">Supplementary Fig. 8</ext-link>). Comparative analysis with data from a 6-week metformin study by Kulkarni et al. (<xref rid="B14" ref-type="bibr">14</xref>), which focused on older adults without diabetes and without GC therapy, identified shared enriched pathways predominantly linked to fatty acid metabolism (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.2337/figshare.28216082" ext-link-type="uri">Supplementary Fig. 9</ext-link>).</p><p>Gastrointestinal symptoms, such as nausea and mild abdominal discomfort, were reported slightly more frequently in the metformin group than the placebo group (<italic toggle="yes">n</italic> = 9 with metformin compared with 6 with placebo). However, this difference was not statistically significant (<italic toggle="yes">P</italic> = 0.45). Moreover, the reported symptoms were generally mild, self-limiting, and did not require treatment discontinuation.</p></sec><sec sec-type="conclusion" id="s4"><title>Conclusions</title><p>In this study, metformin prevented insulin resistance induced by GCs. Metformin enhanced whole-body insulin sensitivity, as assessed by the Matsuda index, by inhibiting the postprandial increase in glucose and insulin levels. This study underscores the role of metformin in preventing GC-induced diabetes (<xref rid="B5" ref-type="bibr">5</xref>).</p><p>The HOMA-IR index—primarily a marker of hepatic insulin sensitivity based on fasting values—remained unaffected by metformin (<xref rid="B7" ref-type="bibr">7</xref>). This is likely due to the distinct properties of GCs, which mainly induce postprandial insulin resistance (<xref rid="B1" ref-type="bibr">1</xref>). We observed no influence of GCs on β-cell function, as assessed through the insulinogenic index, and hence, no apparent impact of metformin. Nevertheless, effects on the HOMA-IR index and insulin secretion may manifest in patients with increased metabolic risk and more pronounced glucotoxicity (<xref rid="B2" ref-type="bibr">2</xref>). Although pretreatment with GCs may enhance the effect of metformin on whole-body insulin sensitivity, based on the sequencing effect observed in the Matsuda index, the absence of a significant interaction effect suggests that the overall magnitude of the treatment effect is not dependent on treatment sequence.</p><p>Our second objective was to investigate the extent of metformin action beyond glucose control. GCs can cause obesity and dyslipidemia by inducing both lipolysis and lipogenesis (<xref rid="B2" ref-type="bibr">2</xref>). Our metabolomic analysis revealed that metformin enhances the postprandial flow of free fatty acids. This effect may be attributed to increased tissue uptake and accelerated clearance of free fatty acids from the bloodstream. Metformin also downregulated key genes involved in fatty acid synthesis in adipose tissue, such as <italic toggle="yes">FADS1</italic>, <italic toggle="yes">FADS2</italic>, and <italic toggle="yes">ELOVL6</italic>, which are linked to type 2 diabetes risk (<xref rid="B15" ref-type="bibr">15–17</xref>). Thus, our findings highlight the potential of metformin in counteracting GC-induced dyslipidemia and obesity.</p><p>Next, we investigated the impact of metformin on bone health. We found that metformin preserved CTX, a marker of bone resorption, whereas CTX level increased with placebo, indicating reduced osteoclast activity with metformin. However, the difference in CTX level did not remain statistically significant after adjustment for multiple testing and, therefore, remains hypothesis-generating. Nonetheless, the observed statistical trend and previous observations in preclinical and human studies suggest an effect of metformin in preventing GC-induced bone loss (<xref rid="B18" ref-type="bibr">18–20</xref>).</p><p>Myopathy is another common side effect of GCs (<xref rid="B21" ref-type="bibr">21</xref>), resulting from increased protein breakdown and diminished protein synthesis (<xref rid="B21" ref-type="bibr">21</xref>). We found that citrulline and ornithine, two metabolites of the urea cycle pathway, were strongly downregulated, suggesting that protein breakdown is slowed with metformin. Similar metabolic shifts have been reported in patients with type 2 diabetes using metformin (<xref rid="B19" ref-type="bibr">19</xref>). Whether metformin can prevent muscle wasting and GC-induced myopathy needs to be further evaluated. Taken together, our study shows that the effects of metformin extend beyond glucose control, providing protective benefits to muscle, adipose, and, possibly, bone tissue.</p><p>Our third objective was to identify the underlying mechanisms of metformin action. The molecular mechanisms of metformin are still not fully elucidated, and several mechanisms have been proposed (<xref rid="B4" ref-type="bibr">4</xref>). Activation of AMPK is considered a key mechanism, but AMPK-independent mechanisms are also under discussion (<xref rid="B4" ref-type="bibr">4</xref>). GCs reduce AMPK activity, and preclinical studies have shown that metformin reverses these effects by activating AMPK (<xref rid="B22" ref-type="bibr">22–24</xref>). In human adipose tissue, metformin-induced AMPK activation has been linked to reduced fatty acid synthesis (<xref rid="B25" ref-type="bibr">25</xref>). Consistent with this, our genetic analysis of adipose tissue revealed a significant downregulation of pathways associated with fatty acid synthesis after metformin treatment. Furthermore, metformin suppressed the expression of genes like <italic toggle="yes">AACS,</italic>
<italic toggle="yes">FADS1</italic>, and <italic toggle="yes">FADS2</italic>, which impair AMPK activation (<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B26" ref-type="bibr">26</xref>). These findings support the hypothesis that metformin counteracts the metabolic effects of GCs through AMPK activation in adipose tissue.</p><p>In recent years, AMPK-independent mechanisms of metformin have gained attention. Among these, GLP-1 has been increasingly recognized as a contributor to metformin action (<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B27" ref-type="bibr">27</xref>). Here, we observed a distinct elevation of GLP-1 after metformin administration, potentially due to alterations in the bile acid pool, a mechanism under investigation (<xref rid="B28" ref-type="bibr">28</xref>). Indeed, metformin reduced bile acid synthesis postprandially, which supports this hypothesis.</p><p>The impact of metformin on bile acids has received considerable attention because metformin was found to exert beneficial metabolic effects by changing the gut microbiome and secondary bile acid levels (<xref rid="B29" ref-type="bibr">29</xref>). In our study, metformin affected both liver-derived primary bile acids and gut-derived secondary bile acids, emphasizing the role of the gut in metformin action.</p><p>Growth differentiation factor 15, which has been implicated in the weight regulatory effects of metformin, was not affected in our study (<xref rid="B30" ref-type="bibr">30</xref>). This may be due to the relatively short duration of the study. In summary, our study shows that metformin acts through various pathways in both AMPK-dependent and independent manners, with tissue-specific mechanisms.</p><p>A limitation of our clinical trial is the short study duration, which restricts our ability to investigate direct clinical outcomes such as the development of type 2 diabetes. Whether the observed changes in surrogate parameters translate to preventing the toxic effects of GCs remains to be seen. However, given that our study population consisted of young and healthy individuals and the treatment duration was short, it is conceivable that the effect of metformin is more potent in a population at risk for metabolic disorders.</p><p>We cannot definitively establish whether the observed changes in white adipose tissue, bone, and muscle directly result from metformin action or indirectly from reduced insulin resistance. However, compared with studies of patients with type 2 diabetes, insulin resistance was mild and limited to the postprandial state. Additionally, comparing our genetic findings with data from a 6-week metformin study of adults without diabetes who were not receiving GC therapy identified several shared enriched pathways predominantly linked to fatty acid metabolism (<xref rid="B14" ref-type="bibr">14</xref>). These findings collectively indicate that the observed effects are largely independent of insulin resistance.</p><p>In conclusion, metformin prevents GC-induced insulin resistance and reduces markers of dyslipidemia, myopathy, and, possibly, bone resorption. This study highlights aspects of metformin beyond glucose control and demonstrates its impact on white adipose tissue, muscle, bone, and the gut. Additionally, we found that metformin activates both AMPK-dependent and -independent pathways. Thus, metformin could prevent GC-related toxicity, including diabetes mellitus, dyslipidemia, myopathy, and possibly osteoporosis. These insights underscore the therapeutic potential of metformin not only in managing GC side effects but also in broader clinical applications.</p><p>Our study provides robust data for designing a larger randomized-controlled trial to investigate the protective effects of metformin in patients during GC treatment. Such a trial should address long-term outcomes, including diabetes mellitus, dyslipidemia, muscle wasting, osteoporosis, and bone fractures.</p></sec><sec sec-type="supplementary-material"><p>This article contains supplementary material online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.2337/figshare.28216082" ext-link-type="uri">https://doi.org/10.2337/figshare.28216082</ext-link>.</p></sec></body><back><ack><title>Article Information</title><p><bold>Acknowledgments.</bold> The authors thank the team at Cardiomatics, especially Rafal Samborski and Nikola Fajkis-Zajaczkowska, for supporting the analysis of heart rate variability. The authors thank Lucia Seeger for her support in conducting the study. The authors thank Mirjam Christ-Crain, Ulrich Keller, and Fabian Meienberg for reviewing the manuscript. We used BioRender for creating the graphical abstract. During the course of preparing this work, the author(s) used ChatGPT for the purpose of improving the readability of the manuscript. Following the use of this tool/service, the authors formally reviewed the content for its accuracy and edited it as necessary. The authors take full responsibility for all the content of this publication.</p><p content-type="COI-statement"><bold>Duality of Interest.</bold> No potential conflicts of interest relevant to this article were reported.</p><p><bold>Author Contributions.</bold> S.T., C.J.P., and V.I. collected the data; M.E. conducted the statistical analysis; S.T., S.P., C.M., T.D., C.S.Z., M.K., M.E., A.O., N.Z., I.R., A.G., C.W., and E.S. contributed to the analysis and interpretation of the data; S.T., S.P., and E.S. did the literature search; E.S. designed and supervised the study and drafted the manuscript; S.T. and P.A.T. wrote the protocol, which E.S. edited; S.T., C.J.P., V.I., C.M., T.D., C.S.Z., M.K., M.E., A.O., N.Z., I.R., A.G., and C.W. revised the manuscript. E.S., S.T., and M.E. verified the data and had access to all raw data. All authors had final responsibility for the decision to submit for publication. E.S. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis</p><p><bold>Prior Presentation.</bold> This study was presented in part at the European Association for the Study of Diabetes conference, Hamburg, Germany, 2–6 October 2023; the Swiss Society of Endocrinology and Diabetology Congress, Bern, Switzerland, 14–15 November 2023; and the European Congress of Endocrinology, Istanbul, Turkey, 13–16 May 2023.</p><p><bold>Handling Editors.</bold> The journal editors responsible for overseeing the review of the manuscript were Elizabeth Selvin and Naveed Sattar.</p></ack><fn-group><fn id="fn1" fn-type="other"><p>Clinical trial reg. no. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04659915" ext-link-type="uri">NCT04659915</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.clinicaltrials.gov" ext-link-type="uri">clinicaltrials.gov</ext-link></p></fn></fn-group><fn-group><fn id="fn3"><p>
<bold>See accompanying article, p. 688.</bold>
</p></fn></fn-group><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><caption><title>Supplementary Material</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="dc242039_supp.pdf" id="d67e1288" position="anchor" orientation="portrait"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Pofi</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Caratti</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ray</surname>
<given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Tomlinson</surname>
<given-names>JW.</given-names></string-name></person-group>
<article-title>Treating the side effects of exogenous glucocorticoids; can we separate the good from the bad?</article-title>
<source>Endocr Rev</source>
<year>2023</year>;<volume>44</volume>:<fpage>975</fpage>–<lpage>1011</lpage><pub-id pub-id-type="pmid">37253115</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/endrev/bnad016</pub-id><pub-id pub-id-type="pmcid">PMC10638606</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Li</surname>
<given-names>J-X</given-names></string-name>, <string-name name-style="western"><surname>Cummins</surname>
<given-names>CL.</given-names></string-name></person-group>
<article-title>Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions</article-title>. <source>Nat Rev Endocrinol</source>
<year>2022</year>;<volume>18</volume>:<fpage>540</fpage>–<lpage>557</lpage><pub-id pub-id-type="pmid">35585199</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41574-022-00683-6</pub-id><pub-id pub-id-type="pmcid">PMC9116713</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Sanpawithayakul</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Korbonits</surname>
<given-names>M.</given-names></string-name></person-group>
<article-title>Metabolic complications of glucocorticoids - prevention by metformin</article-title>. <source>Ann Endocrinol (Paris)</source>
<year>2023</year>;<volume>84</volume>:<fpage>483</fpage>–<lpage>497</lpage><pub-id pub-id-type="pmid">36965849</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ando.2023.03.018</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Foretz</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Guigas</surname>
<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Viollet</surname>
<given-names>B.</given-names></string-name></person-group>
<article-title>Metformin: update on mechanisms of action and repurposing potential</article-title>. <source>Nat Rev Endocrinol</source>
<year>2023</year>;<volume>19</volume>:<fpage>460</fpage>–<lpage>476</lpage><pub-id pub-id-type="pmid">37130947</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41574-023-00833-4</pub-id><pub-id pub-id-type="pmcid">PMC10153049</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Seelig</surname>
<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Meyer</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Timper</surname>
<given-names>K</given-names></string-name>, <etal/></person-group>. <article-title>Metformin prevents metabolic side effects during systemic glucocorticoid treatment</article-title>. <source>Eur J Endocrinol</source>
<year>2017</year>;<volume>176</volume>:<fpage>349</fpage>–<lpage>358</lpage><pub-id pub-id-type="pmid">28073907</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1530/EJE-16-0653</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Matthews</surname>
<given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Hosker</surname>
<given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Rudenski</surname>
<given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Naylor</surname>
<given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Treacher</surname>
<given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname>
<given-names>RC.</given-names></string-name></person-group>
<article-title>Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man</article-title>. <source>Diabetologia</source>
<year>1985</year>;<volume>28</volume>:<fpage>412</fpage>–<lpage>419</lpage><pub-id pub-id-type="pmid">3899825</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00280883</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Matsuda</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>DeFronzo</surname>
<given-names>RA.</given-names></string-name></person-group>
<article-title>Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp</article-title>. <source>Diabetes Care</source>
<year>1999</year>;<volume>22</volume>:<fpage>1462</fpage>–<lpage>1470</lpage><pub-id pub-id-type="pmid">10480510</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diacare.22.9.1462</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Phillips</surname>
<given-names>DI</given-names></string-name>, <string-name name-style="western"><surname>Clark</surname>
<given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Hales</surname>
<given-names>CN</given-names></string-name>, <string-name name-style="western"><surname>Osmond</surname>
<given-names>C.</given-names></string-name></person-group>
<article-title>Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion</article-title>. <source>Diabet Med</source>
<year>1994</year>;<volume>11</volume>:<fpage>286</fpage>–<lpage>292</lpage><pub-id pub-id-type="pmid">8033528</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1464-5491.1994.tb00273.x</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Hennings</surname>
<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Coslovsky</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Paladini</surname>
<given-names>RE</given-names></string-name>, <etal/>; <collab>Swiss-AF Investigators</collab></person-group>. <article-title>Assessment of the atrial fibrillation burden in Holter electrocardiogram recordings using artificial intelligence</article-title>. <source>Cardiovasc Digit Health J</source>
<year>2023</year>;<volume>4</volume>:<fpage>41</fpage>–<lpage>47</lpage><pub-id pub-id-type="pmid">37101946</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cvdhj.2023.01.003</pub-id><pub-id pub-id-type="pmcid">PMC10123500</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Fuhrer</surname>
<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Heer</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Begemann</surname>
<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zamboni</surname>
<given-names>N.</given-names></string-name></person-group>
<article-title>High-throughput, accurate mass metabolome profiling of cellular extracts by flow injection-time-of-flight mass spectrometry</article-title>. <source>Anal Chem</source>
<year>2011</year>;<volume>83</volume>:<fpage>7074</fpage>–<lpage>7080</lpage><pub-id pub-id-type="pmid">21830798</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ac201267k</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Hatakeyama</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Opitz</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Russo</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Qi</surname>
<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Schlapbach</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Rehrauer</surname>
<given-names>H.</given-names></string-name></person-group>
<article-title>SUSHI: an exquisite recipe for fully documented, reproducible and reusable NGS data analysis</article-title>. <source>BMC Bioinformatics</source>
<year>2016</year>;<volume>17</volume>:<fpage>228</fpage><pub-id pub-id-type="pmid">27255077</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12859-016-1104-8</pub-id><pub-id pub-id-type="pmcid">PMC4890512</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Chen</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname>
<given-names>J.</given-names></string-name></person-group>
<article-title>fastp: An ultra-fast all-in-one FASTQ preprocessor</article-title>. <source>Bioinformatics</source>
<year>2018</year>;<volume>34</volume>:<fpage>i884</fpage>–<lpage>i890</lpage><pub-id pub-id-type="pmid">30423086</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/bty560</pub-id><pub-id pub-id-type="pmcid">PMC6129281</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Bray</surname>
<given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Pimentel</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Melsted</surname>
<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Pachter</surname>
<given-names>L.</given-names></string-name></person-group>
<article-title>Near-optimal probabilistic RNA-seq quantification</article-title>. <source>Nat Biotechnol</source>
<year>2016</year>;<volume>34</volume>:<fpage>525</fpage>–<lpage>527</lpage><pub-id pub-id-type="pmid">27043002</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.3519</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Kulkarni</surname>
<given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Brutsaert</surname>
<given-names>EF</given-names></string-name>, <string-name name-style="western"><surname>Anghel</surname>
<given-names>V</given-names></string-name>, <etal/></person-group>. <article-title>Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults</article-title>. <source>Aging Cell</source>
<year>2018</year>;<volume>17</volume><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.12723</pub-id><pub-id pub-id-type="pmcid">PMC5847877</pub-id><pub-id pub-id-type="pmid">29383869</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Yuan</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Larsson</surname>
<given-names>SC.</given-names></string-name></person-group>
<article-title>Association of genetic variants related to plasma fatty acids with type 2 diabetes mellitus and glycaemic traits: a Mendelian randomisation study</article-title>. <source>Diabetologia</source>
<year>2020</year>;<volume>63</volume>:<fpage>116</fpage>–<lpage>123</lpage><pub-id pub-id-type="pmid">31690987</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-019-05019-0</pub-id><pub-id pub-id-type="pmcid">PMC6890658</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Xu</surname>
<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Brandmaier</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Messias</surname>
<given-names>AC</given-names></string-name>, <etal/></person-group>. <article-title>Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes</article-title>. <source>Diabetes Care</source>
<year>2015</year>;<volume>38</volume>:<fpage>1858</fpage>–<lpage>1867</lpage><pub-id pub-id-type="pmid">26251408</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc15-0658</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Matsuzaka</surname>
<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Shimano</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yahagi</surname>
<given-names>N</given-names></string-name>, <etal/></person-group>. <article-title>Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance</article-title>. <source>Nat Med</source>
<year>2007</year>;<volume>13</volume>:<fpage>1193</fpage>–<lpage>1202</lpage><pub-id pub-id-type="pmid">17906635</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm1662</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Vogel</surname>
<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Braun</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Rubinstein</surname>
<given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>Metformin and bone metabolism in endogenous glucocorticoid excess: an exploratory study</article-title>. <source>Front Endocrinol (Lausanne)</source>
<year>2021</year>;<volume>12</volume>:<fpage>765067</fpage><pub-id pub-id-type="pmid">34777259</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2021.765067</pub-id><pub-id pub-id-type="pmcid">PMC8578886</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Adam</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Brandmaier</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Leonhardt</surname>
<given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Metformin effect on nontargeted metabolite profiles in patients with type 2 diabetes and in multiple murine tissues</article-title>. <source>Diabetes</source>
<year>2016</year>;<volume>65</volume>:<fpage>3776</fpage>–<lpage>3785</lpage><pub-id pub-id-type="pmid">27621107</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db16-0512</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Bahrambeigi</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yousefi</surname>
<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Rahimi</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Shafiei-Irannejad</surname>
<given-names>V.</given-names></string-name></person-group>
<article-title>Metformin; an old antidiabetic drug with new potentials in bone disorders</article-title>. <source>Biomed Pharmacother</source>
<year>2019</year>;<volume>109</volume>:<fpage>1593</fpage>–<lpage>1601</lpage><pub-id pub-id-type="pmid">30551413</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2018.11.032</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Pereira</surname>
<given-names>RMR</given-names></string-name>, <string-name name-style="western"><surname>Freire de Carvalho</surname>
<given-names>J.</given-names></string-name></person-group>
<article-title>Glucocorticoid-induced myopathy</article-title>. <source>Joint Bone Spine</source>
<year>2011</year>;<volume>78</volume>:<fpage>41</fpage>–<lpage>44</lpage><pub-id pub-id-type="pmid">20471889</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbspin.2010.02.025</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Christ-Crain</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kola</surname>
<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Lolli</surname>
<given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome</article-title>. <source>Faseb J</source>
<year>2008</year>;<volume>22</volume>:<fpage>1672</fpage>–<lpage>1683</lpage><pub-id pub-id-type="pmid">18198220</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.07-094144</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Kola</surname>
<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Christ-Crain</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lolli</surname>
<given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>Changes in adenosine 5'-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2008</year>;<volume>93</volume>:<fpage>4969</fpage>–<lpage>4973</lpage><pub-id pub-id-type="pmid">18782871</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2008-1297</pub-id><pub-id pub-id-type="pmcid">PMC7611639</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Pernicova</surname>
<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Kelly</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ajodha</surname>
<given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial</article-title>. <source>Lancet Diabetes Endocrinol</source>
<year>2020</year>;<volume>8</volume>:<fpage>278</fpage>–<lpage>291</lpage><pub-id pub-id-type="pmid">32109422</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(20)30021-8</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Boyle</surname>
<given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Logan</surname>
<given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname>
<given-names>GC</given-names></string-name>, <etal/></person-group>. <article-title>AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study</article-title>. <source>Diabetologia</source>
<year>2011</year>;<volume>54</volume>:<fpage>1799</fpage>–<lpage>1809</lpage><pub-id pub-id-type="pmid">21455728</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-011-2126-4</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Narishima</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yamasaki</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hasegawa</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yoshida</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tanaka</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Fukui</surname>
<given-names>T.</given-names></string-name></person-group>
<article-title>Leptin controls ketone body utilization in hypothalamic neuron</article-title>. <source>Neurosci Lett</source>
<year>2011</year>;<volume>490</volume>:<fpage>185</fpage>–<lpage>190</lpage><pub-id pub-id-type="pmid">21194556</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2010.11.081</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Mannucci</surname>
<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ognibene</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cremasco</surname>
<given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects</article-title>. <source>Diabetes Care</source>
<year>2001</year>;<volume>24</volume>:<fpage>489</fpage>–<lpage>494</lpage><pub-id pub-id-type="pmid">11289473</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diacare.24.3.489</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>McCreight</surname>
<given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Bailey</surname>
<given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Pearson</surname>
<given-names>ER.</given-names></string-name></person-group>
<article-title>Metformin and the gastrointestinal tract</article-title>. <source>Diabetologia</source>
<year>2016</year>;<volume>59</volume>:<fpage>426</fpage>–<lpage>435</lpage><pub-id pub-id-type="pmid">26780750</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-015-3844-9</pub-id><pub-id pub-id-type="pmcid">PMC4742508</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Sun</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname>
<given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>Gut microbiota and intestinal FXR mediate the clinical benefits of metformin</article-title>. <source>Nat Med</source>
<year>2018</year>;<volume>24</volume>:<fpage>1919</fpage>–<lpage>1929</lpage><pub-id pub-id-type="pmid">30397356</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-018-0222-4</pub-id><pub-id pub-id-type="pmcid">PMC6479226</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western"><surname>Coll</surname>
<given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Taskar</surname>
<given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>GDF15 mediates the effects of metformin on body weight and energy balance</article-title>. <source>Nature</source>
<year>2020</year>;<volume>578</volume>:<fpage>444</fpage>–<lpage>448</lpage><pub-id pub-id-type="pmid">31875646</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-019-1911-y</pub-id><pub-id pub-id-type="pmcid">PMC7234839</pub-id></mixed-citation></ref></ref-list></back></article><article id="cts70120" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Transl Sci</journal-id><journal-id journal-id-type="iso-abbrev">Clin Transl Sci</journal-id><journal-id journal-id-type="pmc-domain-id">2996</journal-id><journal-id journal-id-type="pmc-domain">cts</journal-id><journal-id journal-id-type="publisher-id">CTS</journal-id><journal-title-group><journal-title>Clinical and Translational Science</journal-title></journal-title-group><issn pub-type="ppub">1752-8054</issn><issn pub-type="epub">1752-8062</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11821731</article-id><article-id pub-id-type="pmcid-ver">PMC11821731.1</article-id><article-id pub-id-type="pmcaid">11821731</article-id><article-id pub-id-type="pmcaiid">11821731</article-id><article-id pub-id-type="pmid">39943692</article-id><article-id pub-id-type="doi">10.1111/cts.70120</article-id><article-id pub-id-type="publisher-id">CTS70120</article-id><article-id pub-id-type="other">CTS-2024-0516-T</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Pharmacokinetic Interaction Between Metformin and the Natural Product Goldenseal Is Metformin Dose‐Dependent: A Three‐Arm Crossover Study in Adults With Type 2 Diabetes</article-title></title-group><contrib-group><contrib id="cts70120-cr-0001" contrib-type="author"><name name-style="western"><surname>Nguyen</surname><given-names initials="JT">James T.</given-names></name><xref rid="cts70120-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cts70120-cr-0002" contrib-type="author"><name name-style="western"><surname>Arian</surname><given-names initials="CM">Christopher M.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6595-7717</contrib-id><xref rid="cts70120-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cts70120-cr-0003" contrib-type="author"><name name-style="western"><surname>Tanna</surname><given-names initials="RS">Rakshit S.</given-names></name><xref rid="cts70120-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cts70120-cr-0004" contrib-type="author"><name name-style="western"><surname>Cherel</surname><given-names initials="MG">Maxey G.</given-names></name><xref rid="cts70120-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cts70120-cr-0005" contrib-type="author"><name name-style="western"><surname>Layton</surname><given-names initials="ME">Matthew E.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3287-9203</contrib-id><xref rid="cts70120-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cts70120-cr-0006" contrib-type="author"><name name-style="western"><surname>White</surname><given-names initials="JR">John R.</given-names></name><xref rid="cts70120-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="cts70120-cr-0007" contrib-type="author"><name name-style="western"><surname>Thummel</surname><given-names initials="KE">Kenneth E.</given-names></name><xref rid="cts70120-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cts70120-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="cts70120-cr-0008" contrib-type="author" corresp="yes"><name name-style="western"><surname>Paine</surname><given-names initials="MF">Mary F.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3331-1839</contrib-id><xref rid="cts70120-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cts70120-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><address><email>mary.paine@wsu.edu</email></address></contrib></contrib-group><aff id="cts70120-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences</named-content>
<institution>Washington State University</institution>
<city>Spokane</city>
<named-content content-type="country-part">Washington</named-content>
<country country="US">USA</country>
</aff><aff id="cts70120-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Pharmaceutics, School of Pharmacy</named-content>
<institution>University of Washington</institution>
<city>Seattle</city>
<named-content content-type="country-part">Washington</named-content>
<country country="US">USA</country>
</aff><aff id="cts70120-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Elson S. Floyd College of Medicine</named-content>
<institution>Washington State University</institution>
<city>Spokane</city>
<named-content content-type="country-part">Washington</named-content>
<country country="US">USA</country>
</aff><aff id="cts70120-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences</named-content>
<institution>Washington State University</institution>
<city>Spokane</city>
<named-content content-type="country-part">Washington</named-content>
<country country="US">USA</country>
</aff><aff id="cts70120-aff-0005">
<label>
<sup>5</sup>
</label>
<institution>Center of Excellence for Natural Product Drug Interaction Research</institution>
<city>Spokane</city>
<named-content content-type="country-part">Washington</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Mary F. Paine (<email>mary.paine@wsu.edu</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>18</volume><issue seq="80">2</issue><issue-id pub-id-type="pmc-issue-id">480585</issue-id><issue-id pub-id-type="doi">10.1111/cts.v18.2</issue-id><elocation-id>e70120</elocation-id><history><date date-type="rev-recd"><day>02</day><month>12</month><year>2024</year></date><date date-type="received"><day>27</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>14</day><month>12</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>02</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-17 17:25:17.167"><day>17</day><month>02</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">© 2025 The Author(s). <italic toggle="yes">Clinical and Translational Science</italic> published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CTS-18-e70120.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CTS-18-e70120.pdf"/><abstract><title>ABSTRACT</title><p>Pharmacokinetic drug interactions can lead to unexpected changes in plasma concentrations of the object drug, potentially increasing the risk for adverse effects and/or decreasing therapeutic efficacy. The botanical product goldenseal was previously shown to decrease metformin systemic exposure in healthy adults. This three‐arm, open‐label, crossover clinical study assessed the pharmacokinetic goldenseal–metformin interaction in adults with type 2 diabetes stabilized on therapeutic doses of metformin (500–2550 mg daily). The aggregate pharmacokinetic data indicated no clinically meaningful interaction as determined by the metformin area under the plasma concentration‐time curve (AUC) geometric mean ratio [90% confidence interval] of 0.93 [0.86–1.01] laying within the predefined no‐effect range (0.80–1.25). However, metformin AUC decreased by ~20%, 14%, and 0% after goldenseal coadministration at low (500–750 mg), moderate (1000–1500 mg), and high (2000–2550 mg) metformin doses, respectively; renal clearance and half‐life remained unchanged throughout. The exploratory pharmacodynamic endpoint, HbA1c, decreased on average from 6.8% to 6.5%, regardless of the effects of goldenseal on metformin pharmacokinetics. The decreasing effect of goldenseal on metformin systemic exposure with increasing metformin dose, coupled with no changes in renal excretion and elimination half‐life, indicated that both the pharmacokinetic goldenseal–metformin interaction and the nonlinear absorption of metformin are governed by saturable, intestinal transport mechanism(s). The disconnect between changes in metformin systemic exposure and therapeutic effects emphasizes the need to evaluate clinical biomarkers to comprehensively assess drug interaction risks, particularly those involving natural products. Healthcare providers may consider cautioning patients about supplementing metformin pharmacotherapy with goldenseal to avoid risks for undesired changes in glycemic control.</p><p>
<bold>Trial Registration:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://clinicaltrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> identifier: NCT05081583</p></abstract><abstract abstract-type="graphical"><p>
<boxed-text position="anchor" content-type="graphic" id="cts70120-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="CTS-18-e70120-g003.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cts70120-kwd-0001">berberine</kwd><kwd id="cts70120-kwd-0002">clinical study</kwd><kwd id="cts70120-kwd-0003">drug interaction</kwd><kwd id="cts70120-kwd-0004">goldenseal</kwd><kwd id="cts70120-kwd-0005">metformin</kwd><kwd id="cts70120-kwd-0006">natural product</kwd><kwd id="cts70120-kwd-0007">pharmacokinetics</kwd><kwd id="cts70120-kwd-0008">type 2 diabetes</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>National Institutes of Health National Center for Complementary &amp; Integrative Health</funding-source><award-id>U54AT008909</award-id><award-id>F31AT011698</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>National Center for Advancing Translational Sciences
</institution><institution-id institution-id-type="doi">10.13039/100006108</institution-id></institution-wrap></funding-source><award-id>TL1 RR025016</award-id></award-group></funding-group><counts><fig-count count="5"/><table-count count="1"/><page-count count="10"/><word-count count="6400"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.3 mode:remove_FC converted:13.02.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="cts70120-ntgp-0001"><fn fn-type="funding" id="cts70120-note-0001"><p>
<bold>Funding:</bold> This work was supported by the National Institutes of Health National Center for Complementary and Integrative Health and the Office of Dietary Supplements, specifically the Center of Excellence for Natural Product Drug Interaction Research (U54 AT008909 and F31 AT011698), and the National Center for Advancing Translational Sciences (TL1 RR025016); Bethesda, Maryland.</p></fn><fn fn-type="equal" id="cts70120-note-0002"><p>Christopher M. Arian: Contributed significantly to the completion of this work and is recognized as a co‐first author.</p></fn></fn-group></notes></front><body id="cts70120-body-0001"><p>
<boxed-text position="anchor" content-type="box" id="cts70120-blkfxd-0002" orientation="portrait"><caption><title>Summary</title></caption><p>
<list list-type="bullet" id="cts70120-list-0001"><list-item id="cts70120-li-0001"><p>What is the current knowledge on the topic?
<list list-type="simple" id="cts70120-list-0002"><list-item id="cts70120-li-0002"><label>○</label><p>Coadministration of the natural product goldenseal with a subtherapeutic dose of metformin (50 mg) was previously shown to decrease metformin systemic exposure in healthy adult participants.</p></list-item></list>
</p></list-item><list-item id="cts70120-li-0003"><p>What question did this study address?
<list list-type="simple" id="cts70120-list-0003"><list-item id="cts70120-li-0004"><label>○</label><p>This study investigated the pharmacokinetic goldenseal–metformin interaction, along with the potential consequent effects on clinical biomarkers of glucose control, in adults with type 2 diabetes taking therapeutic doses of metformin (500–2250 mg).</p></list-item></list>
</p></list-item><list-item id="cts70120-li-0005"><p>What does this study add to our knowledge?
<list list-type="simple" id="cts70120-list-0004"><list-item id="cts70120-li-0006"><label>○</label><p>The risk of goldenseal precipitating a pharmacokinetic interaction with metformin decreased with increasing metformin dose, indicating that the interaction and the nonlinear absorption of metformin are driven by saturable transport mechanism(s). The mechanism of this presumed transporter‐mediated pharmacokinetic drug interaction appears to be competitive inhibition because the magnitude diminished at increasing metformin doses. The apparent decrease in HbA1c, irrespective of the change in metformin exposure, provides a framework for future controlled studies to investigate the potential glucose lowering effects of goldenseal.</p></list-item></list>
</p></list-item><list-item id="cts70120-li-0007"><p>How might this change clinical pharmacology or translational science?
<list list-type="simple" id="cts70120-list-0005"><list-item id="cts70120-li-0008"><label>○</label><p>Caution may be warranted for patients taking metformin concomitantly with goldenseal, regardless of changes in metformin systemic exposure, due to potential additive blood glucose lowering effects.</p></list-item></list>
</p></list-item></list>
</p></boxed-text>
</p><sec id="cts70120-sec-0003"><label>1</label><title>Introduction</title><p>Despite groundbreaking advances in promising new pharmacotherapeutics throughout the past decade, drug–drug interactions (DDIs) remain a major public health concern worldwide [<xref rid="cts70120-bib-0001" ref-type="bibr">1</xref>]. Regarding the economic and health care burdens, DDIs have been estimated to account for &gt; 70,000 emergency room visits and ~200,000 hospitalizations annually in the United States [<xref rid="cts70120-bib-0002" ref-type="bibr">2</xref>, <xref rid="cts70120-bib-0003" ref-type="bibr">3</xref>]. DDIs are of particular concern in low‐ and middle‐income countries due to the lack of robust pharmacovigilance programs, contributing to the disproportionate rate of poor health outcomes in these communities [<xref rid="cts70120-bib-0004" ref-type="bibr">4</xref>, <xref rid="cts70120-bib-0005" ref-type="bibr">5</xref>]. Pharmacokinetic DDIs can lead to changes in the systemic exposure to the object drug, potentially resulting in increased off‐target effects and/or decreased efficacy. These risks are further exacerbated by the fact that many pharmacotherapeutics are dose‐limited by toxicities. Hence, rigorous evaluation of pharmacokinetic DDIs is critical for optimal dose selection to improve therapeutic outcomes.</p><p>People with diabetes often experience polypharmacy due to uncontrolled blood glucose and/or comorbidities, greatly increasing the risk for adverse DDIs. Drug interactions, which are typically perceived to result from concomitant drugs, can also be precipitated by botanical dietary supplements and other natural products [<xref rid="cts70120-bib-0006" ref-type="bibr">6</xref>]. Grapefruit juice and St. John's wort are two textbook examples of natural products that precipitate clinically significant pharmacokinetic drug interactions. Grapefruit juice can greatly increase systemic exposure to certain drugs by inhibiting the prominent drug‐metabolizing enzyme cytochrome P450 (CYP) 3A4, potentially leading to drug toxicity. In contrast, grapefruit juice can decrease systemic drug exposure by inhibiting the apically localized intestinal uptake transporters organic anion transporting polypeptides (OATPs), potentially leading to reduced drug efficacy [<xref rid="cts70120-bib-0007" ref-type="bibr">7</xref>]. St. John's wort also can reduce drug systemic exposure by inducing CYP3A4 expression. Despite these well‐known examples, natural products remain relatively understudied and overlooked based on the common (mis)perception that they are safe because they are derived from natural sources. Concerns for natural product–drug interactions are further compounded as more and more patients seek natural alternatives to self‐treat a variety of medical complications, including type 2 diabetes [<xref rid="cts70120-bib-0008" ref-type="bibr">8</xref>, <xref rid="cts70120-bib-0009" ref-type="bibr">9</xref>], contributing to the exponential growth in sales of these ubiquitous and readily accessible products [<xref rid="cts70120-bib-0010" ref-type="bibr">10</xref>].</p><p>An established but lesser‐known natural product precipitant of pharmacokinetic drug interactions is goldenseal [<styled-content style="fixed-case" toggle="no">
<italic toggle="no">Hydrastis canadensis</italic>
</styled-content> L. (Ranunculaceae)], which is commonly used to self‐treat the common cold, indigestion, and allergic rhinitis [<xref rid="cts70120-bib-0011" ref-type="bibr">11</xref>, <xref rid="cts70120-bib-0012" ref-type="bibr">12</xref>]. Goldenseal also has been used for glucose control because berberine, the predominant phytoconstituent present in goldenseal products [<xref rid="cts70120-bib-0013" ref-type="bibr">13</xref>], reportedly has glucose lowering effects in both rodent models with diabetes and adults with type 2 diabetes [<xref rid="cts70120-bib-0014" ref-type="bibr">14</xref>, <xref rid="cts70120-bib-0015" ref-type="bibr">15</xref>, <xref rid="cts70120-bib-0016" ref-type="bibr">16</xref>]. Like grapefruit juice, goldenseal is a CYP3A4 inhibitor and has been shown to increase systemic exposure to susceptible drugs [<xref rid="cts70120-bib-0017" ref-type="bibr">17</xref>, <xref rid="cts70120-bib-0018" ref-type="bibr">18</xref>]. More recently, our group observed an ~25% decrease in metformin systemic exposure after coadministration of a subtherapeutic dose (50 mg) of metformin with goldenseal to 16 healthy adults [<xref rid="cts70120-bib-0019" ref-type="bibr">19</xref>]. This minor pharmacokinetic interaction may be clinically relevant as incremental changes in metformin exposure have been shown to affect glucose control [<xref rid="cts70120-bib-0020" ref-type="bibr">20</xref>]. The working hypothesis is that goldenseal inhibited intestinal uptake transporters involved in metformin absorption because the drug does not readily permeate the intestinal epithelial lining (<italic toggle="yes">P</italic>
<sub>app</sub>: 1.4–5.0 × 10<sup>−7</sup> cm/s) due to its hydrophilicity (log <italic toggle="yes">D</italic>), −3.41 (pH 7.4), pK<sub>a</sub> (12.4), and lack of metabolism [<xref rid="cts70120-bib-0021" ref-type="bibr">21</xref>, <xref rid="cts70120-bib-0022" ref-type="bibr">22</xref>, <xref rid="cts70120-bib-0023" ref-type="bibr">23</xref>]. Subsequent mechanistic studies confirmed that goldenseal is an inhibitor of various intestinal uptake transporters (e.g., OCT1/3, PMAT, and ThTR2) both in HEK293 cells overexpressing select transporters and in mice [<xref rid="cts70120-bib-0024" ref-type="bibr">24</xref>].</p><p>Although this first documented clinical pharmacokinetic interaction involving metformin and a natural product generated novel information, several questions remain: (i) Is this interaction relevant to people with diabetes taking therapeutic doses of metformin? (ii) Does chronic goldenseal administration increase interaction risk? (iii) Does the pharmacokinetic interaction affect glucose control? Accordingly, the aims of the present study were to evaluate the effects of a well‐characterized goldenseal product on metformin pharmacokinetics in adults with type 2 diabetes, after both acute and chronic goldenseal exposure, and assess for potential changes in clinical biomarkers of glucose control (i.e., HbA1c, glycated albumin %, HOMA‐IR). Although a metformin dose‐dependent pharmacokinetic interaction was observed that did not lead to anticipated changes in clinical biomarkers, goldenseal appeared to affect HbA1c independent of the pharmacokinetic interaction. Results highlight a potential disconnect between a pharmacokinetic natural product–drug interaction and anticipated changes in therapeutic effects.</p></sec><sec sec-type="methods" id="cts70120-sec-0004"><label>2</label><title>Methods</title><sec id="cts70120-sec-0005"><label>2.1</label><title>Participant Eligibility and Enrollment</title><p>Adults with type 2 diabetes who were stabilized on metformin (immediate or extended‐release formulations), with doses ranging from 500 to 2550 mg daily, were recruited to participate in a 3‐arm, open‐label, crossover pharmacokinetic study (Figure <xref rid="cts70120-supitem-0001" ref-type="supplementary-material">S1</xref>). The clinical protocol was approved by the Washington State University (WSU) Institutional Review Board (IRB registration #18889) and registered in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://clinicaltrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> database (NCT #05081583). All activities took place at the WSU Human Research Clinic on the Health Sciences Campus in accordance with 45 CFR 46 and adherence to Good Clinical Practice guidelines. Signed written informed consent and Health Insurance Portability and Accountability Act compliance forms were obtained from all potential participants prior to screening, which consisted of medical history assessment, physical exam, and clinical laboratory testing (complete blood count with differentials and platelets, complete metabolic panel, HbA1c, and urinalysis). Participation eligibility was based on screening evaluation and inclusion/exclusion criteria (Table <xref rid="cts70120-supitem-0002" ref-type="supplementary-material">S1</xref>). A compiled list of concomitant medications is included in the supplemental information; none of these drugs are known to affect metformin pharmacokinetics.</p></sec><sec id="cts70120-sec-0006"><label>2.2</label><title>Clinical Study Design</title><p>On the morning of each inpatient study day, participants were provided a standardized meal (~500 kcal; ~37 g fat, 16 g carbohydrate, 22 g protein) immediately prior to metformin administration. During Arm 1 (baseline), they consumed their entire daily intake of metformin as a single oral dose (Figure <xref rid="cts70120-fig-0001" ref-type="fig">1</xref>). During Arm 2 (acute goldenseal exposure), they were administered 3.3 g of a well‐characterized oral goldenseal product (550 mg whole root; Solaray, Nutraceutical Corp., Park City, UT) 30 min prior to metformin. Each gram of the goldenseal product contained 28.9 mg of berberine, 18.6 mg of (−)‐β‐hydrastine, and 0.73 mg of canadine. During Arm 3 (chronic goldenseal exposure), they self‐administered 1.1 g of goldenseal thrice daily for 27 consecutive days; compliance was monitored via a video messaging app. On the morning of day 28, participants were administered 1.1 g of goldenseal 30 min prior to metformin; two additional doses of goldenseal (1.1 g) were administered at 4‐h intervals. Participants were instructed to administer their daily dose of metformin as prescribed throughout the entire duration of the study without a drug holiday. They were also instructed to take all other medications as prescribed throughout the entirety of the study. During all three arms, blood (8 mL) was collected into BD Vacutainer EDTA tubes (Becton, Dickinson and Company, Franklin Lakes, NJ) from an arm vein via an indwelling peripheral venous catheter at designated time points before and up to 12 h post‐metformin administration; a single venous blood draw was collected the following morning at the 24‐h time point. An additional blood sample (8 mL) was collected into BD Vacutainer SST tubes for clinical biomarker assessment at the beginning of each study arm when participants were fasted overnight. Urine was collected during the 0–12 and 12–24 h intervals after metformin administration. Vital signs (blood pressure, oxygen saturation, pulse) and fasting blood glucose were measured periodically during each visit. Inpatient visits for each arm were separated by a 7‐day goldenseal washout period, with Arm 3 being the final arm completed by all participants. A washout period was also necessary to ensure participants did not consume food/liquids known to affect drug metabolizing enzymes and transporters prior to participation in the study.</p><fig position="float" fig-type="FIGURE" id="cts70120-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Clinical study design: 3‐arm, open‐label, crossover. Participants consumed their entire daily dose of metformin (500–2550 mg) at the start of each arm. Plasma and urine were collected up to 24 h after metformin administration. During Arm 2 (acute goldenseal exposure), a single dose of goldenseal (3.3 g) was administered ~30 min prior to metformin. During Arm 3 (chronic goldenseal exposure), participants self‐administered goldenseal (1.1 g) thrice daily for 27 days; compliance was monitored via a video messaging app. On Day 28, a single dose of goldenseal (1.1 g) was administered ~30 min prior to metformin; 2 additional doses of goldenseal were administered in 4‐h increments (depicted with gold arrows). Each arm was separated by at least a 7‐day goldenseal washout period. The washout period was also necessary to ensure participants did not consume food/alcohol known to affect drug metabolizing enzyme and transporters prior to participation in the study.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="CTS-18-e70120-g002.jpg"/></fig></sec><sec id="cts70120-sec-0007"><label>2.3</label><title>Bioanalytical Method</title><p>Plasma was separated from red blood cells via centrifugation (1600 <italic toggle="yes">g</italic> × 10 min) and subsequently transferred to cryovials. Prior to quantitative analysis, plasma and urine samples were processed by adding 250 μL acetonitrile (containing <italic toggle="yes">d</italic>
<sub>
<italic toggle="yes">6</italic>
</sub>‐metformin as internal standard) to 100 μL of the sample, followed by centrifugation at 20,800 <italic toggle="yes">g</italic> and 4°C for 10 min to precipitate proteins. Supernatants were collected, diluted 1:50 in acetonitrile, and analyzed using an established UHPLC–MS/MS method [<xref rid="cts70120-bib-0025" ref-type="bibr">25</xref>].</p></sec><sec id="cts70120-sec-0008"><label>2.4</label><title>Pharmacokinetic Analysis</title><p>Metformin pharmacokinetics were determined via noncompartmental analysis using Phoenix WinNonlin (v7.0, Certara, Radnor, PA). Because metformin could not be discontinued in these participants, area under the plasma concentration vs. time curve (AUC) from time zero to the last measured concentration (AUC<sub>0‐tlast</sub>) and maximum plasma concentration (<italic toggle="yes">C</italic>
<sub>max</sub>) were corrected for residual drug. That is, metformin concentrations in the collected samples were corrected by subtracting the calculated decayed concentrations of residual metformin at each respective timepoint using the terminal elimination rate constant determined for each participant. This correction for residual metformin concentration was necessary to standardize comparisons between study arms due to potential differences in the time during which metformin was administered the day prior. The following additional metrics were recovered from the plasma concentration vs. time data as described: terminal half‐life (<italic toggle="yes">t</italic>
<sub>1/2</sub>), time to reach <italic toggle="yes">C</italic>
<sub>max</sub> (<italic toggle="yes">t</italic>
<sub>max</sub>), and renal clearance (CL<sub>R</sub>) [<xref rid="cts70120-bib-0019" ref-type="bibr">19</xref>].</p></sec><sec id="cts70120-sec-0009"><label>2.5</label><title>Statistical and Power Analyses</title><p>A sample size of 20 evaluable participants was determined to provide &gt; 80% power to detect a 20% change in metformin AUC with a Type I error of 0.05, assuming 29.4% intra‐individual variability [<xref rid="cts70120-bib-0026" ref-type="bibr">26</xref>]. The primary endpoints were the geometric mean ratio (GMR; goldenseal exposure‐to‐baseline) of metformin AUC<sub>0‐tlast</sub> and <italic toggle="yes">C</italic>
<sub>max</sub>. The predefined no effect range was 0.80–1.25; that is, if the GMR lay outside this range, a pharmacokinetic interaction was evident. Secondary pharmacokinetic endpoints included <italic toggle="yes">t</italic>
<sub>1/2</sub>, <italic toggle="yes">t</italic>
<sub>max</sub>, and CL<sub>R</sub>. When appropriate, secondary endpoints were compared using the Wilcoxon matched‐pairs signed‐rank test. Descriptive statistics were recovered using GraphPad Prism 9 (GraphPad Software Inc., La Jolla, CA).</p></sec><sec id="cts70120-sec-0010"><label>2.6</label><title>Pharmacodynamic Assessments</title><p>Clinical biomarkers were measured in serum samples collected at the beginning of study participation and after 28 days of goldenseal administration. Hemoglobin A1c (HbA1c) was evaluated using the Tina‐quant assay (Roche Diagnostics International Ltd., Rotkreuz, Switzerland). Glycated albumin % was calculated as the ratio of glycated albumin to albumin, which was measured using the Lucica (EKF Diagonistics, Texas, USA) and ALB Flex (Siemens Healthcare Diagnostics Inc., Delaware, USA) assay, respectively. Insulin and glucose concentrations were measured using recombinant ELISA kits (ab278123; Abcam Inc., Cambridge, UK) and Contour Next glucose monitor kit (Ascensia Diabetes Care, New Jersey, USA), respectively. Homeostatic Model Assessment for Insulin Resistance (HOMA‐IR) was calculated using the following equation: <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="jats-math-1" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mtext>glucose</mml:mtext><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mfrac><mml:mi>mg</mml:mi><mml:mi>dL</mml:mi></mml:mfrac></mml:mfenced><mml:mo>×</mml:mo><mml:mtext>insulin</mml:mtext><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mfrac><mml:mi>μIU</mml:mi><mml:mi>mL</mml:mi></mml:mfrac></mml:mfenced></mml:mrow><mml:mn>405</mml:mn></mml:mfrac></mml:mrow></mml:mrow></mml:math> [<xref rid="cts70120-bib-0027" ref-type="bibr">27</xref>].</p></sec></sec><sec sec-type="results" id="cts70120-sec-0011"><label>3</label><title>Results</title><sec id="cts70120-sec-0012"><label>3.1</label><title>Participant Demographics</title><p>A total of 22 participants (12 males,10 females) completed the study; none withdrew from the study. Using the NIH demographics form, 20 participants self‐identified as White, 1 as American Indian, and 1 as two or more races. Median age [range] was 47 [22–65] years. Mean weight and BMI [90% confidence interval] were, respectively, 106 [96–117] kg and 32 [29–35] kg/m<sup>2</sup> for males and 98 [87–110] kg and 36 [32–40] kg/m<sup>2</sup> for females.</p></sec><sec id="cts70120-sec-0050"><label>3.2</label><title>Pharmacokinetic Goldenseal‐Metformin Interaction Study</title><p>All participants tolerated goldenseal well during Arms 2 and 3. No serious adverse effects were reported. Because metformin is known to exhibit nonlinear absorption at therapeutic doses [<xref rid="cts70120-bib-0028" ref-type="bibr">28</xref>, <xref rid="cts70120-bib-0029" ref-type="bibr">29</xref>, <xref rid="cts70120-bib-0030" ref-type="bibr">30</xref>], the concentration‐time profiles (Figure <xref rid="cts70120-fig-0002" ref-type="fig">2</xref>) and pharmacokinetics (Table <xref rid="cts70120-tbl-0001" ref-type="table">1</xref>) of metformin were categorized according to the total daily dose: ≤ 750, 1000–1500, and ≥ 2000 mg. The changes in metformin AUC and <italic toggle="yes">C</italic>
<sub>max</sub> did not differ between acute and chronic goldenseal administration; hence, the GMRs for both arms were combined for assessment (Figure <xref rid="cts70120-fig-0003" ref-type="fig">3</xref>). At the lower metformin doses (500–750 mg; <italic toggle="yes">n</italic> = 8), AUC<sub>0–12h</sub> and <italic toggle="yes">C</italic>
<sub>max</sub> GMRs were 0.80 [0.62–1.04] and 0.79 [0.66–0.94], respectively. At the moderate doses (1000–1500 mg; <italic toggle="yes">n</italic> = 15), AUC<sub>0–12h</sub> and <italic toggle="yes">C</italic>
<sub>max</sub> GMRs were 0.85 [0.72–1.02] and 0.86 [0.71–1.02], respectively. At the high doses (2000–2250 mg; <italic toggle="yes">n</italic> = 21), AUC<sub>0–12h</sub> and <italic toggle="yes">C</italic>
<sub>max</sub> GMRs were 1.00 [0.91–1.08] and 1.00 [0.90–1.10], respectively. Metformin AUC and <italic toggle="yes">C</italic>
<sub>max</sub> GMRs were 0.86 [0.76–0.96] and 0.88 [0.78–0.99], respectively, for participants taking immediate release formulations (<italic toggle="yes">n</italic> = 14) and were 1.00 [0.92–1.11] and 0.96 [0.86–1.05], respectively, for those taking extended‐release dosages (<italic toggle="yes">n</italic> = 8).</p><fig position="float" fig-type="FIGURE" id="cts70120-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Dose‐adjusted metformin plasma concentration versus time profiles for the (A) aggregate data and for data binned into (B) low, (C) moderate, and (D) high metformin dose groups. Symbols denote the geometric mean of metformin concentrations in the absence of goldenseal (gray circles) and after acute (solid blue squares) and chronic (open blue squares) exposure to goldenseal. Error bars are excluded from the graphs for visual clarity; readers are referred to Table <xref rid="cts70120-tbl-0001" ref-type="table">1</xref> for metformin pharmacokinetic variability. One participant reported a change in metformin dose (1000–2000 mg) midway through the study, thus the baseline arm was repeated for this participant at the new dose to provide an appropriate paired analysis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="CTS-18-e70120-g001.jpg"/></fig><table-wrap position="float" id="cts70120-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Pharmacokinetics of metformin (500–2550 mg) after oral administration alone and after acute (single 3.3‐g dose) and chronic (1.1 g thrice daily for 28 days) exposure to goldenseal. Data represent geometric means [90% confidence intervals] unless noted otherwise.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Baseline</th><th align="center" valign="bottom" rowspan="1" colspan="1">Acute goldenseal exposure</th><th align="center" valign="bottom" rowspan="1" colspan="1">Chronic goldenseal exposure</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Metformin 500–2550 mg (<italic toggle="yes">n</italic>)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">23<xref rid="cts70120-note-0006" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">22</td><td align="center" valign="top" rowspan="1" colspan="1">22</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AUC<sub>0–12h</sub> (nM ╳ h/mg)<xref rid="cts70120-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">59.6 [52.0–68.5]</td><td align="center" valign="top" rowspan="1" colspan="1">54.5 [48.2–61.7]</td><td align="center" valign="top" rowspan="1" colspan="1">57.3 [50.3–65.3]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">C</italic>
<sub>max</sub> (nM/mg)<xref rid="cts70120-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">8.92 [7.86–10.1]</td><td align="center" valign="top" rowspan="1" colspan="1">8.36 [7.55–9.27]</td><td align="center" valign="top" rowspan="1" colspan="1">8.26 [7.37–9.25]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>
<sub>1/2</sub> (h)</td><td align="center" valign="top" rowspan="1" colspan="1">4.73 [4.18–5.35]</td><td align="center" valign="top" rowspan="1" colspan="1">4.70 [4.22–5.23]</td><td align="center" valign="top" rowspan="1" colspan="1">4.79 [4.27–5.37]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>
<sub>max</sub> (h)<xref rid="cts70120-note-0008" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">3.50 [1.00–10.00]</td><td align="center" valign="top" rowspan="1" colspan="1">4.50 [1.50–6.00]</td><td align="center" valign="top" rowspan="1" colspan="1">4.50 [1.50–6.00]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CL<sub>R</sub> (mL/min)</td><td align="center" valign="top" rowspan="1" colspan="1">259 [203–331]</td><td align="center" valign="top" rowspan="1" colspan="1">249 [200–309]</td><td align="center" valign="top" rowspan="1" colspan="1">250 [199–314]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Metformin 500–750 mg (<italic toggle="yes">n</italic>)</bold>
<xref rid="cts70120-note-0009" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AUC<sub>0–12h</sub> (nM ╳ h/mg)<xref rid="cts70120-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">61.6 [31.8–82.0]</td><td align="center" valign="top" rowspan="1" colspan="1">43.0 [29.6–62.9]<xref rid="cts70120-note-0010" ref-type="table-fn">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">53.6 [23.9–74.2]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">C</italic>
<sub>max</sub> (nM/mg)<xref rid="cts70120-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">9.87 [7.18–11.4]</td><td align="center" valign="top" rowspan="1" colspan="1">6.87 [5.22–9.49]<xref rid="cts70120-note-0010" ref-type="table-fn">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">7.76 [4.64–10.4]<xref rid="cts70120-note-0010" ref-type="table-fn">*</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>
<sub>1/2</sub> (h)</td><td align="center" valign="top" rowspan="1" colspan="1">3.24 [2.12–4.94]</td><td align="center" valign="top" rowspan="1" colspan="1">3.83 [2.21–6.63]</td><td align="center" valign="top" rowspan="1" colspan="1">3.63 [2.40–5.50]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>
<sub>max</sub> (h)<xref rid="cts70120-note-0008" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">5.50 [3.00–6.00]</td><td align="center" valign="top" rowspan="1" colspan="1">4.5 [3.00–6.00]</td><td align="center" valign="top" rowspan="1" colspan="1">4.75 [2.50–6.00]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CL<sub>R</sub> (mL/min)</td><td align="center" valign="top" rowspan="1" colspan="1">458 [225–712]</td><td align="center" valign="top" rowspan="1" colspan="1">282 [186–555]</td><td align="center" valign="top" rowspan="1" colspan="1">402 [162–564]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Metformin 1000–1500 mg (<italic toggle="yes">n</italic>)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">7<xref rid="cts70120-note-0006" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AUC<sub>0–12h</sub> (nM ╳ h/mg)<xref rid="cts70120-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">67.2 [50.0–90.2]</td><td align="center" valign="top" rowspan="1" colspan="1">58.8 [44.8–77.1]</td><td align="center" valign="top" rowspan="1" colspan="1">60.0 [46.2–77.8]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">C</italic>
<sub>max</sub> (nM/mg)<xref rid="cts70120-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">10.3 [7.94–13.4]</td><td align="center" valign="top" rowspan="1" colspan="1">9.15 [7.44–11.2]</td><td align="center" valign="top" rowspan="1" colspan="1">8.91 [7.14–11.1]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>
<sub>1/2</sub> (h)</td><td align="center" valign="top" rowspan="1" colspan="1">4.43 [3.62–5.42]</td><td align="center" valign="top" rowspan="1" colspan="1">4.66 [3.76–5.76]</td><td align="center" valign="top" rowspan="1" colspan="1">4.56 [3.38–6.15]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>
<sub>max</sub> (h)<xref rid="cts70120-note-0008" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">3.50 [1.00–6.00]</td><td align="center" valign="top" rowspan="1" colspan="1">4.5 [2.00–6.00]</td><td align="center" valign="top" rowspan="1" colspan="1">3.5 [2.00–6.00]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CL<sub>R</sub> (mL/min)</td><td align="center" valign="top" rowspan="1" colspan="1">279 [189–410]</td><td align="center" valign="top" rowspan="1" colspan="1">260 [145–465]</td><td align="center" valign="top" rowspan="1" colspan="1">208 [137–316]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Metformin 2000–2550 mg (<italic toggle="yes">n</italic>)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">11<xref rid="cts70120-note-0006" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">11<xref rid="cts70120-note-0006" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AUC<sub>0–12h</sub> (nM ╳ h/mg)<xref rid="cts70120-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">56.1 [46.2–68.0]</td><td align="center" valign="top" rowspan="1" colspan="1">56.6 [48.7–65.8]</td><td align="center" valign="top" rowspan="1" colspan="1">59.7 [50.2–71.1]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">C</italic>
<sub>max</sub> (nM/mg)<xref rid="cts70120-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">8.00 [6.69–9.57]</td><td align="center" valign="top" rowspan="1" colspan="1">8.39 [7.24–9.71]</td><td align="center" valign="top" rowspan="1" colspan="1">8.23 [6.94–9.77]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>
<sub>1/2</sub> (h)</td><td align="center" valign="top" rowspan="1" colspan="1">5.80 [5.2–6.46]</td><td align="center" valign="top" rowspan="1" colspan="1">5.14 [4.70–5.61]</td><td align="center" valign="top" rowspan="1" colspan="1">5.46 [5.06–5.89]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>
<sub>max</sub> (h)<xref rid="cts70120-note-0008" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">3.50 [1.00–10.00]</td><td align="center" valign="top" rowspan="1" colspan="1">4.75 [1.50–6.00]</td><td align="center" valign="top" rowspan="1" colspan="1">5.00 [1.50–6.00]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CL<sub>R</sub> (mL/min)</td><td align="center" valign="top" rowspan="1" colspan="1">207 [138–312]</td><td align="center" valign="top" rowspan="1" colspan="1">225 [188–270]</td><td align="center" valign="top" rowspan="1" colspan="1">249 [200–309]</td></tr></tbody></table><table-wrap-foot id="cts70120-ntgp-0002"><fn id="cts70120-note-0003"><p>
<italic toggle="yes">Note:</italic> AUC<sub>0–12h</sub>, area under the plasma concentration versus time curve from 0 to 12 h. No statistical significance was observed for secondary endpoints (<italic toggle="yes">t</italic>
<sub>1/2</sub>, <italic toggle="yes">t</italic>
<sub>max</sub>, and CL<sub>R</sub>) based on Wilcoxon matched‐pairs signed‐rank test (<italic toggle="yes">p</italic> &lt; 0.05).</p></fn><fn id="cts70120-note-0005"><p>Abbreviations: CL<sub>R</sub>, renal clearance; <italic toggle="yes">C</italic>
<sub>max</sub>, maximum plasma concentration; <italic toggle="yes">t</italic>
<sub>½</sub>, terminal half‐life; <italic toggle="yes">t</italic>
<sub>max</sub>, time to reach <italic toggle="yes">C</italic>
<sub>max</sub>.</p></fn><fn id="cts70120-note-0006"><label>
<sup>a</sup>
</label><p>One participant reported a change in metformin dose (1000–2000 mg) midway through the study, thus the baseline arm was repeated to provide an appropriate paired analysis.</p></fn><fn id="cts70120-note-0007"><label>
<sup>b</sup>
</label><p>Normalized based on metformin hydrochloride dose.</p></fn><fn id="cts70120-note-0008"><label>
<sup>c</sup>
</label><p>Median [range].</p></fn><fn id="cts70120-note-0009"><label>
<sup>d</sup>
</label><p>Due to the small sample size, median [range] is reported.</p></fn><fn id="cts70120-note-0010"><label>*</label><p>Significant difference as determined by the pre‐defined no effect range of 0.80–1.25 for the goldenseal exposure‐to‐baseline AUC ratio.</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="FIGURE" id="cts70120-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Mean change in metformin systemic exposure after goldenseal co‐administration. The relative change in metformin AUC<sub>0–12h</sub> (A) and <italic toggle="yes">C</italic>
<sub>max</sub> (B) after goldenseal exposure is grouped by metformin dose. Effects of acute and chronic goldenseal administration are combined. <sup>†</sup>Effects of goldenseal administration on the pharmacokinetics of metformin (50 mg) in healthy adult participants are reproduced with permission from the American Society for Clinical Pharmacology and Therapeutics (Nguyen et al. 2020).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="CTS-18-e70120-g004.jpg"/></fig></sec><sec id="cts70120-sec-0013"><label>3.3</label><title>Clinical Biomarkers of Glucose Control</title><p>Clinical biomarker data for three participants were not included in the analysis due to changes to their diabetic pharmacotherapy midway through study participation; an additional four participants were not included in the HbA1c analysis due to the inability to obtain lab results. Of those with evaluable results (<italic toggle="yes">n</italic> = 15), mean [90% confidence interval] HbA1c decreased from 6.8% [6.5%–7.1%] at baseline to 6.5% [6.2%–6.8%] after 28 consecutive days of goldenseal administration (Figure <xref rid="cts70120-fig-0004" ref-type="fig">4A</xref>). Mean fasting blood glucose and glycated albumin were 141 mg/dL [131–151 mg/dL] and 14.7% [13.4%–16.0%], respectively, at baseline and were 140 mg/dL [131–150 mg/dL] and 14.5% [13.5%–15.4%], respectively, after goldenseal exposure (Figure <xref rid="cts70120-fig-0004" ref-type="fig">4B,C</xref>). Mean HOMA‐IR at baseline and after goldenseal exposure were 13.0 [10.2–15.8] and 14.9 [11.6–18.1], respectively (Figure <xref rid="cts70120-fig-0004" ref-type="fig">4D</xref>).</p><fig position="float" fig-type="FIGURE" id="cts70120-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Clinical biomarkers of glucose control measured for each participant at the beginning of the study (Baseline) and after 28 days of goldenseal co‐administration (GS Exposure): HbA1c (A), glycated albumin (B), fasting blood glucose (C), and HOMA‐IR (D). Intraindividual changes for each participant are shown in the right side of the plots; the red center and extreme horizontal lines denote means and 90% confidence intervals, respectively.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="CTS-18-e70120-g005.jpg"/></fig></sec></sec><sec sec-type="discussion" id="cts70120-sec-0014"><label>4</label><title>Discussion</title><p>Natural product–drug interactions are a growing public health concern as more patients seek botanical and other natural alternatives to supplement their pharmacotherapeutic regimens [<xref rid="cts70120-bib-0031" ref-type="bibr">31</xref>, <xref rid="cts70120-bib-0032" ref-type="bibr">32</xref>]. The botanical product goldenseal was recently shown to precipitate a pharmacokinetic interaction with a subtherapeutic dose of metformin (50 mg) in healthy adults [<xref rid="cts70120-bib-0019" ref-type="bibr">19</xref>]. Specifically, goldenseal decreased metformin systemic exposure by ~25% relative to baseline. The logical question subsequently arose: how do these results translate to people with type 2 diabetes taking metformin? The aims of the current study were to (i) evaluate whether goldenseal precipitates a pharmacokinetic interaction with therapeutic doses of metformin, (ii) determine if duration of exposure to goldenseal affects the magnitude of interaction risk, and (iii) assess if any pharmacokinetic changes affect clinical endpoints in this patient population.</p><p>Based on the predefined no‐effect range (metformin AUC<sub>0–12h</sub> GMR: 0.80–1.25), the aggregate data indicated no pharmacokinetic interaction between goldenseal and metformin at therapeutic doses (GMR, 0.93) (Figure <xref rid="cts70120-fig-0002" ref-type="fig">2A</xref>). However, when the data were binned into different metformin dose groups, the change in metformin systemic exposure after goldenseal coadministration decreased with increasing metformin dose (Figure <xref rid="cts70120-fig-0003" ref-type="fig">3</xref>). Specifically, at the lowest dose range (500–750 mg), goldenseal decreased metformin AUC and C<sub>max</sub> by ~20% relative to baseline, recapitulating observations from our previous study involving a subtherapeutic dose of metformin [<xref rid="cts70120-bib-0019" ref-type="bibr">19</xref>]. At moderate metformin doses (1000–1500 mg), goldenseal decreased AUC and <italic toggle="yes">C</italic>
<sub>max</sub> by ~14%. At the highest metformin doses (2000–2550 mg), the risk of an interaction was effectively null (Figure <xref rid="cts70120-fig-0003" ref-type="fig">3</xref>). The pharmacokinetic interaction appeared to be dependent on metformin formulation (immediate vs. extended release) but independent of the duration of goldenseal coadministration. These observations, coupled with no significant change in metformin half‐life and renal clearance, suggested that goldenseal decreased metformin systemic exposure at low therapeutic doses primarily by attenuating a saturable intestinal process involved in metformin absorption. A limitation with the current observations is that there were a limited number of participants in each of the various dose groups. Hence, a study sufficiently powered to detect differences in the magnitude of the goldenseal‐metformin pharmacokinetic interaction at the different metformin dose ranges, as well as differences between acute and chronic goldenseal administration, is necessary to confirm this hypothesis.</p><p>The nonlinear absorption kinetics of metformin (less than proportional increase in AUC with increasing dose) are well documented [<xref rid="cts70120-bib-0028" ref-type="bibr">28</xref>, <xref rid="cts70120-bib-0029" ref-type="bibr">29</xref>, <xref rid="cts70120-bib-0030" ref-type="bibr">30</xref>]. However, the underlying mechanism remains equivocal. Previous in vitro studies identified two mechanisms as potential contributors to this nonlinearity: saturable paracellular diffusion and saturable active transport through a transcellular absorption pathway [<xref rid="cts70120-bib-0022" ref-type="bibr">22</xref>, <xref rid="cts70120-bib-0033" ref-type="bibr">33</xref>]. If paracellular diffusion is the primary saturable component of metformin absorption, then the relative contribution of active transport will <italic toggle="yes">increase</italic> with increasing metformin dose, which will result in a greater magnitude of change in a transporter‐mediated interaction. In contrast, if active transport is the primary saturable component, then the relative contribution of active transport will <italic toggle="yes">decrease</italic> with increasing metformin dose, which will reduce the magnitude of a transporter‐mediated drug interaction. Regarding the current study, the diminished interaction at the higher metformin doses indicated that saturation of active transport is the underlying mechanism of the nonlinear absorption of metformin. These clinical results are also consistent with mechanistic studies that identified goldenseal and berberine, the predominant alkaloid in goldenseal, as inhibitors of select intestinal transporters presumed to be involved in metformin absorption (i.e., OCT1/3, PMAT, ThTr‐2) [<xref rid="cts70120-bib-0024" ref-type="bibr">24</xref>, <xref rid="cts70120-bib-0034" ref-type="bibr">34</xref>, <xref rid="cts70120-bib-0035" ref-type="bibr">35</xref>, <xref rid="cts70120-bib-0036" ref-type="bibr">36</xref>]. Indeed, the estimated luminal concentration of berberine after administration of a single 1.1 g dose of the goldenseal product (~350 μM) was at least 10‐fold higher than the IC<sub>50</sub> for each transporter, further supporting potential contributions by these transporters to the goldenseal–metformin interaction [<xref rid="cts70120-bib-0019" ref-type="bibr">19</xref>, <xref rid="cts70120-bib-0024" ref-type="bibr">24</xref>].</p><p>The effects of goldenseal on clinical biomarkers of glucose control were discordant with those expected from the changes in metformin systemic exposure. Based on the decrease in metformin AUC and <italic toggle="yes">C</italic>
<sub>max</sub> (dose range: 500–1500 mg) after goldenseal coadministration, a decrease in drug efficacy (increased blood glucose concentrations) was anticipated. However, efficacy was apparently enhanced, as mean HbA1c decreased from 6.8% to 6.5% after coadministration of goldenseal with metformin for 28 days (Figure <xref rid="cts70120-fig-0004" ref-type="fig">4A</xref>). These observations are consistent with those from previous clinical studies where daily administration of 1500 and 1000 mg berberine to adults with type 2 diabetes reduced HbA1c from 9.5% to 7.5% and from 7.5% to 6.6%, respectively [<xref rid="cts70120-bib-0037" ref-type="bibr">37</xref>, <xref rid="cts70120-bib-0038" ref-type="bibr">38</xref>]. The amount of berberine administered in the current study was ~95 mg daily. Collectively, these observations suggest that the magnitude of HbA1c reduction may depend on berberine dose. Regarding the current study, the presumed antihyperglycemic effects of goldenseal could have offset the projected adverse impact from the pharmacokinetic interaction (if any) with metformin.</p><p>Because HbA1c is a measure of average blood glucose for the preceding 3–4 months, this clinical biomarker may have underestimated the presumed antihyperglycemic effects of goldenseal, which was administered for only ~1 month. Glycated albumin, an emerging but less established biomarker, reflects average blood glucose for the preceding 6–8 weeks, representing a potential tool for assessing therapeutic effects over a shorter duration [<xref rid="cts70120-bib-0039" ref-type="bibr">39</xref>, <xref rid="cts70120-bib-0040" ref-type="bibr">40</xref>]. Results from this secondary assessment, as well as fasting blood glucose and HOMA‐IR, did not support the antihyperglycemic effects of goldenseal (Figure <xref rid="cts70120-fig-0004" ref-type="fig">4B–D</xref>). A potential confounding factor is a sequence effect stemming from the study design (chronic goldenseal exposure was the final arm completed by all participants), which was implemented due to logistical constraints. That is, participants may have altered their behavior (e.g., improved dietary habits and increased physical activity) because they were monitored throughout the study. This type of participation bias may have contributed to the apparent decrease in HbA1c. Another confounder is that the study was not powered to detect clinically meaningful changes in these biomarkers. Collectively, results support the need for an expanded study with a larger sample size and extended administration duration (&gt; 90 days) to confirm the effects of goldenseal on blood glucose.</p><p>Pharmacokinetic results from this clinical study are the first to demonstrate that the nonlinear absorption of metformin is driven primarily by saturable intestinal transporter(s). This concept can be applied to other orally administered drugs that are absorbed predominantly via this mechanism (e.g., uptake of fexofenadine by OATP2B1). That is, at higher therapeutic doses of the object drug, the risk of transporter‐mediated drug interactions in the intestine diminishes because of the high luminal concentrations saturating active transport processes, assuming transporter inhibition occurs in a competitive manner. A range of goldenseal doses would provide further insights into the mechanism of inhibition.</p><p>The current study demonstrated the utility of including clinical biomarkers in the evaluation of pharmacokinetic natural product–drug interactions. In general, a change in object drug systemic exposure should correlate with a change in pharmacological effects. However, because natural products contain multiple constituents (many of which could be pharmacologically active), the change in drug systemic exposure resulting from a pharmacokinetic natural product–drug interaction may not necessarily correlate with the anticipated effects on clinical endpoints. Regarding the current study, had the clinical biomarkers not been measured, the potential glucose lowering effects of goldenseal would not have been detected. These observations highlight the need to measure changes in clinical biomarkers to comprehensively assess the impact of natural product–drug interactions.</p><p>In summary, results from this comprehensive clinical study provided mechanistic insight into a pharmacokinetic natural product–drug interaction and identified potential pharmacologic effects of the natural product that are independent of the interaction. The aggregate pharmacokinetic data suggested that there was no interaction between goldenseal and metformin. However, at metformin doses &lt; 1000 mg, goldenseal coadministration appeared to decrease exposure to the antidiabetic drug. Finally, the combination of metformin and goldenseal could have additive/synergistic antihyperglycemic effects as observed by the decrease in HbA1c, potentially necessitating closer monitoring of blood glucose. Additional studies are needed to determine conclusively whether goldenseal has therapeutic benefits, which are essential to guide patients and healthcare providers about supplementing pharmacotherapeutic regimens with this natural product.</p></sec><sec id="cts70120-sec-0015"><title>Author Contributions</title><p>J.T.N. and M.F.P. wrote the manuscript; J.T.N., K.E.T., J.R.W., and M.F.P. designed the research; J.T.N., C.M.A., R.S.T., M.G.C., M.E.L., and J.R.W. performed the research; J.T.N. and C.M.A. analyzed the data; C.M.A. and K.E.T. contributed the analytical tools.</p></sec><sec sec-type="COI-statement" id="cts70120-sec-0017"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec id="cts70120-sec-0018"><title>Prior Presentation</title><p>Parts of this work were presented as a poster at the American Society for Clinical Pharmacology and Therapeutics annual meeting held in Atlanta, GA, 22–24 March 2023.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="cts70120-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
Figure S1.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CTS-18-e70120-s002.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="cts70120-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>
Table S1.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CTS-18-e70120-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="cts70120-sec-0016"><title>Acknowledgments</title><p>The authors thank Judy Griffin and Kate Newbill for their expert nursing skills and Deena Hadi for her assistance with clinical study logistics. M.F.P. dedicates this article to Dr. David P. Paine.</p></ack><ref-list content-type="cited-references" id="cts70120-bibl-0001"><title>References</title><ref id="cts70120-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cts70120-cit-0001">
<string-name name-style="western">
<given-names>B.</given-names>
<surname>Guthrie</surname>
</string-name>, <string-name name-style="western">
<given-names>B.</given-names>
<surname>Makubate</surname>
</string-name>, <string-name name-style="western">
<given-names>V.</given-names>
<surname>Hernandez‐Santiago</surname>
</string-name>, and <string-name name-style="western">
<given-names>T.</given-names>
<surname>Dreischulte</surname>
</string-name>, “<article-title>The Rising Tide of Polypharmacy and Drug‐Drug Interactions: Population Database Analysis 1995–2010</article-title>,” <source>BMC Medicine</source>
<volume>13</volume> (<year>2015</year>): <fpage>74</fpage>.<pub-id pub-id-type="pmid">25889849</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-015-0322-7</pub-id><pub-id pub-id-type="pmcid">PMC4417329</pub-id></mixed-citation></ref><ref id="cts70120-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cts70120-cit-0002">
<string-name name-style="western">
<given-names>B.</given-names>
<surname>Percha</surname>
</string-name> and <string-name name-style="western">
<given-names>R. B.</given-names>
<surname>Altman</surname>
</string-name>, “<article-title>Informatics Confronts Drug–Drug Interactions</article-title>,” <source>Trends in Pharmacological Sciences</source>
<volume>34</volume> (<year>2013</year>): <fpage>178</fpage>–<lpage>184</lpage>.<pub-id pub-id-type="pmid">23414686</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2013.01.006</pub-id><pub-id pub-id-type="pmcid">PMC3808975</pub-id></mixed-citation></ref><ref id="cts70120-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cts70120-cit-0003">
<string-name name-style="western">
<given-names>N. P.</given-names>
<surname>Tatonetti</surname>
</string-name>, <string-name name-style="western">
<given-names>G. H.</given-names>
<surname>Fernald</surname>
</string-name>, and <string-name name-style="western">
<given-names>R. B.</given-names>
<surname>Altman</surname>
</string-name>, “<article-title>A Novel Signal Detection Algorithm for Identifying Hidden Drug–Drug Interactions in Adverse Event Reports</article-title>,” <source>Journal of the American Medical Informatics Association</source>
<volume>19</volume> (<year>2012</year>): <fpage>79</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="pmid">21676938</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/amiajnl-2011-000214</pub-id><pub-id pub-id-type="pmcid">PMC3240755</pub-id></mixed-citation></ref><ref id="cts70120-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cts70120-cit-0004">
<string-name name-style="western">
<given-names>R.</given-names>
<surname>Kiguba</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Olsson</surname>
</string-name>, and <string-name name-style="western">
<given-names>C.</given-names>
<surname>Waitt</surname>
</string-name>, “<article-title>Pharmacovigilance in Low‐ and Middle‐Income Countries: A Review With Particular Focus on Africa</article-title>,” <source>British Journal of Clinical Pharmacology</source>
<volume>89</volume> (<year>2023</year>): <fpage>491</fpage>–<lpage>509</lpage>.<pub-id pub-id-type="pmid">34937122</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.15193</pub-id></mixed-citation></ref><ref id="cts70120-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cts70120-cit-0005">
<string-name name-style="western">
<given-names>R.</given-names>
<surname>Hussain</surname>
</string-name>, <string-name name-style="western">
<given-names>M. A.</given-names>
<surname>Hassali</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Ur Rehman</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>Muneswarao</surname>
</string-name>, and <string-name name-style="western">
<given-names>F.</given-names>
<surname>Hashmi</surname>
</string-name>, “<article-title>Physicians' Understanding and Practices of Pharmacovigilance: Qualitative Experience From A Lower Middle‐Income Country</article-title>,” <source>International Journal of Environmental Research and Public Health</source>
<volume>17</volume> (<year>2020</year>): <elocation-id>2209</elocation-id>.<pub-id pub-id-type="pmid">32218355</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijerph17072209</pub-id><pub-id pub-id-type="pmcid">PMC7178000</pub-id></mixed-citation></ref><ref id="cts70120-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cts70120-cit-0006">
<string-name name-style="western">
<given-names>M. F.</given-names>
<surname>Paine</surname>
</string-name>, <string-name name-style="western">
<given-names>D. D.</given-names>
<surname>Shen</surname>
</string-name>, and <string-name name-style="western">
<given-names>J. S.</given-names>
<surname>McCune</surname>
</string-name>, “<article-title>Recommended Approaches for Pharmacokinetic Natural Product‐Drug Interaction Research: A NaPDI Center Commentary</article-title>,” <source>Drug Metabolism and Disposition</source>
<volume>46</volume> (<year>2018</year>): <fpage>1041</fpage>–<lpage>1045</lpage>.<pub-id pub-id-type="pmid">29735755</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.117.079962</pub-id><pub-id pub-id-type="pmcid">PMC6003437</pub-id></mixed-citation></ref><ref id="cts70120-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cts70120-cit-0007">
<string-name name-style="western">
<given-names>D. G.</given-names>
<surname>Bailey</surname>
</string-name>, <string-name name-style="western">
<given-names>G. K.</given-names>
<surname>Dresser</surname>
</string-name>, <string-name name-style="western">
<given-names>B. F.</given-names>
<surname>Leake</surname>
</string-name>, and <string-name name-style="western">
<given-names>R. B.</given-names>
<surname>Kim</surname>
</string-name>, “<article-title>Naringin Is a Major and Selective Clinical Inhibitor of Organic Anion‐Transporting Polypeptide 1A2 (OATP1A2) in Grapefruit Juice</article-title>,” <source>Clinical Pharmacology and Therapeutics</source>
<volume>81</volume> (<year>2007</year>): <fpage>495</fpage>–<lpage>502</lpage>.<pub-id pub-id-type="pmid">17301733</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.clpt.6100104</pub-id></mixed-citation></ref><ref id="cts70120-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cts70120-cit-0008">
<string-name name-style="western">
<given-names>V.</given-names>
<surname>Vuksan</surname>
</string-name> and <string-name name-style="western">
<given-names>J. L.</given-names>
<surname>Sievenpiper</surname>
</string-name>, “<article-title>Herbal Remedies in the Management of Diabetes: Lessons Learned From the Study of Ginseng</article-title>,” <source>Nutrition, Metabolism, and Cardiovascular Diseases</source>
<volume>15</volume> (<year>2005</year>): <fpage>149</fpage>–<lpage>160</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.numecd.2005.05.001</pub-id><pub-id pub-id-type="pmid">15955462</pub-id></mixed-citation></ref><ref id="cts70120-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cts70120-cit-0009">
<string-name name-style="western">
<given-names>J.</given-names>
<surname>Kesavadev</surname>
</string-name>, <string-name name-style="western">
<given-names>B.</given-names>
<surname>Saboo</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Sadikot</surname>
</string-name>, et al., “<article-title>Unproven Therapies for Diabetes and Their Implications</article-title>,” <source>Advances in Therapy</source>
<volume>34</volume> (<year>2017</year>): <fpage>60</fpage>–<lpage>77</lpage>.<pub-id pub-id-type="pmid">27864668</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12325-016-0439-x</pub-id><pub-id pub-id-type="pmcid">PMC5216071</pub-id></mixed-citation></ref><ref id="cts70120-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cts70120-cit-0010">
<string-name name-style="western">
<given-names>T.</given-names>
<surname>Smith</surname>
</string-name>, <string-name name-style="western">
<given-names>H.</given-names>
<surname>Resetar</surname>
</string-name>, and <string-name name-style="western">
<given-names>C.</given-names>
<surname>Morton</surname>
</string-name>, “<article-title>US Sales of Herbal Supplements Increase by 9.7% in 2021</article-title>,” <source>HerbalGram</source>
<volume>136</volume> (<year>2022</year>): <fpage>42</fpage>–<lpage>69</lpage>.</mixed-citation></ref><ref id="cts70120-bib-0011"><label>11</label><mixed-citation publication-type="miscellaneous" id="cts70120-cit-0011">
<article-title>“National Center for Complementary and Integrative Health (NCCIH) Goldenseal,”</article-title>
<italic toggle="yes">National Center for Complementary and Integrative Health</italic> (<year>2021</year>), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://nccih.nih.gov/health/goldenseal%3e" ext-link-type="uri">https://nccih.nih.gov/health/goldenseal</ext-link>.</mixed-citation></ref><ref id="cts70120-bib-0012"><label>12</label><mixed-citation publication-type="miscellaneous" id="cts70120-cit-0012">
<string-name name-style="western">
<given-names>L.</given-names>
<surname>Shane‐McWhorter</surname>
</string-name>, <article-title>“Goldenseal,”</article-title>
<italic toggle="yes">Merck Manual</italic> (<year>2023</year>), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.merckmanuals.com/professional/special-subjects/dietary-supplements/goldenseal%3e" ext-link-type="uri">https://www.merckmanuals.com/professional/special‐subjects/dietary‐supplements/goldenseal</ext-link>.</mixed-citation></ref><ref id="cts70120-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cts70120-cit-0013">
<string-name name-style="western">
<given-names>E. D.</given-names>
<surname>Wallace</surname>
</string-name>, <string-name name-style="western">
<given-names>N. H.</given-names>
<surname>Oberlies</surname>
</string-name>, <string-name name-style="western">
<given-names>N. B.</given-names>
<surname>Cech</surname>
</string-name>, and <string-name name-style="western">
<given-names>J. J.</given-names>
<surname>Kellogg</surname>
</string-name>, “<article-title>Detection of Adulteration in <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Hydrastis canadensis</italic>
</styled-content> (Goldenseal) Dietary Supplements via Untargeted Mass Spectrometry‐Based Metabolomics</article-title>,” <source>Food and Chemical Toxicology</source>
<volume>120</volume> (<year>2018</year>): <fpage>439</fpage>–<lpage>447</lpage>.<pub-id pub-id-type="pmid">30031041</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.fct.2018.07.033</pub-id><pub-id pub-id-type="pmcid">PMC6434943</pub-id></mixed-citation></ref><ref id="cts70120-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cts70120-cit-0014">
<string-name name-style="western">
<given-names>W.</given-names>
<surname>Xie</surname>
</string-name>, <string-name name-style="western">
<given-names>F.</given-names>
<surname>Su</surname>
</string-name>, <string-name name-style="western">
<given-names>G.</given-names>
<surname>Wang</surname>
</string-name>, et al., “<article-title>Glucose‐Lowering Effect of Berberine on Type 2 Diabetes: A Systematic Review and Meta‐Analysis</article-title>,” <source>Frontiers in Pharmacology</source>
<volume>13</volume> (<year>2022</year>): <elocation-id>1015045</elocation-id>.<pub-id pub-id-type="pmid">36467075</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2022.1015045</pub-id><pub-id pub-id-type="pmcid">PMC9709280</pub-id></mixed-citation></ref><ref id="cts70120-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cts70120-cit-0015">
<string-name name-style="western">
<given-names>Y.</given-names>
<surname>Liang</surname>
</string-name>, <string-name name-style="western">
<given-names>X.</given-names>
<surname>Xu</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Yin</surname>
</string-name>, et al., “<article-title>Effects of Berberine on Blood Glucose in Patients With Type 2 Diabetes Mellitus: A Systematic Literature Review and a Meta‐Analysis</article-title>,” <source>Endocrine Journal</source>
<volume>66</volume> (<year>2019</year>): <fpage>51</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="pmid">30393248</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1507/endocrj.EJ18-0109</pub-id></mixed-citation></ref><ref id="cts70120-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cts70120-cit-0016">
<string-name name-style="western">
<given-names>X.</given-names>
<surname>Xia</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>Yan</surname>
</string-name>, <string-name name-style="western">
<given-names>Y.</given-names>
<surname>Shen</surname>
</string-name>, et al., “<article-title>Berberine Improves Glucose Metabolism in Diabetic Rats by Inhibition of Hepatic Gluconeogenesis</article-title>,” <source>PLoS One</source>
<volume>6</volume> (<year>2011</year>): <elocation-id>e16556</elocation-id>.<pub-id pub-id-type="pmid">21304897</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0016556</pub-id><pub-id pub-id-type="pmcid">PMC3033390</pub-id></mixed-citation></ref><ref id="cts70120-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cts70120-cit-0017">
<string-name name-style="western">
<given-names>B. J.</given-names>
<surname>Gurley</surname>
</string-name>, <string-name name-style="western">
<given-names>S. F.</given-names>
<surname>Gardner</surname>
</string-name>, <string-name name-style="western">
<given-names>M. A.</given-names>
<surname>Hubbard</surname>
</string-name>, et al., “<article-title>In Vivo Effects of Goldenseal, Kava Kava, Black Cohosh, and Valerian on Human Cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 Phenotypes</article-title>,” <source>Clinical Pharmacology and Therapeutics</source>
<volume>77</volume> (<year>2005</year>): <fpage>415</fpage>–<lpage>426</lpage>.<pub-id pub-id-type="pmid">15900287</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clpt.2005.01.009</pub-id><pub-id pub-id-type="pmcid">PMC1894911</pub-id></mixed-citation></ref><ref id="cts70120-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cts70120-cit-0018">
<string-name name-style="western">
<given-names>B. J.</given-names>
<surname>Gurley</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Swain</surname>
</string-name>, <string-name name-style="western">
<given-names>M. A.</given-names>
<surname>Hubbard</surname>
</string-name>, et al., “<article-title>Supplementation With Goldenseal (<styled-content style="fixed-case" toggle="no">
<italic toggle="no">Hydrastis canadensis</italic>
</styled-content>), but Not Kava Kava (<styled-content style="fixed-case" toggle="no">
<italic toggle="no">Piper methysticum</italic>
</styled-content>), Inhibits Human CYP3A Activity In Vivo</article-title>,” <source>Clinical Pharmacology and Therapeutics</source>
<volume>83</volume> (<year>2008</year>): <fpage>61</fpage>–<lpage>69</lpage>.<pub-id pub-id-type="pmid">17495878</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.clpt.6100222</pub-id></mixed-citation></ref><ref id="cts70120-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cts70120-cit-0019">
<string-name name-style="western">
<given-names>J. T.</given-names>
<surname>Nguyen</surname>
</string-name>, <string-name name-style="western">
<given-names>D. D.</given-names>
<surname>Tian</surname>
</string-name>, <string-name name-style="western">
<given-names>R. S.</given-names>
<surname>Tanna</surname>
</string-name>, et al., “<article-title>Assessing Transporter‐Mediated Natural Product–Drug Interactions via In Vitro–In Vivo Extrapolation: Clinical Evaluation With a Probe Cocktail</article-title>,” <source>Clinical Pharmacology and Therapeutics</source>
<volume>109</volume> (<year>2021</year>): <fpage>1342</fpage>–<lpage>1352</lpage>.<pub-id pub-id-type="pmid">33174626</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.2107</pub-id><pub-id pub-id-type="pmcid">PMC8058163</pub-id></mixed-citation></ref><ref id="cts70120-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cts70120-cit-0020">
<string-name name-style="western">
<given-names>K.</given-names>
<surname>Kanto</surname>
</string-name>, <string-name name-style="western">
<given-names>H.</given-names>
<surname>Ito</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Noso</surname>
</string-name>, et al., “<article-title>Effects of Dosage and Dosing Frequency on the Efficacy and Safety of High‐Dose Metformin in Japanese Patients With Type 2 Diabetes Mellitus</article-title>,” <source>Journal of Diabetes Investigation</source>
<volume>9</volume> (<year>2018</year>): <fpage>587</fpage>–<lpage>593</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jdi.12755</pub-id><pub-id pub-id-type="pmcid">PMC5934269</pub-id><pub-id pub-id-type="pmid">28963752</pub-id></mixed-citation></ref><ref id="cts70120-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cts70120-cit-0021">
<string-name name-style="western">
<given-names>K. M.</given-names>
<surname>Huttunen</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Mannila</surname>
</string-name>, <string-name name-style="western">
<given-names>K.</given-names>
<surname>Laine</surname>
</string-name>, et al., “<article-title>The First Bioreversible Prodrug of Metformin With Improved Lipophilicity and Enhanced Intestinal Absorption</article-title>,” <source>Journal of Medicinal Chemistry</source>
<volume>52</volume> (<year>2009</year>): <fpage>4142</fpage>–<lpage>4148</lpage>.<pub-id pub-id-type="pmid">19522462</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jm900274q</pub-id></mixed-citation></ref><ref id="cts70120-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cts70120-cit-0022">
<string-name name-style="western">
<given-names>W. R.</given-names>
<surname>Proctor</surname>
</string-name>, <string-name name-style="western">
<given-names>D. L.</given-names>
<surname>Bourdet</surname>
</string-name>, and <string-name name-style="western">
<given-names>D. R.</given-names>
<surname>Thakker</surname>
</string-name>, “<article-title>Mechanisms Underlying Saturable Intestinal Absorption of Metformin</article-title>,” <source>Drug Metabolism and Disposition</source>
<volume>36</volume> (<year>2008</year>): <fpage>1650</fpage>–<lpage>1658</lpage>.<pub-id pub-id-type="pmid">18458049</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.107.020180</pub-id></mixed-citation></ref><ref id="cts70120-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cts70120-cit-0023">
<string-name name-style="western">
<given-names>X.</given-names>
<surname>Liang</surname>
</string-name> and <string-name name-style="western">
<given-names>K. M.</given-names>
<surname>Giacomini</surname>
</string-name>, “<article-title>Transporters Involved in Metformin Pharmacokinetics and Treatment Response</article-title>,” <source>Journal of Pharmaceutical Sciences</source>
<volume>106</volume> (<year>2017</year>): <fpage>2245</fpage>–<lpage>2250</lpage>.<pub-id pub-id-type="pmid">28495567</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xphs.2017.04.078</pub-id></mixed-citation></ref><ref id="cts70120-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cts70120-cit-0024">
<string-name name-style="western">
<given-names>V. O.</given-names>
<surname>Oyanna</surname>
</string-name>, <string-name name-style="western">
<given-names>K. Y.</given-names>
<surname>Garcia‐Torres</surname>
</string-name>, <string-name name-style="western">
<given-names>B. J.</given-names>
<surname>Bechtold</surname>
</string-name>, et al., “<article-title>Goldenseal‐Mediated Inhibition of Intestinal Uptake Transporters Decreases Metformin Systemic Exposure in Mice</article-title>,” <source>Drug Metabolism and Disposition</source>
<volume>51</volume> (<year>2023</year>): <fpage>1483</fpage>–<lpage>1489</lpage>, <pub-id pub-id-type="doi">10.1124/dmd.123.001360</pub-id>.<pub-id pub-id-type="pmid">37562957</pub-id>
<pub-id pub-id-type="pmcid">PMC10586506</pub-id></mixed-citation></ref><ref id="cts70120-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cts70120-cit-0025">
<string-name name-style="western">
<given-names>O.</given-names>
<surname>Scherf‐Clavel</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Kinzig</surname>
</string-name>, <string-name name-style="western">
<given-names>M. S.</given-names>
<surname>Stoffel</surname>
</string-name>, <string-name name-style="western">
<given-names>U.</given-names>
<surname>Fuhr</surname>
</string-name>, and <string-name name-style="western">
<given-names>F.</given-names>
<surname>Sörgel</surname>
</string-name>, “<article-title>A HILIC‐MS/MS Assay for the Quantification of Metformin and Sitagliptin in Human Plasma and Urine: A Tool for Studying Drug Transporter Perturbation</article-title>,” <source>Journal of Pharmaceutical and Biomedical Analysis</source>
<volume>175</volume> (<year>2019</year>): <elocation-id>112754</elocation-id>.<pub-id pub-id-type="pmid">31336285</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpba.2019.07.002</pub-id></mixed-citation></ref><ref id="cts70120-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="cts70120-cit-0026">
<string-name name-style="western">
<given-names>A.</given-names>
<surname>Frid</surname>
</string-name>, <string-name name-style="western">
<given-names>G. N.</given-names>
<surname>Sterner</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Löndahl</surname>
</string-name>, et al., “<article-title>Novel Assay of Metformin Levels in Patients With Type 2 Diabetes and Varying Levels of Renal Function: Clinical Recommendations</article-title>,” <source>Diabetes Care</source>
<volume>33</volume> (<year>2010</year>): <fpage>1291</fpage>–<lpage>1293</lpage>.<pub-id pub-id-type="pmid">20215446</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc09-1284</pub-id><pub-id pub-id-type="pmcid">PMC2875440</pub-id></mixed-citation></ref><ref id="cts70120-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cts70120-cit-0027">
<string-name name-style="western">
<given-names>T. M.</given-names>
<surname>Wallace</surname>
</string-name>, <string-name name-style="western">
<given-names>J. C.</given-names>
<surname>Levy</surname>
</string-name>, and <string-name name-style="western">
<given-names>D. R.</given-names>
<surname>Matthews</surname>
</string-name>, “<article-title>Use and Abuse of HOMA Modeling</article-title>,” <source>Diabetes Care</source>
<volume>27</volume> (<year>2004</year>): <fpage>1487</fpage>–<lpage>1495</lpage>.<pub-id pub-id-type="pmid">15161807</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diacare.27.6.1487</pub-id></mixed-citation></ref><ref id="cts70120-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cts70120-cit-0028">
<string-name name-style="western">
<given-names>N. C.</given-names>
<surname>Sambol</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>Chiang</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>O'Conner</surname>
</string-name>, et al., “<article-title>Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Subjects and Patients With Noninsulin‐Dependent Diabetes Mellitus</article-title>,” <source>Journal of Clinical Pharmacology</source>
<volume>36</volume> (<year>1996</year>): <fpage>1012</fpage>–<lpage>1021</lpage>.<pub-id pub-id-type="pmid">8973990</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/009127009603601105</pub-id></mixed-citation></ref><ref id="cts70120-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cts70120-cit-0029">
<string-name name-style="western">
<given-names>G. T.</given-names>
<surname>Tucker</surname>
</string-name>, <string-name name-style="western">
<given-names>C.</given-names>
<surname>Casey</surname>
</string-name>, <string-name name-style="western">
<given-names>P. J.</given-names>
<surname>Phillips</surname>
</string-name>, <string-name name-style="western">
<given-names>H.</given-names>
<surname>Connor</surname>
</string-name>, <string-name name-style="western">
<given-names>J. D.</given-names>
<surname>Ward</surname>
</string-name>, and <string-name name-style="western">
<given-names>H. F.</given-names>
<surname>Woods</surname>
</string-name>, “<article-title>Metformin Kinetics in Healthy Subjects and in Patients With Diabetes Mellitus</article-title>,” <source>British Journal of Clinical Pharmacology</source>
<volume>12</volume> (<year>1981</year>): <fpage>235</fpage>–<lpage>246</lpage>.<pub-id pub-id-type="pmid">7306436</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1981.tb01206.x</pub-id><pub-id pub-id-type="pmcid">PMC1401849</pub-id></mixed-citation></ref><ref id="cts70120-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="cts70120-cit-0030">
<string-name name-style="western">
<given-names>A. J.</given-names>
<surname>Scheen</surname>
</string-name>, “<article-title>Clinical Pharmacokinetics of Metformin</article-title>,” <source>Clinical Pharmacokinetics</source>
<volume>30</volume> (<year>1996</year>): <fpage>359</fpage>–<lpage>371</lpage>.<pub-id pub-id-type="pmid">8743335</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-199630050-00003</pub-id></mixed-citation></ref><ref id="cts70120-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="cts70120-cit-0031">
<string-name name-style="western">
<given-names>E. J.</given-names>
<surname>Johnson</surname>
</string-name>, <string-name name-style="western">
<given-names>V.</given-names>
<surname>González‐Peréz</surname>
</string-name>, <string-name name-style="western">
<given-names>D. D.</given-names>
<surname>Tian</surname>
</string-name>, et al., “<article-title>Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Product–Drug Interactions: A NaPDI Center Recommended Approach</article-title>,” <source>Drug Metabolism and Disposition</source>
<volume>46</volume> (<year>2018</year>): <fpage>1046</fpage>–<lpage>1052</lpage>.<pub-id pub-id-type="pmid">29735752</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.118.081273</pub-id><pub-id pub-id-type="pmcid">PMC6003438</pub-id></mixed-citation></ref><ref id="cts70120-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="cts70120-cit-0032">
<string-name name-style="western">
<given-names>D.</given-names>
<surname>Safari</surname>
</string-name>, <string-name name-style="western">
<given-names>E. C.</given-names>
<surname>DeMarco</surname>
</string-name>, <string-name name-style="western">
<given-names>L.</given-names>
<surname>Scanlon</surname>
</string-name>, and <string-name name-style="western">
<given-names>G. T.</given-names>
<surname>Grossberg</surname>
</string-name>, “<article-title>Over‐The‐Counter Remedies in Older Adults: Patterns of Use, Potential Pitfalls, and Proposed Solutions</article-title>,” <source>Clinics in Geriatric Medicine</source>
<volume>38</volume> (<year>2022</year>): <fpage>99</fpage>–<lpage>118</lpage>.<pub-id pub-id-type="pmid">34794706</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cger.2021.07.005</pub-id></mixed-citation></ref><ref id="cts70120-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cts70120-cit-0033">
<string-name name-style="western">
<given-names>Y.</given-names>
<surname>Shirasaka</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Seki</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Hatakeyama</surname>
</string-name>, et al., “<article-title>Multiple Transport Mechanisms Involved in the Intestinal Absorption of Metformin: Impact on the Nonlinear Absorption Kinetics</article-title>,” <source>Journal of Pharmaceutical Sciences</source>
<volume>111</volume> (<year>2022</year>): <fpage>1531</fpage>–<lpage>1541</lpage>.<pub-id pub-id-type="pmid">35090865</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xphs.2022.01.008</pub-id></mixed-citation></ref><ref id="cts70120-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cts70120-cit-0034">
<string-name name-style="western">
<given-names>T.</given-names>
<surname>Han</surname>
</string-name>, <string-name name-style="western">
<given-names>W. R.</given-names>
<surname>Proctor</surname>
</string-name>, <string-name name-style="western">
<given-names>C. L.</given-names>
<surname>Costales</surname>
</string-name>, <string-name name-style="western">
<given-names>H.</given-names>
<surname>Cai</surname>
</string-name>, <string-name name-style="western">
<given-names>R. S.</given-names>
<surname>Everett</surname>
</string-name>, and <string-name name-style="western">
<given-names>D. R.</given-names>
<surname>Thakker</surname>
</string-name>, “<article-title>Four Cation‐Selective Transporters Contribute to Apical Uptake and Accumulation of Metformin in Caco‐2 Cell Monolayerss</article-title>,” <source>Journal of Pharmacology and Experimental Therapeutics</source>
<volume>352</volume> (<year>2015</year>): <fpage>519</fpage>–<lpage>528</lpage>.<pub-id pub-id-type="pmid">25563903</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.114.220350</pub-id><pub-id pub-id-type="pmcid">PMC4352590</pub-id></mixed-citation></ref><ref id="cts70120-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="cts70120-cit-0035">
<string-name name-style="western">
<given-names>R.</given-names>
<surname>Shi</surname>
</string-name>, <string-name name-style="western">
<given-names>Z.</given-names>
<surname>Xu</surname>
</string-name>, <string-name name-style="western">
<given-names>X.</given-names>
<surname>Xu</surname>
</string-name>, et al., “<article-title>Organic Cation Transporter and Multidrug and Toxin Extrusion 1 Co‐Mediated Interaction Between Metformin and Berberine</article-title>,” <source>European Journal of Pharmaceutical Sciences</source>
<volume>127</volume> (<year>2019</year>): <fpage>282</fpage>–<lpage>290</lpage>.<pub-id pub-id-type="pmid">30428337</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejps.2018.11.010</pub-id></mixed-citation></ref><ref id="cts70120-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="cts70120-cit-0036">
<string-name name-style="western">
<given-names>M.</given-names>
<surname>Kwon</surname>
</string-name>, <string-name name-style="western">
<given-names>Y. A.</given-names>
<surname>Choi</surname>
</string-name>, <string-name name-style="western">
<given-names>M.‐K.</given-names>
<surname>Choi</surname>
</string-name>, and <string-name name-style="western">
<given-names>I.‐S.</given-names>
<surname>Song</surname>
</string-name>, “<article-title>Organic Cation Transporter‐Mediated Drug–Drug Interaction Potential Between Berberine and Metformin</article-title>,” <source>Archives of Pharmacal Research</source>
<volume>38</volume> (<year>2015</year>): <fpage>849</fpage>–<lpage>856</lpage>.<pub-id pub-id-type="pmid">25359200</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12272-014-0510-6</pub-id></mixed-citation></ref><ref id="cts70120-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="cts70120-cit-0037">
<string-name name-style="western">
<given-names>J.</given-names>
<surname>Yin</surname>
</string-name>, <string-name name-style="western">
<given-names>H.</given-names>
<surname>Xing</surname>
</string-name>, and <string-name name-style="western">
<given-names>J.</given-names>
<surname>Ye</surname>
</string-name>, “<article-title>Efficacy of Berberine in Patients With Type 2 Diabetes Mellitus</article-title>,” <source>Metabolism</source>
<volume>57</volume> (<year>2008</year>): <fpage>712</fpage>–<lpage>717</lpage>.<pub-id pub-id-type="pmid">18442638</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.metabol.2008.01.013</pub-id><pub-id pub-id-type="pmcid">PMC2410097</pub-id></mixed-citation></ref><ref id="cts70120-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="cts70120-cit-0038">
<string-name name-style="western">
<given-names>H.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>Wei</surname>
</string-name>, <string-name name-style="western">
<given-names>R.</given-names>
<surname>Xue</surname>
</string-name>, et al., “<article-title>Berberine Lowers Blood Glucose in Type 2 Diabetes Mellitus Patients Through Increasing Insulin Receptor Expression</article-title>,” <source>Metabolism</source>
<volume>59</volume> (<year>2010</year>): <fpage>285</fpage>–<lpage>292</lpage>.<pub-id pub-id-type="pmid">19800084</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.metabol.2009.07.029</pub-id></mixed-citation></ref><ref id="cts70120-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="cts70120-cit-0039">
<string-name name-style="western">
<given-names>N.</given-names>
<surname>Furusyo</surname>
</string-name> and <string-name name-style="western">
<given-names>J.</given-names>
<surname>Hayashi</surname>
</string-name>, “<article-title>Glycated Albumin and Diabetes Mellitus</article-title>,” <source>Biochimica et Biophysica Acta</source>
<volume>1830</volume> (<year>2013</year>): <fpage>5509</fpage>–<lpage>5514</lpage>.<pub-id pub-id-type="pmid">23673238</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbagen.2013.05.010</pub-id></mixed-citation></ref><ref id="cts70120-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="cts70120-cit-0040">
<string-name name-style="western">
<given-names>F. C.</given-names>
<surname>Chume</surname>
</string-name>, <string-name name-style="western">
<given-names>M. H.</given-names>
<surname>Kieling</surname>
</string-name>, <string-name name-style="western">
<given-names>P. A.</given-names>
<surname>Correa Freitas</surname>
</string-name>, <string-name name-style="western">
<given-names>G.</given-names>
<surname>Cavagnolli</surname>
</string-name>, and <string-name name-style="western">
<given-names>J. L.</given-names>
<surname>Camargo</surname>
</string-name>, “<article-title>Glycated Albumin as a Diagnostic Tool in Diabetes: An Alternative or an Additional Test?</article-title>,” <source>PLoS One</source>
<volume>14</volume> (<year>2019</year>): <elocation-id>e0227065</elocation-id>.<pub-id pub-id-type="pmid">31891628</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0227065</pub-id><pub-id pub-id-type="pmcid">PMC6938306</pub-id></mixed-citation></ref></ref-list></back></article><article xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Med Surg (Lond)</journal-id><journal-id journal-id-type="iso-abbrev">Ann Med Surg (Lond)</journal-id><journal-id journal-id-type="pmc-domain-id">2638</journal-id><journal-id journal-id-type="pmc-domain">amsu</journal-id><journal-id journal-id-type="publisher-id">MS9</journal-id><journal-title-group><journal-title>Annals of Medicine and Surgery</journal-title></journal-title-group><issn pub-type="epub">2049-0801</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12333786</article-id><article-id pub-id-type="pmcid-ver">PMC12333786.1</article-id><article-id pub-id-type="pmcaid">12333786</article-id><article-id pub-id-type="pmcaiid">12333786</article-id><article-id pub-id-type="pmid">40787499</article-id><article-id pub-id-type="doi">10.1097/MS9.0000000000003459</article-id><article-id pub-id-type="publisher-id">AMSU-D-24-02240</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Cross-sectional Study</subject></subj-group></article-categories><title-group><article-title>Comparative evaluation of quality attributes among six different brands of metformin hydrochloride tablets marketed in Bahir Dar city, Ethiopia</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4921-6526</contrib-id><name name-style="western"><surname>Siraj</surname><given-names initials="EA">Ebrahim Abdela</given-names></name><degrees>MSc</degrees><email>ibrahim.abdela2008@gmail.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1598-8395</contrib-id><name name-style="western"><surname>Ambaye</surname><given-names initials="AS">Abyou Seyfu</given-names></name><degrees>MSc</degrees><email>aseyfu7@gmail.com</email><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tebabal</surname><given-names initials="AT">Adugna Tasew</given-names></name><degrees>MD</degrees><email>adullatt21@gmail.com</email><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tafere</surname><given-names initials="C">Chernet</given-names></name><degrees>MSc</degrees><email>cheru004@gmail.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tessema</surname><given-names initials="TA">Tewodros Ayalew</given-names></name><degrees>MSc</degrees><email>tayalew950@gmail.com</email><xref rid="aff4" ref-type="aff">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zewdie</surname><given-names initials="S">Segenet</given-names></name><degrees>MSc</degrees><email>segenetzewdie@gmail.com</email><xref rid="aff5" ref-type="aff">
<sup>e</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mekuria</surname><given-names initials="B">Basazinew</given-names></name><degrees>MSc</degrees><email>basazinewmekuria@gmail.com</email><xref rid="aff5" ref-type="aff">
<sup>e</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yimer</surname><given-names initials="S">Selamawit</given-names></name><degrees>MSc</degrees><email>selamy67@gmail.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Addisu</surname><given-names initials="ZD">Zenaw Debasu</given-names></name><degrees>MSc</degrees><email>zenawdebasu@yahoo.co.uk</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yayehrad</surname><given-names initials="AT">Ashagrachew Tewabe</given-names></name><degrees>MSc</degrees><email>ashutewabe@gmail.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><aff id="aff1"><label>a</label>Department of Pharmacy, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia</aff><aff id="aff2"><label>b</label>Department of Pharmacy, Asrat Woldeyes Health Science Campus, Debre Berhan University, Debre Berhan, Ethiopia</aff><aff id="aff3"><label>c</label>School of Medicine, GAMBY Medical and Business College, Bahirdar, Ethiopia</aff><aff id="aff4"><label>d</label>Department of Pharmaceutics and Social Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia</aff><aff id="aff5"><label>e</label>Department of Pharmacy, College of Medicine and Health Sciences, Injibara University, Injibara, Ethiopia</aff></contrib-group><author-notes><corresp id="COR0001"><label>*</label>Corresponding author. Address: Department of Pharmacy, Asrat Woldeyes Health Science Campus, Debre Berhan University, PO BOX 445, Debre Berhan, Ethiopia. Tel.: +251 910685947. E-mail: <email>aseyfu7@gmail.com</email> (A. S. Ambaye).</corresp></author-notes><pub-date pub-type="collection"><month>8</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>16</day><month>6</month><year>2025</year></pub-date><volume>87</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">494674</issue-id><fpage>4888</fpage><lpage>4896</lpage><history><date date-type="received"><day>22</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>17</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>16</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>08</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-08-11 15:25:18.320"><day>11</day><month>08</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution-Non Commercial License 4.0</ext-link> (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ms9-87-4888.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ms9-87-4888.pdf"/><abstract><p>The prevalence of chronic disease such as diabetes is increasing in developing countries like Ethiopia. Metformin has been the most widely used first-line agent for the treatment of type II diabetes for more than 10 decades. Generic substitution is a common practice in community pharmacies. Therefore, ongoing bioequivalence evaluations are needed to ensure therapeutic equivalence among the brands. The main objective of this study is to evaluate and compare the common physicochemical properties and drug release profiles of six brands of metformin HCL 500 mg tablets available in community drug retailers in Bahir Dar city, Ethiopia. To achieve this objective, official and non-official compendial tests were conducted among the sampled brands. The results of the analysis demonstrated that all tested products complied with the specifications of the main test parameters as stipulated in the pharmacopoeias. Hence, the available brands can be regarded as acceptable substitutes for each other. However, an <italic toggle="yes">in vivo</italic> bioequivalence study may be needed for a final assessment of the similarity in efficacy of the generic formulations. Strict abidance to regulatory recommendations and progressive post-market surveillance are still required to promote the rational use of branded drugs and ensure safe and effective pharmacotherapy.</p></abstract><kwd-group><kwd>Bahir Dar city</kwd><kwd><italic toggle="yes">in vitro</italic> evaluation</kwd><kwd>metformin HCl tablet</kwd><kwd>quality</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Diabetes mellitus (DM) is a commonly known non-transmissible chronic disease that causes significant public health concern for both developed and developing nations around the world. The disease significantly affects insulin release and sensitivity<sup>[</sup><xref rid="R1" ref-type="bibr">1</xref><sup>-</sup><xref rid="R3" ref-type="bibr">3</xref><sup>]</sup>. There are two main types of diabetes: type 1 DM and type 2 DM. Type 2 DM is the most common form of diabetes and a rapidly growing health concern in both developed and developing nations. It accounts for 90–95% of all people with diabetes and is expected to increase to 439 million by 2030<sup>[</sup><xref rid="R3" ref-type="bibr">3</xref><sup>]</sup>. The World Health Organization (WHO) has reported that diabetes was responsible for over 6.7 million deaths in 2021, highlighting the severity of the disease’s impact on global health. Notably, type 2 diabetes comprises over 90% of all diabetes cases, driven largely by lifestyle factors such as unhealthy diets, physical inactivity, and obesity. The burden of the disease is particularly acute in low- and middle-income countries, where health care systems often struggle to manage the growing numbers of patients, and the African continent is expected to experience one of the most dramatic increases in prevalence. These alarming statistics underscore the urgent need for comprehensive strategies in diabetes prevention, early diagnosis, and effective management on a global scale<sup>[</sup><xref rid="R4" ref-type="bibr">4</xref><sup>]</sup> The higher prevalence of diabetes may be associated with obesity, age-related problems, life style and lack of physical exercise. Currently, it has become a major cause of morbidity and mortality worldwide due to associated medical complications such as cardiovascular problems, kidney disease, and eye- and nerve-related diseases<sup>[</sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref><sup>]</sup>.<boxed-text id="UBT0001" position="float" orientation="portrait"><sec><title>HIGHLIGHTS</title><p>
<list list-type="bullet"><list-item><p>Conducted a detailed evaluation of six brands of metformin hydrochloride tablets marketed in Bahir Dar city.</p></list-item><list-item><p>Physicochemical properties, such as weight variation, hardness, friability, disintegration, and dissolution, were tested.</p></list-item><list-item><p>All brands were assessed for compliance with pharmacopoeial standards (British Pharmacopoeia/United States Pharmacopoeia).</p></list-item><list-item><p>Significant variation was observed in the dissolution profiles; however, all brands released the required percentage of the drug within the acceptable time frame.</p></list-item><list-item><p>Suggested the need for better regulatory oversight and periodic quality assurance to ensure the consistent therapeutic efficacy of marketed brands.</p></list-item></list></p></sec></boxed-text></p><p>Nowadays, several drugs are available on the market to be administered through different routes to control DM. In this regard, the oral route is found to be the preferred option due to its convenience and easiness<sup>[</sup><xref rid="R7" ref-type="bibr">7</xref><sup>]</sup>. Metformin is one of the oral antidiabetic medications used to treat type II (non-insulin-dependent) DM. It improves insulin sensitivity, decreases fasting and random blood glucose levels, minimizes glucose production in the liver, and reduces its absorption in the gastrointestinal tract<sup>[</sup><xref rid="R8" ref-type="bibr">8</xref><sup>]</sup>. Metformin does not cause hypoglycemia or hyperinsulinemia. It belongs to the biguanide group of drugs and is chemically known as 3-(diaminomethylidene)-1,1-dimethylguanidine. It is soluble in water and practically insoluble in acetone. Under fasting conditions, the bio availability of an orally administered 500 mg metformin tablet reaches around 50–60%. It exhibits insignificant plasma binding properties, has a half-life of 2.5 hours, and a volume of distribution of 63–276 L<sup>[</sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref><sup>]</sup>.</p><p>The Food and Drug Authority (FDA) revealed that a drug product is considered pharmaceutically equivalent when it contains the same active ingredient(s), the same dosage form, the same route of administration, and identical strength or concentration. Pharmaceutical products are considered to be therapeutically equivalent only when they are pharmaceutically equivalent. As is well known, safety and efficacy are not separable concepts from the quality of pharmaceutical products<sup>[</sup><xref rid="R2" ref-type="bibr">2</xref><sup>]</sup>. Many of the quality control tests investigate the quality of medicines during production and in the final product batches. Generic drugs contain similar chemical entities but differ in color, shape, excipients, and manufacturing process<sup>[</sup><xref rid="R11" ref-type="bibr">11</xref><sup>]</sup>. Dissolution testing plays a key role as a quality control parameter in assessing batch-to-batch consistency of drug release from a dosage form. It is also used as a qualitative and quantitative tool, which can provide important information about the bioavailability of a drug<sup>[</sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R12" ref-type="bibr">12</xref><sup>]</sup>. According to a study conducted in Jimma Town, Ethiopia, on available metformin brands in the market using in vitro testing approaches, all brands showed no signs of counterfeiting or substandard products and can be utilized interchangeably. However, only the Insumet brand failed to fulfill the United States Pharmacopoeia (USP) specification for the weight variation test<sup>[</sup><xref rid="R3" ref-type="bibr">3</xref><sup>]</sup>.</p><p>The availability of multisource generic medicines may pose a problem for health care providers in selecting equivalent products. While it is helpful in increasing the accessibility of some medicines and reducing costs, it also addresses affordability issues for some important pharmaceutical products. However, despite these positive impacts, it contributes to the production of fake, substandard, and counterfeit pharmaceutical products<sup>[</sup><xref rid="R13" ref-type="bibr">13</xref><sup>]</sup>. Though the impact of counterfeit medication is significant, it is poorly reported and predominantly affects developing countries, which could depreciate the reliability and accountability of pharmaceutical products and the health care system. According to reports from the WHO, nearly 30% of medication consumed in Africa and parts of Asia consists of counterfeit or substandard products<sup>[</sup><xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R15" ref-type="bibr">15</xref><sup>]</sup>. Both generic and brand-name pharmaceutical products are susceptible to counterfeiting, which may involve genuine or incorrect active ingredients, insufficient active ingredients, or false packaging<sup>[</sup><xref rid="R12" ref-type="bibr">12</xref><sup>]</sup>. Under quality control testing, these counterfeit products fail to meet pharmacopoeial specifications and the quality standards claimed by manufacturers. Numerous studies have indicated that substandard or counterfeit products result in treatment failures for many infectious diseases<sup>[</sup><xref rid="R14" ref-type="bibr">14</xref><sup>]</sup>. The aim of this investigation is to assess various brands of metformin hydrochloride tablets available in the Bahir Dar, Ethiopian market. Their physical, chemical, and pharmaceutical quality standards were checked and compared with official specifications.</p></sec><sec><title>Experimental</title><sec><title>Materials</title><sec><title>Chemicals, reagents, and solvents</title><p>Metformin HCl, with a labeled strength of 500 mg tablets from six different brands (coded A to F), was purchased from registered community drug retailers in Bahir Dar city, Ethiopia. The Metformin reference standard was obtained from the Ethiopian Food and Drug Authority (EFDA). Chemicals such as NaOH pellets (Guangdong Guanghua Sci-Tech Co., Ltd, China) and potassium dihydrogen orthophosphate (Guangdong Guanghua Sci-Tech Co., Ltd, China) were purchased from the market. Freshly prepared distilled water was used throughout the work. The reagents used were analytical grades, and the study was performed within the products’ expiration dates.</p></sec><sec><title>Instruments, apparatus, and equipment</title><p>The instruments used during the study include a disintegration apparatus (ERWEKA, Germany), a dissolution testing apparatus (ERWEKA, Germany), a UV–Vis spectrophotometer (ERWEKA, T80+ Spectrophotometry, Double Beam, Ver 3.3, PG Instruments Ltd), Whatman filtration equipment (0.45 μm PVDF W/GMF), a disintegration apparatus (ERWEKA, Germany), a hardness tester (Sotax HT, Model: HT 1500 N, Switzerland), a thickness tester (Sotax HT, Model: HT 1500 N, Switzerland), a friability tester (FTA-023, Single Drum, India), weighing balances, a pH meter, beakers, filter paper, a water bath, ovens, cuvettes, flasks, pipettes, measuring cylinders, and a mortar and pestle.</p></sec></sec><sec sec-type="methods"><title>Method</title><sec><title>Study area and period</title><p>This study was conducted in community drug retail outlets (drug stores and pharmacies) in Bahir Dar city, the capital city of Amhara Regional State, Ethiopia, which is located 565 km northwest of the capital city, Addis Ababa. The study setting included all registered community drug retailers in the city. There are 6 sub-cities, and within these sub-cities, there are 3 governmental hospitals (2 tertiary-level and 1 primary), 10 governmental health centers, more than 4 private hospitals (primary and general), more than 22 private clinics (medium and specialized), more than 28 pharmaceutical wholesalers, and over 140 community drug retail outlets (75 pharmacies and 65 drug stores). The city has an estimated projected population of 455 901 people, of whom 227 712 are females, as of 2022<sup>[</sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref><sup>]</sup>. A systematic review and meta-analysis on the prevalence and risk factors of type 2 DM in Ethiopia demonstrated that the pooled prevalence of DM in Ethiopia is 6.5%<sup>[</sup><xref rid="R18" ref-type="bibr">18</xref><sup>]</sup>. Recent study reports indicated that the prevalence of DM in Bahir Dar city is estimated to be 7.5% for diagnosed cases and 10.2% for undiagnosed adult cases<sup>[</sup><xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R20" ref-type="bibr">20</xref><sup>]</sup>. A laboratory-based cross-sectional study was conducted from March to June 2022. The reason for selecting this study area was the high population density, the higher prevalence of diagnosed and undiagnosed diabetic cases, and the availability of a large number of community pharmacies, drug stores, wholesalers, and private health organizations (hospitals and clinics). Hence, many clients have access to both prescribed and non-prescribed (over-the-counter) drugs in the study area. Most of the governmental and community pharmacies in the Amhara region purchase pharmaceuticals from this city, as it is the center and capital of the second most densely populated region in Ethiopia.</p></sec><sec><title>Sampling and sample size determination</title><p>Sampling design, sampling, and sample size determination were adapted with some modifications from a previous study conducted by Abebe <italic toggle="yes">et al</italic><sup>[</sup><xref rid="R17" ref-type="bibr">17</xref><sup>]</sup>. The number of available metformin HCl tablet brands in Bahir Dar city during the study period was determined after conducting surveillance in community pharmacies prior to the actual data collection. Six brands (four imported and two manufactured in Ethiopia) were found to be available in the market during the surveillance. These six brands of the drug were selected based on their widespread availability in the market, high prescription rates, and frequent use by patients. This selection ensured a representative assessment of commonly used formulations. Subsequently, all the registered community drug shops were listed alphabetically, numbered, and coded. To avoid repetition of drugs to be sampled, 15 community pharmacies (10 pharmacies and 5 drug stores) were randomly selected using a lottery method. Pharmacy personnel, who were trained and acted as simulated caregivers, visited each of the selected community pharmacies with a prescription for metformin tablets. For each brand, a total of 120 tablets were purchased from the selected community pharmacies. After collection, all samples were subjected to visual inspection, and the collected samples were then randomly coded from “A” to “F” and immediately registered with their expiration dates, batch numbers, manufacturers, and countries of origin. The samples were kept in their original packaging, transported to Bahir Dar, EFDA laboratory of drug quality, and stored under the storage conditions specified on the label of each product until analysis. Detailed information about the samples is presented in Table <xref rid="T1" ref-type="table">1</xref>. The experimental work was conducted at the laboratories of EFDA, Bahir Dar office, and the pharmaceutical laboratory rooms of GAMBY Medical and Business College, Bahir Dar, North-West Ethiopia. To ensure accuracy and reproducibility, all analytical instruments were calibrated before use following standard protocols. The validation of test methods was conducted in accordance with pharmacopoeial guidelines, including assessments of linearity, precision, accuracy, and robustness.
<table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>The coding and details of products used for the study</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Product code</th><th align="center" rowspan="1" colspan="1">Country</th><th align="center" rowspan="1" colspan="1">Batch number</th><th align="center" rowspan="1" colspan="1">Expiration date</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">Cyprus</td><td align="left" rowspan="1" colspan="1">A5k111</td><td align="left" rowspan="1" colspan="1">October 2026</td></tr><tr><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">India</td><td align="left" rowspan="1" colspan="1">BNT0122078</td><td align="left" rowspan="1" colspan="1">December 2024</td></tr><tr><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">Germany</td><td align="left" rowspan="1" colspan="1">AES</td><td align="left" rowspan="1" colspan="1">September 2024</td></tr><tr><td align="left" rowspan="1" colspan="1">D</td><td align="left" rowspan="1" colspan="1">Cyprus</td><td align="left" rowspan="1" colspan="1">93627</td><td align="left" rowspan="1" colspan="1">March 2026</td></tr><tr><td align="left" rowspan="1" colspan="1">E</td><td align="left" rowspan="1" colspan="1">Ethiopia</td><td align="left" rowspan="1" colspan="1">D22018T218</td><td align="left" rowspan="1" colspan="1">August 2025</td></tr><tr><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">Ethiopia</td><td align="left" rowspan="1" colspan="1">01823120010</td><td align="left" rowspan="1" colspan="1">December 2026</td></tr></tbody></table></table-wrap>
</p></sec></sec><sec sec-type="methods"><title><italic toggle="yes">In vitro</italic> quality control test methods</title><p>The collected brands of metformin HCl 500 mg tablets were tested for uniformity of dosage units, friability, hardness, thickness, disintegration time, dissolution, and assay according to procedures described in the USP<sup>[</sup><xref rid="R17" ref-type="bibr">17</xref><sup>]</sup>. The similarity in the % dissolution among the different brands of the formulations was also computed.</p><sec><title>Thickness</title><p>Ten tablets were taken from each batch to assess the thickness of metformin tablets using a tablet caliper slide scale (Sotax HT, Model: HT 1500 N, Switzerland). The results from the measurements were presented as the mean and standard deviation<sup>[</sup><xref rid="R21" ref-type="bibr">21</xref><sup>]</sup>.</p></sec><sec><title>Hardness</title><p>The tablet hardness was examined by randomly taking 10 tablets from each brand using a hardness tester (Sotax HT, Model: HT 1500 N, Switzerland). Each tablet was placed between the anvils, and the force required to break the tablet was measured. The results of the crushing force required were presented as the mean and standard deviation<sup>[</sup><xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R22" ref-type="bibr">22</xref><sup>]</sup>.</p></sec><sec><title>Friability</title><p>Initially, the weight of twenty metformin HCl tablets was measured using an electronic balance after de-dusting them, and they were placed into a friability tester (FTA-023, Single Drum, India) set to 100 revolutions in 4 minutes. After removing the tablets from the friability drum, the tablets were de-dusted, and the percentage weight loss was evaluated using the equation (<xref rid="M0001" ref-type="disp-formula">Eq. 1</xref>) depicted below<sup>[</sup><xref rid="R23" ref-type="bibr">23</xref><sup>]</sup>.
<disp-formula id="M0001"><label>(1)</label>
<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">%</mml:mi><mml:mi mathvariant="normal">F</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">y</mml:mi></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mspace width="thickmathspace"/><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:mrow><mml:mo>−</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">F</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mspace width="thickmathspace"/><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mspace width="thickmathspace"/><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:mfrac></mml:mrow><mml:mo>×</mml:mo><mml:mn>100</mml:mn></mml:math></disp-formula></p></sec><sec><title>Weight variation test</title><p>The weight variation test was conducted by taking twenty tablets from each batch and weighing them individually using a digital analytical electronic balance. The results for the individual tablets were presented as the mean weight and standard deviation<sup>[</sup><xref rid="R21" ref-type="bibr">21</xref><sup>]</sup>.</p></sec><sec><title>Disintegration test</title><p>The disintegration test was conducted using beakers containing 900 ml of dissolution medium (distilled water) at 37 ± 0.5°C. Afterward, the tablets were placed in the basket rack and set into the disintegration apparatus (ERWEKA, Germany). The time required for disintegration was then measured and presented as the mean value and standard deviation<sup>[</sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R24" ref-type="bibr">24</xref><sup>]</sup>.</p></sec><sec><title>Construction of a calibration curve for metformin hydrochloride</title><p>The calibration curve was constructed using a metformin HCl reference standard solution with various concentrations derived from the stock solution (2, 3, 4, 5, 6, and 7 μg/ml) in phosphate buffer as the medium (pH = 6.8). The absorbance was evaluated at the λ max of 233 nm using a UV-Visible spectrometer (ERWEKA, T80+ Spectrophotometry, Double Beam, Ver 3.3, PG Instruments Ltd).</p></sec><sec><title><italic toggle="yes">In vitro</italic> drug release study</title><p>The dissolution test for metformin tablets was evaluated using USP apparatus II (paddle method). Six tablets were taken from each batch, and the dissolution medium (phosphate buffer) was used in a beaker containing 900 ml at pH 6.8 and 37 ± 0.5℃. The paddle method was employed, with the rotation set at 50 rpm. The sample was filtered using Whatman filtration equipment (0.45 μm PVDF W/GMF) after taking sample solutions (5 ml) at 10, 20, 30, 45, 60, 75, and 90 minutes. Proper dilution was then made, and the absorbance was recorded using a UV/Vis spectrophotometer at 233 nm. The dissolution medium was utilized as a blank. The amount of drug released at each time point was assessed using a calibration curve, and the drug release profile was statistically analyzed<sup>[</sup><xref rid="R6" ref-type="bibr">6</xref><sup>]</sup>.</p></sec><sec><title>Similarity (f2) factor</title><p>The similarity factor (f2) is a logarithmic reciprocal square root transformation of the sum of squared errors and is a measurement of the similarity in the % dissolution between two curves. The following equation (<xref rid="M0002" ref-type="disp-formula">Eq. 2)</xref> was used to calculate f2 from the results of <italic toggle="yes">in vitro</italic> drug release.
<disp-formula id="M0002"><label>(2)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M2" overflow="scroll"><mml:mrow><mml:mi>f</mml:mi><mml:mn>2</mml:mn><mml:mo>=</mml:mo><mml:mn>50</mml:mn><mml:mi>log</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mi>n</mml:mi><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>r</mml:mi><mml:mi>t</mml:mi><mml:mo>−</mml:mo><mml:mi>T</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mstyle><mml:mo>×</mml:mo><mml:mn>100</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math>
</disp-formula></p><p>where Rt and Tt are the cumulative percentages of the dissolved drug for the reference and test formulations at time t, respectively, and n is the number of time points.</p></sec><sec><title>Assay of metformin HCl tablets</title><p>The assay test was conducted as per USP guidelines to determine the actual amount of active ingredient present in the tablets of each brand compared with the labeled amount. First, a 10 μg/ml concentration of metformin HCl reference standard in water was prepared as a standard solution from the prepared stock solution (500 μg/ml). Then, a sample solution was prepared by taking samples from each brand. Twenty tablets of each brand of metformin hydrochloride tablets were weighed and finely powdered. A quantity of the powder equivalent to 100 mg of metformin HCl was weighed and transferred into a 100-ml volumetric flask and dissolved in about 70 ml of water. After mechanically shaking for 15 minutes, it was diluted with water to volume and filtered using Whatman filter paper. Ten milliliter of the filtrate was diluted with water to 100 ml after discarding the first 20 ml of the filtrate. Finally, 10 ml of the resulting solution was further diluted with water to 100 ml to obtain the nominal concentration of a 10 μg/ml solution. The absorbances of the standard and sample solutions were determined using a UV/Visible spectrophotometer at 232 nm, with water as a blank. The percentage of the labeled amount of metformin HCl in each brand was calculated using the following equation (<xref rid="M0003" ref-type="disp-formula">Eq. 3</xref>):
<disp-formula id="M0003"><label>(3)</label>
<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M3" overflow="scroll"><mml:mi>A</mml:mi><mml:mi>s</mml:mi><mml:mi>s</mml:mi><mml:mi>a</mml:mi><mml:mi>y</mml:mi><mml:mspace width="thinmathspace"/><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">%</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mrow><mml:msub><mml:mi>A</mml:mi><mml:mi>u</mml:mi></mml:msub></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mi>A</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:mfenced><mml:mo>×</mml:mo><mml:mfenced open="(" close=")"><mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>u</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:mfenced><mml:mo>×</mml:mo><mml:mn>100</mml:mn></mml:math></disp-formula></p></sec><sec><title>Data quality control</title><p>Data were checked for completeness and consistency. The quality of experimental results was assured by performing system suitability tests and by strictly applying the procedures described in the specified monographs of the pharmacopoeia. The work has been reported in line with the STROCSS criteria<sup>[</sup><xref rid="R25" ref-type="bibr">25</xref><sup>]</sup>.</p></sec><sec><title>Statistical analysis</title><p>The overall results of the experiment were statistically analyzed using origin lab software (Origin Lab Corporation, MA, USA). All the results data were evaluated three times and presented as mean ± standard deviation.</p></sec></sec></sec><sec sec-type="discussion"><title>Results and discussion</title><sec><title>Tablet mechanical strength</title><p>Tablets require appropriate strength to resist damage during storage, transportation, and handling, but the hardness of tablets should not interfere with proper disintegration after swallowing. Additionally, the dissolution rate of tablets is influenced by their strength or hardness. Friability, disintegration, and dissolution of tablets are affected by hardness or crushing strength, which is an important parameter. Tablet machine force control during tablet compression is important to limit tablet hardness. Excessive tablet hardness can result in failure to disintegrate within the required period in a suitable medium, while very soft tablets may lose their shape due to mechanical forces during manufacturing processes, such as coating, packaging, and transportation operations<sup>[</sup><xref rid="R24" ref-type="bibr">24</xref><sup>]</sup>. Hardness is one of the characteristics of a tablet that is examined to assess its ability to maintain its form under normal condition<sup>[</sup><xref rid="R25" ref-type="bibr">25</xref><sup>]</sup>. Tablet hardness, and tablet disintegration and dissolution have a direct relationship. Excessive hardness of tablets influences dissolution and absorption rates, bioavailability, and the onset of action of the drug by prolonging disintegration time. Conversely, tablets with poor strength are unable to resist forces during distribution, storage, and usage, compromising their integrity. Therefore, during tablet compression, it is important to fix and manage tablet hardness within an acceptable range<sup>[</sup><xref rid="R26" ref-type="bibr">26</xref><sup>]</sup>. Many factors influence tablet hardness, such as the amount and type of binder used and the compression force applied during production. The friability test is one of the methods used to assess tablet hardness and is designed to evaluate the tablet's ability to withstand changes during manufacturing processes, such as coating, packaging, handling, and distribution. To achieve high consumer acceptance, tablets should have suitable hardness as well as reasonable friability<sup>[</sup><xref rid="R21" ref-type="bibr">21</xref><sup>]</sup>.</p><p>The mean values of the strength-related properties and the thicknesses of the different metformin HCl tablet brands are depicted in Table <xref rid="T2" ref-type="table">2</xref>. The lowest mean tablet hardness (105.8 N) was observed for brand A, and the highest value (146.2 N) was obtained for brand F. Most of the time, tablets having hardness strength greater than 40 N are believed to meet the standard<sup>[</sup><xref rid="R26" ref-type="bibr">26</xref><sup>]</sup>. All of the examined tablets showed a crushing strength higher than 40 N. Based on the USP Convention, the friability value of tablets should be less than 1%<sup>[</sup><xref rid="R27" ref-type="bibr">27</xref><sup>]</sup> and the results showed that all the brands of metformin HCl tablets under this investigation had friability values ranging from 0.11% to 0.26%. Thus, all brands passed the strength test based on percentage friability. The nature and amount of binder used, as well as the compression force, are factors that affect the friability of tablets<sup>[</sup><xref rid="R28" ref-type="bibr">28</xref><sup>]</sup>. Nevertheless, while thickness and diameter are not pharmacopoeial requirements, they do have an effect on packaging and should be considered in the calculation of the tensile strength of tablets. Therefore, these factors should be kept within the minimum range of their mean values <sup>[</sup><xref rid="R25" ref-type="bibr">25</xref><sup>]</sup>.
<table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Thickness, hardness, friability, and disintegration profile of metformin HCl brands</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Product</th><th align="center" rowspan="1" colspan="1">Thickness (mm)</th><th align="center" rowspan="1" colspan="1">Hardness (N)</th><th align="center" rowspan="1" colspan="1">Friability</th><th align="center" rowspan="1" colspan="1">Disintegration time (min)</th></tr><tr><th align="left" rowspan="1" colspan="1">Code</th><th align="center" rowspan="1" colspan="1">(mean ± SD)</th><th align="center" rowspan="1" colspan="1">(mean ± SD)</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">(mean ± SD)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">5.64 ± 0.21</td><td align="center" rowspan="1" colspan="1">105.8 ± 9.81</td><td align="center" rowspan="1" colspan="1">0.26</td><td align="center" rowspan="1" colspan="1">9.15 ± 0.21</td></tr><tr><td align="left" rowspan="1" colspan="1">B</td><td align="center" rowspan="1" colspan="1">5.38 ± 0.18</td><td align="center" rowspan="1" colspan="1">116.3 ± 7.34</td><td align="center" rowspan="1" colspan="1">0.12</td><td align="center" rowspan="1" colspan="1">10.38 ± 0.35</td></tr><tr><td align="left" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">5.85 ± 0.35</td><td align="center" rowspan="1" colspan="1">127.4 ± 4.92</td><td align="center" rowspan="1" colspan="1">0.15</td><td align="center" rowspan="1" colspan="1">9.85 ± 0.18</td></tr><tr><td align="left" rowspan="1" colspan="1">D</td><td align="center" rowspan="1" colspan="1">6.01 ± 0.26</td><td align="center" rowspan="1" colspan="1">118.5 ± 8.81</td><td align="center" rowspan="1" colspan="1">0.22</td><td align="center" rowspan="1" colspan="1">10.04 ± 0.30</td></tr><tr><td align="left" rowspan="1" colspan="1">E</td><td align="center" rowspan="1" colspan="1">5.75 ± 0.25</td><td align="center" rowspan="1" colspan="1">133.7 ± 9.16</td><td align="center" rowspan="1" colspan="1">0.26</td><td align="center" rowspan="1" colspan="1">9.95 ± 0.28</td></tr><tr><td align="left" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">5.90 ± 0.37</td><td align="center" rowspan="1" colspan="1">146.2 ± 6.77</td><td align="center" rowspan="1" colspan="1">0.11</td><td align="center" rowspan="1" colspan="1">11.25 ± 0.14</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>N, Newton; SD, Standard Deviation.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec><title>Tablet disintegration property</title><p>The tablet disintegration test is used to determine the time required for a tablet to entirely break down in the gastrointestinal tract. The quality of tablets depends on disintegration time, which influences the drug release rate<sup>[</sup><xref rid="R29" ref-type="bibr">29</xref><sup>]</sup>. Tablet disintegration is a precondition to dissolution, which subsequently leads to the absorption of a drug from the gastrointestinal tract. The rate of disintegration is directly proportional to the rate of dissolution. Disintegration rate is affected by the amount and time of water inflow into the tablets. When a tablet disintegrates, the active pharmaceutical ingredient (API) is released promptly because the rate of disintegration affects the dissolution rate and, consequently, the therapeutic effects of a drug<sup>[</sup><xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R25" ref-type="bibr">25</xref><sup>]</sup>. Tablet disintegration is influenced by the type of excipients and processes used by different producers during formulation, which subsequently impacts the bioavailability of the drug. Therefore, tablet disintegration is one of the factors that affect the rate of drug absorption<sup>[</sup><xref rid="R12" ref-type="bibr">12</xref><sup>]</sup>. The British Pharmacopoeia (BP) stipulates that the disintegration time for uncoated tablets should not exceed 15 minutes, while film-coated tablets should disintegrate within 30 minutes<sup>[</sup><xref rid="R30" ref-type="bibr">30</xref><sup>]</sup>. The disintegration time data from the experiment showed that all the brands comply with the pharmacopoeial limits, falling within the range of 9.15–11.25 minutes. Low values of disintegration time are most often attributed to the presence of large amounts of disintegrants or lower binder concentrations, in addition to the manufacturing process. Additionally, tablets with good mechanical strength are expected to have relatively higher disintegration time profiles. In this study, it was observed that brand F, characterized by higher crushing strength and lower friability, exhibited the highest disintegration time.</p></sec><sec><title>Weight variation</title><p>Weight variation is appropriate for the test of Uniformity of Dosage Form if uncoated or film-coated tablets contain 25 mg or more of the drug substance, comprising 25% of each tablet’s weight<sup>[</sup><xref rid="R8" ref-type="bibr">8</xref><sup>]</sup>. Deviation from the weight variation limit may result in the absence of a sufficient API crucial for the therapeutic effect of the medicine, which might lead to a decrease in the therapeutic activity of the medicine and cause a reduced treatment outcome. The difference in types of excipients used, i.e., diluents, disintegrants, lubricants, and glidants, during the manufacturing process might lead to weight variation. This variation might also be associated with differences in the manufacturing procedure<sup>[</sup><xref rid="R3" ref-type="bibr">3</xref><sup>]</sup>. According to BP, a deviation of ±5% from the mean tablet weight for uncoated or film-coated tablets weighing 250 mg and above is acceptable under the uniformity of weight test. Furthermore, for the batch to pass the weight test, at least 18 of the 20 tablets must be within the ±5% range, and all tablets must be within ±10%<sup>[</sup><xref rid="R30" ref-type="bibr">30</xref><sup>]</sup>.</p><p>The mean weight of the tablets of the six brands ranged from 559.04 to 627.97 mg. All brands, except brand E, showed acceptable weight uniformity. Compliance with the weight uniformity test is one pre-request to avoid variation in content uniformity and, ultimately, the probability of a sub-therapeutic dose or over dose<sup>[</sup><xref rid="R2" ref-type="bibr">2</xref><sup>]</sup>. Brand E deviated from the standard because one of the tablets in the sample deviated by more than 5% of the mean weight, as stated in the BP<sup>[</sup><xref rid="R29" ref-type="bibr">29</xref><sup>]</sup>. This could be attributed to poor flow properties of the granules, deprived feeding of granules into the die, and poor control of some other process parameters during manufacturing<sup>[</sup><xref rid="R28" ref-type="bibr">28</xref><sup>]</sup>. The details of the weight uniformity evaluation results are presented in Table <xref rid="T3" ref-type="table">3</xref>.
<table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>Weight uniformity evaluation results of metformin HCl tablet brands</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Product code</th><th align="center" rowspan="1" colspan="1">Weight (mg) Mean ± SD</th><th align="center" rowspan="1" colspan="1">Minimum % weight variation</th><th align="center" rowspan="1" colspan="1">Maximum % weight variation</th><th align="center" rowspan="1" colspan="1">Number of tablets out of specification</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">585 ± 5.05</td><td align="center" rowspan="1" colspan="1">579.95</td><td align="center" rowspan="1" colspan="1">590.05</td><td align="center" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">B</td><td align="center" rowspan="1" colspan="1">564 ± 4.96</td><td align="center" rowspan="1" colspan="1">559.04</td><td align="center" rowspan="1" colspan="1">568.96</td><td align="center" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">602 ± 8.84</td><td align="center" rowspan="1" colspan="1">610.84</td><td align="center" rowspan="1" colspan="1">593.16</td><td align="center" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">D</td><td align="center" rowspan="1" colspan="1">625 ± 6.22</td><td align="center" rowspan="1" colspan="1">618.78</td><td align="center" rowspan="1" colspan="1">631.22</td><td align="center" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">E</td><td align="center" rowspan="1" colspan="1">641 ± 13.03</td><td align="center" rowspan="1" colspan="1">627.97</td><td align="center" rowspan="1" colspan="1">654.03</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">605 ± 8.25</td><td align="center" rowspan="1" colspan="1">596.75</td><td align="center" rowspan="1" colspan="1">613.25</td><td align="center" rowspan="1" colspan="1">None</td></tr></tbody></table></table-wrap>
</p></sec><sec><title>In vitro drug release</title><p>Dissolution testing is used to predict drug characteristics <italic toggle="yes">in vivo</italic> and to determine the effects of binders, mixing, granulation procedures, and excipient types on tablets. It is an important control test for assuring product consistency and batch-to-batch equivalence of products. Dissolution testing is applied as an <italic toggle="yes">in vitro</italic> bioequivalence test to identify the similarity of solid dosage forms<sup>[</sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R24" ref-type="bibr">24</xref><sup>]</sup>. Dissolution testing provides information about the drug dissolution rate, which determines how a drug is made available in the body to produce an optimum therapeutic effect<sup>[</sup><xref rid="R26" ref-type="bibr">26</xref><sup>]</sup>. Evaluating the therapeutic effects of two or more formulations containing the same API is a critical factor in using the innovator and other similarly formulated drug products interchangeably<sup>[</sup><xref rid="R31" ref-type="bibr">31</xref><sup>]</sup>. To ensure product similarity in terms of drug release and post-approval changes, sufficient evidence about drug dissolution data is required. Products with different formulations, APIs, and product designs may have different dissolution characteristics, which may subsequently lead to different bioavailability<sup>[</sup><xref rid="R32" ref-type="bibr">32</xref><sup>]</sup>. <italic toggle="yes">In vitro</italic> dissolution testing is more useful for indicating the bioequivalence of drugs than <italic toggle="yes">in vivo</italic> pharmacokinetic studies. Additionally, <italic toggle="yes">in vitro</italic> dissolution studies provide insights into noninvasiveness, lower costs, better assessment of product performance, and improved ethical considerations for the product<sup>[</sup><xref rid="R24" ref-type="bibr">24</xref><sup>]</sup>.</p><p>Factors that affect drug dissolution include the physicochemical properties of the drug, drug design, mechanical strength of the tablet, manufacturing procedure, and testing conditions (i.e., apparatus, agitation, medium, etc.). Studies have reported that different excipients were tested in metformin tablets manufactured via wet granulation and determined that the amount and type of excipients used in the metformin products modified their dissolution behavior <sup>[</sup><xref rid="R32" ref-type="bibr">32</xref>,<xref rid="R33" ref-type="bibr">33</xref><sup>]</sup>. A higher disintegration rate indicates faster break down of a tablet and consequently enhances the dissolution of the API into the bloodstream, thus increasing bioavailability. A good <italic toggle="yes">in vitro</italic>–<italic toggle="yes">in vivo</italic> association can allow the use of <italic toggle="yes">in vitro</italic> dissolution testing to estimate a product's <italic toggle="yes">in vivo</italic> performance, and therefore, <italic toggle="yes">in vitro</italic> dissolution profiles can be employed as a substitute for <italic toggle="yes">in vivo</italic> bioavailability studies<sup>[</sup><xref rid="R21" ref-type="bibr">21</xref><sup>]</sup>. Specifically, <italic toggle="yes">in vitro</italic> dissolution studies can replace expensive and time-consuming <italic toggle="yes">in vivo</italic> dissolution studies to identify the theoretical consistency of generic formulations<sup>[</sup><xref rid="R1" ref-type="bibr">1</xref><sup>]</sup>. According to USP recommendations, the quantity of metformin hydrochloride released within 30 minutes from the tablet should be ≥ 80% of the amount stated on the label claim<sup>[</sup><xref rid="R28" ref-type="bibr">28</xref><sup>]</sup>.</p><p>As shown in Fig. <xref rid="F1" ref-type="fig">1</xref>, the results from the calibration curve revealed the presence of a very strong positive relationship (<italic toggle="yes">r</italic><xref rid="R2" ref-type="bibr">2</xref> = 0.9993) between the concentration and absorbance over the concentration range of 2–6 μg/ml. All the generic products released about 80% of metformin hydrochloride within 30 minutes, hence complying with the USP dissolution tolerance limit with almost similar drug release properties.
<fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p>(a) Calibration curve; (b) dissolution profile of six metformin brands.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ms9-87-4888-g001.jpg"/></fig>
</p></sec><sec><title>Similarity factor (f2)</title><p>To substitute one product with another that contains identical APIs, equivalence in therapeutic effect should be examined and approved. According to the FDA of the US guidelines, the profiles of testing products and comparators are evaluated using the implemented similarity factor (f2), and when 2 profiles are identical, f2 equals 100. The similarity factor is an independent parameter used to evaluate the dissolution rate of samples from different brands<sup>[</sup><xref rid="R16" ref-type="bibr">16</xref><sup>]</sup>. The FDA, European Medicines Agency, and WHO have suggested the use of f2 to identify similarity between the dissolution data of drug products<sup>[</sup><xref rid="R32" ref-type="bibr">32</xref><sup>]</sup>. To conclude that products are bioequivalent based on dissolution profiles, the similarity factor (f2) should be within the range of 50 to 100<sup>[</sup><xref rid="R20" ref-type="bibr">20</xref><sup>]</sup>. Currently, the similarity factor is a major concern in many regulatory policies<sup>[</sup><xref rid="R24" ref-type="bibr">24</xref><sup>]</sup>. The similarity factor (f2) values of the studied generic products are presented in Table <xref rid="T4" ref-type="table">4</xref>. The f2 values for the generic products were found to be in the range of 50–71. Significant differences were not observed in both parameters and this confirmed similarity between all brand formulations. Thus, all brands can be considered equivalent in dissolution profiles, as their f2 values were greater than or equal to 50. Among all generic products, brand A showed a higher f2 value (71), suggesting it is a more potential substitute for the innovator product than other products. This is because as the f2 value becomes higher and closer to 100, the tested generic product exhibits greater similarity to the comparator with respect to the dissolution profile<sup>[</sup><xref rid="R21" ref-type="bibr">21</xref><sup>]</sup>.
<table-wrap position="float" id="T4" orientation="portrait"><label>Table 4</label><caption><p>The similarity factor of different metformin HCl tablet brands</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Brands</th><th align="center" rowspan="1" colspan="1">A</th><th align="center" rowspan="1" colspan="1">B</th><th align="center" rowspan="1" colspan="1">C</th><th align="center" rowspan="1" colspan="1">D</th><th align="center" rowspan="1" colspan="1">E</th><th align="center" rowspan="1" colspan="1">F</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">f2 value</td><td align="center" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">59</td><td align="center" rowspan="1" colspan="1">50</td></tr></tbody></table></table-wrap>
</p></sec><sec><title>Assay of metformin HCl tablet</title><p>The amount of API found in a product influences the quality and efficacy of its therapeutic effect. Products with inappropriate levels of API produce unnecessary therapeutic outcomes, i.e., treatment failure, increased patient morbidity, and mortality. An assay test is a critical method used to measure the amount of API present in a drug and determine the quality of products to optimize the release of the drug from the product. Poor quality and adverse outcomes of treatment occurred due to substandard APIs found in the product<sup>[</sup><xref rid="R3" ref-type="bibr">3</xref><sup>]</sup>. The presence of metformin hydrochloride outside the standard range has severe impacts on patient health care. Amounts of metformin hydrochloride below the limit result in glucose accumulation, leading to treatment failure, resistance, and severe complications, which may ultimately worsen the patient’s health status. Conversely, metformin hydrochloride above the limit results in severe adverse effects, i.e., hypoglycemia, organ failure, coma, or death<sup>[</sup><xref rid="R26" ref-type="bibr">26</xref><sup>]</sup>. According to the BP, metformin hydrochloride tablets should contain 95–105% of the API as indicated on the label claim upon assay<sup>[</sup><xref rid="R30" ref-type="bibr">30</xref><sup>]</sup>. Assay non-compliance has been a principal problem with metformin hydrochloride tablets in many countries<sup>[</sup><xref rid="R34" ref-type="bibr">34</xref><sup>]</sup>. Under this study, all the tested brands complied with this pharmacopoeial specification. The lowest and highest mean percentage drug contents in the brands under investigation were 100.35% (for brand B) and 104.63% (for brand F), respectively. Almost all of the tablets in the brands showed drug contents higher than 100%, which may be caused by inaccuracies in weighing the API, poor mixing during granulation, and the use of excess amounts of API during tablet formulation. This particular problem has also been reported in similar studies <sup>[</sup><xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R28" ref-type="bibr">28</xref><sup>]</sup>. The content assay of the formulation is depicted in Table <xref rid="T5" ref-type="table">5</xref>.
<table-wrap position="float" id="T5" orientation="portrait"><label>Table 5</label><caption><p>The content assay results of different metformin HCl tablet brands</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Brands</th><th align="center" rowspan="1" colspan="1">A</th><th align="center" rowspan="1" colspan="1">B</th><th align="center" rowspan="1" colspan="1">C</th><th align="center" rowspan="1" colspan="1">D</th><th align="center" rowspan="1" colspan="1">E</th><th align="center" rowspan="1" colspan="1">F</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Assay (%)</td><td align="center" rowspan="1" colspan="1">102.20 ± 1.64</td><td align="center" rowspan="1" colspan="1">100.35 ± 0.95</td><td align="center" rowspan="1" colspan="1">104.44 ± 1.48</td><td align="center" rowspan="1" colspan="1">103.27 ± 1.92</td><td align="center" rowspan="1" colspan="1">101.75 ± 2.05</td><td align="center" rowspan="1" colspan="1">104.63 ± 2.41</td></tr></tbody></table></table-wrap>
</p><p>In general, this study demonstrated that the six brands available in the pharmaceutical market of Bahir Dar city passed almost all of the tests conducted for their equivalence evaluation, except for the deviation of one brand (E) in the weight uniformity test. This is a very commendable result, as compliance with all official and non-official pharmacopoeial tests is required for acceptable quality, safety, and efficacy of pharmaceuticals. This finding aligns with study reports from Addis Ababa and Jimma cities in Ethiopia, where all brands of metformin hydrochloride tablets met pharmacopoeial specifications for the tested parameters of physicochemical properties, such as weight variation, tablet hardness, disintegration time, drug release studies, and assay<sup>[</sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R30" ref-type="bibr">30</xref><sup>]</sup>. Similar results were obtained from China<sup>[</sup><xref rid="R1" ref-type="bibr">1</xref><sup>]</sup>, Albania<sup>[</sup><xref rid="R7" ref-type="bibr">7</xref><sup>]</sup>, India<sup>[</sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R10" ref-type="bibr">10</xref><sup>]</sup>, and Uttarakhand<sup>[</sup><xref rid="R35" ref-type="bibr">35</xref><sup>]</sup>. Even though the sampled metformin hydrochloride tablets in the current study area showed acceptable evaluation results, various studies in Ethiopia and abroad have reported non-compliance with one or more of the tests. In two different studies conducted in Tigray (Ethiopia), results indicated differences in f2<sup>[</sup><xref rid="R31" ref-type="bibr">31</xref><sup>]</sup> and dissolution profiles among some generic brands<sup>[</sup><xref rid="R22" ref-type="bibr">22</xref><sup>]</sup>. Similar non-compliant results in one or more test parameters were also reported in studies from developing and developed nations, including Iran<sup>[</sup><xref rid="R9" ref-type="bibr">9</xref><sup>]</sup>, Saudi Arabia<sup>[</sup><xref rid="R23" ref-type="bibr">23</xref><sup>]</sup>, Ghana<sup>[</sup><xref rid="R28" ref-type="bibr">28</xref><sup>]</sup>, Canada<sup>[</sup><xref rid="R32" ref-type="bibr">32</xref><sup>]</sup>, Kenya<sup>[</sup><xref rid="R33" ref-type="bibr">33</xref><sup>]</sup>, Egypt<sup>[</sup><xref rid="R34" ref-type="bibr">34</xref><sup>]</sup>, and Libya<sup>[</sup><xref rid="R36" ref-type="bibr">36</xref><sup>]</sup>. As <italic toggle="yes">in vitro–in vivo</italic> bioequivalence correlation remains a subject of debate for metformin hydrochloride tablets, further <italic toggle="yes">in vivo</italic> bioequivalence (BE) studies should be conducted in accordance with the ICH guidelines on Good Clinical Practice and the Guidance for Industry on Bioavailability and Bioequivalence Studies. These studies can help confirm the bioequivalence of the brands with supportive evidence derived from pharmacokinetic parameter findings after <italic toggle="yes">in vivo</italic> investigations. It must be demonstrated that the safety and efficacy of the generic drugs are comparable to those of the innovator drugs<sup>[</sup><xref rid="R37" ref-type="bibr">37</xref><sup>]</sup>.</p></sec></sec><sec sec-type="conclusions"><title>Conclusion</title><p>From this study, it can be concluded that the six metformin HCl brand tablets available in Bahir Dar city have comparable physicochemical and drug release properties based on pharmacopoeial test parameters. Hence, they can be considered bioequivalent and interchangeable, provided their safety and other therapeutic parameters not covered in this investigation remain similar without significant deviations for each brand. This study had a limitation in that the in-vitro dissolution test was extrapolated to gain insight into in-vivo bioavailability instead of using actual in-vivo bioavailability data. However, an in-vivo bioequivalence study is recommended to confirm the therapeutic similarity between drugs over time. Positive results from such studies should not negate the need for constant post-marketing monitoring of the marketed products to ensure bioequivalence and compliance with pharmacopoeial standards. Further ongoing post-marketing surveillance is highly recommended for other generic brands available in the market to ensure the safety of generics and their interchangeability with both other generics and the innovator product.</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p>Sponsorships or competing interests that may be relevant to the content are disclosed at the end of this article.</p></fn><fn fn-type="equal"><p>Published online 16 June 2025</p></fn></fn-group><sec><title>Ethical approval and consent to participate</title><p>Ethical approval was obtained from the Ethical Review Committee of GAMBY Medical and Business College with the reference number ጋኮ432/2015 in May 2023. The study included community pharmacies that provided their informed consent to participate and supply different brands of metformin 500 mg tablets after receiving a detailed explanation of the study's aim and objectives. Subsequently, the data was collected following consent and in accordance with the relevant guidelines.</p></sec><sec><title>Consent for publication</title><p>Not applicable.</p></sec><sec><title>Sources of funding</title><p>No Funding Available.</p></sec><sec><title>Author contributions</title><p>E.A.S. works on conceptualization, data curation, formal analysis, investigation, methodology, project administration, supervision, validation, visualization, and writing – original draft preparation. A.T.Y., A.S., A.T.T., C.T., T.A.T., S.Z., B.M., S.Y., and Z.D.A. contributed to conceptualization, formal analysis, methodology, validation, writing – review and editing. All authors contributed to data analysis, drafting or revising the article, agreed on the journal to which the article will be submitted, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest disclosure</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Research registration unique identifying number (UIN)</title><p>Not applicable. Since the study is experimental and does not involve human participants.</p></sec><sec><title>Guarantor</title><p>The corresponding author will serve as the guarantor.</p></sec><sec><title>Provenance and peer review</title><p>Not commissioned and externally peer-reviewed.</p></sec><sec sec-type="data-availability"><title>Data availability statement</title><p>All data are included within the article.</p></sec><sec><title>Acknowledgements</title><p>GAMBY Medical and Business College is gratefully acknowledged by the authors for providing the available materials, equipment, and reagents to conduct the studies. EFDA is also acknowledged for providing laboratory equipment and metformin HCl standards.</p></sec><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>In vitro dissolution and in vivo bioequivalence evaluation of two metformin extended-release tablets</article-title>. <source>Clin Pharmacol Drug Dev</source>
<year>2021</year>;<volume>10</volume>:<fpage>414</fpage>-<lpage>19</lpage>.<pub-id pub-id-type="pmid">32706921</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpdd.857</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okafo</surname><given-names>SE.</given-names></name></person-group>
<article-title>Comparative in vitro evaluation of some brands of metformin hydrochloride tablets marketed in Southern Nigeria</article-title>. <source>East African Scholars J Med Sci</source>
<year>2020</year>;<volume>3</volume>:<fpage>116</fpage>-<lpage>21</lpage>.</mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Mekonnen</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Bekele</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Suleiman</surname><given-names>S</given-names></name><etal/></person-group>
<source>Physicochemical quality of metformin hydrochloride tablet brands available in Jimma Town, South_West Ethiopia</source>. <comment>Res Sq [preprint</comment>] <year>2021</year>. doi:<pub-id pub-id-type="doi">10.21203/rs.3.rs-352338/v1</pub-id>.</mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="book"><collab>World Health Organization (WHO). Diabetes</collab> [<comment>Internet</comment>]. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2017</year> [<date-in-citation>cited 2025 Jun 9</date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/health-topics/diabetes#tab=tab_1" ext-link-type="uri">https://www.who.int/health-topics/diabetes#tab=tab_1</ext-link>.</mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahman</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Akter</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Sarker</surname><given-names>MS</given-names></name><etal/></person-group>
<article-title>In vitro comparative quality evaluation of different brands of marketed paracetamol tablets available in Bangladesh</article-title>. <source>J Pharm Res Int</source>
<year>2021</year>;<volume>33</volume>:<fpage>26</fpage>-<lpage>32</lpage>.</mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welegebrial</surname><given-names>BG</given-names></name>
<name name-style="western"><surname>Kahsay</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Eticha</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Comparative in vitro quality evaluation of different brands of ibuprofen tablets marketed in Mekelle, Ethiopia [preprint]</article-title>. <source>Res Sq</source>
<year>2020</year> [<date-in-citation>cited 2025 Jun 9</date-in-citation>].</mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Troja</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Deda</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Boçari</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>A comparative study of three formulations of metformin tablets available on the Albanian market</article-title>. <source>Ajmhs</source>
<year>2015</year>;<volume>46</volume>:<fpage>46</fpage>–<lpage>55</lpage>.</mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mate</surname><given-names>PC</given-names></name>
<name name-style="western"><surname>Gokhale</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Jambhulkar</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>A comparative in-vitro study for evaluation of different marketed brands of metformin hydrochloride (500 mg</article-title>. <source>Tablets</source>
<year>2020</year>;<volume>11</volume>:<fpage>6738</fpage>–<lpage>45</lpage>.</mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zakeri-milani</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Nayyeri-maleki</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Ghanbarzadeh</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>In-vitro bioequivalence study of 8 brands of metformin tablets in Iran market</article-title>. <source>J Appl Pharm Sci</source>
<year>2012</year>;<volume>02</volume>:<fpage>194</fpage>–<lpage>97</lpage>.</mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arora</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Parle</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Dahiya</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Comparative evaluation of metformin tablets available under government supply and brands available in open market in Delhi, India</article-title>. <source>IOSR J Pharm</source>
<year>2021</year>;<volume>11</volume>:<fpage>8</fpage>–<lpage>20</lpage>.</mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandrasekaran</surname><given-names>AR</given-names></name>
<name name-style="western"><surname>Jia</surname><given-names>CY</given-names></name>
<name name-style="western"><surname>Theng</surname><given-names>CS</given-names></name><etal/></person-group>
<article-title>Invitro studies and evaluation of metformin marketed tablets-Malaysia</article-title>.<source>J Appl Pharm Sci</source>
<year>2011</year>;<volume>01</volume>:<fpage>214</fpage>–<lpage>17</lpage>.</mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Shen</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Evaluating bioequivalence of meloxicam tablets: is in-vitro dissolution test overdiscriminating?</article-title>
<source>J Pharm Pharmacol</source>
<year>2018</year>;<volume>70</volume>:<fpage>250</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="pmid">29193077</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jphp.12859</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eraga</surname><given-names>SO</given-names></name>
<name name-style="western"><surname>Arhewoh</surname><given-names>MI</given-names></name>
<name name-style="western"><surname>Oruh</surname><given-names>EP</given-names></name><etal/></person-group>
<article-title>A comparative evaluation of the pharmaceutical quality of different brands of metformin hydrochloride tablets available in Abuja, Nigeria</article-title>. <source>West Afr J Pharm</source>
<year>2017</year>;<volume>28</volume>:<fpage>61</fpage>-<lpage>71</lpage>.</mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olusola</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Adekoya</surname><given-names>AI</given-names></name>
<name name-style="western"><surname>Olanrewaju</surname><given-names>OJ</given-names></name><etal/></person-group>
<article-title>Comparative evaluation of physicochemical properties of some commercially available brands of metformin HCL tablets in Lagos</article-title>. <source>Nigeria</source>
<year>2012</year>;<volume>02</volume>:<fpage>41</fpage>–<lpage>44</lpage>.</mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansour</surname><given-names>O</given-names></name>
<name name-style="western"><surname>Ismail</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Mostafaisbera</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Assessment of physicochemical properties of furosemide (40mg) tablets marketed in Syria</article-title>. <source>J Chem Pharm Sci</source>
<year>2016</year>;<volume>9</volume>:<fpage>2879</fpage>–<lpage>81</lpage>.</mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yayehrad</surname><given-names>AT</given-names></name>
<name name-style="western"><surname>Lule</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Tebabal</surname><given-names>AT</given-names></name><etal/></person-group>
<article-title>Concern on skin lightening product safety: level of awareness and associated factors among female users in Bahir Dar City, Ethiopia</article-title>. <source>Clin Cosmet Investig Dermatol</source>
<year>2023</year>;<volume>16</volume>:<fpage>1753</fpage>-<lpage>61</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/CCID.S416460</pub-id><pub-id pub-id-type="pmcid">PMC10335271</pub-id><pub-id pub-id-type="pmid">37441697</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abebe</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Ketema</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Kassahun</surname><given-names>H</given-names></name></person-group>
<article-title>In vitro comparative quality assessment of different brands of furosemide tablets marketed in northwest Ethiopia</article-title>. <source>Drug Des Devel Ther</source>
<year>2020</year>;<volume>14</volume>:<fpage>5119</fpage>–<lpage>28</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DDDT.S280203</pub-id><pub-id pub-id-type="pmcid">PMC7700078</pub-id><pub-id pub-id-type="pmid">33262573</pub-id></mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeru</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Tesfa</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Mitiku</surname><given-names>AA</given-names></name><etal/></person-group>
<article-title>Prevalence and risk factors of type-2 diabetes mellitus in Ethiopia:systematic review and meta-analysis</article-title>. <source>Sci Rep</source>
<year>2021</year>;<volume>11</volume>:<fpage>1</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">34741064</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-01256-9</pub-id><pub-id pub-id-type="pmcid">PMC8571297</pub-id></mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bantie</surname><given-names>GM</given-names></name>
<name name-style="western"><surname>Wondaye</surname><given-names>AA</given-names></name>
<name name-style="western"><surname>Arike</surname><given-names>EB</given-names></name><etal/></person-group>
<article-title>Prevalence of undiagnosed diabetes mellitus and associated factors among adult residents of Bahir Dar city, northwest Ethiopia: a community-based cross-sectional study</article-title>. <source>BMJ Open</source>
<year>2019</year>;<fpage>9:e030158</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2019-030158</pub-id><pub-id pub-id-type="pmcid">PMC6830649</pub-id><pub-id pub-id-type="pmid">31676649</pub-id></mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biru</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Getinet</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Alayu</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Prevalence and factors associated with diabetes mellitus in Bahir Dar town, Northern Ethiopia, 2019</article-title>. <source>Facil Based Cross-Sect Study</source>
<year>2022</year>;<volume>7</volume>:<fpage>49</fpage>–<lpage>59</lpage>.</mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abate</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Abrham temesgen</surname><given-names>MN</given-names></name></person-group>. <article-title>Comparative in vitro evaluation of different brands of metformin hydrochloride film coated tablets marketed in Addis Ababa, Ethiopia</article-title>. <source>Asian J Pharm Res Dev</source>
<year>2020</year>;<volume>8</volume>:<fpage>44</fpage>–<lpage>50</lpage>.</mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kassahun</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Asres</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Ashenef</surname><given-names>A</given-names></name></person-group>
<article-title>In vitro quality evaluation of metformin hydrochloride tablets marketed in</article-title>.<source>Bangladesh J Sci Ind Res</source>
<year>2019</year>;<volume>54</volume>:<fpage>169</fpage>–<lpage>76</lpage>.</mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samar</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Afifi</surname><given-names>SA</given-names></name></person-group>
<article-title>Comparative study for evaluation of different brands of metformin hydrochloride 500 mg tablets marketed in saudi Arabiaitle</article-title>. <source>Life Sci J</source>
<year>2012</year>;<volume>9</volume>:<fpage>4260</fpage>–<lpage>66</lpage>.</mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>MM</given-names></name>
<name name-style="western"><surname>Gupta</surname><given-names>M</given-names></name></person-group>
<article-title>In-vitro pharmaceutical quality control testing: a comparative study of different brands of metformin tablets available in the Trinidad &amp; Tobago, West Indies</article-title>. <source>J Pharm Sci Res</source>
<year>2016</year>;<volume>8</volume>:<fpage>238</fpage>–<lpage>43</lpage>.</mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathew</surname><given-names>G</given-names></name></person-group>
<article-title>Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery</article-title>. <source>Int J Surg</source>
<year>2021</year>;<volume>96</volume>:<fpage>106165</fpage>.<pub-id pub-id-type="pmid">34774726</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijsu.2021.106165</pub-id></mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>LV</given-names></name>
<name name-style="western"><surname>Popovich</surname><given-names>NG AH</given-names></name></person-group>. <source>Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems</source>. <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Lippincott Williams and Wilkins</publisher-name>; <year>2004</year>.</mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="book"><collab>USP</collab>. <source>USP 30/ NF 25, United States Pharmacopoeial Convention</source>. <publisher-loc>Rockville, Maryland</publisher-loc>: <publisher-name>Inc</publisher-name>; <year>2007</year>.</mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sougi</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Ofori-kwakye</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Kuntworbe</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Evaluation of the physicochemical and in vitro dissolution properties of metformin hydrochloride tablet brands marketed in five cities in Ghana</article-title>.<source>Br J Pharm Res</source>
<year>2016</year>;<volume>9</volume>:<fpage>1</fpage>–<lpage>14</lpage>.</mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="book"><collab>British Pharmacopoeia Commission. British Pharmacopoeia</collab>
<year>2013</year>. Volume <volume>4</volume>. <publisher-loc>London</publisher-loc>: <publisher-name>The Stationery Office</publisher-name>; <comment>2013</comment>.</mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Umeta</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Mohammed</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Duguma</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Dissolution profile evaluation of eight brands of metformin hydrochloride tablets available in</article-title>.<source>Diabetes, Metab Syn Obe</source>
<year>2021</year>;<volume>14</volume>:<fpage>3499</fpage>–<lpage>506</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DMSO.S316187</pub-id><pub-id pub-id-type="pmcid">PMC8352574</pub-id><pub-id pub-id-type="pmid">34385824</pub-id></mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kahsay</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Dinda</surname><given-names>SC</given-names></name></person-group>
<article-title>In vitro quality evaluation of metformin hydrochloride tablets marketed in in vitro quality evaluation of metformin hydrochloride tablets marketed in Western and North Western Tigray. Ethiopia</article-title>. <source>Austin J Anal Pharm Chem</source>
<year>2019</year>;<volume>6</volume>:<fpage>1119</fpage>.</mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stuart</surname><given-names>AV</given-names></name>
<name name-style="western"><surname>Clement</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Sealy</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Comparing the dissolution profiles of seven metformin formulations in simulated intestinal fluid</article-title>.<source>Dissolut Technol</source>
<year>2015</year>;<volume>22</volume>: <fpage>17</fpage>–<lpage>21</lpage>.</mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kariuki</surname><given-names>EM</given-names></name>
<name name-style="western"><surname>Thoith</surname><given-names>GN.</given-names></name></person-group>
<article-title>Quality of metformin tablet products in the Kenyan market</article-title>. <source>East Cent Afr J Pharm Sci</source>
<year>2021</year>;<volume>24</volume>:<fpage>85</fpage>-<lpage>89</lpage>.</mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hashem</surname><given-names>HM</given-names></name>
<name name-style="western"><surname>Ayar</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Mursi</surname><given-names>NM</given-names></name><etal/></person-group>
<article-title>Original article comparative in vitro dissolution study on metformin market products using different dissolution apparatuses</article-title>. <source>Int J Pharm Pharm Sci</source>
<year>2019</year>;<volume>11</volume>:<fpage>65</fpage>-<lpage>72</lpage>.</mixed-citation></ref><ref id="R35"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chauhan</surname><given-names>J</given-names></name></person-group>
<article-title>In-vitro bioequivalence study between four different marketed formulations of gliclazide with sustained release metformin hydrochloride tablet as an anti</article-title>. <source>Diabetic Drug</source>
<year>2020</year>;<volume>9</volume>:<fpage>1239</fpage>–<lpage>48</lpage>.</mixed-citation></ref><ref id="R36"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abozaid</surname><given-names>DM</given-names></name>
<name name-style="western"><surname>Saleh</surname><given-names>WM.</given-names></name></person-group>
<article-title>Evaluation of some metformin hydrochloride brands available in the Libyan market</article-title>. <source>Mediterr J Pharm Pharm Sci</source>
<year>2024</year>;<volume>2</volume>:<fpage>6</fpage>-<lpage>12</lpage>.</mixed-citation></ref><ref id="R37"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adegbola</surname><given-names>AJ</given-names></name>
<name name-style="western"><surname>Awobusuyi</surname><given-names>OJ</given-names></name>
<name name-style="western"><surname>Adeagbo</surname><given-names>BA</given-names></name><etal/></person-group>
<article-title>Original article bioequivalence study of generic metformin hydrochloride in healthy Nigerian volunteers</article-title>. <source>J Exploratory Res in Pharmacology</source>
<year>2017</year>;<volume>2</volume>:<fpage>78</fpage>–<lpage>84</lpage>.</mixed-citation></ref></ref-list></back></article><article xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Infect Dis</journal-id><journal-id journal-id-type="pmc-domain-id">1410</journal-id><journal-id journal-id-type="pmc-domain">jid</journal-id><journal-id journal-id-type="publisher-id">jid</journal-id><journal-title-group><journal-title>The Journal of Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">0022-1899</issn><issn pub-type="epub">1537-6613</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12531128</article-id><article-id pub-id-type="pmcid-ver">PMC12531128.2</article-id><article-id pub-id-type="pmcaid">12531128</article-id><article-id pub-id-type="pmcaiid">12718039</article-id><article-id pub-id-type="pmid">40468972</article-id><article-id pub-id-type="doi">10.1093/infdis/jiaf305</article-id><article-id pub-id-type="publisher-id">jiaf305</article-id><article-version article-version-type="pmc-version">2</article-version><article-categories><subj-group subj-group-type="heading"><subject>Major Article</subject><subj-group subj-group-type="category-toc-heading"><subject>HIV/AIDs</subject></subj-group></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00290</subject></subj-group></article-categories><title-group><article-title>Reduced Metformin Concentrations in Obese Women With Human Immunodeficiency Virus Treated With Dolutegravir</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6464-4257</contrib-id><name name-style="western"><surname>van Rensburg</surname><given-names initials="R">Roland</given-names></name><aff>
<institution>Division of Clinical Pharmacology, Department of Medicine, Stellenbosch University</institution>, <addr-line>Cape Town</addr-line>, <country country="ZA">South Africa</country></aff><xref rid="jiaf305-cor1" ref-type="corresp"/><xref rid="FN01" ref-type="author-notes"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1542-4976</contrib-id><name name-style="western"><surname>Kellermann</surname><given-names initials="T">Tracy</given-names></name><aff>
<institution>Division of Clinical Pharmacology, Department of Medicine, Stellenbosch University</institution>, <addr-line>Cape Town</addr-line>, <country country="ZA">South Africa</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5365-0320</contrib-id><name name-style="western"><surname>Pillay-Fuentes Lorente</surname><given-names initials="V">Veshni</given-names></name><aff>
<institution>Division of Clinical Pharmacology, Department of Medicine, Stellenbosch University</institution>, <addr-line>Cape Town</addr-line>, <country country="ZA">South Africa</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>du Plessis</surname><given-names initials="C">Christiena</given-names></name><aff>
<institution>Division of Clinical Pharmacology, Department of Medicine, Stellenbosch University</institution>, <addr-line>Cape Town</addr-line>, <country country="ZA">South Africa</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1134-7475</contrib-id><name name-style="western"><surname>Orrell</surname><given-names initials="C">Catherine</given-names></name><aff>
<institution>Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Department of Medicine, University of Cape Town</institution>, <addr-line>Cape Town</addr-line>, <country country="ZA">South Africa</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Maposa</surname><given-names initials="I">Innocent</given-names></name><aff>
<institution>Division of Epidemiology and Biostatistics, Department of Global Health, Stellenbosch University</institution>, <addr-line>Cape Town</addr-line>, <country country="ZA">South Africa</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0007-9456-3996</contrib-id><name name-style="western"><surname>Schreuder</surname><given-names initials="C">Chantel</given-names></name><aff>
<institution>Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Department of Medicine, University of Cape Town</institution>, <addr-line>Cape Town</addr-line>, <country country="ZA">South Africa</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4749-2404</contrib-id><name name-style="western"><surname>Jennings</surname><given-names initials="L">Lauren</given-names></name><aff>
<institution>Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Department of Medicine, University of Cape Town</institution>, <addr-line>Cape Town</addr-line>, <country country="ZA">South Africa</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3021-5101</contrib-id><name name-style="western"><surname>van Zyl</surname><given-names initials="G">Gert</given-names></name><aff>
<institution>Division of Medical Virology, Department of Pathology, Stellenbosch University</institution>, <addr-line>Cape Town</addr-line>, <country country="ZA">South Africa</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schifitto</surname><given-names initials="G">Giovanni</given-names></name><aff>
<institution>Department of Neurology, University of Rochester</institution>, <addr-line>Rochester, New York</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1815-5150</contrib-id><name name-style="western"><surname>Decloedt</surname><given-names initials="E">Eric</given-names></name><aff>
<institution>Division of Clinical Pharmacology, Department of Medicine, Stellenbosch University</institution>, <addr-line>Cape Town</addr-line>, <country country="ZA">South Africa</country></aff></contrib></contrib-group><author-notes><corresp id="jiaf305-cor1">Correspondence: Roland van Rensburg, MMed (Clin Pharm), Division of Clinical Pharmacology, Department of Medicine, Stellenbosch University, Office 7056, 7th Floor, Clinical Building, Tygerberg Medical Campus, Francie van Zijl Avenue, Cape Town 7505, South Africa (<email>rvr@sun.ac.za</email>).</corresp><fn id="FN01" fn-type="COI-statement"><p>
<bold>
<italic toggle="yes">Potential conflicts of interest.</italic>
</bold> G. v. Z. received an honorarium for an educational presentation on HIV drug resistance from Thermo Fisher Scientific. All other authors report no potential conflicts.</p><p>All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</p></fn></author-notes><pub-date pub-type="collection"><day>15</day><month>12</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-06-05"><day>05</day><month>6</month><year>2025</year></pub-date><volume>232</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">502822</issue-id><fpage>e1012</fpage><lpage>e1021</lpage><history><date date-type="received"><day>14</day><month>2</month><year>2025</year></date><date date-type="editorial-decision"><day>02</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>03</day><month>6</month><year>2025</year></date><date date-type="corrected-typeset"><day>19</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>21</day><month>12</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-12-21 10:25:12.590"><day>21</day><month>12</month><year>2025</year></date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">12531128</article-id><article-id pub-id-type="doi">10.1093/infdis/jiaf305</article-id><article-id pub-id-type="manuscript-id">NIHMS2115588</article-id><article-version>1</article-version><pub-date><day>20</day><month>12</month><year>2025</year></pub-date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">12718039</article-id><article-id pub-id-type="doi">10.1093/infdis/jiaf305</article-id><article-version>2</article-version><pub-date><day>05</day><month>06</month><year>2025</year></pub-date></event></pub-history><permissions><copyright-statement>© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jiaf305.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jiaf305.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>Obesity among women with human immunodeficiency virus (WWH) is nearly 2-fold higher than in men. Obesity is closely associated with dysglycemia, and frequently necessitates the coadministration of dolutegravir and metformin. A pharmacokinetic study in 15 nonobese healthy volunteers determined that dolutegravir increased metformin plasma exposure by 79%, prompting regulatory and guideline recommendations to limit metformin to 1000 mg/day when coadministered with dolutegravir. Obesity has been linked to lower metformin exposures, and our study aimed to verify the metformin pharmacokinetic exposure in the increasing population of obese WWH.</p></sec><sec id="s2"><title>Methods</title><p>We conducted intensive plasma sampling in virally suppressed WWH receiving metformin extended-release 1000 mg once daily with concomitant dolutegravir 50 mg once daily. Dual-energy X-ray absorptiometry was performed to quantify body fat composition. Noncompartmental analysis of metformin and dolutegravir concentrations was performed, and our findings were compared to the reference study.</p></sec><sec id="s3"><title>Results</title><p>We enrolled 15 participants with a mean body mass index of 45.6 kg/m<sup>2</sup>. Metformin area under the concentration-time curve over the 24-hour dosing interval (AUC<sub>0–24</sub>) was 40.9% lower and dolutegravir AUC<sub>0–24</sub> was 54.4% lower in obese WWH compared to the reference study. Metformin and dolutegravir clearance were 1.7- and 2.2-fold higher, respectively. Linear regression did not show associations between body fat composition and metformin or dolutegravir exposures.</p></sec><sec id="s4"><title>Conclusions</title><p>Limiting metformin to 1000 mg daily is likely to lead to underdosing in obese WWH on dolutegravir. Lower metformin exposure appears to be due to the reduced inhibitory effect of lower dolutegravir concentrations on metformin clearance and increased volume of distribution due to obesity. Our data support the revision of the current maximum dose restriction of metformin in the target population of obese WWH.</p></sec></abstract><abstract abstract-type="teaser"><p>Metformin concentrations are substantially reduced in women with HIV on dolutegravir. The reduced metformin exposure is likely due to the combined effects of lower dolutegravir concentrations and the increase in obesity-related apparent clearance and volume of distribution.</p></abstract><kwd-group><kwd>obesity</kwd><kwd>metformin</kwd><kwd>dolutegravir</kwd><kwd>underdosing</kwd><kwd>drug interaction</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>Fogarty International Center</institution><institution-id institution-id-type="DOI">10.13039/100000061</institution-id></institution-wrap>
</funding-source></award-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>National Institutes of Health</institution><institution-id institution-id-type="DOI">10.13039/100000002</institution-id></institution-wrap>
</funding-source><award-id>R21TW012185</award-id><award-id>D43TW010937</award-id></award-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>South African Medical Research Council</institution><institution-id institution-id-type="DOI">10.13039/501100001322</institution-id></institution-wrap>
</funding-source></award-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>Division of Research Capacity Development</institution><institution-id institution-id-type="DOI">10.13039/501100015777</institution-id></institution-wrap>
</funding-source></award-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>Clinician Researcher Development Programme</institution></institution-wrap>
</funding-source></award-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>South African National Department of Health</institution><institution-id institution-id-type="DOI">10.13039/100009041</institution-id></institution-wrap>
</funding-source></award-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>Discovery Foundation</institution></institution-wrap>
</funding-source></award-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>Harry Crossley Foundation</institution><institution-id institution-id-type="DOI">10.13039/501100004513</institution-id></institution-wrap>
</funding-source></award-group></funding-group><counts><page-count count="10"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>The prevalence of being overweight or obese is increasing among people with human immunodeficiency virus (HIV) [<xref rid="jiaf305-B1" ref-type="bibr">1</xref>], especially in sub-Saharan Africa (SSA) [<xref rid="jiaf305-B2" ref-type="bibr">2</xref>]. Approximately 1 in 3 people with HIV (PWH) in SSA are overweight (body mass index [BMI], 25 to &lt;30 kg/m<sup>2</sup>) or obese (BMI ≥30 kg/m<sup>2</sup>) [<xref rid="jiaf305-B2" ref-type="bibr">2</xref>]. Several contributing factors have been proposed, including off-target effects of antiretroviral therapy (ART), in particular tenofovir alafenamide and the integrase strand transfer inhibitors such as dolutegravir; an aging population; chronic inflammation; and increasingly obesogenic environments [<xref rid="jiaf305-B1" ref-type="bibr">1</xref>, <xref rid="jiaf305-B3" ref-type="bibr">3</xref>]. Women with HIV (WWH) are disproportionately affected, with their obesity prevalence nearly twice that of men (23.6% vs 12.1%) [<xref rid="jiaf305-B4" ref-type="bibr">4</xref>]. Of particular concern is the elevated risk among Black WWH. In pooled data from &gt;5000 PWH in clinical trials, Black WWH on ART gained an additional 2.72 kg over 96 weeks compared to their non-Black counterparts (<italic toggle="yes">P</italic> &lt; .001) [<xref rid="jiaf305-B5" ref-type="bibr">5</xref>].</p><p>Weight gain significantly raises the risk of type 2 diabetes mellitus (T2DM), and this risk is accentuated in PWH. Every 2.3 kg gained increases T2DM risk by 14% in PWH, compared to 8% in people without HIV [<xref rid="jiaf305-B6" ref-type="bibr">6</xref>]. Consequently, approximately one-third of PWH develop dysglycemia (T2DM or insulin resistance/prediabetes), requiring therapy [<xref rid="jiaf305-B7" ref-type="bibr">7</xref>]. Once established, real-world data indicate that glucose control in diabetic PWH is poor, with 1 study showing only 41% achieving glycated hemoglobin targets, compared with 70% of the diabetes-only controls [<xref rid="jiaf305-B8" ref-type="bibr">8</xref>, <xref rid="jiaf305-B9" ref-type="bibr">9</xref>].</p><p>With the rising dual epidemics of HIV and dysglycemia, ART and oral antidiabetic drug co-prescription is increasingly common [<xref rid="jiaf305-B10" ref-type="bibr">10</xref>]. Metformin is the preferred first-line oral antidiabetic drug worldwide due to its favorable side-effect profile, wide dose range, affordability, and, importantly in the context of PWH in SSA, weight neutrality or weight loss [<xref rid="jiaf305-B11" ref-type="bibr">11</xref>]. The first-line ART recommended in all populations by the World Health Organization is a dolutegravir-based regimen and, in South Africa alone—the country with the largest ART program in the world—an estimated 1–1.5 million PWH receive concomitant dolutegravir and metformin [<xref rid="jiaf305-B12" ref-type="bibr">12</xref>, <xref rid="jiaf305-B13" ref-type="bibr">13</xref>].</p><p>Despite the individual safety and tolerability profiles of metformin and dolutegravir, a significant pharmacokinetic (PK) drug interaction exists between the 2 drugs. A phase 1 PK study by Song et al in 15 healthy volunteers showed that dolutegravir significantly increased the steady-state metformin plasma exposure when dosed concomitantly: 79% increase in metformin area under the concentration-time curve (AUC), and 66% increase in the maximum concentration (using metformin immediate-release formulation 500 mg twice daily and dolutegravir 50 mg once daily) [<xref rid="jiaf305-B14" ref-type="bibr">14</xref>]. The proposed mechanism involves dolutegravir inhibiting the organic cation transporters that facilitate the exclusive renal elimination of metformin, leading to decreased metformin excretion in the urine with resultant increased plasma exposure. The drug transporters that have been shown to significantly affect metformin disposition are the organic cationic transporter 2 (OCT2), encoded by the solute carrier gene 22A2 (<italic toggle="yes">SLC22A2</italic>) [<xref rid="jiaf305-B15" ref-type="bibr">15</xref>], with contributions from human multidrug and toxin extrusion 1 (MATE-1) and 2-K (MATE2-K) transporters, encoded by <italic toggle="yes">SLC47A1</italic> and <italic toggle="yes">SLC47A2</italic>, respectively [<xref rid="jiaf305-B16" ref-type="bibr">16</xref>].</p><p>Accordingly, the product information of both drugs was updated, warning of the interaction. Reputable clinical guidelines [<xref rid="jiaf305-B17" ref-type="bibr">17</xref>] and drug interaction tools [<xref rid="jiaf305-B18" ref-type="bibr">18</xref>] subsequently recommend a maximum metformin dose of 1000 mg per day when coadministered with dolutegravir (usual metformin dose range, 500–3000 mg per day). To date, however, this recommendation for the metformin dose adjustment has not been verified in a PK study in the target population of PWH. The largest target population of PWH is in SSA, where most are Black African (97%) [<xref rid="jiaf305-B19" ref-type="bibr">19</xref>] and female (64%) [<xref rid="jiaf305-B20" ref-type="bibr">20</xref>], in contrast to the healthy volunteers in the reference drug interaction study by Song et al, who were mostly White (93%) and male (73%) [<xref rid="jiaf305-B14" ref-type="bibr">14</xref>]. Importantly, the population in this reference study was limited to a BMI between 18.5 and 31.0 kg/m<sup>2</sup> (actual patient data not reported), whereas more than a quarter of PWH in SSA are obese with a BMI of &gt;30 kg/m<sup>2</sup> [<xref rid="jiaf305-B4" ref-type="bibr">4</xref>].</p><p>Our study aimed to compare the steady-state metformin and dolutegravir plasma exposures in the target population of obese WWH to the metformin and dolutegravir exposures reported in nonobese healthy volunteers from the reference study [<xref rid="jiaf305-B14" ref-type="bibr">14</xref>].</p><sec sec-type="materials|methods" id="jiaf305-s1"><title>MATERIALS AND METHODS</title><sec id="jiaf305-s1.1"><title>Study Design and Population</title><p>We conducted an observational, single-period, PK study in obese WWH recruited from the interventional SMART trial (Study of metformin to reduce cerebrovascular dysfunction in South African patients with HIV and metabolic syndrome: a phase II pilot trial, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05571319">NCT05571319</ext-link>). In short, SMART assessed the effects of 12 weeks of metformin to improve cerebrovascular function in virally suppressed PWH with metabolic syndrome, providing a representative cohort of the target population. Participants were recruited from the Gugulethu Community Health Clinic in Cape Town, South Africa, by convenience sampling, and were required to be on dolutegravir-based ART for at least 12 months and at metformin steady-state (at least 7 days) at the time of PK sampling. The study was conducted in the Family Centre for Research with Ubuntu (FAMCRU) clinical trial unit. No formal sample size calculation was performed; however, we enrolled 15 participants in keeping with regulatory guidance and to ensure comparability with the reference study on which the metformin dose adjustment recommendation was based [<xref rid="jiaf305-B14" ref-type="bibr">14</xref>].</p></sec><sec id="jiaf305-s1.2"><title>Interventions</title><p>Participants received metformin extended-release 1000 mg once daily (Glucophage XR, Merck Healthcare) and a fixed-dose combination of dolutegravir 50 mg, tenofovir disoproxil fumarate 300 mg, and lamivudine 300 mg once daily. Both drugs were administered after an overnight 8-hour food and medication fast with a moderate-fat meal under observation. A moderate-fat meal was chosen in keeping with the reference study, due to reduced absorption and exposure of metformin when taken with food. All participants were requested to take their medications for the preceding 3 days before sampling in a staggered dosing schedule to allow spacing of the subsequent sampling times. No other drugs were permitted during the sampling period, but participants were allowed to eat and drink freely 3 hours after drug administration.</p></sec><sec id="jiaf305-s1.3"><title>Pharmacokinetic Sampling and Covariates</title><p>We conducted intensive plasma sampling over 8 timepoints at metformin and dolutegravir steady-state: predose (within 15 minutes of dosing), and at 1, 3, 4, 6, 8, 10, and 12 hours after drug administration. Blood samples were collected in ethylenediaminetetraacetic acid (EDTA) and serum separator tubes. We quantified renal function on the day of sampling, and genotyped selected single-nucleotide polymorphisms (SNPs) of OCT2, MATE-1, and MATE2-K: <italic toggle="yes">SLC22A2</italic> (OCT2)—rs316019, rs8177507, rs8177517, rs145450955, and rs201919874; <italic toggle="yes">SLC47A1</italic> (MATE-1)—rs2289669 and rs8065082; <italic toggle="yes">SLC47A2</italic> (MATE2-K)—rs12943590. We also quantified body composition to determine fat, lean, and bone mass using dual-energy X-ray absorptiometry (DEXA) with the Hologic Discovery W system. We explored an additional metric of body composition, the body roundness index (BRI), as it has shown promise in its predictive correlation with metabolic diseases [<xref rid="jiaf305-B21" ref-type="bibr">21</xref>].</p></sec><sec id="jiaf305-s1.4"><title>Bioanalytical Methods</title><p>Metformin and dolutegravir quantification were performed according to US Food and Drug Administration and European Medicines Agency standards on a Shimadzu LC-MS 8040 triple quadrupole mass spectrometer (MS) connected to a Shimadzu Prominence liquid chromatography (LC) system (Kyoto, Japan). Further details are provided in the <xref rid="sup1" ref-type="supplementary-material">Supplementary Material</xref>.</p><p>For genotyping, human DNA was extracted from buffy coats of centrifuged whole blood collected in EDTA tubes using Quick DNA Miniprep Plus kits (Zymo Research, USA). SNPs were analyzed simultaneously using the MassARRAY (Agena Biosciences, USA) and TaqMan (Thermo Fisher Scientific, USA) systems.</p></sec><sec id="jiaf305-s1.5"><title>Data Analysis</title><p>Pharmacokinetic and statistical analyses were conducted using Phoenix WinNonlin (version 8.4, Certara Inc, USA) and STATA (release 18.5, StataCorp LLC, USA) software. Graphs were generated in RStudio (version 4.3.0, R Core Team, Austria) and GraphPad Prism (version 10.3.1, GraphPad Software, USA). Normally distributed data were expressed as mean and standard deviation, and nonnormally distributed data as median and interquartile range. We determined the following PK parameters from the metformin and dolutegravir plasma concentration-time data: AUC, maximum concentration (C<sub>max</sub>), time to maximum concentration (T<sub>max</sub>), calculated trough concentration (C<sub>trough</sub>), and apparent clearance and volume of distribution after oral dosing (CL/F and Vd/F, respectively). PK parameters were reported as geometric means with the associated coefficient of variation, expressed as a percentage (%CV), in keeping with the reporting method by the reference study [<xref rid="jiaf305-B14" ref-type="bibr">14</xref>]. Due to operational constraints, sampling over the full 24-hour period was not feasible, and the metformin and dolutegravir concentrations at the 24-hour timepoint (C<sub>trough</sub>) were extrapolated using noncompartmental analysis. The extrapolated C<sub>trough</sub> was calculated using the logarithmic interpolation rule, and both the observed AUC<sub>0–12</sub> and the extrapolated AUC<sub>0–24</sub> were calculated using the linear up-log down method. Linear regression was used to identify covariates associated with metformin and dolutegravir exposure.</p></sec><sec id="jiaf305-s1.6"><title>Ethics</title><p>The study was approved by ethics committees at Stellenbosch University (HEA-2022–25044), the University of Cape Town (206/2022), and the provincial and local hospital authorities. The study was conducted in accordance with local and international ethical principles, including the Declaration of Helsinki (2013), International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines, and Good Clinical Practice.</p></sec></sec><sec sec-type="results" id="jiaf305-s2"><title>RESULTS</title><p>We enrolled 15 Black African WWH with a mean BMI of 45.6 kg/m<sup>2</sup> (range, 35.6–56.7 kg/m<sup>2</sup>). Class III obesity was present in 80% of participants. Participant characteristics, renal function, and body composition are summarized in <xref rid="jiaf305-T1" ref-type="table">Table 1</xref>. The metformin and dolutegravir plasma concentration-time curves are shown in <xref rid="jiaf305-F1" ref-type="fig">Figure 1</xref>. The geometric mean AUC over the measured 12-hour sampling period (AUC<sub>0–12</sub>) was 10.1 μg x hour/mL (%CV 28.9) for metformin and 16.9 μg x hour/mL (35.2) for dolutegravir. The extrapolated geometric mean AUC over the 24-hour dosing interval (AUC<sub>0–24</sub>) was 14.42 μg x hour/mL (33.6) for metformin and 24.9 μg x hour/mL (39.9) for dolutegravir (<xref rid="jiaf305-T2" ref-type="table">Table 2</xref>).</p><fig position="float" id="jiaf305-F1" fig-type="figure" orientation="portrait"><label>Figure 1.</label><caption><p>Individual (gray) and average (colored) metformin (<italic toggle="yes">A</italic>) and dolutegravir (<italic toggle="yes">B</italic>) plasma concentration-time curves. Average data are presented as arithmetic means (filled circles) and standard deviation, compared to the table and text that report geometric means and coefficient of variance (%CV). The concentration at 24 hours postdose (triangle) was extrapolated using the logarithmic interpolation rule.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jiaf305f1.jpg"><alt-text>Alt text: Graph depicting the metformin plasma concentration-over-time profile in panel A, and the dolutegravir concentration-over-time profile in panel B.</alt-text></graphic></fig><table-wrap position="float" id="jiaf305-T1" orientation="portrait"><label>Table 1.</label><caption><p>Participant Characteristics (N = 15)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="center" rowspan="1" colspan="1">Mean ± SD<sup><xref rid="tblfn2" ref-type="table-fn">a</xref></sup></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (y)</td><td rowspan="1" colspan="1">43.8 ± 11.5</td></tr><tr><td rowspan="1" colspan="1">Weight (kg)</td><td rowspan="1" colspan="1">115.7 ± 15.4</td></tr><tr><td rowspan="1" colspan="1">Height (cm)</td><td rowspan="1" colspan="1">159.6 ± 8.0</td></tr><tr><td rowspan="1" colspan="1">Waist circumference (cm)</td><td rowspan="1" colspan="1">117.1 ± 10.3</td></tr><tr><td rowspan="1" colspan="1">Hip circumference (cm)</td><td rowspan="1" colspan="1">136.9 ± 11.3<sup><xref rid="tblfn3" ref-type="table-fn">b</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Waist-to-hip circumference ratio</td><td rowspan="1" colspan="1">0.86 ± 0.10<sup><xref rid="tblfn3" ref-type="table-fn">b</xref></sup></td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">45.6 ± 6.6</td></tr><tr><td rowspan="1" colspan="1"> Obesity class I (BMI 30–34.9 kg/m<sup>2</sup>), No. (%)</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1"> Obesity class II (BMI 35–39.9 kg/m<sup>2</sup>), No. (%)</td><td rowspan="1" colspan="1">3 (20)</td></tr><tr><td rowspan="1" colspan="1"> Obesity class III (BMI ≥40 kg/m<sup>2</sup>), No. (%)</td><td rowspan="1" colspan="1">12 (80)</td></tr><tr><td rowspan="1" colspan="1">Body roundness index</td><td rowspan="1" colspan="1">8.9 ± 1.7</td></tr><tr><td rowspan="1" colspan="1">Serum creatinine (μmol/L)</td><td rowspan="1" colspan="1">73.5 ± 7.7</td></tr><tr><td rowspan="1" colspan="1">Estimated glomerular filtration rate (mL/min/1.73 m<sup>2</sup>)</td><td rowspan="1" colspan="1">86.4 ± 11.6<sup><xref rid="tblfn4" ref-type="table-fn">c</xref></sup></td></tr><tr><td colspan="2" rowspan="1">Body composition on DEXA</td></tr><tr><td rowspan="1" colspan="1"> Total body fat percentage (%)</td><td rowspan="1" colspan="1">52.6 ± 3.9</td></tr><tr><td rowspan="1" colspan="1"> Fat mass/height<sup>2</sup> (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">24.6 ± 6.9</td></tr><tr><td rowspan="1" colspan="1"> Lean mass/height<sup>2</sup> (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">19.5 (17.5–21.4)<sup><xref rid="tblfn5" ref-type="table-fn">d</xref></sup></td></tr><tr><td rowspan="1" colspan="1"> Android/gynoid ratio</td><td rowspan="1" colspan="1">1.01 ± 0.06</td></tr><tr><td rowspan="1" colspan="1"> Android total mass (kg)</td><td rowspan="1" colspan="1">9.2 ± 1.4</td></tr><tr><td rowspan="1" colspan="1">  Android fat mass (kg)</td><td rowspan="1" colspan="1">5.1 ± 1.0</td></tr><tr><td rowspan="1" colspan="1">  Android lean bone mineral content (kg)</td><td rowspan="1" colspan="1">4.1 ± 0.5</td></tr><tr><td rowspan="1" colspan="1"> Gynoid total mass (kg)</td><td rowspan="1" colspan="1">18.3 ± 3.2</td></tr><tr><td rowspan="1" colspan="1">  Gynoid fat mass (kg)</td><td rowspan="1" colspan="1">10.0 ± 2.2</td></tr><tr><td rowspan="1" colspan="1">  Gynoid lean bone mineral content (kg)</td><td rowspan="1" colspan="1">8.3 ± 1.3</td></tr><tr><td rowspan="1" colspan="1"> Percentage fat trunk/percentage fat legs ratio</td><td rowspan="1" colspan="1">0.94 ± 0.05</td></tr><tr><td rowspan="1" colspan="1"> Trunk/limb fat mass ratio</td><td rowspan="1" colspan="1">0.88 ± 0.07</td></tr><tr><td rowspan="1" colspan="1"> Estimated visceral adipose tissue mass (kg)</td><td rowspan="1" colspan="1">1.0 ± 0.2</td></tr><tr><td rowspan="1" colspan="1"> Estimated visceral adipose tissue volume (cm<sup>3</sup>)</td><td rowspan="1" colspan="1">1105 ± 255</td></tr><tr><td rowspan="1" colspan="1"> Estimated visceral adipose tissue area (cm<sup>2</sup>)</td><td rowspan="1" colspan="1">212 ± 49</td></tr><tr><td rowspan="1" colspan="1"> Appendage lean/height<sup>2</sup> (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">8.98 (7.85–9.81)<sup><xref rid="tblfn5" ref-type="table-fn">d</xref></sup></td></tr><tr><td rowspan="1" colspan="1"> Total mass (kg)</td><td rowspan="1" colspan="1">114.2 ± 13.9</td></tr><tr><td rowspan="1" colspan="1">  Fat mass (kg)</td><td rowspan="1" colspan="1">60.2 ± 9.4</td></tr><tr><td rowspan="1" colspan="1">  Lean mass (kg)</td><td rowspan="1" colspan="1">51.6 ± 6.7</td></tr><tr><td rowspan="1" colspan="1">  Bone mineral content (kg)</td><td rowspan="1" colspan="1">2.4 ± 0.4</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>Abbreviations: BMI, body mass index; DEXA, dual-energy X-ray absorptiometry.</p></fn><fn id="tblfn2"><p>
<sup>a</sup>Values are mean ± standard deviation, unless otherwise specified.</p></fn><fn id="tblfn3"><p>
<sup>b</sup>n = 14.</p></fn><fn id="tblfn4"><p>
<sup>c</sup>Calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.</p></fn><fn id="tblfn5"><p>
<sup>d</sup>Median (interquartile range).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jiaf305-T2" orientation="portrait"><label>Table 2.</label><caption><p>Metformin and Dolutegravir Pharmacokinetic Parameters</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Metformin (n = 15)</th><th align="center" rowspan="1" colspan="1">Dolutegravir (n = 14)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">AUC<sub>0–24</sub>, μg x h/mL</td><td rowspan="1" colspan="1">14.42 (33.35) [12.29–16.94]</td><td rowspan="1" colspan="1">24.88 (39.88) [20.74–29.84]</td></tr><tr><td rowspan="1" colspan="1">C<sub>max</sub>, μg/mL</td><td rowspan="1" colspan="1">1.18 (29.56) [1.03–1.34]</td><td rowspan="1" colspan="1">1.99 (31.29) [1.73–2.29]</td></tr><tr><td rowspan="1" colspan="1">C<sub>trough</sub>, μg/mL</td><td rowspan="1" colspan="1">0.15 (96.90) [.10–.23]</td><td rowspan="1" colspan="1">0.30 (153.87) [.18–.51]</td></tr><tr><td rowspan="1" colspan="1">T<sub>max</sub>, h<sup><xref rid="tblfn8" ref-type="table-fn">a</xref></sup></td><td rowspan="1" colspan="1">6 (4–8)</td><td rowspan="1" colspan="1">3 (1–8)</td></tr><tr><td rowspan="1" colspan="1">CL/F, L/h</td><td rowspan="1" colspan="1">69.33 (33.35) [59.05–81.40]</td><td rowspan="1" colspan="1">2.01 (39.88) [1.68–2.41]</td></tr><tr><td rowspan="1" colspan="1">Vd/F, L</td><td rowspan="1" colspan="1">613.63 (45.14) [495.96–759.21]</td><td rowspan="1" colspan="1">23.53 (29.75) [20.50–27.00]</td></tr></tbody></table><table-wrap-foot><fn id="tblfn6"><p>Data are geometric mean (coefficient of variation [%CV]) [90% confidence interval] unless otherwise specified.</p></fn><fn id="tblfn7"><p>Abbreviations: AUC<sub>0–24</sub>, area under the concentration-time curve over the 24-hour dosing interval; CL/F, apparent clearance after oral dosing; C<sub>max</sub>, maximum concentration; C<sub>trough</sub>, trough concentration; T<sub>max</sub>, time to maximum concentration; Vd/F, apparent volume of distribution after oral dosing.</p></fn><fn id="tblfn8"><p>
<sup>a</sup>Median (range).</p></fn></table-wrap-foot></table-wrap><p>Compared to nonobese healthy volunteers in the reference study, metformin AUC<sub>0–24</sub> was 40.9% lower in obese WWH (<xref rid="jiaf305-T3" ref-type="table">Table 3</xref>). Dolutegravir AUC<sub>0–24</sub> was 54.4% lower compared to the reference study. The dolutegravir concentration before the next 24-hour dosing interval (C<sub>trough</sub>) was 76% lower than the reference (0.30 vs 1.25 μg/mL); all participants were virally suppressed. In the current study, metformin and dolutegravir clearance were 1.7- and 2.2-fold higher than the reference, respectively (69.33 vs 40.9 L/hour for metformin and 2.01 vs 0.91 L/hour for dolutegravir). The apparent volume of distribution of metformin was 2.4-fold higher in our cohort compared to the reference (613.6 vs 255.6 L, respectively).</p><table-wrap position="float" id="jiaf305-T3" orientation="portrait"><label>Table 3.</label><caption><p>Comparative Metformin and Dolutegravir Pharmacokinetic Parameters Between the Current and Reference Study</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="center" rowspan="1" colspan="1">Current Study</th><th align="center" rowspan="1" colspan="1">Reference Study [<xref rid="jiaf305-B14" ref-type="bibr">14</xref>]</th><th align="center" rowspan="1" colspan="1">Difference Between Current vs Reference Study</th></tr></thead><tbody><tr><td rowspan="2" colspan="1">Dosing strategy</td><td rowspan="1" colspan="1">Metformin XR 1000 mg once daily</td><td rowspan="1" colspan="1">Metformin IR 500 mg twice daily</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Dolutegravir 50 mg once daily</td><td rowspan="1" colspan="1">Dolutegravir 50 mg once daily</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">No. of participants</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Age (y)<sup><xref rid="tblfn10" ref-type="table-fn">a</xref></sup></td><td rowspan="1" colspan="1">43.8 ± 11.5</td><td rowspan="1" colspan="1">37.7 (SD not reported)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Female sex, No. (%)</td><td rowspan="1" colspan="1">15 (100)</td><td rowspan="1" colspan="1">4 (27)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)<sup><xref rid="tblfn10" ref-type="table-fn">a</xref></sup></td><td rowspan="1" colspan="1">45.6 ± 6.6</td><td rowspan="1" colspan="1">18.5–31.0<sup><xref rid="tblfn11" ref-type="table-fn">b</xref></sup></td><td rowspan="1" colspan="1"/></tr><tr><td colspan="4" rowspan="1">Metformin PK parameters<sup><xref rid="tblfn12" ref-type="table-fn">c</xref></sup></td></tr><tr><td rowspan="1" colspan="1"> AUC<sub>0–24</sub> (μg x h/mL)</td><td rowspan="1" colspan="1">14.42 (33.35)</td><td rowspan="1" colspan="1">24.4 (23.1)<sup><xref rid="tblfn13" ref-type="table-fn">d</xref></sup></td><td rowspan="1" colspan="1">↓40.9%</td></tr><tr><td rowspan="1" colspan="1"> C<sub>max</sub> (μg/mL)</td><td rowspan="1" colspan="1">1.18 (29.56)</td><td rowspan="1" colspan="1">1.55 (22.6)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> T<sub>max</sub> (h)<sup><xref rid="tblfn14" ref-type="table-fn">e</xref></sup></td><td rowspan="1" colspan="1">6 (4–8)</td><td rowspan="1" colspan="1">4 (1–6)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"> CL/F (L/h)</td><td rowspan="1" colspan="1">69.33 (33.35)</td><td rowspan="1" colspan="1">40.9 (23.1)</td><td rowspan="1" colspan="1">↑69.5%</td></tr><tr><td rowspan="1" colspan="1"> Vd/F (L)</td><td rowspan="1" colspan="1">613.63 (45.14)</td><td rowspan="1" colspan="1">255.6<sup><xref rid="tblfn15" ref-type="table-fn">f</xref></sup></td><td rowspan="1" colspan="1">↑240%</td></tr><tr><td colspan="4" rowspan="1">DTG PK parameters<sup><xref rid="tblfn12" ref-type="table-fn">c</xref></sup></td></tr><tr><td rowspan="1" colspan="1"> AUC<sub>0–24</sub> (μg x h/mL)</td><td rowspan="1" colspan="1">24.9 (39.9)</td><td rowspan="1" colspan="1">54.6 (25.7)</td><td rowspan="1" colspan="1">↓54.4%</td></tr><tr><td rowspan="1" colspan="1"> C<sub>max</sub> (μg/mL)</td><td rowspan="1" colspan="1">1.99 (31.29)</td><td rowspan="1" colspan="1">3.81 (27.7)</td><td rowspan="1" colspan="1">↓47.8%</td></tr><tr><td rowspan="1" colspan="1"> C<sub>trough</sub> (μg/mL)</td><td rowspan="1" colspan="1">0.30 (153.87)</td><td rowspan="1" colspan="1">1.25 (33.7)</td><td rowspan="1" colspan="1">↓76%</td></tr><tr><td rowspan="1" colspan="1"> T<sub>max</sub> (h)<sup><xref rid="tblfn14" ref-type="table-fn">e</xref></sup></td><td rowspan="1" colspan="1">3 (1–8)</td><td rowspan="1" colspan="1">4 (1–11.9)</td><td rowspan="1" colspan="1">↓25%</td></tr><tr><td rowspan="1" colspan="1"> CL/F (L/h)</td><td rowspan="1" colspan="1">2.01 (39.88)</td><td rowspan="1" colspan="1">0.91 (26.7)</td><td rowspan="1" colspan="1">↑120%</td></tr><tr><td rowspan="1" colspan="1"> Vd/F (L)</td><td rowspan="1" colspan="1">23.53 (29.75)</td><td rowspan="1" colspan="1">Not reported or calculable</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tblfn9"><p>Abbreviations: AUC<sub>0–24</sub>, area under the concentration-time curve over the 24-hour dosing interval; BMI, body mass index; CL/F, apparent clearance after oral dosing; C<sub>max</sub>, maximum concentration; C<sub>trough</sub>, trough concentration; DTG, dolutegravir; IR, immediate-release; PK, pharmacokinetic; SD, standard deviation; T<sub>max</sub>, time to maximum concentration; Vd/F, apparent volume of distribution after oral dosing; XR, extended-release.</p></fn><fn id="tblfn10"><p>
<sup>a</sup>Mean ± SD.</p></fn><fn id="tblfn11"><p>
<sup>b</sup>Range according to inclusion criteria due to lack of descriptive measures reported.</p></fn><fn id="tblfn12"><p>
<sup>c</sup>Data are geometric mean (coefficient of variation [%CV]) unless otherwise specified.</p></fn><fn id="tblfn13"><p>
<sup>d</sup>Extrapolated from AUC<sub>0–12</sub> by multiplying by 2 to obtain AUC<sub>0–24</sub>; %CV assumed the same.</p></fn><fn id="tblfn14"><p>
<sup>e</sup>Median (range).</p></fn><fn id="tblfn15"><p>
<sup>f</sup>Calculated using Vd<sub>beta</sub>/F = t(1/2) × CL/F/0.693, with beta denoting the terminal phase apparent oral volume of distribution (no variance available).</p></fn></table-wrap-foot></table-wrap><p>The majority of SNPs genotyped were homozygous for the reference alleles. For <italic toggle="yes">SLC22A2</italic> (OCT2), rs8177507, rs8177517, rs145450955, and rs201919874 were all homozygous for the reference allele; 3 of 15 participants were heterozygous for rs316019. For <italic toggle="yes">SLC47A1</italic> (MATE-1), 2 of 15 and 7 of 15 were homozygous and heterozygous, respectively, for rs8065082 variants that conferred lower metformin clearance; 1 of 15 was heterozygous for rs2289669. For <italic toggle="yes">SLC47A2</italic> (MATE2-K), 8 of 15 were heterozygous for rs12943590. The full SNP results are reported in the <xref rid="sup1" ref-type="supplementary-material">Supplementary Material</xref>. Linear regression did not reveal any associations of body composition (BMI, BRI, and DEXA), renal function, or SNPs of OCT2, MATE-1, and MATE2-K, with metformin or dolutegravir exposures.</p></sec><sec sec-type="discussion" id="jiaf305-s3"><title>DISCUSSION</title><p>We found that both metformin and dolutegravir concentrations were substantially lower in obese WWH compared to the reference study in nonobese healthy volunteers. These findings argue against the current recommendation to limit metformin to 1000 mg daily when coadministered with dolutegravir, particularly in obese patients, considering metformin's wide therapeutic index. Supporting literature indicates that metformin doses &gt;1000 mg daily with dolutegravir do not lead to increased adverse effects [<xref rid="jiaf305-B22" ref-type="bibr">22</xref>], nor improved glycemic control [<xref rid="jiaf305-B23" ref-type="bibr">23</xref>], implying that the increased exposure in nonobese patients may still be subtherapeutic in obese individuals. Since our data indicate metformin exposure is even lower in obese participants, the metformin dose limitation warrants reconsideration.</p><p>The reduced metformin exposure in our cohort is likely multifactorial—first, due to the direct effect of obesity on the increase in metformin CL/F and Vd/F; second, due to the obesity-related increase in the CL/F and Vd/F of dolutegravir with lower dolutegravir concentrations, which, last, directly decreases the magnitude of the interaction between dolutegravir and metformin with subsequent higher metformin CL/F.</p><p>Obesity-related physiological changes significantly alters PK, and of relevance to metformin is the increase in Vd/F due to increased adipose tissue and the increased clearance of renally excreted drugs [<xref rid="jiaf305-B24" ref-type="bibr">24</xref>]. Lower metformin concentrations have been reported in obese adolescents, due to oral clearance increasing to more than double that of nonobese children (70.2 vs 33 L/hour) [<xref rid="jiaf305-B25" ref-type="bibr">25</xref>]. The magnitude of obesity has also been associated with increased metformin clearance, with an adolescent study of 11 obese participants (mean BMI, 37.5 ± 3.3 kg/m<sup>2</sup>) finding an increase in metformin clearance with increasing BMI: mean CL/F of 76.8, 83.6, and 86.2 L/hour in class I, II, and III obesity, respectively [<xref rid="jiaf305-B26" ref-type="bibr">26</xref>]. In addition to our comparison to Song et al, we contextualized our findings by using a metformin population PK (popPK) model developed by Bardin et al that included a large proportion of obese participants with weight included as a covariate in the final model [<xref rid="jiaf305-B27" ref-type="bibr">27</xref>]. Substituting our population's average values into Bardin and colleagues’ popPK model, CL/F in our population was predicted to be 76.49 L/hour, which was similar to our observed mean clearance of 69.33 L/hour, but notably different from Song and colleagues’ mean value of 40.9 L/hour. Our study also found an increase in the metformin Vd/F. Substituting our average values into the popPK model by Bardin et al, the predicted metformin Vd/F was 498.32 L, compared to our observed value of 613.63 L and Song and colleagues’ value of 255.6 L. It should be noted that we used secondary PK parameters to calculate the volume of distribution for the Song et al study, leading to the calculation of the elimination phase apparent volume (Vd<sub>beta</sub>/F). Still, the Vd/F in our obese participants was 2.4-fold higher compared to the nonobese cohort of Song et al. An interesting observation from Song et al is the difference in the metformin Vd<sub>beta</sub>/F for the period without dolutegravir (419.9 L) compared to the period with dolutegravir (255.6 L) within the same participants (1.6-fold increase). This interoccasion finding from Song et al suggests that dolutegravir itself may impact metformin's volume of distribution as well as clearance. The mechanism behind dolutegravir's suspected increase in metformin's volume of distribution is not yet known, as dolutegravir is not a known inhibitor of non-OCT2 transporters involved in metformin disposition [<xref rid="jiaf305-B14" ref-type="bibr">14</xref>], and further research is needed to investigate this observation.</p><p>Obesity-related physiological changes also alter dolutegravir PK, and higher body weight is associated with increased CL/F and Vd/F [<xref rid="jiaf305-B28" ref-type="bibr">28–30</xref>]. Using a dolutegravir popPK model by Zhang et al that included obese participants from 2 studies [<xref rid="jiaf305-B31" ref-type="bibr">31</xref>], the predicted CL/F in our cohort was 1.14 L, lower than our observed 2.01 L but marginally higher than Song and colleagues’ 0.91 L. Zhang and colleagues’ model included bilirubin concentrations as a covariate, which we could not include in our model estimate as we did not measure bilirubin. Bilirubin accounted for 26% of variability in CL/F in the model and may have affected the prediction accuracy in our participants. Our population's model-predicted Vd/F was 25.59 L, which was in keeping with our observed mean value of 23.53 L (Song and colleagues’ Vd/F was not calculable). In support of our observation that obesity alters dolutegravir exposure, Zhang et al showed in their analysis population that CL/F and Vd/F were 33% and 66% higher, respectively, for a 135-kg participant compared with a 70-kg participant. The mechanism behind the increased dolutegravir clearance with increased body weight is currently not clear. Emerging evidence indicates that the phase 2 enzyme, uridine diphosphate glucuronosyltransferase (UGT) 1A1, may be induced in obesity [<xref rid="jiaf305-B32" ref-type="bibr">32</xref>]. This was suggested by higher UGT1A1 expression in obese compared to lean mice, as well as the observation that bilirubin, a primary substrate of UGT1A1, was lower with a corresponding increased concentration of its metabolite, urobilin, in obese compared to lean human participants [<xref rid="jiaf305-B32" ref-type="bibr">32</xref>]. As the primary metabolic pathway of dolutegravir is UGT1A1 [<xref rid="jiaf305-B33" ref-type="bibr">33</xref>], induction of this enzyme may lead to increased hepatic clearance of dolutegravir. The mechanism underlying the proposed increase in UGT1A1 activity in obesity is yet to be determined.</p><p>In view of the above, it follows that lower dolutegravir plasma concentrations will lead to less metformin renal inhibition and increased clearance, with subsequent lower metformin concentrations, as was found in our study. While Song et al reported a 79% increase in metformin exposure with dolutegravir, this far exceeded the expected 5% increase, suggesting other factors, such as body composition, may explain the discrepancy. By using the Bardin et al model, we confirmed that obesity can explain part of the exposure difference, although the model lacks dolutegravir as a covariate, which may contribute to prediction variation.</p><p>The substantially lower exposure of both metformin and dolutegravir in obese PWH warrants further investigation. Following Song and colleagues’ publication, clinicians reported difficulty managing dysglycemia in diabetic PWH when metformin is restricted to 1000 mg daily [<xref rid="jiaf305-B34" ref-type="bibr">34</xref>]. However, the ideal dose range and maximum dose of metformin in this population have not yet been established. Several popPK models have been developed to investigate the covariates involved in metformin exposure [<xref rid="jiaf305-B35" ref-type="bibr">35</xref>]. Body weight was found to be a consistent descriptor of both metformin CL/F and Vd/F [<xref rid="jiaf305-B27" ref-type="bibr">27</xref>]. However, no model to date has included dolutegravir concentrations as a covariate. Future studies should include interindividual and interoccasion comparisons across body compositions, and future metformin popPK models should incorporate dolutegravir concentrations to better explore the interaction and to determine the optimal metformin dose in PWH on dolutegravir.</p><p>Our finding of lower dolutegravir concentrations may have direct implications for clinical care. In population studies, the standard daily dose of dolutegravir 50 mg results in C<sub>trough</sub> concentrations far exceeding the purported target of the in vitro protein-adjusted 90% inhibitory concentration (PA-IC<sub>90</sub>) of 0.064 μg/mL, often by 15-fold or higher [<xref rid="jiaf305-B30" ref-type="bibr">30</xref>, <xref rid="jiaf305-B36" ref-type="bibr">36</xref>, <xref rid="jiaf305-B37" ref-type="bibr">37</xref>]. Dolutegravir C<sub>trough</sub> also typically exceeds the more clinically relevant minimum effective concentration (MEC) of 0.30 μg/mL [<xref rid="jiaf305-B38" ref-type="bibr">38</xref>], and therapeutic drug monitoring is therefore generally not needed. The present study's extrapolated dolutegravir C<sub>trough</sub> of 0.30 μg/mL approximated the MEC, potentially risking loss of viral suppression in this population. Reassuringly, our morbidly obese participants remained suppressed. Furthermore, a healthy volunteer study found that the enzyme induction effect of rifampicin on dolutegravir was significant, but could be overcome by increasing the once-daily dolutegravir dose to 50 mg every 12 hours [<xref rid="jiaf305-B39" ref-type="bibr">39</xref>]. However, the recent RADIANT-TB trial (Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis) found no difference in viral suppression or resistance between standard and supplementary dolutegravir dosing with rifampicin, supporting simplified dosing [<xref rid="jiaf305-B37" ref-type="bibr">37</xref>]. Given that the actual efficacy target for dolutegravir is not currently known—as neither the PA-IC<sub>90</sub> nor MEC are validated targets [<xref rid="jiaf305-B38" ref-type="bibr">38</xref>]—when common factors that reduce dolutegravir exposure are compounded, such as enzyme induction, suboptimal adherence, and now obesity, the dolutegravir C<sub>trough</sub> may be reduced to below the yet undetermined PK target for effectiveness, potentially leading to HIV replication and drug resistance evolution.</p><p>Our study has several limitations. First, our study did not have a control group, but used the published reference study by Song et al as the comparator. A pre–post design as with Song et al was not feasible, as our participants were on stable dolutegravir-based ART and discontinuation was not ethically justifiable. Additionally, our study used the metformin extended-release formulation in contrast to the immediate-release formulation that was used in Song et al. However, Timmins et al demonstrated bioequivalence between these formulations for the same total daily dose (geometric mean ratio, 1.00 [90% confidence interval, .93–1.07]) [<xref rid="jiaf305-B40" ref-type="bibr">40</xref>], and both studies administered a total of 1000 mg/day. Therefore, formulation differences are unlikely to account for exposure differences.</p><p>Second, we did not directly observe dosing in the days leading up to sampling, but participants confirmed intake times and sampling was planned accordingly. Although minor deviations could contribute to variability, dolutegravir's long half-life and the relatively narrow C<sub>max</sub> to C<sub>trough</sub> difference observed in our study likely minimized any major effect. Third, as we lacked a 24-hour sampling point, we used noncompartmental analysis to extrapolate C<sub>trough</sub> and AUC<sub>0–24</sub> from AUC<sub>0–12</sub>. Fourth, while linear regression did not identify significant association between drug concentrations and selected variables, our study was not powered for such an analysis. A significant relationship may therefore still be present and should be explored in a larger study. Last, due to the prevalence of obesity among WWH and our convenience sampling design, we only included women. According, the findings may not be readily extrapolatable to men. Previous studies have suggested that drug concentrations in general may be higher in women than men, even after adjusting for weight [<xref rid="jiaf305-B41" ref-type="bibr">41</xref>]. For dolutegravir specifically, early-phase trials have shown an approximately 30% lower CL/F in women compared to men, with the reason not currently clear [<xref rid="jiaf305-B42" ref-type="bibr">42</xref>]. Metformin C<sub>max</sub> was also found to be higher in women than men in a healthy volunteer study (women/men C<sub>max</sub> ratio 1.4) [<xref rid="jiaf305-B43" ref-type="bibr">43</xref>]. These observations suggest that obese men may have even lower concentrations than obese women.</p><p>In conclusion, restricting metformin to 1000 mg daily is likely to lead to subtherapeutic concentrations in obese PWH on dolutegravir, as both drug concentrations were substantially lower in obese WWH. These reductions appear to be primarily due to obesity-related pharmacokinetic changes, although the exact mechanisms require further investigation. While additional studies incorporating a wider range of body mass indices and modeling approaches are needed to establish optimal metformin dosing in obese PWH on dolutegravir, the current evidence suggests that the uniform dose restriction is inappropriate for this patient population, given metformin's wide therapeutic index and established safety profile. Our data support the revision of the current maximum dose restriction of metformin in the target population of obese PWH.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data" orientation="portrait"><label>jiaf305_Supplementary_Data</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jiaf305_supplementary_data.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><sec id="jiaf305-s4"><title>Supplementary Data</title><p>
<xref rid="sup1" ref-type="supplementary-material">Supplementary materials</xref> are available at <italic toggle="yes">The Journal of Infectious Diseases</italic> online (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://jid.oxfordjournals.org/" ext-link-type="uri">http://jid.oxfordjournals.org/</ext-link>). <xref rid="sup1" ref-type="supplementary-material">Supplementary materials</xref> consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all <xref rid="sup1" ref-type="supplementary-material">supplementary data</xref> are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.</p></sec><sec id="jiaf305-s5"><title>Notes</title><p>
<bold>
<italic toggle="yes">Acknowledgments.</italic>
</bold> We gratefully acknowledge the community and participants of this study, and the staff of FAMCRU. We also express our gratitude to the staff at the Desmond Tutu Health Foundation Gugulethu site, and Gary Maartens for his insights and suggestions.</p><p>
<bold>
<italic toggle="yes">Author contributions.</italic>
</bold> R. v. R. and E. D. conceptualized the study and methodology. R. v. R., E. D., and G. S. secured funding. R. v. R., C. O., C. S., and L. J. provided study coordination and data management. T. K. and C. d. P. performed the bioanalytical analysis. R. v. R. and V. P.-F. L. conducted the pharmacokinetic analysis, validation, and visualizations. I. M. conducted the statistical analysis. E. D., G. S., and G. v. Z. provided supervision. R. v. R., E. D., V. P.-F. L., T. K., C. d. P., and I. M. directly accessed and verified the underlying data reported in the manuscript. R. v. R. and E. D. wrote the original draft of the manuscript. All authors reviewed the manuscript, provided scientific input to the manuscript, and agreed with the decision to submit the manuscript.</p><p>
<bold>
<italic toggle="yes">Disclaimer.</italic>
</bold> The content hereof is the sole responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the South African Medical Research Council. The funders of the study were not involved in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. Merck Healthcare had no input in the study design, conduct, analysis, results, or the decision to publish.</p><p>
<bold>
<italic toggle="yes">Data availability.</italic>
</bold> Study data will not be publicly available. Data can be made available to interested researchers after submission of a clear proposal to the corresponding author. De-identified participant data with an accompanying data dictionary can be made available and shared under a data transfer agreement.</p><p>
<bold>
<italic toggle="yes">Financial support.</italic>
</bold> This work was supported by the Fogarty International Center at the National Institutes of Health (grant numbers R21TW012185 to E. D. and G. S.; D43TW010937 to R. v. R.) and by the South African Medical Research Council through its Division of Research Capacity Development under the Clinician Researcher Development Programme, with funding received from the South African National Department of Health (to R. v. R.). R. v. R. was also supported with funding by the Discovery Foundation and the Harry Crossley Foundation. Metformin extended-release (XR) tablets were sponsored by Merck Healthcare for the parent SMART trial to E. D. and G. S.</p></sec><ref-list id="ref1"><title>References</title><ref id="jiaf305-B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Bailin</surname>
<given-names>SS</given-names>
</string-name>, <string-name name-style="western"><surname>Gabriel</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Wanjalla</surname><given-names>CN</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Obesity and weight gain in persons with HIV</article-title>. <source>Curr HIV/AIDS Rep</source><year>2020</year>; <volume>17</volume>:<fpage>138</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="pmid">32072466</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11904-020-00483-5</pub-id><pub-id pub-id-type="pmcid">PMC7719267</pub-id></mixed-citation></ref><ref id="jiaf305-B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Moyo-Chilufya</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western"><surname>Maluleke</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kgarosi</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>The burden of non-communicable diseases among people living with HIV in sub-Saharan Africa: a systematic review and meta-analysis</article-title>. <source>eClinicalMedicine</source><year>2023</year>; <volume>65</volume>:<fpage>102255</fpage>.<pub-id pub-id-type="pmid">37842552</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2023.102255</pub-id><pub-id pub-id-type="pmcid">PMC10570719</pub-id></mixed-citation></ref><ref id="jiaf305-B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Bailin</surname>
<given-names>SS</given-names>
</string-name>, <string-name name-style="western"><surname>Koethe</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Rebeiro</surname><given-names>PF</given-names></string-name></person-group>. <article-title>The pathogenesis of obesity in people living with HIV</article-title>. <source>Curr Opin HIV AIDS</source><year>2024</year>; <volume>19</volume>:<fpage>6</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="pmid">37934696</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/COH.0000000000000834</pub-id><pub-id pub-id-type="pmcid">PMC10842175</pub-id></mixed-citation></ref><ref id="jiaf305-B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Gizamba</surname>
<given-names>JM</given-names>
</string-name>, <string-name name-style="western"><surname>Davies</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Africa</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Prevalence of obesity, hypertension and diabetes among people living with HIV in South Africa: a systematic review and meta-analysis</article-title>. <source>BMC Infect Dis</source><year>2023</year>; <volume>23</volume>:<fpage>861</fpage>.<pub-id pub-id-type="pmid">38062372</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12879-023-08736-5</pub-id><pub-id pub-id-type="pmcid">PMC10704741</pub-id></mixed-citation></ref><ref id="jiaf305-B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Sax</surname>
<given-names>PE</given-names>
</string-name>, <string-name name-style="western"><surname>Erlandson</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Lake</surname><given-names>JE</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials</article-title>. <source>Clin Infect Dis</source><year>2020</year>; <volume>71</volume>:<fpage>1379</fpage>–<lpage>89</lpage>.<pub-id pub-id-type="pmid">31606734</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciz999</pub-id><pub-id pub-id-type="pmcid">PMC7486849</pub-id></mixed-citation></ref><ref id="jiaf305-B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Herrin</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western"><surname>Tate</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Akgün</surname><given-names>KM</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Weight gain and incident diabetes among HIV-infected veterans initiating antiretroviral therapy compared with uninfected individuals</article-title>. <source>J Acquir Immune Defic Syndr</source><year>2016</year>; <volume>73</volume>:<fpage>228</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">27171741</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/QAI.0000000000001071</pub-id><pub-id pub-id-type="pmcid">PMC5023454</pub-id></mixed-citation></ref><ref id="jiaf305-B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Asgedom</surname>
<given-names>YS</given-names>
</string-name>, <string-name name-style="western"><surname>Kebede</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Gebrekidan</surname><given-names>AY</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Prevalence of metabolic syndrome among people living with human immunodeficiency virus in sub-Saharan Africa: a systematic review and meta-analysis</article-title>. <source>Scientific Reports</source><year>2024</year>; <volume>14</volume>:<fpage>11709</fpage>.<pub-id pub-id-type="pmid">38777850</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-62497-y</pub-id><pub-id pub-id-type="pmcid">PMC11111734</pub-id></mixed-citation></ref><ref id="jiaf305-B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Fazekas-Lavu</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western"><surname>Tonks</surname><given-names>KTT</given-names></string-name>, <string-name name-style="western"><surname>Samaras</surname><given-names>K</given-names></string-name></person-group>. <article-title>Benchmarks of diabetes care in men living with treated HIV-infection: a tertiary center experience</article-title>. <source>Front Endocrinol</source><year>2018</year>; <volume>9</volume>:<fpage>409862</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2018.00634</pub-id><pub-id pub-id-type="pmcid">PMC6220317</pub-id><pub-id pub-id-type="pmid">30429826</pub-id></mixed-citation></ref><ref id="jiaf305-B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Cattaneo</surname>
<given-names>D</given-names>
</string-name>, <string-name name-style="western"><surname>Gidaro</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rossi</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Management of diabetes mellitus in people living with HIV: a single-center experience</article-title>. <source>Front Pharmacol</source><year>2023</year>; <volume>13</volume>:<fpage>1082992</fpage>.<pub-id pub-id-type="pmid">36712651</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2022.1082992</pub-id><pub-id pub-id-type="pmcid">PMC9873960</pub-id></mixed-citation></ref><ref id="jiaf305-B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Nansseu</surname>
<given-names>JR</given-names>
</string-name>, <string-name name-style="western"><surname>Bigna</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Kaze</surname><given-names>AD</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Incidence and risk factors for prediabetes and diabetes mellitus among HIV-infected adults on antiretroviral therapy</article-title>. <source>Epidemiology</source><year>2018</year>; <volume>29</volume>:<fpage>431</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">29394189</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/EDE.0000000000000815</pub-id></mixed-citation></ref><ref id="jiaf305-B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Solini</surname>
<given-names>A</given-names>
</string-name>, <string-name name-style="western"><surname>Tricò</surname><given-names>D</given-names></string-name></person-group>. <article-title>Clinical efficacy and cost-effectiveness of metformin in different patient populations: a narrative review of real-world evidence</article-title>. <source>Diabetes Obes Metab</source><year>2024</year>; <volume>26</volume>(<issue>Suppl 3</issue>):<fpage>20</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">38939954</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.15729</pub-id></mixed-citation></ref><ref id="jiaf305-B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Grundlingh</surname>
<given-names>N</given-names>
</string-name>, <string-name name-style="western"><surname>Zewotir</surname><given-names>TT</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>DJ</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Assessment of prevalence and risk factors of diabetes and pre-diabetes in South Africa</article-title>. <source>J Health Popul Nutr</source><year>2022</year>; <volume>41</volume>:<fpage>7</fpage>.<pub-id pub-id-type="pmid">35236427</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s41043-022-00281-2</pub-id><pub-id pub-id-type="pmcid">PMC8889060</pub-id></mixed-citation></ref><ref id="jiaf305-B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Magodoro</surname>
<given-names>IM</given-names>
</string-name>, <string-name name-style="western"><surname>Okello</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dungeni</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Association between HIV and prevalent hypertension and diabetes mellitus in South Africa: analysis of a nationally representative cross-sectional survey</article-title>. <source>Int J Infect Dis</source><year>2022</year>; <volume>121</volume>:<fpage>217</fpage>–<lpage>25</lpage>.<pub-id pub-id-type="pmid">35597557</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijid.2022.05.035</pub-id><pub-id pub-id-type="pmcid">PMC9337715</pub-id></mixed-citation></ref><ref id="jiaf305-B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Song</surname>
<given-names>IH</given-names>
</string-name>, <string-name name-style="western"><surname>Zong</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Borland</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects</article-title>. <source>J Acquir Immune Defic Syndr</source><year>2016</year>; <volume>72</volume>:<fpage>400</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">26974526</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/QAI.0000000000000983</pub-id><pub-id pub-id-type="pmcid">PMC4935531</pub-id></mixed-citation></ref><ref id="jiaf305-B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Wang</surname>
<given-names>ZJ</given-names>
</string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>OQP</given-names></string-name>, <string-name name-style="western"><surname>Tomlinson</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine</article-title>. <source>Pharmacogenet Genomics</source><year>2008</year>; <volume>18</volume>:<fpage>637</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="pmid">18551044</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FPC.0b013e328302cd41</pub-id></mixed-citation></ref><ref id="jiaf305-B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Gong</surname>
<given-names>L</given-names>
</string-name>, <string-name name-style="western"><surname>Goswami</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Giacomini</surname><given-names>KM</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Metformin pathways: pharmacokinetics and pharmacodynamics</article-title>. <source>Pharmacogenet Genomics</source><year>2012</year>; <volume>22</volume>:<fpage>820</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">22722338</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FPC.0b013e3283559b22</pub-id><pub-id pub-id-type="pmcid">PMC3651676</pub-id></mixed-citation></ref><ref id="jiaf305-B17"><label>17</label><mixed-citation publication-type="other">
<person-group person-group-type="author">
<collab>Médecins Sans Frontières</collab>
</person-group>. MSF medical guidelines: dolutegravir (DTG oral). <bold>2024</bold>. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://medicalguidelines.msf.org/en/viewport/EssDr/english/dolutegravir-dtg-oral-38537537.html" ext-link-type="uri">https://medicalguidelines.msf.org/en/viewport/EssDr/english/dolutegravir-dtg-oral-38537537.html</ext-link>. Accessed 13 August 2024.</mixed-citation></ref><ref id="jiaf305-B18"><label>18</label><mixed-citation publication-type="other">
<person-group person-group-type="author">
<collab>Liverpool HIV Interactions</collab>
</person-group>. Dolutegravir (DTG)–metformin. <bold>2024</bold>. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hiv-druginteractions.org/interactions/81694" ext-link-type="uri">https://www.hiv-druginteractions.org/interactions/81694</ext-link>. Accessed 13 August 2024.</mixed-citation></ref><ref id="jiaf305-B19"><label>19</label><mixed-citation publication-type="book">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Simbayi</surname>
<given-names>LC</given-names>
</string-name>, <string-name name-style="western"><surname>Zuma</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zungu</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>
<source>South African National HIV prevalence, incidence, behaviour and communication survey, 2017</source>. <publisher-loc>Cape Town</publisher-loc>: <publisher-name>HSRC Press</publisher-name>, <year>2019</year>.</mixed-citation></ref><ref id="jiaf305-B20"><label>20</label><mixed-citation publication-type="other">
<person-group person-group-type="author">
<collab>Joint United Nations Programme on HIV/AIDS</collab>
</person-group>. Country factsheet—South Africa: 2023 estimates. <bold>2023</bold>. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.unaids.org/en/regionscountries/countries/southafrica" ext-link-type="uri">https://www.unaids.org/en/regionscountries/countries/southafrica</ext-link>. Accessed 19 December 2024.</mixed-citation></ref><ref id="jiaf305-B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Rico-Martín</surname>
<given-names>S</given-names>
</string-name>, <string-name name-style="western"><surname>Calderón-García</surname><given-names>JF</given-names></string-name>, <string-name name-style="western"><surname>Sánchez-Rey</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Effectiveness of body roundness index in predicting metabolic syndrome: a systematic review and meta-analysis</article-title>. <source>Obesity Reviews</source><year>2020</year>; <volume>21</volume>:<fpage>e13023</fpage>.<pub-id pub-id-type="pmid">32267621</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/obr.13023</pub-id></mixed-citation></ref><ref id="jiaf305-B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Cattaneo</surname>
<given-names>D</given-names>
</string-name>, <string-name name-style="western"><surname>Resnati</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Rizzardini</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Dolutegravir and metformin: a clinically relevant or just a pharmacokinetic interaction?</article-title>
<source>AIDS</source>
<year>2018</year>; <volume>32</volume>:<fpage>532</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="pmid">29381562</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/QAD.0000000000001720</pub-id></mixed-citation></ref><ref id="jiaf305-B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Gervasoni</surname>
<given-names>C</given-names>
</string-name>, <string-name name-style="western"><surname>Minisci</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Clementi</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>How relevant is the interaction between dolutegravir and metformin in real life?</article-title>
<source>J Acquir Immune Defic Syndr</source>
<year>2017</year>; <volume>75</volume>:<fpage>e24</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">28114188</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/QAI.0000000000001292</pub-id></mixed-citation></ref><ref id="jiaf305-B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Berton</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western"><surname>Bettonte</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Stader</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Repository describing the anatomical, physiological, and biological changes in an obese population to inform physiologically based pharmacokinetic models</article-title>. <source>Clin Pharmacokinet</source><year>2022</year>; <volume>61</volume>:<fpage>1251</fpage>–<lpage>70</lpage>.<pub-id pub-id-type="pmid">35699913</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-022-01132-3</pub-id><pub-id pub-id-type="pmcid">PMC9439993</pub-id></mixed-citation></ref><ref id="jiaf305-B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>van Rongen</surname>
<given-names>A</given-names>
</string-name>, <string-name name-style="western"><surname>van der Aa</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Matic</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Increased metformin clearance in overweight and obese adolescents: a pharmacokinetic substudy of a randomized controlled trial</article-title>. <source>Paediatr Drugs</source><year>2018</year>; <volume>20</volume>:<fpage>365</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">29748932</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40272-018-0293-1</pub-id><pub-id pub-id-type="pmcid">PMC6028885</pub-id></mixed-citation></ref><ref id="jiaf305-B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Halpin</surname>
<given-names>K</given-names>
</string-name>, <string-name name-style="western"><surname>Hosey</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Paprocki</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>LBODP083 pharmacokinetics of metformin in obese non-diabetic youth: drug clearance increases with severity of obesity</article-title>. <source>J Endocr Soc</source><year>2022</year>; <volume>6</volume>(<issue>Suppl 1</issue>):<fpage>A594</fpage>–<lpage>5</lpage>.</mixed-citation></ref><ref id="jiaf305-B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Bardin</surname>
<given-names>C</given-names>
</string-name>, <string-name name-style="western"><surname>Nobecourt</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Larger</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus</article-title>. <source>Eur J Clin Pharmacol</source><year>2012</year>; <volume>68</volume>:<fpage>961</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">22274405</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-011-1207-0</pub-id></mixed-citation></ref><ref id="jiaf305-B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Barcelo</surname>
<given-names>C</given-names>
</string-name>, <string-name name-style="western"><surname>Aouri</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Courlet</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Population pharmacokinetics of dolutegravir: influence of drug–drug interactions in a real-life setting</article-title>. <source>J Antimicrob Chemother</source><year>2019</year>; <volume>74</volume>:<fpage>2690</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">31119275</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dkz217</pub-id></mixed-citation></ref><ref id="jiaf305-B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Parant</surname>
<given-names>F</given-names>
</string-name>, <string-name name-style="western"><surname>Miailhes</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Brunel</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Dolutegravir population pharmacokinetics in a real-life cohort of people living with HIV infection: a covariate analysis</article-title>. <source>Ther Drug Monit</source><year>2019</year>; <volume>41</volume>:<fpage>444</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="pmid">30817698</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FTD.0000000000000618</pub-id></mixed-citation></ref><ref id="jiaf305-B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Mondleki</surname>
<given-names>E</given-names>
</string-name>, <string-name name-style="western"><surname>Banda</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Chandiwana</surname><given-names>NC</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Effect of obesity on dolutegravir exposure in Black southern African adults living with HIV</article-title>. <source>South Afr J HIV Med</source><year>2022</year>; <volume>23</volume>:<fpage>1452</fpage>.<pub-id pub-id-type="pmid">36751628</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.4102/sajhivmed.v23i1.1452</pub-id><pub-id pub-id-type="pmcid">PMC9772744</pub-id></mixed-citation></ref><ref id="jiaf305-B31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Zhang</surname>
<given-names>J</given-names>
</string-name>, <string-name name-style="western"><surname>Hayes</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sadler</surname><given-names>BM</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients</article-title>. <source>Br J Clin Pharmacol</source><year>2015</year>; <volume>80</volume>:<fpage>502</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">25819132</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.12639</pub-id><pub-id pub-id-type="pmcid">PMC4574835</pub-id></mixed-citation></ref><ref id="jiaf305-B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Kipp</surname>
<given-names>ZA</given-names>
</string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bates</surname><given-names>EA</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Bilirubin levels are negatively correlated with adiposity in obese men and women, and its catabolized product, urobilin, is positively associated with insulin resistance</article-title>. <source>Antioxidants (Basel)</source><year>2023</year>; <volume>12</volume>:<fpage>170</fpage>.<pub-id pub-id-type="pmid">36671031</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antiox12010170</pub-id><pub-id pub-id-type="pmcid">PMC9854555</pub-id></mixed-citation></ref><ref id="jiaf305-B33"><label>33</label><mixed-citation publication-type="other">
<person-group person-group-type="author">
<collab>US Food and Drug Administration</collab>
</person-group>. Highlights of prescribing information—Tivicay (dolutegravir). <bold>2024</bold>. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/204790s031,213983s004lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/204790s031,213983s004lbl.pdf</ext-link>. Accessed 13 August 2024.</mixed-citation></ref><ref id="jiaf305-B34"><label>34</label><mixed-citation publication-type="other">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Dawson</surname>
<given-names>E</given-names>
</string-name>, <string-name name-style="western"><surname>Brehaut</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Giguere</surname><given-names>P</given-names></string-name></person-group>. National survey assessing knowledge and management of the drug interaction between dolutegravir and metformin by Canadian HIV practitioners. <bold>2017</bold>. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://tspace.library.utoronto.ca/handle/1807/80571" ext-link-type="uri">https://tspace.library.utoronto.ca/handle/1807/80571</ext-link>. Accessed 1 November 2024.</mixed-citation></ref><ref id="jiaf305-B35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Research progress of population pharmacokinetic of metformin</article-title>. <source>Biomed Res Int</source><year>2022</year>; <volume>2022</volume>:<fpage>4071111</fpage>.<pub-id pub-id-type="pmid">36578804</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/4071111</pub-id><pub-id pub-id-type="pmcid">PMC9792241</pub-id></mixed-citation></ref><ref id="jiaf305-B36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Van Lunzen</surname>
<given-names>J</given-names>
</string-name>, <string-name name-style="western"><surname>Maggiolo</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Arribas</surname><given-names>JR</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial</article-title>. <source>Lancet Infect Dis</source><year>2012</year>; <volume>12</volume>:<fpage>111</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">22018760</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(11)70290-0</pub-id></mixed-citation></ref><ref id="jiaf305-B37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Griesel</surname>
<given-names>R</given-names>
</string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Simmons</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial</article-title>. <source>Lancet HIV</source><year>2023</year>; <volume>10</volume>:<fpage>e433</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">37230101</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2352-3018(23)00081-4</pub-id><pub-id pub-id-type="pmcid">PMC10322729</pub-id></mixed-citation></ref><ref id="jiaf305-B38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Maartens</surname>
<given-names>G</given-names>
</string-name>, <string-name name-style="western"><surname>Griesel</surname><given-names>R</given-names></string-name></person-group>. <article-title>Dolutegravir dosing with rifampicin—authors’ reply</article-title>. <source>Lancet HIV</source><year>2023</year>; <volume>10</volume>:<fpage>e636</fpage>.<pub-id pub-id-type="pmid">37717590</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2352-3018(23)00230-8</pub-id></mixed-citation></ref><ref id="jiaf305-B39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Dooley</surname>
<given-names>KE</given-names>
</string-name>, <string-name name-style="western"><surname>Sayre</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Borland</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects</article-title>. <source>J Acquir Immune Defic Syndr</source><year>2013</year>; <volume>62</volume>:<fpage>21</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">23075918</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/QAI.0b013e318276cda9</pub-id></mixed-citation></ref><ref id="jiaf305-B40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Timmins</surname>
<given-names>P</given-names>
</string-name>, <string-name name-style="western"><surname>Donahue</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Meeker</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Steady-state pharmacokinetics of a novel extended-release metformin formulation</article-title>. <source>Clin Pharmacokinet</source><year>2005</year>; <volume>44</volume>:<fpage>721</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">15966755</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-200544070-00004</pub-id></mixed-citation></ref><ref id="jiaf305-B41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Zucker</surname>
<given-names>I</given-names>
</string-name>, <string-name name-style="western"><surname>Prendergast</surname><given-names>BJ</given-names></string-name></person-group>. <article-title>Sex differences in pharmacokinetics predict adverse drug reactions in women</article-title>. <source>Biol Sex Differ</source><year>2020</year>; <volume>11</volume>:<fpage>32</fpage>.<pub-id pub-id-type="pmid">32503637</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13293-020-00308-5</pub-id><pub-id pub-id-type="pmcid">PMC7275616</pub-id></mixed-citation></ref><ref id="jiaf305-B42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Chen</surname>
<given-names>S</given-names>
</string-name>, <string-name name-style="western"><surname>St Jean</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Borland</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics</article-title>. <source>Pharmacogenomics</source><year>2014</year>; <volume>15</volume>:<fpage>9</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">24329186</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/pgs.13.190</pub-id></mixed-citation></ref><ref id="jiaf305-B43"><label>43</label><mixed-citation publication-type="other">
<person-group person-group-type="author">
<collab>US Food and Drug Administration</collab>
</person-group>. Glumetza label (metformin hydrochloride tablet, film coated, extended release). <bold>2009</bold>. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021748s005lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021748s005lbl.pdf</ext-link>. Accessed 13 August 2024.</mixed-citation></ref></ref-list></back></article><article xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="pmc-domain-id">2103</journal-id><journal-id journal-id-type="pmc-domain">pharmamdpi</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12566952</article-id><article-id pub-id-type="pmcid-ver">PMC12566952.1</article-id><article-id pub-id-type="pmcaid">12566952</article-id><article-id pub-id-type="pmcaiid">12566952</article-id><article-id pub-id-type="pmid">41155987</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17101352</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-01352</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Virtual Bioequivalence Assessment and Dissolution Safe Space Exploration for Fixed-Dose Metformin–Glyburide Tablet Using Physiologically Based Biopharmaceutics Modeling</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="C">Chenshuang</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shen</surname><given-names initials="C">Chaozhuang</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xiao</surname><given-names initials="Y">Yumeng</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3220-6065</contrib-id><name name-style="western"><surname>Wang</surname><given-names initials="L">Ling</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="c1-pharmaceutics-17-01352" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Cichero</surname><given-names initials="E">Elena</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-01352">Department of Clinical Pharmacy and Pharmacy Administration, West China School of Pharmacy, Sichuan University, Chengdu 610064, China; <email>zhaocs@stu.scu.edu.cn</email> (C.Z.); <email>2023324050039@stu.scu.edu.cn</email> (C.S.); <email>2022324050036@stu.scu.edu.cn</email> (Y.X.)</aff><author-notes><corresp id="c1-pharmaceutics-17-01352"><label>*</label>Correspondence: <email>wlin_scu@scu.edu.cn</email></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>17</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">499616</issue-id><elocation-id>1352</elocation-id><history><date date-type="received"><day>09</day><month>9</month><year>2025</year></date><date date-type="rev-recd"><day>29</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>10</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>29</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-30 17:25:24.880"><day>30</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>© 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmaceutics-17-01352.pdf"/><abstract><p><bold>Background/Objectives</bold>: Fixed-dose combinations (FDCs) hold significant clinical value for the management of hypertension, diabetes and other chronic diseases. However, since the complexity of formulations, generic compounds require both in vitro pharmaceutical equivalence and in vivo bioequivalence (BE) for each active pharmaceutical ingredient (API). Physiologically based biopharmaceutics modeling (PBBM) not only bridges in vitro drug properties to in vivo pharmacokinetics but effectively assesses the impact of formulations on systemic exposure. This study was aimed at developing a PBBM for metformin–glyburide FDC and investigating its clinically relevant quality specifications. <bold>Methods</bold>: PK-Sim<sup>®</sup> software (Version 11.3) was used to establish a PBBM for a metformin–glyburide FDC. Sensitivity analysis identified critical parameters and guided design of virtual populations. Subsequently, virtual bioequivalence (VBE) was assessed between both reference and test formulations, and BE-ensuring dissolution space was explored by the change in dissolution characteristics. <bold>Results</bold>: The in vivo behavior of products was successfully captured by the developed model. Sensitivity analysis indicated that systemic exposure was primarily sensitive to gastrointestinal (GI) pH and transit times. VBE analysis confirmed BE between the reference and test formulations. The dissolution safe space for the FDC was defined as the concurrent achievement of ≥ 50% dissolution within 25 min for metformin and between 35 and 170 min for glyburide, which constituted equivalent specification. <bold>Conclusions</bold>: The PBBM developed in this study systematically evaluated the VBE of metformin–glyburide FDC, optimized the acceptance criteria for traditional in vitro dissolution testing, and thereby explored its clinically relevant quality specification. </p></abstract><kwd-group><kwd>fixed-dose combination (FDC)</kwd><kwd>physiologically based biopharmaceutics modeling (PBBM)</kwd><kwd>virtual bioequivalence (VBE)</kwd><kwd>sensitivity analysis</kwd><kwd>safe space</kwd><kwd>metformin</kwd><kwd>glyburide</kwd><kwd>PK-Sim</kwd></kwd-group><funding-group><award-group><funding-source>Key Research and Development Program of Science and Technology Department of the Sichuan Province 111 Project</funding-source><award-id>B18035</award-id></award-group><funding-statement>This work was supported by the Key Research and Development Program of Science and Technology Department of the Sichuan Province 111 Project (B18035).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-01352"><title>1. Introduction</title><p>Fixed-dose combination (FDC) preparations typically contain no less than two active pharmaceutical ingredients (APIs) within a single formulation [<xref rid="B1-pharmaceutics-17-01352" ref-type="bibr">1</xref>]. These formulations offer several advantages, including improved patient compliance, reduced healthcare costs, simplified clinical decision-making, and a diminished risk of adverse drug reactions. These benefits are especially valuable in conditions like diabetes, which often require long-term combination therapy, making FDCs an attractive strategic option for patients facing polypharmacy. Over the past two decades, the approval of FDCs has steadily increased, accounting for a median of 7–10 new approvals annually, or approximately 9% of new drug applications [<xref rid="B2-pharmaceutics-17-01352" ref-type="bibr">2</xref>]. The therapeutic scope of FDCs has also diversified considerably. They are abundantly available for comorbid conditions such as hypertension and diabetes, pain and muscle relaxation, and various infectious diseases. Furthermore, FDCs within the same pharmacological category are widely used to treat single ailments, including tuberculosis, Parkinson’s disease, and urinary tract infections, underscoring their broad global application and acceptance [<xref rid="B3-pharmaceutics-17-01352" ref-type="bibr">3</xref>].</p><p>Diabetes represents a major global chronic disease burden. According to the International Diabetes Federation (IDF), approximately 589 million adults aged 20–79 were living with diabetes worldwide in 2024 [<xref rid="B4-pharmaceutics-17-01352" ref-type="bibr">4</xref>]. International treatment guidelines consistently recommend metformin as the first-line pharmacological therapy. For a significant proportion of patients who fail to achieve adequate glycemic control with metformin monotherapy, combination therapy with agents possessing complementary mechanisms of action is recommended [<xref rid="B5-pharmaceutics-17-01352" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceutics-17-01352" ref-type="bibr">6</xref>]. This clinical need makes FDC strategies particularly valuable for the long-term, often lifelong, management of diabetes, as they simplify regimens and potentially improve adherence. Consequently, numerous antihyperglycemic FDCs have been developed. Among these, the combination of metformin and glyburide is one of the earliest and most widely used FDCs. </p><p>As a classic FDC hypoglycemic agent, metformin–glyburide tablets exhibit superior efficacy in glycemic control. The metformin–glyburide FDC tablet is indicated for patients with T2DM who have not achieved adequate glycemic control through diet and/or exercise alone, or with monotherapy using either sulfonylureas or metformin. Glyburide, a representative second-generation sulfonylurea, lowers blood glucose primarily by stimulating insulin secretion from pancreatic β-cells. Metformin, an insulin sensitizer, reduces glucose levels through multiple mechanisms, including inhibition of hepatic gluconeogenesis, decreased intestinal glucose absorption, and enhanced peripheral glucose uptake and utilization. This combined therapy not only effectively regulates blood glucose levels but also improves overall glucose metabolism in patients. A meta-analysis has reported that metformin is associated with faster glycemic control and reduced postprandial glucose concentrations, whereas glyburide is linked to reductions in fasting plasma glucose and HbA1c. Moreover, a bioequivalence study was conducted comparing two formulations of metformin hydrochloride/glyburide tablets (500 mg/5 mg) under both fasting and fed conditions, which confirmed the bioequivalence and safety of the two formulations [<xref rid="B7-pharmaceutics-17-01352" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceutics-17-01352" ref-type="bibr">8</xref>]. However, the marked differences in the physicochemical properties of metformin and glyburide present considerable challenges to formulations. Metformin, classified as a Biopharmaceutics Classification System (BCS) Class III drug, possesses high solubility but low permeability, while glyburide as a BCS Class II drug, demonstrates low solubility and high permeability. The differences in chemical and physical properties between the two active pharmaceutical ingredients necessitate additional considerations during the development of the FDC product. </p><p>Despite appearing as combinations of more than two single-ingredient drugs, the development of FDC products presents inherent complexities, which may result in APIs failing to reach the target site at the desired concentration predictably and reproducibly. An example is that the dissociation of one active ingredient may affect the stability of others or even result in the generation of new degradation products, particularly for APIs unstable in gastrointestinal environments or requiring specialized formulation processes. Consequently, national and regional regulatory guidelines for the in vivo bioequivalence (BE) assessment of FDCs are considerably more stringent than those for the in vivo BE assessment of single-entity formulations, and require demonstrating BE for all the medication components in a FDC product. The entire combination fails when one component fails to demonstrate BE [<xref rid="B9-pharmaceutics-17-01352" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceutics-17-01352" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-17-01352" ref-type="bibr">11</xref>].</p><p>Advances in drug modeling technology have contributed to the growing prevalence of model-informed drug development (MIDD). These approaches offer several benefits, including a reduced need for subject exposure, lower development costs, and accelerated market entry for novel therapeutics. Notably, the application of physiologically based biopharmaceutics modeling (PBBM) has gained significant traction in the development of generic drug in recent years. As an advanced extension of the physiologically based pharmacokinetic (PBPK) model, PBBM is specifically tailored for biopharmaceuticals. The PBPK model incorporates physiological and drug parameters and predicts the in vivo exposure levels of the drug [<xref rid="B12-pharmaceutics-17-01352" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-17-01352" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceutics-17-01352" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-17-01352" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-17-01352" ref-type="bibr">16</xref>], while PBBM focuses on how in vivo processes are influenced by formulation properties [<xref rid="B17-pharmaceutics-17-01352" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-17-01352" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-17-01352" ref-type="bibr">19</xref>]. PBBM integrates the characteristics of various formulations with human physiological properties, especially the gastrointestinal state, and encompasses all the quality attributes of APIs and drugs affecting in vivo performance. In particular, PBBM is useful in developing prescriptions, assessing biopharmaceutical risks, comparing formulation dissolution profiles, evaluating food effects and facilitating bio-waivers during the process of generic drug development [<xref rid="B19-pharmaceutics-17-01352" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceutics-17-01352" ref-type="bibr">20</xref>].</p><p>PBBM enables the integration of formulation characteristics with the in vivo processes of metformin–glyburide FDC. The aim of this study was to develop a robust model and further investigate: (1) key sensitivity factors influencing drug absorption and systemic disposition; (2) virtual bioequivalence in populations under varying gastrointestinal physiological conditions; (3) the establishment of a safe dissolution space ensuring bioequivalence.</p></sec><sec id="sec2-pharmaceutics-17-01352"><title>2. Materials and Methods</title><sec id="sec2dot1-pharmaceutics-17-01352"><title>2.1. Chemicals and Reagents</title><p>The metformin–glyburide tablets investigated were reference (Glucovance<sup>®</sup>, Merck Sante S.A.S, Lyon, France) and test tables. The specification used was 500 mg/2.5 mg IR tablets containing 500 mg metformin hydrochloride and 2.5 mg glyburide.</p></sec><sec id="sec2dot2-pharmaceutics-17-01352"><title>2.2. Software</title><p>PK-Sim<sup>®</sup> and Mobi<sup>®</sup> (Version 11.3, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.open-systems-pharmacology.org">www.open-systems-pharmacology.org</uri>) were utilized to develop models. R (Version 4.4.1, The R Project for Statistical Computing, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.R-project.org">www.R-project.org</uri>) was adopted to compare and analyze BE between test and reference products.</p></sec><sec id="sec2dot3-pharmaceutics-17-01352"><title>2.3. In Vitro Dissolution Tests</title><p>The tests were carefully designed based on the physicochemical properties of the drugs and in accordance with relevant guidelines.</p><p>The paddle method was employed to determine the dissolution profiles of the tablets in 1000 mL of three different dissolution media: hydrochloric acid solution (pH 1.2, 0.1 mol/L), acetate buffer (pH 4.5, 0.2 mol/L, buffer capacity: 0.1 mol/L⋅pH<sup>−1</sup>), and phosphate buffer (pH 6.8, 0.2 mol/L, buffer capacity: 0.1 mol/L⋅pH<sup>−1</sup>) at 37 °C and 50 rpm. For glyburide, which has poor solubility, the sink condition was achieved by adding the surfactant sodium lauryl sulfate (SDS) to the medium. Samples were withdrawn at 5, 10, 15, 30, 45, and 60 min for metformin and collected at 5, 10, 15, 30, 45, 60, 90, 120, 180, and 240 min for glyburide. All the samples were filtered through a 0.45 μm cellulose membrane, and the concentration of metformin and glyburide were detected by UV and HPLC-UV, respectively. The detailed methodological considerations and dissolution profiles with f2 factor are summarized in <xref rid="app1-pharmaceutics-17-01352" ref-type="app">Supplementary Material Section S1</xref>. </p></sec><sec id="sec2dot4-pharmaceutics-17-01352"><title>2.4. In Vivo Pharmacokinetic Studies</title><p>The data on plasma concentrations were obtained from an open-label, two-part and two period crossover BE study performed on 72 healthy Chinese participants (<xref rid="pharmaceutics-17-01352-f001" ref-type="fig">Figure 1</xref>). Enrolled participants were randomly assigned to two groups using a computer-generated randomization schedule. Blood samples were collected at 22 time points: pre-dose (0 h) and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 6.5, 7, 7.5, 8, 10, 12, 24, 36 and 48 hours post-dose. Drug concentrations in plasma were quantified using validated HPLC-MS/MS methods. The data were used for the model development and validation. Although the clinical study included both fasted and fed conditions, only the data from the fasted treatment arm were used for model validation.</p><p>The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Ethics Committee of the First Affiliated Hospital of Shantou University Medical College before implementation (protocol code A-2023-016-CS and protocol date 7 October 2023). All participants signed written informed consent before inclusion in the experimental group. </p></sec><sec id="sec2dot5-pharmaceutics-17-01352"><title>2.5. In Silico Model Development</title><p>PK-Sim<sup>®</sup> was applied to develop metformin and glyburide PBPK models, respectively. The PBPK models incorporated PK-Sim<sup>®</sup> integrated population database and employing a bottom-up approach to systematically combine compound-specific physicochemical properties with human physiological system parameters [<xref rid="B21-pharmaceutics-17-01352" ref-type="bibr">21</xref>]. </p><sec id="sec2dot5dot1-pharmaceutics-17-01352"><title>2.5.1. Physiology and Pharmacokinetic Parameters</title><p>The Asian population (Tanaka, 1996) embedded in the software was selected as the demographic configuration for model parameterization, which was consistent with <xref rid="app1-pharmaceutics-17-01352" ref-type="app">Supplementary Table S1</xref>. In the base PBPK framework, system-specific physiological parameters including gastrointestinal characteristics were retained at default values. </p><p>The physicochemical parameters of metformin and glyburide were acquired from the literature and databases via extensive efforts to collect data. The parameters of these two drugs associated with the process of absorption, distribution, metabolism and excretion in the human body were obtained from three sources, literature data, model assumption and model optimization, as shown in <xref rid="pharmaceutics-17-01352-t001" ref-type="table">Table 1</xref>. </p></sec><sec id="sec2dot5dot2-pharmaceutics-17-01352"><title>2.5.2. Model Development</title><p>The pharmacokinetic profiles of metformin and glyburide were characterized in a thorough way to construct PBPK base models for each drug. The physicochemical parameters collected in <xref rid="sec2dot5dot1-pharmaceutics-17-01352" ref-type="sec">Section 2.5.1</xref> were first input into the respective building blocks.</p><p>Metformin is a typical BCS Class III drug, characterized by high solubility but low permeability. It dissolves rapidly and is primarily absorbed in the small intestine upon administration. In the small intestine, metformin is transported through the plasma membrane monoamine transporter (PMAT) located at the apical membrane of the intestinal mucosal epithelium [<xref rid="B24-pharmaceutics-17-01352" ref-type="bibr">24</xref>,<xref rid="B26-pharmaceutics-17-01352" ref-type="bibr">26</xref>]. For the purpose of accurately representing this critical transport, the distribution of PMAT incorporated into the model was quantified using RT-PCR data, and the specific transport kinetics were described by the Hill’s equation. The predicted PMAT Vmax was optimized to a final value of 53.36 1/min. Metformin demonstrates negligible plasma protein binding and its in vivo elimination does not undergo hepatic metabolism or biliary excretion. Instead, it is mainly excreted unchanged in urine, with renal tubular secretion being the predominant route [<xref rid="B27-pharmaceutics-17-01352" ref-type="bibr">27</xref>]. To describe this elimination process, the renal tubular secretion panel of PK-Sim<sup>®</sup> was utilized, and the process was defined with the Michaelis-Menten equation. The optimized TS<sub>max_spec</sub> for this process was 68.42 μmol/L/min.</p><p>Unlike metformin, glyburide is classified as a BCS Class II drug and typified by low solubility and high permeability. Therefore, its in vivo absorption is limited by the rate and extent of dissolution. The solubility of glyburide is pH-dependent—extremely low in acidic environments like gastric fluid, where glyburide primarily exists as undissociated molecules, and slightly increased in neutral to weakly alkaline environments like in the small intestine. The reference pH for solubility was optimized in the PBPK model in order to reflect this behavior. Glyburide is 99.9% bound to protein in plasma with &gt; 98% accounted for by binding to serum albumin [<xref rid="B28-pharmaceutics-17-01352" ref-type="bibr">28</xref>]. Glyburide is primarily eliminated in vivo via hepatic biotransformation, with the subsequent biliary and urinary excretion of its metabolites. Given the negligible hypoglycemic activity of glyburide metabolites, the model used in this study focused exclusively on the parent compound. Total hepatic plasma clearance in PK-Sim<sup>®</sup> was used for describing the elimination process, and the final fitted specific clearance value was determined to be 4.14 L/mL. </p><p>For the purpose of reflecting the differences across formulations, the model was developed by incorporating a formulation-specific release process. The dissolution behavior of the formulation was empirically depicted using the Weibull function, which is widely employed for modeling drug release kinetics. The Weibull equation is given as follows:<disp-formula id="FD1-pharmaceutics-17-01352"><label>(1)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="mm1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>F</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mo>−</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>b</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:mfrac></mml:mstyle><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
where <italic toggle="yes">F(t)</italic> represents the fraction of drug released at time <italic toggle="yes">t</italic>; <italic toggle="yes">a</italic> stands for the scale parameter that defines time after the start of dissolution when 50% of the administered dose is dissolved; <italic toggle="yes">T<sub>lag</sub></italic> denotes the location parameter and represents lag time before the onset of drug release; and <italic toggle="yes">b</italic> indicates the shape parameter, which determines the curvature of the release profile. The application of the Weibull function requires defining these parameters in PK-Sim<sup>®</sup> in advance. The calculation and verification of these parameters from in vitro experiments was performed with ddsolver [<xref rid="B29-pharmaceutics-17-01352" ref-type="bibr">29</xref>], and the calculations results were input into the building block. </p><p>After the establishment of structural models for the two drug components, the parameter identification function in PK-Sim<sup>®</sup> was employed. The Monte Carlo algorithm was employed to optimize models.</p></sec><sec id="sec2dot5dot3-pharmaceutics-17-01352"><title>2.5.3. Model Validation</title><p>A virtual population corresponding to 100 cases was constructed for each simulation in accordance with to the demographic information (<xref rid="app1-pharmaceutics-17-01352" ref-type="app">Supplemental Table S1</xref>) of human BE study subjects.</p><p>The model was validated in a multidimensional manner. Firstly, the reported mean blood concentration profiles were compared with the predicted population PK profiles for evaluating the similarity of model fit. Secondly, the relevant pharmacokinetic parameters representing systemic exposure levels, i.e., C<sub>max</sub> and AUC, were systematically evaluated for Fold Error (FE) and Prediction Error (PE) (Equations (2) and (3). FE ≤ 2 and PE ≤ 20% indicated the good predictive ability of the model.<disp-formula id="FD2-pharmaceutics-17-01352"><label>(2)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="mm2" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mrow><mml:mo>|</mml:mo><mml:mi>predicted</mml:mi></mml:mrow><mml:mo>−</mml:mo><mml:mi>observed</mml:mi><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mi>observed</mml:mi></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="FD3-pharmaceutics-17-01352"><label>(3)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="mm3" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>F</mml:mi><mml:mi>E</mml:mi><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math></disp-formula></p></sec></sec><sec id="sec2dot6-pharmaceutics-17-01352"><title>2.6. Virtual Bioequivalence Study Design</title><sec id="sec2dot6dot1-pharmaceutics-17-01352"><title>2.6.1. Assessment of Parameter Sensitivity</title><p>Sensitivity analyses were performed separately on the models developed in <xref rid="sec2dot5-pharmaceutics-17-01352" ref-type="sec">Section 2.5</xref> to assess whether pharmacokinetic parameters (C<sub>max</sub>, T<sub>max</sub> and AUC) were sensitive to each parameter in the model. The purpose of this part of work was to screen out the parameters with the most impact on the model. In this way, appropriate variants can be added to the virtual population. The sensitivity of the PK parameter to the input parameter was calculated as Equation (4):<disp-formula id="FD4-pharmaceutics-17-01352"><label>(4)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="mm4" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mo>∆</mml:mo><mml:mi>P</mml:mi><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mo>∆</mml:mo><mml:msub><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>·</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math></disp-formula>
where S<sub>ij</sub> represents sensitivity, ΔPK<sub>j</sub> stands for the change in PK<sub>j</sub> parameter; P<sub>i</sub> denotes original model parameter values. The purpose of the equation is to quantify how a small change in an input parameter affects the output result, such as pharmacokinetic parameters like AUC or Cmax. The sign of the calculated sensitivity coefficient indicates the direction of the effect, while the magnitude reflects the strength of the impact. For example, a coefficient of −1.0 indicates that a 10% increase in the input parameter would lead to a proportional 10% decrease in the pharmacokinetic parameter. Conversely, a coefficient of +0.5 implies that a 10% increase in the input parameter would result in only a 5% increase in the pharmacokinetic parameter. </p><p>Parameters with sensitivity scores &lt; 0.05 were excluded from this study. GI tract-related parameters affecting absorption were selected as main variants in the population. The encompassed pH at various sites in the GI tract (including stomach, duodenum, jejunum, ileum, colon and rectum), gastric emptying time, pH in the fasted state, undisintegrated portion of the GET, and large and small intestinal transit time. By setting the variation in gastrointestinal parameters in the population, the formulation would be absorbed in different states. Thus, the demonstration of the differences between formulations.</p></sec><sec id="sec2dot6dot2-pharmaceutics-17-01352"><title>2.6.2. Virtual Population Construction and BE Analysis</title><p>Virtual populations were constructed for virtual BE studies in PK-Sim<sup>®</sup>. Variants were set for the virtual population on the basis of the sensitivity analysis results. The variation ranges for delineation parameters were obtained from Mobi<sup>®</sup> and the literature (<xref rid="app1-pharmaceutics-17-01352" ref-type="app">Table S2</xref>). The population with the set range of variants was subjected to the random generation of GI parameters by R. Other settings were aligned with those portrayed in <xref rid="sec2dot4-pharmaceutics-17-01352" ref-type="sec">Section 2.4</xref>. Virtual bioequivalence (VBE) assessment was also conducted using a 2 × 2 crossover study design. Based on the established workflow, the pre-designed virtual population was randomly assigned to two sequences (TR and RT). Each sequence was further stratified into two subgroups representing different gastrointestinal (GI) conditions (GI1 and GI2). For example, the TR sequence was divided into P1 (GI1) and P2 (GI2), which were administered the test and reference formulations, respectively. In the first sequence, one group received the reference product followed by the test product, whereas in the second sequence, the order was reversed, with the test product administered first, followed by the reference product (<xref rid="app1-pharmaceutics-17-01352" ref-type="app">Table S3</xref>). The BE of the final simulation was compared between the reference and the test preparation, and the analysis of bioequivalence was also achieved by R.</p></sec></sec><sec id="sec2dot7-pharmaceutics-17-01352"><title>2.7. Development of Safe Space</title><p>The safe dissolution space is a concept delineating the in vivo BE range through in vitro dissolution profiling [<xref rid="B17-pharmaceutics-17-01352" ref-type="bibr">17</xref>]. In this study, the dissolution space was generated by the modulation parameters in the Weibull model (Equation (1)), which characterizes drug dissolution through three parameters: dissolution time (<italic toggle="yes">a</italic>), shape factor (<italic toggle="yes">b</italic>), and lag time (<italic toggle="yes">T<sub>lag</sub></italic>). In light of the optimized dissolution parameters of the test formulation (<xref rid="pharmaceutics-17-01352-t001" ref-type="table">Table 1</xref>), time to 50% dissolution was systematically varied to alter dissolution profiles, which thereby simulated distinct formulation variants. Through the systematic change in dissolution parameters in the model and the subsequent incorporation of the modified parameters, new population PK profiles were generated, and virtual population BE analysis was conducted using R 4.3.1. This iterative process continued to achieve 90% CI of C<sub>max</sub> and AUC ratios ranging between 80.00% to 125.00%.</p></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-17-01352"><title>3. Results</title><sec id="sec3dot1-pharmaceutics-17-01352"><title>3.1. PBPK Models and Validation</title><p>The PBPK models of metformin and glyburide were developed and validated as described in <xref rid="sec2dot5-pharmaceutics-17-01352" ref-type="sec">Section 2.5</xref>. A virtual Asian population that comprised 100 subjects aged 18-60 with BMI ranging from 19 to 27 was later constructed for model validation. PK-Sim<sup>®</sup> was utilized to develop the PBPK model. The predicted pharmacokinetic parameters significantly aligned with the observed ones, and the generated simulated profiles matched the observed data closely (<xref rid="pharmaceutics-17-01352-f002" ref-type="fig">Figure 2</xref>). In all cases, the predicted error did not exceed 0.2, which was indicative of excellent model performance (<xref rid="pharmaceutics-17-01352-t002" ref-type="table">Table 2</xref>). </p></sec><sec id="sec3dot2-pharmaceutics-17-01352"><title>3.2. Virtual Bioequivalence Study</title><sec id="sec3dot2dot1-pharmaceutics-17-01352"><title>3.2.1. Sensitivity Analysis</title><p>Sensitivity analysis is a critical component of PBPK modeling [<xref rid="B30-pharmaceutics-17-01352" ref-type="bibr">30</xref>], which was conducted in both metformin and glyburide models. For metformin, key human factors affecting C<sub>max</sub>, AUC and T<sub>max</sub> (sensitivity ≥ 5%) were small bowel transit time, gastric emptying time and large bowel transit time in descending order. For glyburide, GI pH exhibited greater influence, and jejunal/ileal pH, small bowel transit time, duodenal pH and gastric emptying time showed descending sensitivity. Notably, colonic pH impacted AUC<sub>0-t</sub> for glyburide but demonstrated zero sensitivity for C<sub>max</sub>. Comprehensive sensitivity results are presented in <xref rid="pharmaceutics-17-01352-f003" ref-type="fig">Figure 3</xref>.</p></sec><sec id="sec3dot2dot2-pharmaceutics-17-01352"><title>3.2.2. Virtual Population</title><p>A virtual population was established based on the sensitivity analysis results, and a virtual BE study was performed in this population. The inter-individual variability (IIV) or between-subject variability (BSV) between individuals of a population was stored in population database of PK-Sim<sup>®</sup>. Based on the sensitivity analysis results in <xref rid="sec3dot2dot1-pharmaceutics-17-01352" ref-type="sec">Section 3.2.1</xref>, a representative virtual population was constructed to simulate within-subject variability (WSV) within the real population. WSV parameters ranged according to the variability specified in <xref rid="app1-pharmaceutics-17-01352" ref-type="app">Table S2</xref> and were further defined for two distinct GI states. Afterwards, a 2 × 2 crossover study group was established for systematically conducting a VBE study (<xref rid="app1-pharmaceutics-17-01352" ref-type="app">Table S3</xref>).</p></sec><sec id="sec3dot2dot3-pharmaceutics-17-01352"><title>3.2.3. Virtual Bioequivalence Analysis</title><p>The relevant pharmacokinetic parameters of the VBE model were analyzed, and the results are displayed in <xref rid="pharmaceutics-17-01352-f004" ref-type="fig">Figure 4</xref>. The results showed that the predicted C<sub>max</sub> for the test and reference formulations of metformin were 1263.52 ng/mL and 1215.67 ng/mL, respectively, and AUC<sub>0-t</sub> was 6099.01 ng/h/mL and 5770.53 ng/h/mL. The test and reference formulations of glyburide predicted C<sub>max</sub> of 66.74 ng/mL and 67.44 ng/mL with AUC<sub>0-t</sub> of 413.15 ng/h/mL and 408.98 ng/h/mL, respectively. The 90% confidence intervals fell within 80–125% of each other within the limits. The 90% CI for geometric mean ratios all fell within the 80–125% acceptance range, for metformin C<sub>max</sub> 90%CI was 100.13–107.88% and AUC was 100.78–110.85%, while for glyburide C<sub>max</sub> 90%CI was 95.35–102.75% and AUC was 97.34–104.84%. Hence, both the drug components of the combination were bioequivalent in the constructed virtual population.</p></sec></sec><sec id="sec3dot3-pharmaceutics-17-01352"><title>3.3. Dissolution Safe Spaces</title><p>The dissolution space and associated failure boundaries for the compound were defined by adjusting dissolution time in Weibull function. The subsequent analysis of safe dissolution spaces demonstrated that bioequivalence could be achieved when 50% dissolution occurred within 25 min for compound metformin and within 35 to 170 min for compound glyburide (<xref rid="pharmaceutics-17-01352-f005" ref-type="fig">Figure 5</xref>, <xref rid="pharmaceutics-17-01352-t003" ref-type="table">Table 3</xref> and <xref rid="pharmaceutics-17-01352-t004" ref-type="table">Table 4</xref>). </p></sec></sec><sec sec-type="discussion" id="sec4-pharmaceutics-17-01352"><title>4. Discussion</title><p>In the present study, a PBPK model was developed for metformin–glyburide tablets, and formulation dissolution kinetics were simulated using the Weibull function. Sensitivity analysis was followed by the establishment of a virtual population. Then, the virtual bioequivalence between the test and reference formulations was compared. Finally, a safe dissolution space was constructed to predict the in vivo performance of different formulations and their variations. </p><p>PBPK modeling typically requires numerous input parameters, but the impact on outputs is often unclear. Sensitivity analysis quantifies the influence of individual parameter variations on model results [<xref rid="B30-pharmaceutics-17-01352" ref-type="bibr">30</xref>]. In the current study, sensitivity analysis for each API in the combination product revealed that metformin absorption was predominantly sensitive to gastrointestinal transit time. However, glyburide absorption was affected by both gastrointestinal pH and transit time. These findings align with the known properties of the drugs. The high solubility and low permeability of metformin are intrinsically determined by its molecular structure. The drug contains a strongly polar guanidine group, exhibits an extremely low log P value (−1.43) [<xref rid="B22-pharmaceutics-17-01352" ref-type="bibr">22</xref>], and behaves as a strong base (pKa ≈ 11.5) [<xref rid="B23-pharmaceutics-17-01352" ref-type="bibr">23</xref>]. Consequently, metformin exists predominantly in a hydrophilic, cationic form throughout the physiological pH range of the gastrointestinal (GI) tract, resulting in its characteristic high solubility and low permeability. Following oral administration, the tablet disintegrates in the gastric fluid within minutes due to the action of disintegrants and GI motility, breaking down into fine particles or powder. This process significantly increases the surface area of the drug. Owing to its high hydrophilicity, metformin rapidly dissolves in the aqueous GI environment, forming a drug solution. However, its poor solubility in lipid environments hinders passive diffusion across the intestinal epithelium. Absorption primarily relies on specific membrane transporters, whose limited number, function, variable distribution, and significant inter-individual variability collectively contribute to the low intestinal permeability of metformin. Dissolution study results (<xref rid="app1-pharmaceutics-17-01352" ref-type="app">Supplementary Material Section S1</xref>) confirm that both the reference and test formulations of the compound tablet release over 85% of the drug within 30 min, meeting the criteria for rapid release. Furthermore, the solubility of metformin in pH 6.8 medium can reach 350.9 g/L [<xref rid="B23-pharmaceutics-17-01352" ref-type="bibr">23</xref>]. Therefore, dissolution is not the rate-limiting step for the absorption of metformin in vivo; the API dissolves rapidly and completely in the GI fluid. However, due to its slow intestinal permeability, dissolved drug accumulates in the GI tract. For this reason, transit time becomes the critical determinant for absorption. A longer residence time in the intestine allows for more complete absorption. For glyburide, the low solubility and high permeability are similarly dictated by its molecular structure. Its high lipophilicity (log P 3.75) results in low equilibrium solubility in water. Molecules on the surface of drug particles require considerable time to enter the solution and form a saturated layer, making dissolution rate and solubility the primary rate-limiting factors for its absorption. Additionally, the sulfonylurea group in glyburide’s structure contains a nitrogen-bound hydrogen atom with notable acidity, rendering glyburide a weak acid (pKa ≈ 5.3) [<xref rid="B25-pharmaceutics-17-01352" ref-type="bibr">25</xref>]. According to the pH-partition hypothesis, a weak acid exists in equilibrium between its molecular (unionized) and ionic forms in solution, with the ratio determined by the environmental pH and the drug’s pKa. In its unionized form (predominant at low pH), glyburide is highly lipophilic but exhibits very poor aqueous solubility. Conversely, the ionized form (predominant at higher pH) demonstrates significantly enhanced water solubility. Therefore, slight variations in GI pH can markedly alter the dissolution kinetics of glyburide, directly impacting its absorption rate and extent. This mechanism aligns perfectly with the sensitivity analysis results, which indicated that the pH in various segments of the small intestine and the transit time significantly influence the in vivo performance of glyburide. Based on the above analysis: (1) In the stomach (pH ~ 1.2, absence of bile salts, low volume), where the pH is far below glyburide’s pKa, the drug exists almost exclusively in its unionized form. Consequently, solubility is extremely low, and negligible dissolution or absorption occurs. (2) In the small intestine (pH ~ 6.0–6.8, high bile salt concentration, large volume), the elevated pH favors ionization, significantly increasing intrinsic solubility. Furthermore, the high concentration of bile salts forms micelles, providing potent micellar solubilization for glyburide. This makes the small intestine the primary and most efficient site for its absorption. (3) In the colon (pH ~ 6.5–7.5, near absence of bile salts, low fluid volume, high viscosity), while the pH conditions are favorable for ionization, the critical lack of bile salts eliminates the micellar solubilization effect. Combined with the extended time required to reach the colon and the unfavorable fluid dynamics, the colon is not a significant absorption site for glyburide. Two distinct PK-Sim<sup>®</sup> population variant sequences were used to generate virtual population (<xref rid="app1-pharmaceutics-17-01352" ref-type="app">Table S3</xref>). For population segmentation across different dosing cycles within each sequence, differentiated GI physiological parameters, primarily GI transit time and segment-specific pH, were incorporated based on key sensitivity analysis findings. Notably, sensitivity analysis identified the significant effects of elimination-phase parameters (renal tubular secretion Km and TSmax_spec for metformin, and hepatic clearance for glyburide), but these parameters were held constant across cycles within individual subjects. This design aligned with the study objective of specifically assessing differences between test and reference formulations. With regard to oral solid dosage forms, formulation differences primarily manifest during drug absorption. Variability in the absorption environment was simulated and amplified by varying GI parameters, which thereby maximized the detection of formulation differences under physiologically fluctuating conditions. In contrast, elimination-phase parameters characterized post-absorption systemic drug disposition after absorption. These are governed by the API’s chemical structure and subject physiology/pathology of the API, rather than formulation characteristics. Introducing variability here would add unnecessary noise and obscure the specific formulation differences under investigation. However, in designing the virtual population, we introduced interindividual variability to drug-sensitive parameters in order to maximize the differentiation between the test and reference formulations. However, the virtual subjects in this study were modeled as healthy individuals, whereas the FDC product under investigation is intended for use in patients with diabetes—particularly those with long-standing disease. Some physiological parameters in diabetic patients differ significantly from those of healthy individuals. Under such altered physiological conditions, whether the two formulations can still achieve bioequivalence is a more clinically relevant question. This will be a key focus of our future research. </p><p>Model validation plays a critical role in the modeling process, as effective validation ensures the credibility and reliability of the model. In this study, external validation was primarily employed by comparing model-simulated results with independent clinical datasets. Goodness-of-fit and prediction error analyses were used to evaluate the consistency between simulated and observed data. In addition, model-predicted VBE outcomes were compared with key pharmacokinetic parameters of the drug itself, such as bioavailability, AUC and Cmax. These are commonly accepted approaches in PBPK model validation. However, these methods also have inherent limitations. First, as a bottom-up modeling approach, PBPK modeling involves numerous parameters, many of which are derived from in vitro experiments and may require optimization during model integration [<xref rid="B21-pharmaceutics-17-01352" ref-type="bibr">21</xref>,<xref rid="B31-pharmaceutics-17-01352" ref-type="bibr">31</xref>]. The validation of such parameters is challenging. One commonly adopted strategy is multi-dose validation using clinical datasets under different dosing conditions to constrain the model’s applicability domain. This approach has been explored in our earlier work, though it is not presented in the current manuscript. Second, regarding the validation of the dissolution space, we conducted dissolution safe space predictions only after verifying the robustness and predictability of the model in prior work. Regulatory agencies (e.g., FDA, EMA) often require applicants to submit clinical data from non-bioequivalent (non-BE) batches to verify the model’s predictive accuracy [<xref rid="B20-pharmaceutics-17-01352" ref-type="bibr">20</xref>]. If the model is able to correctly distinguish non-BE batches, its predictive capability would be further substantiated.</p><p>FDCs necessitate more complicated study designs than single-agent formulations. Ideally, the dissolution profiles of each ingredient in an FDC should closely resemble those of the corresponding single-agent formulations. However, discrepancies are often observed in practice. It has been observed that for glyburide single-ingredient drug, the T<sub>max</sub> typically occurs around 2 hours [<xref rid="B32-pharmaceutics-17-01352" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-17-01352" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceutics-17-01352" ref-type="bibr">34</xref>]; however, in combination formulations, the T<sub>max</sub> is significantly delayed. The first reason is that physicochemical properties of metformin and glyburide are vastly different. Different ingredients may also interact and affect drug release. To overcome the issue of poor solubility, glyburide single-ingredient drugs are typically formulated using techniques such as micronization to enhance rapid disintegration and dissolution [<xref rid="B35-pharmaceutics-17-01352" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceutics-17-01352" ref-type="bibr">36</xref>], thereby accelerating absorption and resulting in a relatively short T<sub>max</sub>. In contrast, although metformin is rapidly absorbed, its formulation often requires modulation of the release rate and site within the gastrointestinal tract in order to mitigate common gastrointestinal adverse effects (e.g., diarrhea, nausea) and to maintain stable plasma drug concentrations. The co-formulation of these two drugs, which differ markedly in their physicochemical and pharmacokinetic properties, poses a formulation challenge. If the combination tablet is designed for rapid disintegration to favor glyburide release, it may lead to immediate release of metformin, potentially triggering pronounced gastrointestinal reactions. Conversely, controlling the release of metformin to minimize side effects may inadvertently delay the release of glyburide. Given the critical importance of gastrointestinal tolerability for patient adherence, the combination formulation is designed to modulate the overall release kinetics, thereby reducing the release and dissolution rate of glyburide compared to its immediate-release monotherapy counterpart. Thus, CPPs and CMAs need to be carefully selected during the design phase to ensure the proper release and dissolution of different ingredients. The second reason is that the formulation contains 500 mg of metformin and only 2.5 mg of glyburide. The hundreds fold dose difference between these two APIs renders it extremely challenging to ensure that low dose glyburide is uniformly distributed in large dose metformin [<xref rid="B37-pharmaceutics-17-01352" ref-type="bibr">37</xref>]. This is a core difficulty in developing compounded formulation. The inherent difficulty stems from the need to achieve a homogeneous distribution of a minute quantity of the API within a much larger mass of excipients during powder blending and subsequent processing steps. Any inadequacy in mixing or subsequent particle segregation could lead to substantial tablet-to-tablet content variability, critically compromising the safety and efficacy of the final product. To address this challenge, a systematic strategy integrating formulation optimization and process control was employed. From a formulation perspective, the approach included optimizing the composition ratio, carefully controlling the particle size distribution of both the API and excipients, and incorporating suitable binders and glidants [<xref rid="B35-pharmaceutics-17-01352" ref-type="bibr">35</xref>,<xref rid="B37-pharmaceutics-17-01352" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-17-01352" ref-type="bibr">38</xref>]. These measures aimed to enhance blend homogeneity by improving powder flow properties and reducing disparities in particle characteristics between glyburide and the excipients. Regarding processing, critical parameters were rigorously controlled. This involved optimizing the blending equipment and parameters (such as blending time and rotational speed) and strictly controlling conditions during subsequent unit operations like drying and tablet compression (e.g., temperature, pressure, and speed) to prevent segregation and ensure consistent product quality.</p><p>Many factors increase the likelihood of or even the failure of dissolution profile disparities, between test and reference compounded formulations during in vitro testing. Notably, such in vitro failures may not preclude in vivo bioequivalence. To address this, a safe dissolution space was constructed for compounded preparations. Within this defined space, formulations with different dissolution behaviors are all bioequivalent to the reference preparation. However, only batches of compounded formulations satisfying the safety space for both APIs are considered equivalent. It should be emphasized that this space is based solely on the characteristics of the compounded formulation, not just a combination of two individual drugs. </p><p>Current modeling approaches that bridge in vitro dissolution with in vivo performance encompass both non-mechanistic (e.g., Weibull) and mechanistic methods (e.g., Johnson, Wang–Flanagan, Z-factor model). Mechanistic models such as those developed by Johnson, Wang–Flanagan, and the Z-factor approach are often more mechanistically driven, aiming to describe specific physical processes such as diffusion and erosion. The absorption of BCS Class II drugs, like glyburide, involves complex and dynamic processes including dissolution, precipitation, nucleation, and re-dissolution, and may also involve interactions with luminal components such as bile acids. However, in complex systems such as the FDC formulation studied in this work, the dissolution process diverges significantly from that of single-API formulations. In such cases, not only must the aforementioned factors be considered, but the dissolution behavior of each API may also be altered due to formulation-specific interactions. Moreover, incorporating all these parameters into a mechanistic model presents two major challenges: (1) reliable and accurate data for these parameters are often unavailable, particularly for combination products; (2) validating such a highly complex model is itself a significant challenge. In addition, the selected dissolution model must be capable of simultaneously and appropriately describing the dissolution kinetics of both APIs in the FDC. Due to this complexity, the Weibull function was employed to empirically simulate the dissolution kinetics of glyburide. The Weibull model is an empirical approach whose main advantage lies in its flexibility. It does not assume a predefined dissolution mechanism, but instead uses a shape parameter (β) to flexibly describe various dissolution profiles, including exponential, sigmoidal, and parabolic curves. This allows for a superior fit to experimental data. Furthermore, the Weibull model is readily integrated within the PK-Sim<sup>®</sup> platform. Our primary objective was to establish a mathematical model that can accurately capture the entire dissolution process to provide a reliable input for subsequent PBPK simulations. In this context, the Weibull model has been widely demonstrated to be highly effective. </p><p>Formulation variants spanning diverse release kinetics were generated by modulating model dissolution parameters. Subsequently, VBE studies were conducted against the reference formulation, and the dissolution safe space was determined. This helps spot potential quality issues, as dissolution behavior outside this space may indicate quality defects. Also, the space is able to not only guide prescription screening and manufacturing process adjustments, but also evaluate the impact of variability in APIs and key excipients on the performance of formulation [<xref rid="B12-pharmaceutics-17-01352" ref-type="bibr">12</xref>,<xref rid="B39-pharmaceutics-17-01352" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceutics-17-01352" ref-type="bibr">40</xref>]. However, current dissolution spaces face a challenge: Can in vitro dissolution methods accurately mirror in vivo release behavior? This is especially problematic for glyburide dissolution. Due to its low solubility, SDS is normally added in in vitro dissolution experiments to create leaky tank conditions, but resulting dissolution curves may not align well with actual in vivo dissolution. Existing studies frequently employ two or three step dissolution set-ups [<xref rid="B41-pharmaceutics-17-01352" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-17-01352" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-17-01352" ref-type="bibr">43</xref>], which adjust the pH of dissolution media and use media with different components. Then, they construct models using mechanistic approaches by deconvoluting key parameters which reflect the release characteristics of formulations. The next study will focus on further refining the model through the integration of more physiological variables affecting in vivo drug dissolution and release to better reflect in vivo release behavior and validate/optimize the dissolution design space.</p><p>Currently, BCS-based biowaivers are receiving increasing attention. However, according to regulatory guidelines from various countries and regions, only a subset of BCS Class I and III drugs are eligible for BE waivers, and the criteria are even more stringent for FDC products [<xref rid="B44-pharmaceutics-17-01352" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceutics-17-01352" ref-type="bibr">45</xref>]. For drugs that are not eligible for biowaivers, in vivo BE studies remain the gold standard for assessing bioequivalence between test and reference formulations. Nevertheless, the application of VBE and dissolution safe space approaches can provide valuable support in the evaluation of BE for FDCs. In the present study, PBPK model-based sensitivity analysis revealed that glyburide absorption is highly sensitive to gastrointestinal pH, while metformin absorption is more influenced by GI transit time. These findings highlight that intra- and inter-individual variability in GI pH may significantly affect BE outcomes for such combinations. Furthermore, considering the more pronounced fluctuations in GI pH under fed conditions and the clinical recommendation that metformin be administered with food, fed-state BE studies may be more relevant and informative for this FDC. The integration strategy combining the dissolution safe space with a validated PBPK model provides a framework toward establishing robust in vitro–in vivo correlations (IVIVC). In the future, we anticipate that this approach may offer a scientific basis for supporting biowaiver applications in the context of certain minor formulation changes. </p></sec><sec sec-type="conclusions" id="sec5-pharmaceutics-17-01352"><title>5. Conclusions</title><p>This study successfully establishes a PBBM for a metformin–glyburide FDC tablet, marking a significant advancement over single-entity modeling approaches. The model uniquely captures the distinct in vivo behaviors of both APIs, accounting for metformin’s solubility-driven and transporter-mediated absorption and glyburide’s pH-dependent dissolution and permeability-limited uptake. By leveraging VBE simulations and the exploration of dual dissolution safe spaces, this work provides a scientifically robust framework to ensure combined BE despite the divergent biopharmaceutical properties of the two drugs.</p><p>The significance of this research lies in its ability to broaden the acceptance criteria for traditional in vitro dissolution testing by providing a mechanistic foundation for establishing clinically relevant dissolution specifications. Furthermore, it offers a powerful tool to streamline the development and quality control of metformin–glyburide FDC products, potentially reducing regulatory risk and supporting waiver requests for certain post-approval changes.</p><p>Looking forward, future research can focus on prospectively validating the established dissolution safe space with clinical data. Additionally, extending the VBE to specific subpopulations, such as patients with type 2 diabetes who may present altered gastrointestinal physiology, would enhance the model’s clinical relevance and utility. This approach paves the way for more efficient and scientifically grounded development of complex generic and innovative FDC products.</p></sec></body><back><ack><title>Acknowledgments</title><p>We are grateful to all people for the contributions to the manuscript.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher’s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceutics-17-01352"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/pharmaceutics17101352/s1">https://www.mdpi.com/article/10.3390/pharmaceutics17101352/s1</uri>; Figure S1: In vitro dissolution profiles of reference and test formulations; Table S1: Demographic Characteristics of Subjects in the Human Bioequivalence Study; Table S2: Parameter ranges of gastrointestinal variants in virtual population; Table S3: Virtual Bioequivalence Population Stratification [<xref rid="B26-pharmaceutics-17-01352" ref-type="bibr">26</xref>,<xref rid="B44-pharmaceutics-17-01352" ref-type="bibr">44</xref>,<xref rid="B46-pharmaceutics-17-01352" ref-type="bibr">46</xref>].</p><supplementary-material id="pharmaceutics-17-01352-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceutics-17-01352-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, C.Z. and L.W.; methodology, C.Z. and C.S.; software, C.Z.; validation, C.Z. and Y.X.; investigation, C.Z. and C.S.; data curation, C.Z. and Y.X.; writing—original draft preparation, C.Z.; writing—review and editing, C.S., Y.X. and L.W.; supervision, L.W. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee of Shantou University Medical College before implementation (protocol code A-2023-016-CS and protocol date 7 October 2023). Clinical trials are subject to all policies regarding Research Involving Human Subjects, this study was officially registered at the Center for Drug Evaluation (CDE), National Medical Products Administration (NMPA), China (with the registration number: CTR20233289 and the registration date: 16 October 2023).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects. Subjects in the clinical trials used for model development and validation cannot be identified from the data published in this article and <xref rid="app1-pharmaceutics-17-01352" ref-type="app">Supplementary Materials</xref>.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Most data supporting the reported results can be found in the article and <xref rid="app1-pharmaceutics-17-01352" ref-type="app">Supplementary Materials</xref>, but some of the original data are not publicly available due to confidentiality requirements; interested readers may contact the corresponding author for more information. </p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array orientation="portrait"><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">FDC</td><td align="left" valign="top" rowspan="1" colspan="1">fixed-dose combination</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BE</td><td align="left" valign="top" rowspan="1" colspan="1">bioequivalence</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">API</td><td align="left" valign="top" rowspan="1" colspan="1">active pharmaceutical ingredient</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PBBM</td><td align="left" valign="top" rowspan="1" colspan="1">physiologically based biopharmaceutics modeling</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PBPK</td><td align="left" valign="top" rowspan="1" colspan="1">physiologically based pharmacokinetic</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PK</td><td align="left" valign="top" rowspan="1" colspan="1">pharmacokinetics</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VBE</td><td align="left" valign="top" rowspan="1" colspan="1">virtual bioequivalence</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GI</td><td align="left" valign="top" rowspan="1" colspan="1">gastrointestinal</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIDD</td><td align="left" valign="top" rowspan="1" colspan="1">model-informed drug development</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BCS</td><td align="left" valign="top" rowspan="1" colspan="1">biopharmaceutics classification system </td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PMAT</td><td align="left" valign="top" rowspan="1" colspan="1">plasma membrane monoamine transporter </td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FE</td><td align="left" valign="top" rowspan="1" colspan="1">fold errors</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PE</td><td align="left" valign="top" rowspan="1" colspan="1">predict errors </td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IIV</td><td align="left" valign="top" rowspan="1" colspan="1">inter-individual variability</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BSV</td><td align="left" valign="top" rowspan="1" colspan="1">between-subject variability</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">WSV</td><td align="left" valign="top" rowspan="1" colspan="1">within-subject variability</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-pharmaceutics-17-01352"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>U.S. Food and Drug Administration (FDA)</collab>
</person-group><source>Hypertension: Developing Fixed-Combination Drug Products for Treatment</source><comment>Guidance for Industry</comment><publisher-name>Center for Drug Evaluation and Research (CDER)</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2018</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm" ext-link-type="uri">https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-09-28">(accessed on 28 September 2025)</date-in-citation></element-citation></ref><ref id="B2-pharmaceutics-17-01352"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Fillinger</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Walter</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Ley</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Kęska-Izworska</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Dehkordi</surname><given-names>L.G.</given-names></name>
<name name-style="western"><surname>Kratochwill</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Perco</surname><given-names>P.</given-names></name>
</person-group><article-title>Computational Modeling Approaches and Regulatory Pathways for Drug Combinations</article-title><source>Drug Discov. Today</source><year>2025</year><volume>30</volume><fpage>104345</fpage><pub-id pub-id-type="doi">10.1016/j.drudis.2025.104345</pub-id><pub-id pub-id-type="pmid">40158836</pub-id></element-citation></ref><ref id="B3-pharmaceutics-17-01352"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Sen</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Ganta</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Rachel</surname><given-names>V.N.</given-names></name>
<name name-style="western"><surname>Gogikar</surname><given-names>S.K.</given-names></name>
<name name-style="western"><surname>Singh</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Sonti</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Dikundwar</surname><given-names>A.G.</given-names></name>
</person-group><article-title>Mapping Advantages and Challenges in Analytical Development for Fixed Dose Combination Products, a Review</article-title><source>J. Pharm. Sci.</source><year>2024</year><volume>113</volume><fpage>2028</fpage><lpage>2043</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2024.04.025</pub-id><pub-id pub-id-type="pmid">38697403</pub-id></element-citation></ref><ref id="B4-pharmaceutics-17-01352"><label>4.</label><element-citation publication-type="webpage"><article-title>IDF Diabetes Atlas</article-title><year>2025</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://diabetesatlas.org/resources/idf-diabetes-atlas-2025/" ext-link-type="uri">https://diabetesatlas.org/resources/idf-diabetes-atlas-2025/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-09-28">(accessed on 28 September 2025)</date-in-citation></element-citation></ref><ref id="B5-pharmaceutics-17-01352"><label>5.</label><element-citation publication-type="webpage"><article-title>The American Diabetes Association Releases the Standards of Care in Diabetes—2024</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://diabetes.org/newsroom/press-releases/american-diabetes-association-releases-standards-care-diabetes-2024" ext-link-type="uri">https://diabetes.org/newsroom/press-releases/american-diabetes-association-releases-standards-care-diabetes-2024</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-09-28">(accessed on 28 September 2025)</date-in-citation></element-citation></ref><ref id="B6-pharmaceutics-17-01352"><label>6.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>NICE</collab>
</person-group><article-title>Type 2 Diabetes in Adults: Management</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nice.org.uk/guidance/ng28" ext-link-type="uri">https://www.nice.org.uk/guidance/ng28</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-09-28">(accessed on 28 September 2025)</date-in-citation></element-citation></ref><ref id="B7-pharmaceutics-17-01352"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Shuster</surname><given-names>D.L.</given-names></name>
<name name-style="western"><surname>Shireman</surname><given-names>L.M.</given-names></name>
<name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Shen</surname><given-names>D.D.</given-names></name>
<name name-style="western"><surname>Flood Nichols</surname><given-names>S.K.</given-names></name>
<name name-style="western"><surname>Ahmed</surname><given-names>M.S.</given-names></name>
<name name-style="western"><surname>Clark</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Caritis</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Venkataramanan</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Haas</surname><given-names>D.M.</given-names></name>
<etal/>
</person-group><article-title>Pharmacodynamics of Glyburide, Metformin, and Glyburide/Metformin Combination Therapy in the Treatment of Gestational Diabetes Mellitus</article-title><source>Clin. Pharmacol. Ther.</source><year>2020</year><volume>107</volume><fpage>1362</fpage><lpage>1372</lpage><pub-id pub-id-type="doi">10.1002/cpt.1749</pub-id><pub-id pub-id-type="pmid">31869430</pub-id><pub-id pub-id-type="pmcid">PMC7561209</pub-id></element-citation></ref><ref id="B8-pharmaceutics-17-01352"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name>
</person-group><article-title>Pharmacokinetic and Bioequivalence Studies of 2 Metformin Glibenclamide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions</article-title><source>Clin. Pharmacol. Drug Dev.</source><year>2023</year><volume>12</volume><fpage>509</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1002/cpdd.1219</pub-id><pub-id pub-id-type="pmid">36642944</pub-id></element-citation></ref><ref id="B9-pharmaceutics-17-01352"><label>9.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>International Council for Harmonisation</collab>
</person-group><source>ICH M13A: Bioequivalence for Immediate-Release Solid Oral Dosage Forms</source><publisher-name>ICH</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2023</year></element-citation></ref><ref id="B10-pharmaceutics-17-01352"><label>10.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>European Medicines Agency</collab>
</person-group><source>Guideline on Clinical Development of Fixed Combination Medicinal Products</source><publisher-name>European Medicines Agency (EMA)</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2017</year></element-citation></ref><ref id="B11-pharmaceutics-17-01352"><label>11.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Center for Drug Evaluation</collab>
</person-group><source>Technical Guideline for Bioavailability and Bioequivalence Studies of Chemical Drug Products</source><publisher-name>National Medical Products Administration (NMPA)</publisher-name><publisher-loc>Beijing, China</publisher-loc><year>2005</year></element-citation></ref><ref id="B12-pharmaceutics-17-01352"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Bhattiprolu</surname><given-names>A.K.</given-names></name>
<name name-style="western"><surname>Kollipara</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Boddu</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Arumugam</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Khan</surname><given-names>S.M.</given-names></name>
<name name-style="western"><surname>Ahmed</surname><given-names>T.</given-names></name>
</person-group><article-title>A Semi-Mechanistic Physiologically Based Biopharmaceutics Model to Describe Complex and Saturable Absorption of Metformin: Justification of Dissolution Specifications for Extended Release Formulation</article-title><source>Aaps Pharmscitech</source><year>2024</year><volume>25</volume><fpage>193</fpage><pub-id pub-id-type="doi">10.1208/s12249-024-02904-9</pub-id><pub-id pub-id-type="pmid">39168956</pub-id></element-citation></ref><ref id="B13-pharmaceutics-17-01352"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hanke</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Türk</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Selzer</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Ishiguro</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Ebner</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Wiebe</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Müller</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Stopfer</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Nock</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Lehr</surname><given-names>T.</given-names></name>
</person-group><article-title>A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Drug–Drug–Gene Interaction Model of Metformin and Cimetidine in Healthy Adults and Renally Impaired Individuals</article-title><source>Clin. Pharmacokinet.</source><year>2020</year><volume>59</volume><fpage>1419</fpage><lpage>1431</lpage><pub-id pub-id-type="doi">10.1007/s40262-020-00896-w</pub-id><pub-id pub-id-type="pmid">32449077</pub-id><pub-id pub-id-type="pmcid">PMC7658088</pub-id></element-citation></ref><ref id="B14-pharmaceutics-17-01352"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Kong</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name>
</person-group><article-title>A Whole-Body Physiologically Based Pharmacokinetic Model Characterizing Interplay of OCTs and MATEs in Intestine, Liver and Kidney to Predict Drug-Drug Interactions of Metformin with Perpetrators</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>698</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13050698</pub-id><pub-id pub-id-type="pmid">34064886</pub-id><pub-id pub-id-type="pmcid">PMC8151202</pub-id></element-citation></ref><ref id="B15-pharmaceutics-17-01352"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Li</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Zhong</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>
</person-group><article-title>Prediction of Drug Disposition in Diabetic Patients by Means of a Physiologically Based Pharmacokinetic Model</article-title><source>Clin. Pharmacokinet.</source><year>2015</year><volume>54</volume><fpage>179</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1007/s40262-014-0192-8</pub-id><pub-id pub-id-type="pmid">25316573</pub-id></element-citation></ref><ref id="B16-pharmaceutics-17-01352"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Klumpp</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Dressman</surname><given-names>J.</given-names></name>
</person-group><article-title>Physiologically Based Pharmacokinetic Model Outputs Depend on Dissolution Data and Their Input: Case Examples Glibenclamide and Dipyridamole</article-title><source>Eur. J. Pharm. Sci.</source><year>2020</year><volume>151</volume><fpage>105380</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2020.105380</pub-id><pub-id pub-id-type="pmid">32442630</pub-id></element-citation></ref><ref id="B17-pharmaceutics-17-01352"><label>17.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Food and Drug Administration</collab>
</person-group><source>The Use of Physiologically Based Pharmacokinetic Analyses—Biopharmaceutics Applications for Oral Drug Product Development, Manufacturing Changes, and Controls: Guidance for Industry (Draft)</source><publisher-name>U.S. Food and Drug Administration (U.S. FDA)</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2020</year></element-citation></ref><ref id="B18-pharmaceutics-17-01352"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Derbalah</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Abdulla</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>De Sousa Mendes</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Stader</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Jamei</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Gardner</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Sepp</surname><given-names>A.</given-names></name>
</person-group><article-title>Accelerating Biologics PBPK Modelling with Automated Model Building: A Tutorial</article-title><source>Pharmaceutics</source><year>2025</year><volume>17</volume><elocation-id>604</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics17050604</pub-id><pub-id pub-id-type="pmid">40430895</pub-id><pub-id pub-id-type="pmcid">PMC12115112</pub-id></element-citation></ref><ref id="B19-pharmaceutics-17-01352"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Mackie</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Arora</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Seo</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Moody</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Rege</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Pepin</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Heimbach</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Tannergren</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Mitra</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Suarez-Sharp</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report</article-title><source>Mol. Pharm.</source><year>2024</year><volume>21</volume><fpage>2065</fpage><lpage>2080</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.4c00202</pub-id><pub-id pub-id-type="pmid">38600804</pub-id><pub-id pub-id-type="pmcid">PMC11080464</pub-id></element-citation></ref><ref id="B20-pharmaceutics-17-01352"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Arora</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Pepin</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Jamei</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Sharma</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Heimbach</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Wagner</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Bransford</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Kollipara</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Ahmed</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Hingle</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Development of a Physiologically Based Biopharmaceutics Model Report Template: Considerations for Improved Quality in View of Regulatory Submissions</article-title><source>Mol. Pharm.</source><year>2025</year><volume>22</volume><fpage>2735</fpage><lpage>2746</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.5c00225</pub-id><pub-id pub-id-type="pmid">40300064</pub-id><pub-id pub-id-type="pmcid">PMC12135060</pub-id></element-citation></ref><ref id="B21-pharmaceutics-17-01352"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kuepfer</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Niederalt</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Wendl</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Schlender</surname><given-names>J.-F.</given-names></name>
<name name-style="western"><surname>Willmann</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Lippert</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Block</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Eissing</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Teutonico</surname><given-names>D.</given-names></name>
</person-group><article-title>Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model</article-title><source>CPT Pharmacomet. Syst. Pharmacol.</source><year>2016</year><volume>5</volume><fpage>516</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1002/psp4.12134</pub-id><pub-id pub-id-type="pmid">27653238</pub-id><pub-id pub-id-type="pmcid">PMC5080648</pub-id></element-citation></ref><ref id="B22-pharmaceutics-17-01352"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Graham</surname><given-names>G.G.</given-names></name>
<name name-style="western"><surname>Punt</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Arora</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Day</surname><given-names>R.O.</given-names></name>
<name name-style="western"><surname>Doogue</surname><given-names>M.P.</given-names></name>
<name name-style="western"><surname>Duong</surname><given-names>J.K.</given-names></name>
<name name-style="western"><surname>Furlong</surname><given-names>T.J.</given-names></name>
<name name-style="western"><surname>Greenfield</surname><given-names>J.R.</given-names></name>
<name name-style="western"><surname>Greenup</surname><given-names>L.C.</given-names></name>
<name name-style="western"><surname>Kirkpatrick</surname><given-names>C.M.</given-names></name>
<etal/>
</person-group><article-title>Clinical Pharmacokinetics of Metformin</article-title><source>Clin. Pharmacokinet.</source><year>2011</year><volume>50</volume><fpage>81</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.2165/11534750-000000000-00000</pub-id><pub-id pub-id-type="pmid">21241070</pub-id></element-citation></ref><ref id="B23-pharmaceutics-17-01352"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Desai</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Wong</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Ye</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Tang</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Timmins</surname><given-names>P.</given-names></name>
</person-group><article-title>Surfactant-Mediated Dissolution of Metformin Hydrochloride Tablets: Wetting Effects versus Ion Pairs Diffusivity</article-title><source>J. Pharm. Sci.</source><year>2014</year><volume>103</volume><fpage>920</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1002/jps.23852</pub-id><pub-id pub-id-type="pmid">24549733</pub-id></element-citation></ref><ref id="B24-pharmaceutics-17-01352"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Xia</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>
</person-group><article-title>Metformin Transport by a Newly Cloned Proton-Stimulated Organic Cation Transporter (Plasma Membrane Monoamine Transporter) Expressed in Human Intestine</article-title><source>Drug Metab. Dispos.</source><year>2007</year><volume>35</volume><fpage>1956</fpage><lpage>1962</lpage><pub-id pub-id-type="doi">10.1124/dmd.107.015495</pub-id><pub-id pub-id-type="pmid">17600084</pub-id><pub-id pub-id-type="pmcid">PMC2672958</pub-id></element-citation></ref><ref id="B25-pharmaceutics-17-01352"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Greupink</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Schreurs</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Benne</surname><given-names>M.S.</given-names></name>
<name name-style="western"><surname>Huisman</surname><given-names>M.T.</given-names></name>
<name name-style="western"><surname>Russel</surname><given-names>F.G.M.</given-names></name>
</person-group><article-title>Semi-Mechanistic Physiologically-Based Pharmacokinetic Modeling of Clinical Glibenclamide Pharmacokinetics and Drug–Drug-Interactions</article-title><source>Eur. J. Pharm. Sci.</source><year>2013</year><volume>49</volume><fpage>819</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2013.06.009</pub-id><pub-id pub-id-type="pmid">23806476</pub-id></element-citation></ref><ref id="B26-pharmaceutics-17-01352"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Shirasaka</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Seki</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Hatakeyama</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Kurokawa</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Uchiyama</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Takemura</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Yasugi</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Kishimoto</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Tamai</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Multiple Transport Mechanisms Involved in the Intestinal Absorption of Metformin: Impact on the Nonlinear Absorption Kinetics</article-title><source>J. Pharm. Sci.</source><year>2022</year><volume>111</volume><fpage>1531</fpage><lpage>1541</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2022.01.008</pub-id><pub-id pub-id-type="pmid">35090865</pub-id></element-citation></ref><ref id="B27-pharmaceutics-17-01352"><label>27.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Bristol-Myers Squibb Company</collab>
</person-group><source>GLUCOVANCE<sup>®</sup> (Glyburide and Metformin Hydrochloride) Tablets: Highlights of Prescribing Information</source><comment>Initial U.S. Approval</comment><publisher-name>Bristol-Myers Squibb Company</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2000</year></element-citation></ref><ref id="B28-pharmaceutics-17-01352"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Proks</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Kramer</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Haythorne</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Ashcroft</surname><given-names>F.M.</given-names></name>
</person-group><article-title>Binding of Sulphonylureas to Plasma Proteins—A KATP Channel Perspective</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0197634</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0197634</pub-id><pub-id pub-id-type="pmid">29772022</pub-id><pub-id pub-id-type="pmcid">PMC5957440</pub-id></element-citation></ref><ref id="B29-pharmaceutics-17-01352"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Huo</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Zou</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Yao</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Xie</surname><given-names>S.</given-names></name>
</person-group><article-title>DDSolver: An Add-In Program for Modeling and Comparison of Drug Dissolution Profiles</article-title><source>AAPS J.</source><year>2010</year><volume>12</volume><fpage>263</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1208/s12248-010-9185-1</pub-id><pub-id pub-id-type="pmid">20373062</pub-id><pub-id pub-id-type="pmcid">PMC2895453</pub-id></element-citation></ref><ref id="B30-pharmaceutics-17-01352"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Najjar</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Hamadeh</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Krause</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Schepky</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Edginton</surname><given-names>A.</given-names></name>
</person-group><article-title>Global Sensitivity Analysis of Open Systems Pharmacology Suite Physiologically Based Pharmacokinetic Models</article-title><source>CPT Pharmacomet. Syst. Pharmacol.</source><year>2024</year><volume>13</volume><fpage>2052</fpage><lpage>2067</lpage><pub-id pub-id-type="doi">10.1002/psp4.13256</pub-id><pub-id pub-id-type="pmcid">PMC11646943</pub-id><pub-id pub-id-type="pmid">39498820</pub-id></element-citation></ref><ref id="B31-pharmaceutics-17-01352"><label>31.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>European Medicines Agency</collab>
</person-group><article-title>Guideline on the Reporting of Physiologically Based Pharmacokinetic (PBPK) Modelling and Simulation. EMA/CHMP/458101/2016</article-title><year>2018</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/Documents/Scientific-Guideline/Guideline-Reporting-Physiologically-Based-Pharmacokinetic-Pbpk-Modelling-Simulation_en.pdf" ext-link-type="uri">https://www.ema.europa.eu/en/Documents/Scientific-Guideline/Guideline-Reporting-Physiologically-Based-Pharmacokinetic-Pbpk-Modelling-Simulation_en.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-28">(accessed on 28 January 2021)</date-in-citation></element-citation></ref><ref id="B32-pharmaceutics-17-01352"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Niemi</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Backman</surname><given-names>J.T.</given-names></name>
<name name-style="western"><surname>Neuvonen</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Neuvonen</surname><given-names>P.J.</given-names></name>
<name name-style="western"><surname>Kivistö</surname><given-names>K.T.</given-names></name>
</person-group><article-title>Effects of Rifampin on the Pharmacokinetics and Pharmacodynamics of Glyburide and Glipizide</article-title><source>Clin. Pharmacol. Ther.</source><year>2001</year><volume>69</volume><fpage>400</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1067/mcp.2001.115822</pub-id><pub-id pub-id-type="pmid">11406737</pub-id></element-citation></ref><ref id="B33-pharmaceutics-17-01352"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lilja</surname><given-names>J.J.</given-names></name>
<name name-style="western"><surname>Niemi</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Fredrikson</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Neuvonen</surname><given-names>P.J.</given-names></name>
</person-group><article-title>Effects of Clarithromycin and Grapefruit Juice on the Pharmacokinetics of Glibenclamide</article-title><source>Br. J. Clin. Pharmacol.</source><year>2007</year><volume>63</volume><fpage>732</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2006.02836.x</pub-id><pub-id pub-id-type="pmid">17223855</pub-id><pub-id pub-id-type="pmcid">PMC2000598</pub-id></element-citation></ref><ref id="B34-pharmaceutics-17-01352"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Varma</surname><given-names>M.V.S.</given-names></name>
<name name-style="western"><surname>Scialis</surname><given-names>R.J.</given-names></name>
<name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Bi</surname><given-names>Y.-A.</given-names></name>
<name name-style="western"><surname>Rotter</surname><given-names>C.J.</given-names></name>
<name name-style="western"><surname>Goosen</surname><given-names>T.C.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name>
</person-group><article-title>Mechanism-Based Pharmacokinetic Modeling to Evaluate Transporter-Enzyme Interplay in Drug Interactions and Pharmacogenetics of Glyburide</article-title><source>AAPS J.</source><year>2014</year><volume>16</volume><fpage>736</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1208/s12248-014-9614-7</pub-id><pub-id pub-id-type="pmid">24839071</pub-id><pub-id pub-id-type="pmcid">PMC4070267</pub-id></element-citation></ref><ref id="B35-pharmaceutics-17-01352"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Donahue</surname><given-names>S.R.</given-names></name>
<name name-style="western"><surname>Turner</surname><given-names>K.C.</given-names></name>
<name name-style="western"><surname>Patel</surname><given-names>S.</given-names></name>
</person-group><article-title>Pharmacokinetics and Pharmacodynamics of Glyburide/Metformin Tablets (Glucovance<sup>TM</sup>) Versus Equivalent Doses of Glyburide and Metformin in Patients with Type 2 Diabetes</article-title><source>Clin. Pharmacokinet.</source><year>2002</year><volume>41</volume><fpage>1301</fpage><lpage>1309</lpage><pub-id pub-id-type="doi">10.2165/00003088-200241150-00004</pub-id><pub-id pub-id-type="pmid">12452739</pub-id></element-citation></ref><ref id="B36-pharmaceutics-17-01352"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Arnqvist</surname><given-names>H.J.</given-names></name>
<name name-style="western"><surname>Karlberg</surname><given-names>B.E.</given-names></name>
<name name-style="western"><surname>Melander</surname><given-names>A.</given-names></name>
</person-group><article-title>Pharmacokinetics and Effects of Glibenclamide in Two Formulations, HB 419 and HB 420, in Type 2 Diabetes</article-title><source>Ann. Clin. Res.</source><year>1983</year><volume>15</volume><issue>(Suppl. S37)</issue><fpage>21</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">6433769</pub-id></element-citation></ref><ref id="B37-pharmaceutics-17-01352"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Desai</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Wen</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Timmins</surname><given-names>P.</given-names></name>
</person-group><article-title>Formulation Design, Challenges, and Development Considerations for Fixed Dose Combination (FDC) of Oral Solid Dosage Forms</article-title><source>Pharm. Dev. Technol.</source><year>2013</year><volume>18</volume><fpage>1265</fpage><lpage>1276</lpage><pub-id pub-id-type="doi">10.3109/10837450.2012.660699</pub-id><pub-id pub-id-type="pmid">22339230</pub-id></element-citation></ref><ref id="B38-pharmaceutics-17-01352"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Belayneh</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Molla</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Kahsay</surname><given-names>G.</given-names></name>
</person-group><article-title>Formulation and Optimization of Monolithic Fixed-Dose Combination of Metformin HCl and Glibenclamide Orodispersible Tablets</article-title><source>Adv. Pharm. Pharm. Sci.</source><year>2020</year><volume>2020</volume><fpage>3546597</fpage><pub-id pub-id-type="doi">10.1155/2020/3546597</pub-id><pub-id pub-id-type="pmcid">PMC7094173</pub-id><pub-id pub-id-type="pmid">32259103</pub-id></element-citation></ref><ref id="B39-pharmaceutics-17-01352"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Bhattiprolu</surname><given-names>A.K.</given-names></name>
<name name-style="western"><surname>Kollipara</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Boddu</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Ahmed</surname><given-names>T.</given-names></name>
</person-group><article-title>Justification of Widened Dissolution Specifications of an Extended-Release Product Using Physiologically Based Biopharmaceutics Modeling</article-title><source>Xenobiotica</source><year>2024</year><volume>54</volume><fpage>781</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1080/00498254.2024.2411980</pub-id><pub-id pub-id-type="pmid">39361244</pub-id></element-citation></ref><ref id="B40-pharmaceutics-17-01352"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Tannergren</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Arora</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Babiskin</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Borges</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Chatterjee</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Cheng</surname><given-names>Y.-H.</given-names></name>
<name name-style="western"><surname>Dallmann</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Govada</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Heimbach</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Hingle</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Current State and New Horizons in Applications of Physiologically Based Biopharmaceutics Modeling (PBBM): A Workshop Report</article-title><source>Mol. Pharm.</source><year>2025</year><volume>22</volume><fpage>5</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.4c01148</pub-id><pub-id pub-id-type="pmid">39680866</pub-id><pub-id pub-id-type="pmcid">PMC11707736</pub-id></element-citation></ref><ref id="B41-pharmaceutics-17-01352"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Loisios-Konstantinidis</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Cristofoletti</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Fotaki</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Turner</surname><given-names>D.B.</given-names></name>
<name name-style="western"><surname>Dressman</surname><given-names>J.</given-names></name>
</person-group><article-title>Establishing Virtual Bioequivalence and Clinically Relevant Specifications Using in Vitro Biorelevant Dissolution Testing and Physiologically-Based Population Pharmacokinetic Modeling. Case Example</article-title><source>Eur. J. Pharm. Sci.</source><year>2020</year><volume>143</volume><fpage>105170</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2019.105170</pub-id><pub-id pub-id-type="pmid">31783158</pub-id></element-citation></ref><ref id="B42-pharmaceutics-17-01352"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Rudolph</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Charbe</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Plano</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Shoyaib</surname><given-names>A.A.</given-names></name>
<name name-style="western"><surname>Pal</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Boyce</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Polli</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Dressman</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>A Physiologically Based Biopharmaceutics Modeling (PBBM) Framework for Characterizing Formulation-Dependent Food Effects: Paving the Road towards Fed State Virtual BE Studies for Itraconazole Amorphous Solid Dispersions</article-title><source>Eur. J. Pharm. Sci.</source><year>2025</year><volume>209</volume><fpage>107047</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2025.107047</pub-id><pub-id pub-id-type="pmid">39983931</pub-id></element-citation></ref><ref id="B43-pharmaceutics-17-01352"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Gonzalez-Alvarez</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Ruiz-Picazo</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Selles-Talavera</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Figueroa-Campos</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Merino</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Bermejo</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Gonzalez-Alvarez</surname><given-names>M.</given-names></name>
</person-group><article-title>In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>390</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16030390</pub-id><pub-id pub-id-type="pmid">38543284</pub-id><pub-id pub-id-type="pmcid">PMC10974868</pub-id></element-citation></ref><ref id="B44-pharmaceutics-17-01352"><label>44.</label><element-citation publication-type="gov"><article-title>Guideline for the Testing and Comparison of Dissolution Curves of Ordinary Oral Solid Preparations</article-title><year>2016</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nmpa.gov.cn/directory/web/nmpa/zhuanti/ypqxgg/ggzhcfg/20160318210001633.html" ext-link-type="uri">https://www.nmpa.gov.cn/directory/web/nmpa/zhuanti/ypqxgg/ggzhcfg/20160318210001633.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-09-28">(accessed on 28 September 2025)</date-in-citation></element-citation></ref><ref id="B45-pharmaceutics-17-01352"><label>45.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Therapeutic Goods Administration</collab>
</person-group><article-title>ICH M9 Guideline on Biopharmaceutics Classification System-Based Biowaivers</article-title><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/ich-m9-biopharmaceutics-classification-system-based-biowaivers-scientific-guideline" ext-link-type="uri">https://www.ema.europa.eu/en/ich-m9-biopharmaceutics-classification-system-based-biowaivers-scientific-guideline</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-09-28">(accessed on 28 September 2025)</date-in-citation></element-citation></ref><ref id="B46-pharmaceutics-17-01352"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Abuhelwa</surname><given-names>A.Y.</given-names></name>
<name name-style="western"><surname>Williams</surname><given-names>D.B.</given-names></name>
<name name-style="western"><surname>Upton</surname><given-names>R.N.</given-names></name>
<name name-style="western"><surname>Foster</surname><given-names>D.J.R.</given-names></name>
</person-group><article-title>Food, gastrointestinal pH, and models of oral drug absorption</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2017</year><volume>112</volume><fpage>234</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2016.11.034</pub-id><pub-id pub-id-type="pmid">27914234</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-01352-f001" orientation="portrait"><label>Figure 1</label><caption><p>Study design and subject flow. The diagram illustrates the participant flow for the entire bioequivalence study. The study included both fasted and fed treatment arms in a crossover design. For the purpose of validating the model developed in this work, only the pharmacokinetic data from the fasted treatment arm were used.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01352-g001.jpg"/></fig><fig position="float" id="pharmaceutics-17-01352-f002" orientation="portrait"><label>Figure 2</label><caption><p>Model fitting results and GOF plots: (<bold>a</bold>,<bold>b</bold>) represent the model fitting outcomes for the reference formulations of metformin (<bold>a</bold>) and glyburide (<bold>b</bold>); (<bold>c</bold>) depicts the goodness-of-fit (GOF) plot after simulation, where the solid line represents the standard line and the dashed line indicates the two-fold error line.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01352-g002.jpg"/></fig><fig position="float" id="pharmaceutics-17-01352-f003" orientation="portrait"><label>Figure 3</label><caption><p>Global sensitivity analysis for key pharmacokinetic parameters of metformin–glyburide tablets: (<bold>a</bold>) displays the results for metformin component and (<bold>b</bold>) for glyburide component.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01352-g003.jpg"/></fig><fig position="float" id="pharmaceutics-17-01352-f004" orientation="portrait"><label>Figure 4</label><caption><p>Pharmacokinetic parameter plots of the virtual population. (<bold>a</bold>,<bold>b</bold>) C<sub>max</sub>, AUC<sub>0-t</sub> of metformin with different sequences, respectively. (<bold>c</bold>,<bold>d</bold>) C<sub>max</sub>, AUC<sub>0-t</sub> of glyburide with different sequences, respectively.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01352-g004.jpg"/></fig><fig position="float" id="pharmaceutics-17-01352-f005" orientation="portrait"><label>Figure 5</label><caption><p>Expected bioequivalent dissolution safe space for metformin (<bold>a</bold>) and glyburide (<bold>b</bold>). Gray shaded areas delineate the dissolution curves of metformin and glyburide where bioequivalence can be achieved under the fastest and slowest conditions. Virtual batches represented by dashdot lines failed to achieve bioequivalence with the reference batch, including the red dashed lines in Figure a (Virtual Batch 1) and the red and purple dashed line in Figure b (Virtual Batch 1 and 5).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01352-g005.jpg"/></fig><table-wrap position="float" id="pharmaceutics-17-01352-t001" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-01352-t001_Table 1</object-id><label>Table 1</label><caption><p>Physicochemical and biopharmaceutical properties of metformin and glyburide.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parameters</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Unit</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Value</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Source</th></tr></thead><tbody><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Metformin</td></tr><tr><td colspan="4" align="center" valign="middle" rowspan="1">Physicochemical properties</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LogP</td><td align="center" valign="middle" rowspan="1" colspan="1">Log unit</td><td align="center" valign="middle" rowspan="1" colspan="1">−1.43</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B22-pharmaceutics-17-01352" ref-type="bibr">22</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MW </td><td align="center" valign="middle" rowspan="1" colspan="1">g/mol</td><td align="center" valign="middle" rowspan="1" colspan="1">129.16</td><td align="center" valign="middle" rowspan="1" colspan="1">Pubchem</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">pKa<sub>1</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">\</td><td align="center" valign="middle" rowspan="1" colspan="1">2.8</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B23-pharmaceutics-17-01352" ref-type="bibr">23</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">pKa<sub>2</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">\</td><td align="center" valign="middle" rowspan="1" colspan="1">11.5</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B23-pharmaceutics-17-01352" ref-type="bibr">23</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Solubility (Ref-pH 6.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">g/L</td><td align="center" valign="middle" rowspan="1" colspan="1">350.9</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B23-pharmaceutics-17-01352" ref-type="bibr">23</xref>]</td></tr><tr><td colspan="4" align="center" valign="middle" rowspan="1">Absorption</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Intestinal permeability (transcellular)</td><td align="center" valign="middle" rowspan="1" colspan="1">cm/min</td><td align="center" valign="middle" rowspan="1" colspan="1">5.80 × 10<sup>−8</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">optimized</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PMAT Hill coefficient</td><td align="center" valign="middle" rowspan="1" colspan="1">\</td><td align="center" valign="middle" rowspan="1" colspan="1">2.64</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B24-pharmaceutics-17-01352" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PMAT Km </td><td align="center" valign="middle" rowspan="1" colspan="1">μmol/L</td><td align="center" valign="middle" rowspan="1" colspan="1">1320</td><td align="center" valign="middle" rowspan="1" colspan="1">optimized</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PMAT Vmax </td><td align="center" valign="middle" rowspan="1" colspan="1">1/min</td><td align="center" valign="middle" rowspan="1" colspan="1">53.36</td><td align="center" valign="middle" rowspan="1" colspan="1">optimized</td></tr><tr><td colspan="4" align="center" valign="middle" rowspan="1">Distribution</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fraction unbound</td><td align="center" valign="middle" rowspan="1" colspan="1">%</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">Drugbank</td></tr><tr><td colspan="4" align="center" valign="middle" rowspan="1">Elimination</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TSmax_spec</td><td align="center" valign="middle" rowspan="1" colspan="1">μmol/L/min</td><td align="center" valign="middle" rowspan="1" colspan="1">85.42</td><td align="center" valign="middle" rowspan="1" colspan="1">optimized</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Km(kidney)</td><td align="center" valign="middle" rowspan="1" colspan="1">μmol/L</td><td align="center" valign="middle" rowspan="1" colspan="1">65.6</td><td align="center" valign="middle" rowspan="1" colspan="1">optimized</td></tr><tr><td colspan="4" align="center" valign="middle" rowspan="1">Formulation</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">50% dissolved time</td><td rowspan="2" align="center" valign="middle" colspan="1">min</td><td align="center" valign="middle" rowspan="1" colspan="1">9.7</td><td align="center" valign="middle" rowspan="1" colspan="1">optimized</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">experiment</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Dissolution shape</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">\</td><td align="center" valign="middle" rowspan="1" colspan="1">1.37</td><td align="center" valign="middle" rowspan="1" colspan="1">optimized</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">optimized</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Glyburide</td></tr><tr><td colspan="4" align="center" valign="middle" rowspan="1">Physicochemical properties</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LogP</td><td align="center" valign="middle" rowspan="1" colspan="1">Log unit</td><td align="center" valign="middle" rowspan="1" colspan="1">3.75</td><td align="center" valign="middle" rowspan="1" colspan="1">Pubchem</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MW </td><td align="center" valign="middle" rowspan="1" colspan="1">g/mol</td><td align="center" valign="middle" rowspan="1" colspan="1">494</td><td align="center" valign="middle" rowspan="1" colspan="1">Pubchem</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">pKa</td><td align="center" valign="middle" rowspan="1" colspan="1">\</td><td align="center" valign="middle" rowspan="1" colspan="1">5.3</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B25-pharmaceutics-17-01352" ref-type="bibr">25</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Solubility at Reference pH</td><td align="center" valign="middle" rowspan="1" colspan="1">g/L</td><td align="center" valign="middle" rowspan="1" colspan="1">2.06 × 10<sup>−3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">Pubchem</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Reference pH</td><td align="center" valign="middle" rowspan="1" colspan="1">\</td><td align="center" valign="middle" rowspan="1" colspan="1">8.31</td><td align="center" valign="middle" rowspan="1" colspan="1">optimized</td></tr><tr><td colspan="4" align="center" valign="middle" rowspan="1">Absorption</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Intestinal permeability (transcellular)</td><td align="center" valign="middle" rowspan="1" colspan="1">cm/min</td><td align="center" valign="middle" rowspan="1" colspan="1">6.27 × 10<sup>−5</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">optimized</td></tr><tr><td colspan="4" align="center" valign="middle" rowspan="1">Distribution</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fraction unbound</td><td align="center" valign="middle" rowspan="1" colspan="1">%</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Pubchem</td></tr><tr><td colspan="4" align="center" valign="middle" rowspan="1">Elimination</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Total hepatic clearance </td><td align="center" valign="middle" rowspan="1" colspan="1">1/min</td><td align="center" valign="middle" rowspan="1" colspan="1">4.15</td><td align="center" valign="middle" rowspan="1" colspan="1">optimized</td></tr><tr><td colspan="4" align="center" valign="middle" rowspan="1">Formulation</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">50% dissolved time</td><td rowspan="2" align="center" valign="middle" colspan="1">min</td><td align="center" valign="middle" rowspan="1" colspan="1">77.22</td><td align="center" valign="middle" rowspan="1" colspan="1">optimized</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">82.78</td><td align="center" valign="middle" rowspan="1" colspan="1">optimized</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Dissolution shape</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">\</td><td align="center" valign="middle" rowspan="1" colspan="1">1.06</td><td align="center" valign="middle" rowspan="1" colspan="1">optimized</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">optimized</td></tr></tbody></table><table-wrap-foot><fn><p>LogP: Log Partition coefficient, MW: Molecular Weight, pKa<sub>1</sub>: p value of the first acid dissociation constant, pKa<sub>2</sub>: p value of the second acid dissociation constant.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-01352-t002" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-01352-t002_Table 2</object-id><label>Table 2</label><caption><p>Predicted and Observed Pharmacokinetic Parameters for Both Drug Components of Reference and Test Formulations, with Fold Errors (FE) and Predict Errors (PE) Estimates.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compounds</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PK Parameters</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Formulations</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">FE</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PE</th></tr></thead><tbody><tr><td rowspan="4" align="center" valign="middle" colspan="1">Metformin</td><td rowspan="2" align="center" valign="middle" colspan="1">AUC<sub>0-t</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">T</td><td align="center" valign="middle" rowspan="1" colspan="1">0.95</td><td align="center" valign="middle" rowspan="1" colspan="1">0.05</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">R</td><td align="center" valign="middle" rowspan="1" colspan="1">0.97</td><td align="center" valign="middle" rowspan="1" colspan="1">0.03</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">C<sub>max</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">T</td><td align="center" valign="middle" rowspan="1" colspan="1">1.001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">R</td><td align="center" valign="middle" rowspan="1" colspan="1">1.07</td><td align="center" valign="middle" rowspan="1" colspan="1">0.07</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Glyburide</td><td rowspan="2" align="center" valign="middle" colspan="1">AUC<sub>0-t</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">T</td><td align="center" valign="middle" rowspan="1" colspan="1">1.07</td><td align="center" valign="middle" rowspan="1" colspan="1">0.07</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">R</td><td align="center" valign="middle" rowspan="1" colspan="1">1.13</td><td align="center" valign="middle" rowspan="1" colspan="1">0.13</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">C<sub>max</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">T</td><td align="center" valign="middle" rowspan="1" colspan="1">0.80</td><td align="center" valign="middle" rowspan="1" colspan="1">0.20</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.20</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-01352-t003" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-01352-t003_Table 3</object-id><label>Table 3</label><caption><p>Dissolution Safe Space for Metformin.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virtual Batch</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dissolution Time (50% Dissolved)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parameters</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">T</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">R</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">T/R %</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">90% CI</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">30 min</td><td align="center" valign="middle" rowspan="1" colspan="1">C<sub>max</sub> (ng·mL<sup>−1</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">1418.05</td><td align="center" valign="middle" rowspan="1" colspan="1">1215.67</td><td align="center" valign="middle" rowspan="1" colspan="1">116.65%</td><td align="center" valign="middle" rowspan="1" colspan="1">112.75–120.68%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">AUC<sub>0-t</sub> (ng·h·mL<sup>−1</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">7030.46</td><td align="center" valign="middle" rowspan="1" colspan="1">5770.53</td><td align="center" valign="middle" rowspan="1" colspan="1">121.83%</td><td align="center" valign="middle" rowspan="1" colspan="1">116.62–127.28%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">25 min</td><td align="center" valign="middle" rowspan="1" colspan="1">C<sub>max</sub> (ng·mL<sup>−1</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">1387.88</td><td align="center" valign="middle" rowspan="1" colspan="1">1215.67</td><td align="center" valign="middle" rowspan="1" colspan="1">114.17%</td><td align="center" valign="middle" rowspan="1" colspan="1">110.31–118.15%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">AUC<sub>0-t</sub> (ng·h·mL<sup>−1</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">6801.63</td><td align="center" valign="middle" rowspan="1" colspan="1">5770.53</td><td align="center" valign="middle" rowspan="1" colspan="1">117.87%</td><td align="center" valign="middle" rowspan="1" colspan="1">112.75–123.21%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">10 min</td><td align="center" valign="middle" rowspan="1" colspan="1">C<sub>max</sub> (ng·mL<sup>−1</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">1263.52</td><td align="center" valign="middle" rowspan="1" colspan="1">1215.67</td><td align="center" valign="middle" rowspan="1" colspan="1">103.94%</td><td align="center" valign="middle" rowspan="1" colspan="1">100.13–107.88%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">AUC<sub>0-t</sub> (ng·h·mL<sup>−1</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">6099.01</td><td align="center" valign="middle" rowspan="1" colspan="1">5770.53</td><td align="center" valign="middle" rowspan="1" colspan="1">105.69%</td><td align="center" valign="middle" rowspan="1" colspan="1">100.78–110.85%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">1 min</td><td align="center" valign="middle" rowspan="1" colspan="1">C<sub>max</sub> (ng·mL<sup>−1</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">1197.00</td><td align="center" valign="middle" rowspan="1" colspan="1">1215.67</td><td align="center" valign="middle" rowspan="1" colspan="1">98.46%</td><td align="center" valign="middle" rowspan="1" colspan="1">94.64–102.45%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AUC<sub>0-t</sub> (ng·h·mL<sup>−1</sup>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5798.47</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5769.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100.51%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.63–105.58%</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-01352-t004" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-01352-t004_Table 4</object-id><label>Table 4</label><caption><p>Dissolution Safe Space for Glyburide.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virtual Batch</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dissolution Time (50% Dissolved)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parameters</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">T</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">R</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">T/R %</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">90% CI</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">175 min</td><td align="center" valign="middle" rowspan="1" colspan="1">C<sub>max</sub> (ng·mL<sup>−1</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">55.32</td><td align="center" valign="middle" rowspan="1" colspan="1">67.44</td><td align="center" valign="middle" rowspan="1" colspan="1">82.03%</td><td align="center" valign="middle" rowspan="1" colspan="1">79.16–84.98%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">AUC<sub>0-t</sub> (ng·h·mL<sup>−1</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">412.71</td><td align="center" valign="middle" rowspan="1" colspan="1">408.98</td><td align="center" valign="middle" rowspan="1" colspan="1">100.91%</td><td align="center" valign="middle" rowspan="1" colspan="1">97.04–104.94%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">170 min</td><td align="center" valign="middle" rowspan="1" colspan="1">C<sub>max</sub> (ng·mL<sup>−1</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">56.01</td><td align="center" valign="middle" rowspan="1" colspan="1">67.44</td><td align="center" valign="middle" rowspan="1" colspan="1">83.05%</td><td align="center" valign="middle" rowspan="1" colspan="1">80.16–86.02%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">AUC<sub>0-t</sub> (ng·h·mL<sup>−1</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">414.75</td><td align="center" valign="middle" rowspan="1" colspan="1">408.98</td><td align="center" valign="middle" rowspan="1" colspan="1">101.41%</td><td align="center" valign="middle" rowspan="1" colspan="1">97.54–105.43%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">83 min</td><td align="center" valign="middle" rowspan="1" colspan="1">C<sub>max</sub> (ng·mL<sup>−1</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">66.74</td><td align="center" valign="middle" rowspan="1" colspan="1">67.44</td><td align="center" valign="middle" rowspan="1" colspan="1">98.98%</td><td align="center" valign="middle" rowspan="1" colspan="1">95.35–102.75%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">AUC<sub>0-t</sub> (ng·h·mL<sup>−1</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">413.15</td><td align="center" valign="middle" rowspan="1" colspan="1">408.98</td><td align="center" valign="middle" rowspan="1" colspan="1">101.03%</td><td align="center" valign="middle" rowspan="1" colspan="1">97.34–104.84%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">35 min</td><td align="center" valign="middle" rowspan="1" colspan="1">C<sub>max</sub> (ng·mL<sup>−1</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">65.33</td><td align="center" valign="middle" rowspan="1" colspan="1">67.44</td><td align="center" valign="middle" rowspan="1" colspan="1">96.87%</td><td align="center" valign="middle" rowspan="1" colspan="1">92.75–101.17%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">AUC<sub>0-t</sub> (ng·h·mL<sup>−1</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">343.75</td><td align="center" valign="middle" rowspan="1" colspan="1">408.98</td><td align="center" valign="middle" rowspan="1" colspan="1">84.05%</td><td align="center" valign="middle" rowspan="1" colspan="1">80.60–87.65%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">30 min</td><td align="center" valign="middle" rowspan="1" colspan="1">C<sub>max</sub> (ng·mL<sup>−1</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">64.19</td><td align="center" valign="middle" rowspan="1" colspan="1">67.44</td><td align="center" valign="middle" rowspan="1" colspan="1">95.18%</td><td align="center" valign="middle" rowspan="1" colspan="1">91.04–99.49%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AUC<sub>0-t</sub> (ng·h·mL<sup>−1</sup>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">331.65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">408.98</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81.09%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">77.67–84.66%</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>